WO2016042089A1 - Macrocyclic lrrk2 kinase inhibitors - Google Patents

Macrocyclic lrrk2 kinase inhibitors Download PDF

Info

Publication number
WO2016042089A1
WO2016042089A1 PCT/EP2015/071349 EP2015071349W WO2016042089A1 WO 2016042089 A1 WO2016042089 A1 WO 2016042089A1 EP 2015071349 W EP2015071349 W EP 2015071349W WO 2016042089 A1 WO2016042089 A1 WO 2016042089A1
Authority
WO
WIPO (PCT)
Prior art keywords
6alkyl
halo
optionally
independently
substituted
Prior art date
Application number
PCT/EP2015/071349
Other languages
French (fr)
Inventor
Jan Hoflack
Petra Blom
Olivier Lavergne
Sylvie Gomez
Original Assignee
Oncodesign S.A.
Ipsen Pharma S.A.S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201580061216.1A priority Critical patent/CN107108641A/en
Priority to AU2015316801A priority patent/AU2015316801B2/en
Priority to EA201790626A priority patent/EA032838B1/en
Priority to DK15766801.3T priority patent/DK3194405T3/en
Priority to BR112017005299A priority patent/BR112017005299A2/en
Priority to ES15766801T priority patent/ES2717510T3/en
Priority to JP2017515823A priority patent/JP2017529365A/en
Priority to SG11201701936WA priority patent/SG11201701936WA/en
Application filed by Oncodesign S.A., Ipsen Pharma S.A.S filed Critical Oncodesign S.A.
Priority to EP15766801.3A priority patent/EP3194405B1/en
Priority to CA2960777A priority patent/CA2960777A1/en
Priority to US15/511,879 priority patent/US10377772B2/en
Priority to MX2017003470A priority patent/MX2017003470A/en
Priority to KR1020177010322A priority patent/KR20170048599A/en
Priority to PL15766801T priority patent/PL3194405T3/en
Publication of WO2016042089A1 publication Critical patent/WO2016042089A1/en
Priority to IL251054A priority patent/IL251054B/en
Priority to ZA2017/01841A priority patent/ZA201701841B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Definitions

  • i niotvovresl m ina pcraorctiycculliacr c aosm ipnohuibnitdosrs an odf L cRoRmKp2os (iLtioenuscin ceo-nRtaicihnin Rgep seaaidt compounds, as well as methods of uesnition provides processes for the preparation of the disclosed particular for the treatment and/or diagng them, for instance as a medicine or diagnostic agent, in as neurological disorders includedin nosis of diseases characterized by LRRK2 kinase activity such 10 g Parkinson’s disease and Alzheimer’s disease.
  • o f dopaminergic e is a degenerative disorder of the central nervous system. It results from the death 15 symptoms are mo nveeumroennet-s in the midbrain. In the early stages of the disease the most obvious L aadtvearnc oend a slstaoge csog onfit tihvee related such as shaking, slowness of movement and difficulty with walking.
  • Parkinson’s disease is generally considered to be sporadic, linked to Parkinsond’es, a d few mutations in the LRRK2 (leucine rich repeat kinase 2) gene have been dardarin, is a member ofi tsheeas leeuc (iWneO-2006068492 and WO2006045392).
  • LRRK2 also known as 20 p 2 a 0 r L tic R u R la K r 2 in m t u h t e at b io ra n i s n, in bu fa t also in otherirc this rseupeesa tth krionuagsheo fuatm thiley b hoadviyn.g R mesixeeadr-clhineerasg hea kviena idseen aticfiteivdit oy,ve inr c o-segregates with autmilies with late-onset Parkinson Disease.
  • n W e O ur 2 o 0 n 0 a 9 l 12 d 7 is 6 o 5 rd 2 e , r W s, O d 2 o 01 not ceolmopperdise LR mRaKc2ro kcinyaclsice i pnyhriabzitoolrosp,y inrim paidritniceula mro thieotisees fo (sre thee f torera etmxaemntp olef N onetheless, there is a1 c0o3n8t572).
  • t 5i;tu wehnetsre sinele ecatcehd o frfo smai–dh -aClo1-, -OlkRyl36 is, - oNpRti2o3nRa2l4l,y - aOn-dC1 in-6daelkpyel,n adnednt -lSy- sCu1b-6satliktuytle;d with from 1 -3-
  • R2 is o selected from–H, -halo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1-6alkyl is apntdio -nNaRlly13 and independently substituted with from 1 to 3 substituents selected from–halo,–OR27, 5 R3 is o selectedR f1r4o;m–H, -halo, -OH, -C1-6al
  • R 4 and R8 areR1 e6a;ch independently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, - R, RN7R,1 R7R18
  • Ar6, and Ar7 are each independently a 5- to 10-membered aromatic cycle optionally beingr oispintigon 1al tloy 3 an hde itneroatoms selected from O, N and S; each of said Ar1, Ar4, Ar5, Ar6, and Ar7 OH, -C1-6alkyl, -O-C1-d6aelpkeynl,dently substituted with from 1 to 3 substituents selected from–halo, - optionally and independently su -Sb-sCti1tu-6taeldky wl,i and–NR19R20; wherein each of said -C1-6alkyl is 30 Het1 f,ro Hmet21, H toet 34, h Heetet5r,o Haetot6m,s an sdel Hecette7d ar fero emac Oh, itnh
  • R1 is R selected from–H,–halo, -OH, -C1-6alkdyrla,t -eO,- NC-1o-6xide form, or solvate thereof, wherein
  • R5 isS a-Ctta1-c6ahlekdyl, to - ZN1R o6rR Z5
  • each of said -C1-6alkyl is i s an
  • each of said -C1-6alkyl is 20 a om 1 to 3 substituents selected from–halo,–OR28, R4 a Nnn
  • s wuhbesrtietuinen etsac shele octfed sa friodm -–Ch1a-6laol,ky–lOH is, - oOp-tCio1n-6aalllkyyl, a -nSd- R and R, are each ind , -Het6, -Ar6 and–NR37R38
  • R nd R38 are each indeeppeennddeently selected from–H, -C1-6alkyl, -C3-6cycloalkyl and -Het2
  • 3 7 a 30 -C3-6cycloalkyl, -Ar7 ntly selected from–H, -halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, X1 is selected from–C1- a6anldky–lH-,e–t7O;-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1-6alkyl-, -X2 is N
  • 1 -l6lcyycle having from 1 to 3 het t l td from O, N and S; alk aynl,d -C in1d-6eaplkeynledneen,tl -yC1 s-6uablsktyilt-uCte3-d6
  • a Zr4e a enadc Zh5 in are each independently selected from C and N; atnadched to X2
  • 1 -6alkyl is optionally and independently subst cycloalkyl, -Ar1 and–Het1; wherein each of 20 from–halo, -OR35, -NR11R12, -O-C1-6alkyl, and -S-C1-ituted with from 1 to 3 substituents selected R s N a R ttached to O Z )-R R m–H,–ha6
  • each of said -C1-6alkyl is 30 and -N
  • a nd 8 are each independently and–NR37R38
  • 2 is NRl-,tdd f -O-; w–Che1-r6eailnky el-a,c–hO o-Cf1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1-6alkyl-, - from 1 to 3 substituents selected f sroamid– -Cha1-l6oa,lk -Oyl-H, is -C o1p-6tiaolnkyall,ly -O a-nCd1-6 inadlkeypl,e -nSd-eCn1t-l6yal substituted with -N R32; kyl, -phenyl and 10 Ar1, AR31 beinp A
  • I -7- R1 isR4 s,e -leScOte2-dR f4r,o -mCN–,H -N,–Rh9-aSloO,2 --ORH4,, -C -C1-6
  • R 2 is op s t elected from–H, -halo, -OH, -C 1-6 alkyl, and -C 3-6 cycloalkyl; whereidn - eSa-Cch1-6 oaflk syal;id -C 1
  • Ar6, and Ar7 are each independently a 5- to 10-membered aromatic cycle op 35 comprising 1 to 3 heteroatoms selected from O tionally b OeHin,g - oCp , N and S; each of said Ar1, Ar4, Ar5, Ar6, and Ar7 1t-6ioanlkayllly and independently substituted with from 1 to 3 substituents selected from–halo, - optionally and i,nd -Oep-Cen1-d6aelnktyl, -S-C1-6alkyl, and–NR19R20; wherein each of said -C1-6alkyl is Het1 f,ro Hmet21, H toet 34, h Heetet5r,o Haetot6m,s an sdly
  • R1 is selected from–H,–halo, -OH, -C1-6alkyl, -O-C1-drate, N-oxide form, or solvate thereof, wherein 15 R 6
  • Ra3lk3,yl R,3 -4S,- RC35 36 are each indepen 1- 6 inadlkeypl,en -dCe3n-6tclyyc sluobaslktiytul,te -dA wr6ith an frdom–Het6; wherein each of said -C1-6alkyl is optionally and C 1 to 3 substituents selected from–halo,–OH, -O-C1-6
  • Ar6, and Ar7 are each independently a 5- to 10-membered aromatic cycle optionally being opintigon 1al tloy 3 an hde itnedroeatoms selected from O, N and S; each of said Ar1, Ar4, Ar5, Ar6, and Ar7 5 OH, -C1-6alkyl, -O-C1-6alkpyel,nd -ently substituted with from 1 to 3 substituents selected from–halo, - Het1 and independently substitutedS w-Cith1-6 falkyl,–NR19R20; wherein each of said -C1-6alkyl is optionally f,ro Hmet21, H toet 34, h Heetet5r,o Haetot6m,s an sdel Hecette7d ar fero
  • Z2, Z3, Z4 and Z5 are each independently selected from C and N. 20 I tn
  • 2 7 aRnd38 R;28 are each independently selected from–H, -C1-6alkyl, -C3-6cycloalkyl and -Het2: -10- R37 a -Cnd3-6 Rcy38c,lo aarelk eyla,c -hAr i7nd aenpde–nHdeetn7tly selected from–H, -halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, X1 is
  • 2 isN sRe2l-e,c atendd f -rOom-; w–Che1-r6eailnky el-a,c–hO o-Cf1 s-6aaidlky -Cl-,1-–6aSlk-Cyl1--6 iaslk oypl-t,io -nCa1l-6lyalk aynld-N iRnd3-eCp1e-6nadlkeynlt-l,y -N suRb2s-Ctit1u-6talkyl-, - from 1 to 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl ed with 10 Ar1, - c AN
  • the present invention provides a compound of Formula Ia or a stereoisomer, wheomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, s aebloer
  • a d s farid Het8 is a saturated 3- to 10-membered heterocycle having from 1 to 3 heteroatoms 40 pploym. O, N and S; and wherein the further definitions and provisions as defined herein -11- I tnau ato fmurethr,e rra ecmbodiment, the present invention provides a compound of Formula I or a stereoisomer, whe emic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, 5 R A1 ar
  • R 5 is s seleecctted frroomm––HH, a -nhda–dheanltoly; selected from C and N;
  • R 2 is selec lo and -C1-6alkyl;
  • R 3 is selectteedd f frroomm––HH a anndd - -CC1-6
  • 10 X X1 is selected from–O-C1-6alkyl-, -lNkyRl;3-C1-6alkyl- H2et is8 s isele act 3e-d t foro 1m0- -mC1e-6mablkyl-,–O-C1-6alkyl-, -NR,2 --NCR3
  • R 2 is selec o and -C1-6alkyl
  • R 3 ted from–H and -C1-6alkyl
  • X 1 i iss s seelleecctteedd f frroomm––OH-C and -C1-6,a -lkyl;
  • H 2et is8 s -NNRR3
  • Z2c,y Zcl3o,a Zl4ky aln;d an Zd5 are each C.
  • the present invention provides a compound of Formula I or a stereoisomer, A arn,d ra Ace2m isic C,. metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, wherein 35 -12- I t n au a to f m ur e th r, e r r a e c m em bo ic d , im m e e n ta t, b t o h l e ite p , r p e r s o e - n o t r in p v re e d n r ti u o g n , p sa ro lt v , id h e yd s r a ate co , m N- p o o x
  • H et is 8 selected from–O-C1-6alky R3-C1-6alkyl-, -NR3-, 1 is t 0
  • M ore in particular the present invention provides a compound selected from the list comprising:
  • the present invention provides a compound according to this the numbering as prov iisde lidnk ined Fo torm thuela a Iry olr oCDC.
  • the present invention provides a compound according to Inhis ye intv ae fnutriothne,r w phaerrteiciunla srai edm cboomdp
  • p iound is the S-enantiomer.
  • the compounds and m edicine.T n h s e a c c o c m or p d o in u g nds to a t n h d is c in o v m e p n o ti s o i n tion a s re a s c u c i o ta rd ble for use as a human or veterinary i nhibiting the activity of a kinase, in particular LRRK2 kininagse t,o an tdhi msa iynv been utiosend a forer th seuitable for 15 a dnisde/aosre. prevention of neurological disorders such as Alzheimer’s disease or Pa trrekiantsmoenn’st
  • I onf a a f nineaulr ooblojegcictiavle d,i tshoerd perer,se suncth inv aesn Atioln provides a method for the prevention and/or treatment 20 c toom thpisri isninvegn atidomn.inistering to a subject iznh neeimeedr’ tshe driesoefa ase co omrp Poaurknidns oorn a’s c doimsepaosseit;io snai adc mcoertdhinogd
  • R 2 is aunbstituted6 with from 1 to 3 substituents selected from–halo, -OR36, -NR23R24, -O-C1-6alkyl, is sed
  • each of said -C1-6alkyl is –OH, -O-C1-6alkyl, -S-C1-6alkyl, -C3-6cycloalkyl, -Het o 3 substituents selected from–halo, R dently selected from–H, - 6
  • R 7 and R28 are each indepen C , 1 -- A 6a r6 lk a y n l, d -C – 3 N -6 R cy 37 c R l 38
  • R37 and R38 are each independently selected from–H, -halo, -OH, -C1-6alkoyall,k -yOl- aCn1d-6 -aHlkeytl2,: -S-C1- X 6
  • each of said -C1-6alkyl is optio cycloalkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1; 20 substituents selected from–halo, -O nally a11nRd12 i,n -dOe-pCe1n-6daelknytlly, a snudbs -Stit-uCte1-d6a wlkiythl; from 1 to 3 R5 is 6 a a lk tt y a l c , he -S d - t C o1- Z1
  • substituents selected from– 4 8 are ea pRe1n6d;ently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- R R 6a 7 l,k Ryl 9 ,, - RN 1 R17
  • a 2r isa sleklyelc-,te adnd fro -NmR- ,–3
  • Ar 4 Ar5, Ar6 7 are each independently aalk 5y-l-, to -N 1R02--m, aend -O-;
  • o ptionally comprising 1 to 3 heteroatoms selected from O, N and Smbered aromatic cycle Ar5, Ar6, and Ar7 being optionally and independently substitute; each of said Ar1, Ar4, 10 s w u h b e s r t e it i u n e e n a ts ch se o l f e s c a te id d - f C ro 1- m 6al – ky h l a i l s o, o - p O tio H n , a - l C ly 1- a 6a n l d ky in l, d - e O p - e C1-6alkyl, -S-C1d-6al wkyitlh, a fnrodm–N 1R1 t9oR203;
  • each of said -C1-6alkyl- is optionally and independently S -C1-6alkyl, -phenyl, and -NR33R3 uents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, - 25 X 4
  • 2 is selected from–C1-6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1- 6 saulbksytl-it,ut -eNdR w2-i,th a fnrdom -O 1-; to w 3he sruebinsti etuaecnhts o sfe sleacidted -C fr1o-6malk–yhl-al ios, o -OptHio,n -aCll1y-6a alknydl, i -nOd-eCp1e-6nadlkently S-C1-6
  • 1 -6alkyl is optionall ; - wherein each of said - Het1, Het2, Het4, Het5, Het6, and Het7 are each independently a 3- to 10-mhaelmo;bered heterocycl 35 having from 1 to 3 heteroatoms selected from O, N e
  • t arp ach independently selected from C and N;
  • R 4 and R8 are each independently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- R R 6alkyl, -NR17R18, -C3-6cycloalkyl, -O-C3-6
  • each of said -C1-6alkyl is —OH, -O-C1-6alkydlependently substituted with from 1 to 3 substituents selected from–halo, R and R8, are each , in -S d - e C p 1 e -6 n a d lk e y n l t , -C3-6cycloalkyl, -Het6, -Ar6 and–NR37R38
  • R and R8 are each independenlyt selected from–H, -C1-6alkyl, -C3-6cycloalkyl and -Het2
  • each of said -C1-6alkyl- is optionally and independently S-C th from 1 to 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6
  • n g Ad be 1r7 -N in to aR y
  • each of said -C1-6alkyl i pti lly an h d e e r p e e in nd w e h n e tl n y R su 1 b
  • R is–h ; stituted with from 1 to 3 substituents selected from 3 op sa

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.

Description

-1- MACROCYCLIC LRRK2 KINASE INHIBITORS
Fie
5 T
K coh
inmeld ap p o sor
euef 2ns th )de
.snet in M a i
ocnv rtve einen ognttiio ve aon r,sn
th k r
eienlaa
pste
res
es ien to
nhtib n
iniotvovresl, m ina pcraorctiycculliacr c aosm ipnohuibnitdosrs an odf L cRoRmKp2os (iLtioenuscin ceo-nRtaicihnin Rgep seaaidt compounds, as well as methods of uesnition provides processes for the preparation of the disclosed particular for the treatment and/or diagng them, for instance as a medicine or diagnostic agent, in as neurological disorders includin nosis of diseases characterized by LRRK2 kinase activity such 10 g Parkinson’s disease and Alzheimer’s disease.
B Paarckkingsroonu’nsd di osfea thse invention
of dopaminergic e is a degenerative disorder of the central nervous system. It results from the death 15 symptoms are mo nveeumroennet-s in the midbrain. In the early stages of the disease the most obvious L aadtvearnc oend a slstaoge csog onfit tihvee related such as shaking, slowness of movement and difficulty with walking.
d and behavioural problems arise, with dementia commonly occurring in the within the last deca isease. Although Parkinson’s disease is generally considered to be sporadic, linked to Parkinsond’es, a d few mutations in the LRRK2 (leucine rich repeat kinase 2) gene have been dardarin, is a member ofi tsheeas leeuc (iWneO-2006068492 and WO2006045392). LRRK2, also known as 20 p 2 a 0 r L tic R u R la K r 2 in m t u h t e at b io ra n i s n, in bu fa t also in otherirc this rseupeesa tth krionuagsheo fuatm thiley b hoadviyn.g R mesixeeadr-clhineerasg hea kviena idseen aticfiteivdit oy,ve inr co-segregates with autmilies with late-onset Parkinson Disease. For example the G2019S mutation Parkinson’s disease casoessom aanld d 3ominant Parkinsonism and accounts for about 6% of familial 25 mutation occurs in the highly conse%rve sdporadic Parkinson’s disease cases in Europe. The G2019S G su2b0s1ti9tuStio mnusta attio an s mecaoyn hda rveesi adnue ef Rfe1c4t4 o1n ki
a kniansaese do amctaivinity a (nWdO it2 h0a0s60 th6e8r4e9fo2r)e. F buerethne prmosoturela,t aemdi tnhoat a tchied been shown to elevate LRRK2 kinase activrie also associated with Parkinson’s disease and have also in transgenic mouse models (Li, Y et al.20ty0.9 Over-expression of the mutant LRRK2 protein R1441G symptoms of Parkinson’s disease as well as re,d Nature Neuroscience 12:826-828) is associated with 30 L coRnRdKit2ion csou cldha arlascote priozseidtive blyy r reegduulaceted d dooppaammineuc reedle daospea amninde h raevleeas peo,te snutgiagles uttiinlitgy th inat tr inehaitbmiteonrst o off associated with drug addiction; Tauopathy diseiane levels, such as withdrawal sypmtoms/relapse disease, Pick’s disease, corticobasal degeneses such as Alzheimer’s disease, argyrophilic grain 35 Parkinson’s disease. Two further mutations in LraRtion; inherited frontotemporal dementia; and t prraonvsiditieon e fvriodmen mceild th caotgn inithiviebit iomrpsai ormfe LnRtR toK2 Alz khineaimRK2 have been clinically associated with the ser’s disease (WO200714979). These data further dementias and related neurodegenerative disorders.e activity could be useful for the treatment of -2- T thheursa,p piehsar inma nceoulroogdiceagle innehribaittiivoen d oifs LorRdRerKs2, s kuincase is an attractive strategy towards mechanism-based was therefore an object h as Parkinson’s disease and Alzheimer’s disease. It sa of the present invention to provide compounds and compositions comprising 5 Udo s
neni
utirll c
on tom
adlapo
dyu
is sn
oed
rvs
de,
er a
rac
slt
, (i
inn
nogn a
p-am i
rtan
icch
uri
lob
acit
ryos
Acrllizc o
h)f
e p L
imyRreaR
rzK
o2
slo k
dpi
isyn
eraiamse
siedsi.n aensd/ hoarv Pea brkeiennso snuggested for the treatment of EP1908764, US6194410, EP1354884, EP0729758 and U ’s disease (see for example compounds disclosed in said references have S6194410). However, none of the 10 Furthermore, the currently dev been shown to have LRRK2 inhibitory activity.
n W e O ur 2 o 0 n 0 a 9 l 12 d 7 is 6 o 5 rd 2 e , r W s, O d 2 o 01 not ceolmopperdise LR mRaKc2ro kcinyaclsice i pnyhriabzitoolrosp,y inrim paidritniceula mro thieotisees fo (sre thee f torera etmxaemntp olef Nonetheless, there is a1 c0o3n8t572).
treatment of inuing need to design and develop LRRK2 kinase inhibitors for the pharmaceutic naellyur aocncaelp dtiasbolrede crosm.p Woesit hioanvse a ncocword foinugnd to th thaits th ineve mnaticrocyclic pyrazolopyrimidines and 15 several neuronal disorders associated with LRRK2 kinase activity. on are useful for the treatment of S WUeM hMavAeR sYur OpFris TinHgEly I fNoVunENTION 20 in r d that the macrocyclic compounds described herein act as kinase inhibitors, I tn p
au aa
tom ftiirc
esu
rtla
, r or
ab L
cjeeR
mcRtiiK
cv,e2 k
m tehin
teas
ab pe
orle in
itsh
eei
,nb
ptito
ro inrs
-v.
oern ptrioendru pgro,v siadlet,s hy adr caotem,p No-uonxdide o ffor Fmo,rm oru slaolv Ia oter t ahe sreteorfe,oisomer,
Where si
Figure imgf000004_0001
I 25 R1 isRenlected -S-C- lkyl, -NR9R10, -(C=O)-R4
sa4i,d -S -CO2
1-- , -(C=S)- 6R f
al4r
k,o
y -m
lC iN–
s,H
o -pN,–h
tiRo9n-a
aSlo
lO,
ly2 --O
aRH
n4d,, - inC -C- d3e-6pcyl
eck
nly
dol
ea,
nl -kO
tly-C- lkyl,
yl, s -uOb-sCt3it-u6cteydclo wailtkhyl f,ro -Amr11 an tod 3–H seutb1s;t wituheenretsin s eealeccht of from–ha e l d o, to -O Z R35
1 o , r -N Z5 R a 11 n R d 12 i , s - s O e-l C ec 1- ed R t 6 e a d lky fr l o , m and –H -S ,- C h 1 a -6
5 is attach lo a , lk -y O l; H, -C1-6alkyl, -O-C1-6alkyl, -S
30 NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8
6a, -CN, -NR6-SO2-R8, -C3cycloalkyl, -O-C3-6cycl-oCa1lk-6yall,ky -Al,r5 - a tond 3 s–uHbest -6
t5i;tu wehnetsre sinele ecatcehd o frfo smai–dh -aClo1-, -OlkRyl36 is, - oNpRti2o3nRa2l4l,y - aOn-dC1 in-6daelkpyel,n adnednt -lSy- sCu1b-6satliktuytle;d with from 1 -3- R2 is o selected from–H, -halo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1-6alkyl is apntdio -nNaRlly13 and independently substituted with from 1 to 3 substituents selected from–halo,–OR27, 5 R3 is o selectedR f1r4o;m–H, -halo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1-6alkyl is ap n t d io -n N a R lly 1 and independently substituted with from 1 to 3 substituents selected from–halo,–OR28, R 5
4 and R8 areR1 e6a;ch independently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, - R, RN7R,1 R7R18
9, R,1 -0C,3 R-6
1c1y,c Rlo1a2,lk Ry1l,3, -O R-1C3-6
4, Rc15y,c Rlo1a6l,kyl, -Ar4 and -Het4
6 ;
10 6 and R are each independently selecte Rd17 f,ro Rm18,– RH1,9 -,h Ra2lo0,, R =2O1,, R -O22H,, R -2C3,1- R24
6alk,y Rl,3 -1O, R-C32 3
1,-6 Ralk3,yl R,3 -4 36 S,- RC35
1- inadlkeypl,en -dCe3n-6tclyyc sluobaslktiytul,te -dA wr6ith an frdom– 1He tot63; s wuhbesrtietuinen etsac shele octfed sa friodm -–Ch1-6alkyl is optionally and C1-6alkyl, -C3-6cycloal alo,–OH, -O-C1-6alkyl, -S- R kyl, -Het6, -Ar6 and–NR37R38
27 and R28 are each inde ;
15 R -Cnd3-6 Rcyclre each indeppeennddeennttllyy s seelelecctteedd f frroomm––HH,, - -Ch1a-6laol,k -yOl,H -C, -3C-6c1-y6callokayll,ky -Ol a-Cnd1-6 -aHlkeyt2
37 a 38 a l,: -S-C1-6alkyl, X oalkyl, -Ar7 and–Het7
1 is ;
N sRe3l-e,c atendd f -rOom-; w–Che1-r6eailnky el-a,c–hO o-Cf1 s-6aaidlky -Cl-,1-–6aSlk-Cyl1--6 iaslk oyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1-6alkyl-, - from 1 to ptionally and independently substituted with 20 X2 is an
N sd
Re2l - -eN
,cR
ate3
nd3R 3 d f -r3
Oo4 s;ubstituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, -phenyl, m-; w–Che1-r6eailnky el-a,c–hO o-Cf1 s-6aaidlky -Cl-,1-–6aSlk-Cy1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1-6alkyl-, - f l- is optionally and independently substituted with -rNoRm 1 to 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6
3 alkyl, -phenyl and 25 Ar 1
1, c Aorm4,p A R r 32
5, ; Ar6, and Ar7 are each independently a 5- to 10-membered aromatic cycle optionally beingr oispintigon 1al tloy 3 an hde itneroatoms selected from O, N and S; each of said Ar1, Ar4, Ar5, Ar6, and Ar7 OH, -C1-6alkyl, -O-C1-d6aelpkeynl,dently substituted with from 1 to 3 substituents selected from–halo, - optionally and independently su -Sb-sCti1tu-6taeldky wl,i and–NR19R20; wherein each of said -C1-6alkyl is 30 Het1 f,ro Hmet21, H toet 34, h Heetet5r,o Haetot6m,s an sdel Hecette7d ar fero emac Oh, itnh
Nd fero
apmen 1de tont 3ly - aha 3l-o; to 10-membered heterocycle having Het6, a nd S; wherein each of said Het1, Het2, Het4, Het5, from–hnadlo H,e -Ot7H is,– optionally and independently substituted with from 1 to 3 substituents selected each of said -C1-6alC1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, =O, -
Figure imgf000005_0001
(C=O)-C1-6alkyl, and -NR21R22; wherein 35 Het8 w ishle a
erce 3
tei-n to
d f s 1
ra0
oimd-m
He
hem
at8bkey lo, isrle isd o -O oHp hp ,tet
i–otieo Cnrn
aoa 1-l6lcl substittd ith f 1 to 3 -halo;
yylyc
alk al aen ynl,d hda i -C ivn
nid 1dnependently -6eg
ap f
lkero
ynm
ledne 1
en,t tl -yo 3
C1 s-6u h
abe
lst
ktyilt-uCtet
3-d6cy wciltohl
al fkrot
ylmd
, -C 1 from O, N and S; se 3-6 tcoyc 3lo saulkbysl,ti -tuOe-nCt1s- 6 -Cal1k-y6al,lk -ySl-C is1 o-6patlikoynl,a =llyO a, -
Figure imgf000005_0002
(dC i=Od)-pC1-6dalkytll, -C1-6alkyl-O-C1-6alkyl and -NR21R22; wherein each of said 40 Z1, Z w2,h Zer3e,i Zn whnedn Z R1
5 ar–eH e,a thch indte lpentdently h y s
sete u
ler b o s
ca ti
tet t o u
dm ted
fro omf w H it
Ce h t a8 fr
n i o s m
d a Nt 1 t;a t
ac o
nh 3
ded -h t a o lo X ; 2
4 a -4- A1 and A2 are each independently selected from C and N.
I rnac peamrtiicc,u mlaer,ta tbhoeli pter,e pseron-t o inrv perendtiorung, p sroavlti,d heys a compound of Formula I or a stereoisomer, tautomer, 5 R1 is R selected from–H,–halo, -OH, -C1-6alkdyrla,t -eO,- NC-1o-6xide form, or solvate thereof, wherein
4, -SO2-R4, -CN, -NR9-SO2-R4, -C3-6cycloa alkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, -(C=S)- said -C1-6alkyl is optionally and independlkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1; wherein each of from–halo, -OR35, -NR11R12, -O-C1-6alkyl,ently substituted with from 1 to 3 substituents selected 10 R5 isS a-Ctta1-c6ahlekdyl, to - ZN1R o6rR Z5
7, a -(nCd= iOs) s-eRl8e,ct -e(Cd= frSo)m a
-R–n
8Hd
,, - -S–Sh- OaC
2l-o1- R,6a
8 -,Olk
-Hyl
C,;
N -,C1 --N6aRlk6-ySl,O -O2-HR,8, -C -C1-6
3a-6lckyycl,lo -Oal-kCy1l,-6a -Olk-yCl,3 -- 6 scuybcslotitaulkteydl, w -Aithr5 fr aonmd 1– tHoe 3t5; su wbhsteitrueeinnts ea scehlec otefd sa friodm -C–h1-a6alolk,y -lOR is36 o,p -NtioRn2a3Rlly24, a -nOd- independently S-C1-6a C1-6alkyl, and - 15 R2 is op steiolencatl
leky
lydl;
a fnrodm ind–eHp,e -nhdaelon,tl -yO sHu,bs -Ctit1u-6taeldky wl,it ahn fdrom -C31-6 tcoyc 3lo saulbkyslt;itu weherein each of said -C1-6alkyl is is an
op s d nts selected from–halo,–OR27, R teiol -e N
nc R
atle 1
lyd 3R
a f 1
nr 4
3 o ;
dm ind–eHp,e -nhdaelon,tl -yO sHu,bs -Ctit1u-6taeldky wl,it ahn fdr -C3-6cycloalkyl; wherein each of said -C1-6alkyl is 20 a om 1 to 3 substituents selected from–halo,–OR28, R4 a Nnn
RddN
1 R - 7R8R
18 a1
,r5
-eR1
C e6
3-a;
6ccyhcl ionadlekpyle,n -Ode-Cnt3ly- selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, - R 6
6, R an7,d R R9, R a10re, R e1a1c,h R1 in2,d Rep13e,n Rd1e4n,t Rc
ly1y5 s,cl
e Roa
le1c6l
t,ky
e Rl,
d17 - fr,A
o Rr4
m18 a
,n
H Rd
,1 -9H
-,h Ret4
al2o0;
,, = RO21,, - RO2H2,, R -C23
1,-6 Ra2lk4,yl R,3 -1O,- RC32
1-,6a Rlk33yl R,3 -4 36 S,- RC35
1-25 6
C ina
1dlk
-6ey
apl,
lekyn - ldC
,e3
-Cn-6tc
3l-yyc
6c sl
yuo
cba
loslk
atiy
ltkul,
yte - ldA wr6ith an frdom– 1He tot63; s wuhbesrtietuinen etsac shele octfed sa friodm -–Ch1a-6laol,ky–lOH is, - oOp-tCio1n-6aalllkyyl, a -nSd- R and R, are each ind , -Het6, -Ar6 and–NR37R38
27 28 ;
R nd R38, are each indeeppeennddeently selected from–H, -C1-6alkyl, -C3-6cycloalkyl and -Het2
37 a : 30 -C3-6cycloalkyl, -Ar7 ntly selected from–H, -halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, X1 is selected from–C1- a6anldky–lH-,e–t7O;-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1-6alkyl-, - X2 is N
N sR
Re3l-e acntedd– fOro-m;–C1-6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1-6alky 35 cr2
4,-,
p A a l-, - Ar1, A rrn5,d A -Or6-,; and Ar7 are ea
boeming oispintigon 1al tloy 3 an hde itnedroeapteonmdsc
en sh
te i
lylned
scuteependently a 5- to 10-membered aromatic cycle optionally bdst fitruom O, N and S; each of said Ar1, Ar4, Ar5, Ar6, and Ar7 OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl,ted with from 1 to 3 substituents selected from–halo, - optionally and independently substituted with an frdom–NR19R20; wherein each of said -C1-6alkyl is 40 Het1 f,ro Hmet21, H toet 34, h Heetet5r,o Haetot6m,s an sdel Hecette7d ar fero emac Oh, in Nde apnedn 1o
Sde t
;n wt 3lhy - e aha
re 3l
in-o; t eoa 1c0h-m ofe smabider Hedet h1,e Hteerot2c,y Hcelet4 h,a Hveint5g, -5- H froemt6,– ahnadlo H,e -Ot7H is,– oCp1ti-o6anlaklylyl, - aOn-dC i1n-6daelkpyeln,d -Se-nCtl1y-6 saulkbysl,tit =uOte,d -
Figure imgf000007_0001
( wCi=thO) fr-oCm1-6a 1lk tyol, 3 an sudb -sNtiRtu2e1Rnt2s2; s welected each of said -C1-6alk e yl is optionally and i ; herein 5 Het8 w is a 3 ndependently substittd ith f 1 to 3 -halo sehleercetei-n to
d f s 1
ra0
oimd-m
He
hem
at8b
lo, isred
-O oHp h
,tei–ote
Cnrao
1-l6lcyycle having from 1 to 3 het t l td from O, N and S; alk aynl,d -C in1d-6eaplkeynledneen,tl -yC1 s-6uablsktyilt-uCte3-d6
6 cy wciltohal fkroylm, -C 13-6 tcoyc 3lo saulkbysl,ti -tuOe-nCt1s- -Cal1k-y6al,lk -ySl-C is1 o-6patlikoyl, =O, -
Figure imgf000007_0002
(C=O)-C1-6alkyl, -C1-6alkyl-O-C1-6alkyl and -NR21R22; wherein each of said wherein when R1n iasll–yH a, tdh idtp l dt tly s huebtesrtoituatteodm w oifth H ferot8m is 1 a tto 3 -halo;
10 Z A1
1, a Zn2d, Z A3
2, a Zr4e a enadc Zh5 in are each independently selected from C and N; atnadched to X2
dependently selected from C and N.
More tau intom paerrt,ic rauclaerm tihce, m perteasbeonlitte i,n pveron-ti oorn pr perdorvuidge,s sa alt, c hoymdrpaoteu,n Nd-o oxfid Feo frmula I or a stereoisomer, 15 whe orm, or solvate thereof, R1 isre
R4 sin
,e -leScOte2-dR f4r,o -mCN–,H -N,–Rh9-aSloO,2 --ORH4,, -C -C1-6
3-6caylcklyola,l -kOyl-,C -1O-6-aClk3y-l, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, -(C=S)- said -C 6
1-6alkyl is optionally and independently subst cycloalkyl, -Ar1 and–Het1; wherein each of 20 from–halo, -OR35, -NR11R12, -O-C1-6alkyl, and -S-C1-ituted with from 1 to 3 substituents selected R s N a R ttached to O Z )-R R m–H,–ha6
5 i 1 or Z 5 and is selected fro loa,lk -yOl;H, -C 1-6 alkyl, -O-C 1-6 alkyl, -S-C 1-6
6R7, -(C= 8, -(C=S)-R8, -SO2-8, -CN, -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3-6c alkyl, - a tond 3 s–uHbest ycloalkyl, -Ar5 t5i;tu wehnetsre sinele ecatcehd o frfo smai–dh -aClo1-,6a -OlkRyl36 is, - oNpRti2o3nRa2l4l,y - aOn-dC1 in-6daelkpyel,n adnednt -lSy- sCu1b-6satituted with from 1 25 R2 is op stelected from–H, -halo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each oflk syal;id -C1- andio -nNaRlly13R an14d independently substituted with from 1 to 3 substituents selected from–halo,6a–lOkyRl2 i7s, R3 is op steiolencatlelyd a fnro;
dm ind–eHp,e -nhdaelon,tl -yO sHu,bs -Ctit1u-6taeldky wl,it ahn fdrom -C31-6 tcoyc 3lo saulbkyslt;itu wehnetrein each of said -C1-6alkyl is 30 and -N
NR 8R
17R18 a1 s selected from–halo,–OR28, R ,r5
4 and R -eR1
O e6
-Ca;c3-h6cy incdloeapleknyld,e -Cnt3ly-6c syeclleocatlekdyl, fr -oAmr–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, - R and R , R 4
6, R7, R9, R10, R11, R12, R13, R14, R15 16, R17, R18 a,n Rd1 -9H, Ret4
20;, R21, R22, R23, R24, R31, R32, R33, R34 R35 36 are each independently selected from–H, -halo, =O, -OH, -C1-6alkyl, -O-C1-6alkyl, l -S-C1- 35 i 6
Cnalkyl, -C3-6cycloalkyl, -Ar6 and–Het6; wherein each of said -C1-6alkyl is optional
1d-6eaplekynld,e -Cnt3l-y6c syucblosatiltkuytel,d -H weitth6, f -rAorm 1 to 3 substituents selected from–halo,–OH, -O-C1-6alkyyl, a -nSd- R 6
and 8, are each independently and–NR37R38
27 and R2 ;
R7
3-6 Rcy38c,lo aarelk eyla,c -hAr i7nd aenpde–nHdeetn7t;ly s seelleecctteedd f frroomm––HH,, - -Cha1-l6oa,lk -Oyl,H -,C -3C-6
1c-6yacllkoyal,lk -yOl- aCn1d-6a -Hlkeytl2
3 ,:
-C -S-C1-6alkyl, -6- X1 isN sRe3l-e,c atendd f -rOom-; w–Che1-r6eailnky el-a,c–hO o-Cf1 s-6aaidlky -l-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1-6alkyl-, - from 1 to 3 substituents selected fromC1–-h6aallkoy,l- -O isH o,p -tCio1n-6aalllkyyl a,n -dO- iCnd1-e6apleknydl,e -nSt-lyC1 s-6uablskytilt,ut -ed with 5 and -NR33R phenyl, X 34
2 is NRl-,tdd f -O-; w–Che1-r6eailnky el-a,c–hO o-Cf1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1-6alkyl-, - from 1 to 3 substituents selected f sroamid– -Cha1-l6oa,lk -Oyl-H, is -C o1p-6tiaolnkyall,ly -O a-nCd1-6 inadlkeypl,e -nSd-eCn1t-l6yal substituted with -N R32; kyl, -phenyl and 10 Ar1, AR31 beinp A
g oipitig Ar
on 16,
al tlo an 3d
y an hde A
itr
ne7
dro a
eare
pteonm ea
dsc
e she ilencdteepden frdoemnt Oly, a N 5 a-nd to S 1;0 e-amcehm obfe sraeidd A arro1,m Aart4i,c A cry5,cl Aer6 o,p atinodna Allry7 OH, -C1-6a ntly substituted with from 1 to 3 substituents selected from–halo, - and indepe lk n y d l, e -n O tly -C s 1-6alkyl, -S-C1-6alkyl, and–NR19R20; wherein each of said -C1-6alkyl is optionally 15 Het1, H ubstituted with from 1 to 3 -halo;
f Hroemet2
t6, 1, H
an toet
d 34,
He h H
tee e
7tet5
isr,o H
oaptot6
tiom,
ns an
al sd
lyel H
aence
dtte7d ar
ind fereo e
pmac
en Oh
d, in
e Nde
ntly apne en
sdn
u Sd; wtlhye are 3in- t eoa 1c0h-m ofe smabider Hedet h1,e Hteerot2c,y Hcelet4 h,a Hveint5g, from–halo, -OH,–C1-6alkyl, bstituted with from 1 to 3 substituents selected each of said -C1-6alkyl is opti -oOn-aClly1-6 aanlkdy iln,d -Se-pCe1n-6daelknytlly, = sOub,s -t
Figure imgf000008_0001
(iCt=tOd)-Ci1th-6a flkyl, 1 an tod 3 -N -Rha21R22; wherein Het8 is a bivalent 3- to 10-membered heterocycle having from 1 t 3 ht t s seleclo;
20 a wn
whder Se; ted from O, N in at least one of said heteroatoms is attached to X1 o
wheri
sehleere
ceteinn w
d f sh
rae
oimdn R
H1
heat is8–
lo, isH,
-O o t
Hph
,tei–on
Cn aat
1-l6l lyea
alk as
ynt
l,d on
-C ien1d h
-6ee
apte
lker
yno
leda
net
eno
,tml -y o
C1 sf
-6u H
abe
lst
kt8r yilt i X -us2 Cte a; 3-dtta
6cy wch
cilte
ohd
al f t
krooylm X2;
, -C 1 and 25 3-6 tcoyc 3lo saulkbysl,ti -tuOe-nCt1s- 6 -Cal1k-y6al,lk -ySl-C is1 o-6patlikoynl,a =llyO a, -
Figure imgf000008_0002
(dC i=Od)-pC1-6dalkyl, -C1-6alkyl-O-C1-6alkyl and -NR21R22; wherein each of said Z1 tly substituted with from 1 to 3 -halo;
A1, a Zn2d, Z A3
2, a Zr4e a enadc Zh5 in adreep eeancdhe intdlyp seledctedtly froemle Ccte adnd fro Nm. C and N; and 30 M taourtoem iner, p raarctiecmuliacr, m theeta pbroelistee,nt pr ion-v oernt piorendr purgo,v sidaelts, h ayd croamtep,o Nu-noxdid oef fo Fromrm, ourla so Ilava oter t ahe sreteorfe,oisomer,
Wherein
Figure imgf000008_0003
I -7- R1 isR4 s,e -leScOte2-dR f4r,o -mCN–,H -N,–Rh9-aSloO,2 --ORH4,, -C -C1-6
3-6caylcklyola,l -kOyl-,C -1-6alkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, -(C=S)- sai O-C3-6cycloalkyl, -Ar1 and–Het1; wherein each of 5 fromd -–Ch1a-6loa,lkyl is optionally and independently substituted with from 1 to 3 substituents selected R5 is N aRt6tRac7,he -(dC t=o -O
O ZR35
)-1R o,
8r -N
, Z -(5R
C a11
=nR
Sd12
)-R i,s - 8, sOe- -SlCeOc1-t6
2ea
-Rdlky
8 f,rlo,
-Cm and
N–,H -S
-N,- R–Ch1
6-a-6
Sloa
O,lk
2 -y
-Ol;
R8H,, - -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, - and–Het5; wherein each of said -C1-6alkyl is optionally and inCd3e-6cycloalkyl, -O-C3-6cycloalkyl, -Ar5 to 3 substituents selected from–halo, -OR36, -NR23R24, -O-C1-6alkpyel,n adnently substituted with from 1 10 R 2 is op s t elected from–H, -halo, -OH, -C 1-6 alkyl, and -C 3-6 cycloalkyl; whereidn - eSa-Cch1-6 oaflk syal;id -C 1
andio -nally and independently substituted with from 1 to 3 substituents selected from–halo-,6 a l O ky R l 2 is
optioeN
ncR 7 atle1 , R lyd3
3 is sel R
a f1
nr4o;
dm ind–eHp,e -nhdaelon,tl -yO sHu,bs -Ctit1u-6taeldky wl,it ahn fdrom -C31-6 tcoyc 3lo saulbkyslt;itu wehnetrse sinel eeactcehd o frfo smai–dh -aClo1-,6a–lkyl is 15 and -N
NR 8R OR28, R 17R18 a1
,r5
4 and R -eR1
C e6
3-a;
6ccyhcl ionadlekpyle,n -Ode-Cnt3ly-6c syelected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, - R6, R7, R9, R10, R11, R12, R13 cloalkyl, -Ar4 and -Het4;
and R are each indepe,n Rd1e4n,t Rly15 s,e Rle1c6t,e Rd17 fr,o Rm18–,H R,19 -,h Ral2o0,, = RO21,, - RO2H2,, R -C23
1,-6 Ra2lk4,yl R,3 -1O,- RC32
1-,6a Rlk33yl R,3 -4 36 S,- RC35
1-20 6
C inadlkeypl,en -dCe3n-6tclyyc sluobaslktiytul,te -dA wr6ith an frdom– 1He tot63; s wuhbesrtietuinen etsac shele octfed sa friodm -–Ch1a-6laol,ky–lOH is, - oOp-tCio1n-6ally and 1-6alkyl, alkyl, -S- R7 and R2 -C3-6cycloalkyl, -Het6, -Ar6 and–NR37R38
2 ;
R 8
7 and R38,, a arree e eaacchh i innddependently selected from–H, -C1-6alkyl, -C3-6cycloalkyl and -Het2
3 : 25 -C3-6cycloalkyl, -Ar7 ependently selected from–H, -halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, X is N sRe3l-e,c atendd f -rOom-; w–Che1- a
r6ean
ild
nky–
elH-a,e
c–t7
1 hO;
o-Cf1 s-6aaidlky -Cl-,1-–6aSlk-Cyl1--6 iaslk oypl-t,io -nCa1l-6lyalk aynld-N iRnd3-eCp1e-6nadlkeynlt-l,y -N suRb3s-Ctit1-6alkyl-, - from 1 to 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl,ut -epdhe wnith and -NR33 yl, 30 X R34
2 is N s
froR e
m2 l-e , c
1 a te
tn d
od f
3 - r
sO om
u-b;s w –C
tithue 1- er 6
ne a
ti l
sn ky
s e l- ea ,
lec
ch O
te o -C
df 1
f s -6
roa a
mid lky
-C l-,
ha1-
l6oa S
,lk -C
-Oyl 1--6
H, i a s lk
-C o y
1p l- -6t , iao - ln C
kya 16
ll- ,ly alk
-O a y
-n l
Cd -N
1-6 i R nad 3- lke C
yp 1
l,e -6
-n a
Sd lk
-e y
Cn l
1t- -l ,
6y -N
al sku R
ylb 2
,s -C tit 1 u -6 t a e l d ky w l- i , th - - -phenyl and Ar ANrR31
4, ARr32
1, 5,; Ar6, and Ar7 are each independently a 5- to 10-membered aromatic cycle op 35 comprising 1 to 3 heteroatoms selected from O tionally b OeHin,g - oCp , N and S; each of said Ar1, Ar4, Ar5, Ar6, and Ar7 1t-6ioanlkayllly and independently substituted with from 1 to 3 substituents selected from–halo, - optionally and i,nd -Oep-Cen1-d6aelnktyl, -S-C1-6alkyl, and–NR19R20; wherein each of said -C1-6alkyl is Het1 f,ro Hmet21, H toet 34, h Heetet5r,o Haetot6m,s an sdly
el H s
eceu
ttb
e7s
d atrit
feut
ro ee
madc w
Ohi
, itnh
Nd fero
apm
nedn 1 to
Sde;n wt 3lhy - e aha
re 3l;
in-o t eoa 1c0h-m ofe smabider Hedet h1,e Hteerot2c,y Hcele having 40 Het6, and Het7 is optionally and independently substituted with from 1 to 3 substituents ste4,le Hcetet5d, -8- f eraocmh– ohfa slaoi,d -O -CH1-,6a–lCky1-l6a islk oypl,ti -oOn-aClly1-6 aanlkdy iln,d -Se-C1-6alkyl, =O, -
Figure imgf000010_0001
(C=O)-C1-6alkyl, and -NR21R22; wherein Het8 is a 3- to 1 pendently substittd ith f 1 to 3 -halo; 5 wherein sa0id-m Heemt8be isred op hteiotenraollcyyc alend ha ivnidneg from 1 to 3 het t l td from O, N and S; selected from–halo, -OH,–C1-6alkyl, -C1-6aplkeynledneen,tl -yC1 s-6uablsktyilt-uCte3-d6cy wciltohal fkroylm, -C 13-6 tcoyc 3lo saulkbysl,ti -tuOe-nCt1s- 6 -Cal1k-y6al,lk -ySl-C is1 o-6patlikoynl,a =llyO a, -
Figure imgf000010_0002
(dC i=Od)-pC1-6dalkytlly, - sCu1-6alkyl-O-C1-6alkyl and -NR21R22; wherein each of said wherein when R1 is–H bstituted with from 1 to 3 -halo; 10 Z , Z4 and Z5 are eac,h th indepte lndetntly s heeletectreodat foromm o Cf H aentd8 i Ns. attached to X2
1, Z2, Z3
M taourtoem iner, p raarctiecmuliacr, m theeta pbroelistee,nt pr ion-v oernt piorendr purgo,v sidaelts, h ay compound of Formula Ia or a stereoisomer, R1 is selected from–H,–halo, -OH, -C1-6alkyl, -O-C1-drate, N-oxide form, or solvate thereof, wherein 15 R 6
4, -SO2-R4, -CN, -NR9-SO2-R4, -C3-6cycloalkyl, alkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, -(C=S)- s fraoimd -–Ch1a-6loa,lk -yOlR is35 o,p -NtioRn1a1Rlly12, a -nOd-C in1d-6eaplkeynld, aenndtly -S s - -uO-C3-6cycloalkyl, -Ar1 and–Het1; wherein each of Cbstituted with from 1 to 3 substituents selected R is N a R ttached to Z R o C m N , H -N , R –h1a-6
5 1 or Z5 and is selected fr loa,lk -yOl;H, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6
6R7, -(C=O)-8, -(C=S)-R8, -SO2-R8, - 6-SO2-R8, -C3-6cycloalkyl, -O-C3-6cycloa alkyl, - 0 and–Het5; wherein each of said -C1-6alkyl is optionally and independently substituted witlhkyl, -Ar5 2 R2 is to 3 substituents selected from–halo, -OR36, -NR23R24, -O-C1-6alkyl, and -S-C1-6alkyl; from 1 op stelected from–H, -halo, -OH, -C1-6alkyl, and -C3-6cycloalkyl,; wherein each of said -C1-6alkyl is andio -nNaRlly and independently substituted with from 1 to 3 substituents selected from–halo,–OR27, 25 R i osp stieolneaclt1
le3
3 ydR1
an f4
dr;o imnde–pHe,n -dheanlotly, s -OubHs,tit -uCte1-d6a wlkiythl, fr -oCm3-61cy tcolo 3al skuybl;st wituheenretsin se elaecchted of fro smaid–h -aCl1o-6,a–lkOyRl2 i8s, R a a
Nnn
Rdd R1
1 R -N
7R18,r5
-eR1
C e6
4 8 a 3-a;
6ccyhcl ionadlekpyle,n -Ode-Cnt3ly-6 selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, - 30 R R R cycloalkyl, -Ar4 and -Het4
6, 7, R9, 10, R11, R12 ;
and R , R13, Rd1e4n,t Rly15 s,e Rle1c6,te Rd17 f,ro Rm18,– RH1,9 -,h Ra2lo0,, R =2O1,, R -O22H,, R -2C3,1- R24
6alk,y Rl,3 -1O, R-C32
1,-6 Ra3lk3,yl R,3 -4S,- RC35 36 are each indepen 1- 6 inadlkeypl,en -dCe3n-6tclyyc sluobaslktiytul,te -dA wr6ith an frdom–Het6; wherein each of said -C1-6alkyl is optionally and C 1 to 3 substituents selected from–halo,–OH, -O-C1-6
1-6alkyl, -C3-6cycloalkyl, -Het6, -A alkyl, -S- 35 R R 8
37 and R38 , , a a r r e e e e a a c c h h i i n n d d e e p p e e n n d d e e n n t t l l y y sr
se6
el l e a
ecn
ctd
te e d–N
d f f rR
ro o m37R
m–3
H8
27 and R2 ;
H, , - -C ha 1- l 6 o a , lk -O yl, H -, C -3 C -6
1c -6 y a c l l k o y a l, lk -y O l- a C n 1 d -6a -H lk e y t l 2 , : -S- s -C s3e-6lecycctelo C1-6alkyl, X da flkroyml, -A–Cr7
1- a6anldky–lH-,e–t7
1 i O;-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1-6 40 sN
N sR
Re3 alkyl-, - X2 i l-e acntedd– fOro-m;–C1-6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2
2-, and -O-; -C1-6alkyl-, -NR2-C1-6alkyl-, - -9- Ar1, c Aorm4,p Arisr5, Ar6, and Ar7 are each independently a 5- to 10-membered aromatic cycle optionally being opintigon 1al tloy 3 an hde itnedroeatoms selected from O, N and S; each of said Ar1, Ar4, Ar5, Ar6, and Ar7 5 OH, -C1-6alkyl, -O-C1-6alkpyel,nd -ently substituted with from 1 to 3 substituents selected from–halo, - Het1 and independently substitutedS w-Cith1-6 falkyl,–NR19R20; wherein each of said -C1-6alkyl is optionally f,ro Hmet21, H toet 34, h Heetet5r,o Haetot6m,s an sdel Hecette7d ar fero
ro em
mac 1
Oh t
, ion Nd 3e - aph
nea
dnlo
Sd;ently a 3- to 10-membered heterocycle having Het6, and ; wherein each of said Het 1 , Het 2 , Het 4 , Het 5 , 10 from–halo H,e -Ot7H is,– oCp1tionally and independently substituted with from 1 to 3 substituents selected Het
Figure imgf000011_0001
8 e iasc ah 3 o-f t soa 1id0- -mC -6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, =O, -(C=O)-C1-6
1e-6mablkey alkyl, and -NR21R22; wherein rle isd o hpettieornoaclylycl aen hda ivnidependently substittd ith f 1 to 3 -halo;
wherein said Het8 is optionally and indnegp feronmde 1nt tloy 3 su hbesttitutetd withl frotmd 1 from O, N and S; selected from–halo, -OH,–C1-6alkyl, -C1-6alkylene, -C1-6alkyl-C3-6cycloalkyl, -C3-6 tcoyc 3lo saulkbysl,ti -tuOe-nCt1s- 15 - 6alkyl, -S-Cs1-6alkyl, =O, -
Figure imgf000011_0002
(C=O)-C1-6alkyl, -C1-6alkyl-O-C1-6alkyl and -NR21R22;
wCh1e-6raeliknyl w ihe onpt Rionally ad idp d tly substituted with from 1 to 3 -halo; wherein each of said Z 1 is–H, th t l t heteroatom of Het8 is attached to X2
1, Z2, Z3, Z4 and Z5 are each independently selected from C and N. 20 I tn
Ra1u at io further embodiment, the present invention provides a compound of Formula Ia or a stereoisomer, sm seerle,c ratecdem friocm, m–eHta,b–ohlaitelo,, p -rOo-H o,r -C pr1e-6darlukgyl,, s -aOlt-,C h1y-6darlaktyel,, N -S--oCx1id-6eal fkoyrlm, -,N oRr s9Rol1v0ate thereof, wherein R4, - , -(C=O)-R4, -(C=S)- saidS -CO2
1--6R4, -CN, -NR9-SO2-R4, -C3-6cycloalkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1; wherein each of 25 from–haloa,lk -yOlR is35 o,ptionally and independently substituted with from 1 to 3 substituents selected R5 is N aRttached t=oO Z)-1R or -N Z5R a11nRd12 i,s - sOe-lCec1-t6eadlky frlo,m and–H -S,-–Ch1a-6loa,lk -yOl;H, -C1-6
6R7, -(C 8, -(C=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, - and–Het5; wherein each of said -C1-6alkyl is optionally and indep c e y n cl d oalkyl, -O-C3-6cycloalkyl, -Ar5 to 3 substituents selected from–halo, -OR36, -NR23R24, -O-C1-6alkyl, anednt -lSy- substituted with from 1 30 R2 is op steiolencatlelyd a fnrodm ind–eHp,e -nhdaelon,tl -yO sHu,bs -Ctit1u-6taeldky wl,it ahn fdrom -C31-6 tcoyc 3lo saulbkyslt;itu wehnetrse sinel eeaC
ctceh1-6
d oa
frflk
o sy
mal;i–dh -aClo1-,6a–lOkyRl2 i7s, R s an
op sd
teiol -eN
ncR
atle1
lyd3R
a f1
nr4
3 i o;
dm ind–eHp,e -nhdaelon,tl -yO sHu,bs -Ctit1u-6taeldky wl,it ahn fdrom -C31-6 tcoyc 3lo saulbkyslt;itu wehnetrse sinel eeactcehd o frfo smai–dh -aClo1-,6a–lOkyRl is 35 and -NR 28 i ,1 R5 , R, R7, R9 R16
6 10,; R11, R12, R13, R14, R15, R16, R19, R20, R21, R22, R31, R32, R33 and R34 are each Anrd6e apnedn–dHenettl6y; w sehleerceteind e farocmh o–fH s,a -idha -lCo1,-6 =aOlk,y -lO isH o,p -tCio1n-6aalllkyy al,n -dO i-nCd1e-6paelknydle,n -Stly-C s1u-6baslktiytul,te -Cd3 w-6icthyc flrooamlkyl, - 3NR s3ubstituents selected from–halo,–OH, -O-C1-6alkyl, -S-C1-6alkyl, -C3-6cycloalkyl, -Het6, -Ar6 an 1d to– 40 R 7
27 aRnd38 R;28, are each independently selected from–H, -C1-6alkyl, -C3-6cycloalkyl and -Het2: -10- R37 a -Cnd3-6 Rcy38c,lo aarelk eyla,c -hAr i7nd aenpde–nHdeetn7tly selected from–H, -halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, X1 is
5 N sRe3l-e,c atendd f -rOom-; w–Che1-r6eailnky el-a,c–hO;
o-C
ef1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1-6alkyl-, - from 1 to 3 substituents selectd sa friodm -C1–-h6aallkoy,l- -O isH o,p -tCio1n-6aalllkyyl a,n -dO- iCnd1-e6apleknydl,e -nSt-lyC1 s-6uablskytilt,ut -epdhe wniythl, X and -NR33R34
2 isN sRe2l-e,c atendd f -rOom-; w–Che1-r6eailnky el-a,c–hO o-Cf1 s-6aaidlky -Cl-,1-–6aSlk-Cyl1--6 iaslk oypl-t,io -nCa1l-6lyalk aynld-N iRnd3-eCp1e-6nadlkeynlt-l,y -N suRb2s-Ctit1u-6talkyl-, - from 1 to 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl ed with 10 Ar1, - c AN
orR31
m4,p AR
risr32
5in,; , -phenyl and g Ar 16, to an 3d he Atre7ro aaretom easc she ilnedcteepden frdoemnt Oly, a N 5 a-nd to S 1;0 e-amcehm obfe sraeidd A arro1,m Aart4i,c cycle optionally being optionally and independently substituted with from 1 to 3 substituents sel Ar5, Ar6, and Ar7 OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, and–NR19R20; wherein each of e s c a te i d from–halo, - 15 Het1 o,p Htieotn2,a Hllyet and independently substituted with from 1 to 3 -halo; d -C1-6alkyl is from 1 to 34, h Heett5, Het6, and Het7 are each independently a 3- to 10-membered heterocycle having Het6, and Het7e isro oaptotims selected from O, N and S; wherein each of said Het1, Het2, Het4, Het5, from–halo, -OH,–C1-o6nally and independently substituted with from 1 to 3 substituents selected 20 Het each of said -C1-6 alkyl, -O-C1-6alkyl, -S-C1-6alkyl, =O, -
Figure imgf000012_0001
(C=O)-C1-6alkyl, and -NR21R22; wherein
8 is a 3- to 10-meamlkbyelr iesd o hpetiotenraolclyyc alned h ianvdienpge fnrodmen 1tly to su 3bs htitttdtith f lc 1te tod 3 fr -ohmalo O;, N and S; werin
5 whhereein a wt
2 h leenas Rt1 o inse– oHf, s tahiedn h aette leroaatto omnes i hse atettraocahtoemd t oof X H1e otr X2
8 is a;
w ttached to
sehle s
er X2; and
ceteind f sraoimd– Hheat8lo, is -O oHp,ti–oCna1-l6lyalk aynl,d -C in1d-6eaplkeynledneen,tl -yC1 s-6uablsktyilt-uCte3-d6cy wciltohal fkroylm, -C 13-6 tcoyc 3lo saulkbysl,ti -tuOe-nCt1s- 6 -Cal1k-y6al,lk -ySl-C is1 o-6patlikoynl,a =llyO a, -
Figure imgf000012_0002
(dC i=Od)-pC1-6dalkyl, -C1-6alkyl-O-C1-6alkyl and -NR21R22; wherein each of said 0 Z1, Z2, Z3, Z4 and Z5 are each idp d tltyly seulebcstteitdut ferdom wi Cth a frnodm N 1. to 3 -halo;
3 In a a fu srttheerero eimsobmoedrim, teanutt,o tmheer p,re rasceenmt iincv,e mnetiotanbo plriotev,id perso a compound of Formula Ia or of Formula I or solvate thereof, wherein each of said Z1, Z2, Z3, Z4 a-n or predrug, salt, hydrate, N-oxide form, or and p d Z5 is C; and wherein the further definitions 35 rovisions as defined herein above apply.
In a t fauurtther embodiment, the present invention provides a compound of Formula Ia or a stereoisomer, wheomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, s aebloer
vce
etein
ad s farid Het8 is a saturated 3- to 10-membered heterocycle having from 1 to 3 heteroatoms 40 pploym. O, N and S; and wherein the further definitions and provisions as defined herein -11- I tnau ato fmurethr,e rra ecmbodiment, the present invention provides a compound of Formula I or a stereoisomer, whe emic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, 5 R A1 ar
isnedin
e Al2 aered e fach indepen
R1
5 is s seleecctted frroomm––HH, a -nhda–dheanltoly; selected from C and N; R2 is selec lo and -C1-6alkyl;
R3 is selectteedd f frroomm––HH a anndd - -CC1-6
1-6aalkyl; 10 X X1 is selected from–O-C1-6alkyl-, -lNkyRl;3-C1-6alkyl- H2et is8 s isele act 3e-d t foro 1m0- -mC1e-6mablkyl-,–O-C1-6alkyl-, -NR,2 --NCR3
1-6-a,l -kOyl--;, -NR2-, -O-;
substituents selectede frreodm he–thearlooc,yc -OleH;, wh–eCr1e-6inalk syal,id -C H1e-6ta8lk isyle onpeti,on -aCll3y-6c syucblosatiltkuytel,d -C w1it-6hal 1ky tl-oC 33- Z 6
1, Z2c,y Zcl3o,a Zl4ky aln,d -
Figure imgf000013_0001
(C Z=O)-C1-6ahlkyl, and -(C=O)-C3-6cycloalkyl ; and
15 C
I tnau ato fmurethr,e rra ecmemboicd,i mmeetnatb,o thliete p,r persoe-n otr i pnrveedntion provides a compound of Formula I or a stereoisomer, wher rug, salt, hydrate, N-oxide form, or solvate thereof, 20 A R1
R1 a isne
sdin A2 aered e frach independently selected from C and N;
5 is s e e l l e e c c t ted fr o o m m H H, a -n h d al –halo;
R2 is selec o and -C1-6alkyl;
R3 ted from–H and -C1-6alkyl;
X1 i iss s seelleecctteedd f frroomm––OH-C and -C1-6,a -lkyl;
25 X 1-6 -C
H2et is8 s -NNRR3
2-C1-6
1-6aallkkyyll--,, - -NNRR3
2--,, - -OO- su iselected from–O-C1-6aallkkyyll--, -;
- ;
bs atit 3uen tots 1 s0e-lemcetemdb ferroemd– hheateloro,c -OycHle,;– wCh1-e6arelkinyl, s -aCid1-6 Halekty8le inse o,p -Ctio3-n6cayllcylo saulkbyslt,itu atnedd -C w1it-6hal 1ky tl-oC 33- 30 Z 6
1, Z2c,y Zcl3o,a Zl4ky aln;d an Zd5 are each C.
I t n a1u a
itso f m ur
Ne ther embodiment, the present invention provides a compound of Formula I or a stereoisomer, A arn,d ra Ace2m isic C,. metabolite, pro- or predrug, salt, hydrate, N-oxide form, or solvate thereof, wherein 35 -12- I t n au a to f m ur e th r, e r r a e c m em bo ic d , im m e e n ta t, b t o h l e ite p , r p e r s o e-n o t r in p v re e d n r ti u o g n , p sa ro lt v , id h e yd s r a ate co , m N- p o o x u id n e d f o o f rm Fo , r o m r u s l o a lv I a a te or th a e s re te o r f eoisomer,
5 Whe
Figure imgf000014_0001
I R R1 i isr
s seeinlected from–H and–
R5
2 is a settlaecchteedd f troom Z1– aHnd an is sehleaclote;d from–H and -C1-6alkyl;
R3 is selected fr d -C1-6alkyl; 10 X1 is selected froomm––OH- aCn 1- 1d-6a -Clkyl6-a,l -kNyl;
X2 -O-;
Het is 8 selected from–O-C1-6alky R3-C1-6alkyl-, -NR3-, 1 is t 0
-o a
C 33 s-u tobs 1titu-menetm
-sb seerleecdte Nd- l- c ,
fo - ron N
mt R ai 2
n- hi C n 1
ag -6
lo h a
,e lk
-Ot y e l
Hr-o ,
,c -N
yCc R l1e 2- -6; ,
a w -O
lkhye -;
l,re -Cin1- s6aalikdy Hleente8, is -C o3p-6tcioyncalolalylk syul,b -sOtit-uCted with -S
Figure imgf000014_0002
(C=O)-C 1-6 1-6alkyl, =O, 1-6alkyl, -C1-6alk alkyl, Z1, Z2, Z3, yl-O-C1-6alkyl and -NR21R22 ; and
15 Z4 and Z5 a h C
More in particular the present invention provides a compound selected from the list comprising:
C
Figure imgf000014_0003
p d N1 E pl N1 C p d N2 E pl N2 -13- C
Figure imgf000015_0001
p d N3 E pl N3 Cp d N4 E pl N4 Cp d N5 E pl N5 Cp d N6 E pl N6 C
Figure imgf000015_0002
p d N7 E pl N7 Cp d N8 E pl N8 C
Figure imgf000015_0003
p d N9 E pl N9 Cp d N10 E pl N10 -14- C
Figure imgf000016_0001
p d N11 E pl N11 Cp d N12 E pl N12 C
Figure imgf000016_0002
p d N13 E pl N13 Cp d N14 E pl N14 C
Figure imgf000016_0003
p d N15 E pl N15 Cp d N16 E pl N16 C
Figure imgf000016_0004
p d N17, E pl N17 Cp d N18, E pl N18 -15- C
Figure imgf000017_0001
p d N19 E pl N19 Cp d N20 E pl N20 C
Figure imgf000017_0002
p d N21, E pl N21 Cp d N22, E pl N22 C
Figure imgf000017_0003
p d N23 E pl N23 Cp d N24 E pl N24 C
Figure imgf000017_0004
p d N25 E pl N25 Cp d N26 E pl N26 -16- C
Figure imgf000018_0001
p d N27 E pl N27 Cp d N28 E pl N28 C
Figure imgf000018_0002
p d N29 E pl N29 Cp d N30 E pl N30 C
Figure imgf000018_0003
p d N31 E pl N31 Cp d N32, Example N32 C
Figure imgf000018_0004
p d N33 E pl N33 Cp d N34 E pl N34 -17- C
Figure imgf000019_0001
p d N35 E pl N35 Cp d N36 E ple N36 C
Figure imgf000019_0002
p d N37, E pl N37 Cp d N38, E pl N38 Cp d N39 E pl N39 Cp d N40 E pl N40 C
Figure imgf000019_0003
p d N41, E pl N41 Cp d N42, E pl N42 -18- C
Figure imgf000020_0001
p d N43 E pl N43 Cp d N44 E pl N44 C
Figure imgf000020_0002
p d N45 E pl N45 Cp d N46 E pl N46 C
Figure imgf000020_0003
p d N47 E pl N47 Cp d N48 E pl N48 C
Figure imgf000020_0004
p d N49, E pl N49 Cp d N50, E pl N50 -19- C
Figure imgf000021_0001
p d N51 E pl N51 Cp d N52 E pl N52 C
Figure imgf000021_0002
p d N53 E pl N53 Cp d N54 E pl N54 C
Figure imgf000021_0003
p d N55, E pl N55 Cp d N56, E pl N56 C
Figure imgf000021_0004
p d N57 E pl N57 Cp d N58 E pl N58 -20-
C
Figure imgf000022_0001
p d N59, E pl N59 Cp d N60, E pl N60
C
Figure imgf000022_0002
p d N61, E pl N61 Cp d N62, E pl N62
C M p i p d t N i 63 l E th p pl N6 t 3 i ti pid p dltd f th lit piing:
Figure imgf000022_0003
Cp d N46 E pl N46 Cp d N47 E pl N47 -21-
Co
Figure imgf000023_0001
p d N48 E pl N48 Cp d N49, E pl N49
Cp d N43 E pl N43 Cp d N45 E pl N45
Cp d N50 E pl N50 Cp d N27 E pl N27
C
Figure imgf000023_0002
p d N44 E pl N44 Cp d N59, E pl N59 -22-
Cop d N60 E pl N60 Cp d N63 E pl N63
Comp
Figure imgf000024_0001
d N62, E pl N62;d More in particular the present invention provides a compou C nd om se p l o e u ct n e d d N fr 4 o 4 m , E th x e am lis p t l c e o N m 4 p 4 rising:
Cp d N27 E pl N27 Cp d N45 E pl N45
C
Figure imgf000024_0002
p d N43 E pl N43
Figure imgf000024_0003
-23-
C
Figure imgf000025_0001
p d N59, E pl N59 Cp d N62 E pl N62
C
Figure imgf000025_0002
p d N60, E pl N60 Cp d N63 E pl N63 More in particular the present invention provides a compound selected from the list comprising:
Co
Figure imgf000025_0003
p a d n N d 60, E pl N60
Co
Figure imgf000025_0004
p d N45 E pl N45 -24- I innv aen futirothne,r w phaerrteicinula Rr5 embodiment, the present invention provides a compound according to this the numbering as prov iisde lidnk ined Fo torm thuela a Iry olr o Iar. heteroaryl moiety at position Z1 in accordance with 5 I tnhis ye intv ae fnutriothne,r w phaerrteiciunla srai edm cboomdiment, the present invention provides a compound according to Inhis ye intv ae fnutriothne,r w phaerrteiciunla srai edm cboomdp
piound is the S-enantiomer.
t mouenndt, i tshe the pr Res-eennatn intivoemnetior.n provides a compound according to 10 I ctom ispr aisin fugrth aer co ombjpeoctun odf a thceco prdreinsgen tt invention to provide (pharmaceutical) compositions compositio o this invention. In particular, the compounds and medicine.T n h s e a c c o c m or p d o in u g nds to a t n h d is c in o v m e p n o ti s o i n tion a s re a s c u c i o ta rd ble for use as a human or veterinary inhibiting the activity of a kinase, in particular LRRK2 kininagse t,o an tdhi msa iynv been utiosend a forer th seuitable for 15 a dnisde/aosre. prevention of neurological disorders such as Alzheimer’s disease or Pa trrekiantsmoenn’st
I onf a a f nineaulr ooblojegcictiavle d,i tshoerd perer,se suncth inv aesn Atioln provides a method for the prevention and/or treatment 20 c toom thpisri isninvegn atidomn.inistering to a subject iznh neeimeedr’ tshe driesoefa ase co omrp Poaurknidns oorn a’s c doimsepaosseit;io snai adc mcoertdhinogd
A talutetornmaetirv,e rlayc,e tmheic, p mreesteanbtol iintev,e pnrtoio-n or p prroevdidruegs, s aal ct,o hmypdorautned, N o-fox Fiodrem fourlam, I o orr so alva stteer tehoeirseoomf,er,
25 Wh
Figure imgf000026_0001
I
R1 iesrein
(C s=eSle)c-Rted frSoOm–H,–halo, -OH, -C1-6lkyl, -O-C1-6lkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4 4, - 2-R4, -CN, -NR , - 30 w suhbesrteitiune enatsch se olefc staeidd f -rC 9
om1-6a–lhkayl- lo i S s O
, - o 2
Op- Rt R i3o 4
5n ,
,a - -Nl C ly 3- R a 6c
11n y
Rd cl
12 i o
,n a
-d l
Oe k
-p y
Ce l,
1n -O-C3-6cycloalkyl, -Ar1 and–Het1; -6daelknytlly, a snudbs -Stit-uCte1-d6a wlkiythl; from 1 to 3 -25- R5 is attached to Z1 or Z5 and is selected from–H,–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- 6alkyl, -NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3- 6cycloalkyl, -Ar5 and–Het5; wherein each of said -C1-6alkyl is optionally and independently 5 s
R2 is aunbstituted6 with from 1 to 3 substituents selected from–halo, -OR36, -NR23R24, -O-C1-6alkyl, is sed
olpe -S
tciot-eC
nd1- al flra
yolkmyl
an–;
dH i,n -dheapleo,n -dOeHnt,ly -C s1u-6baslktiytul,te adnd w -iCth3-6 frcoymclo 1alk toyl; 3 w shuebrsetinitu eeanch of said -C1-6alkyl i a
10 sh
i ,14
3 n
hs selo a olpe, ts selected from– R tc–
iotOe 7
ndR2
al flryo,m an
an–d R
dH -N
i,n -dh1
ea3
plR
eon -;
dOeHnt,ly -C s1u-6baslktiytul,te adnd w -iCth3-6 frcoymclo 1alk toyl; 3 w shuebrsetiitu eeanctsh o sfe sleacidte -dC f1r-o6amlky–l R4 andlo, R–8O aRre28, e aancdh - iNnRde15pRe1n6d;ently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- 15 R 6
6, Ra7l,ky Rl,9, -N RR17
10,R R18
11,, - RC3-6
12,c Ry1c3l,oa Rlk14y,l, R -1O5,-C R3-6
16c,y Rc1lo7,alkyl, -Ar4 and -Het4;
R34, R35 and R36 are each independently selec R te 1 d 8, f R ro 1 m 9, R –H 20 , , - R ha 21 l , o, R = 2 O 2, , R -O 23 H , R , - 2 C 4, 1- R31
6alk , y R l, 3 -2 O , R -C 33
1,- 6 oapltkioyln,a -llSy- aCn1d-6a inlkdyel,pe -Cnd3-e6cnytlcylo saulbkyslt,itu -tAerd6 w ainthd fr–oHmet 16; t wherein each of said -C1-6alkyl is –OH, -O-C1-6alkyl, -S-C1-6alkyl, -C3-6cycloalkyl, -Het o 3 substituents selected from–halo, R dently selected from–H, - 6
7 and R28 are each indepen C , 1 --A 6a r6 lk a y n l, d -C 3 N -6 R cy 37 c R l 38
2 ;
20 R37 and R38 are each independently selected from–H, -halo, -OH, -C1-6alkoyall,k -yOl- aCn1d-6 -aHlkeytl2,: -S-C1- X 6
1 is al s k e y l l e , c -C te 3 d -6c f y ro c m loa lk C y 1 l, -6 -a A lk r7 yl a -, nd –O -H C e 1 t7
-6 ; alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3 6a -C1- sulbksytl-it,ut -eNdR w3-i,th a fnrdom -O 1-; to wherein each of said -C1-6alkyl- is optionally and independently 25 X2 isS- sCe1l-e6acltkeydl, f -rpohmen–yCl,1 a 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, - -6nadlk -yNl-R,3–3RO3-4C;1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1- 6 saulbksytl-it,ut -eNdR w2-i,th a fnrdom -O 1-; to w 3he sruebinsti etuaecnhts o sfe sleacidted -C fr1o-6malk–yhl-al ios, o -OptHio,n -aCll1y-6a alknyd independently 30 S-C1-6alkyl, -phenyl and -N l, -O-C1-6alkyl, - Ar, o Aprti4o,n Aalrl5y, c Aorm6,pr aisnidng A 1r7 to aR
3re31R
he e3
ta2
1 ec;
rhoa itnodmespe snedleecntetlyd a 5- to 10-membered aromatic cycle Ar5, Ar6, and Ar7 being optionally and indepen frdoemntl Oy, s Nub asntdit S; each of said Ar1, Ar4, substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S u -C te 1 d -6a with from 1 to 3 wherein each of said -C1-6alkyl is optionally and independently substitutlkyl, and–NR19R20; 35 Het1h
h,a
a Hlo
ve; ed with from 1 to 3 - int2g, H froemt4, 1 H teot53, H heett6e,r aoantdom Hest7 se alreect eeadch fro inmde Op,e Nnd aenndtly S a; w 3h-e tore 1in0- emaechmb oefr seadid h Heterocycle Het4, Het5, Het6, and Het7 is optionally and independently substituted with fromet11, H toet23, -26- 6 s a ubstituents selected from–halo, -OH,–C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, =O, -
Figure imgf000028_0001
(C=O)-C1- sulkyl, and -NR21R22; wherein each of said -C1-6alkyl is optionally and ind 5 a isb
d asti
S 3tu
;-te tod 1 w0it p d tly Het8 -hm ferommbe 1re tod 3 he -htearloo;cycle having from 1 to 3 heteroatoms selected from O, N wn
sehleerceteind s faroidm H–eht8a ilso, o -pOtiHon,a–llCy1 a-6nadlky inl,de -Ope-Cnd1-e6anltklyyl, su -Sbs-Ctit1u-6taeldky wl,ith =O fr,om -
Figure imgf000028_0002
(C 1=O to)- 3C s1-u6ablsktyitlu,e 6 -nCt1s- inadlkeypl-eOn-dCe1n-6talylk syulbs atnitdute -dN wRi2th1R fr2o2;m w 1h toer 3ei -nha each of said -C1-6alkyl i pti lly and 10 Z wherein when R1–H, then at least one heteroalot;om of Het8 is attached to X2
A1
1, a Zn2d, Z A3
2, a Zr4e a enadc Zh5 in adreep eeancdhe inntdlyep seenledently selected from C and N; and
I tnau ptoamrteicru,la rar,ce tmheic, p mreesteanbtol iintev,en ptrioo-n o pc
rrte
porvdd f
eidero
rusm
g, a C
sa c a
lon
t,md
hp N
yodu.
rantde, o Nf- Foxoirdmeu fla I or a stereoisomer, 15 w orm, or solvate thereo Rh1e isre
(C sin f, =eSle)c-Rte4d, - frSoOm2-–RH4,, -–ChNal,o, -N -ORH9-,S -OC1-6
2-Ra4l,ky -Cl,3 --O6-C1-6alkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, - wherein each of said -C1-6alkyl is optio cycloalkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1; 20 substituents selected from–halo, -O nally a11nRd12 i,n -dOe-pCe1n-6daelknytlly, a snudbs -Stit-uCte1-d6a wlkiythl; from 1 to 3 R5 is 6a alkttyalc,he -Sd- tCo1- Z1
6al okyrl Z,5 - aNnRd6 iRs7 s,el -e(Cct=eOdR
) f3
-r5, -NR
Rom8, -H(C,=Sha)-lRo,8, -O -HS,O -2C-R1-6
8a,lk -yCl,N -,OH -N,R -C1-6
6-SaOlk2-yRl,8 - -C o ,O -C1- 3- 6 acnydcl inadlkeyple,n -dOe-nCt3ly-6c syucblosatilkyl, -Ar5 and–Het5; wherein each of said -C1-6alkyl is optionally NR23R24, -O-C1-6alkyl, antuted with from 1 to 3 substituents selected from–halo, -OR36, - 25 R2 is is se olpetciotendal flryom an–dH i,n -dheapleod, - - ndOS
eH-C
nt,1
ly --C6a
s1u-l6k
bay
sllk;
tiytul,te adnd w -iCth3-6 frcoymclo 1alk toyl; wherein each of said -C1-6alkyl halo,–OR27, a 3 substituents selected from– R s
0 is se olpetciotendal flryomn
an–d
dH -N
i,n -R
dh1a3lRo,14
3 i -;OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1-6alkyl 3 R ahnadlo, R–OR28, ancdh - iNnRe
de1p5endently substituted with from 1 to 3 substituents selected from– 4 8 are ea pRe1n6d;ently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- R R 6a 7 l,k Ryl 9 ,, - RN 1 R17
0, RR18
11 ,, R -C3-6
12 , Rc 1 y 3 c,lo Ra 14 lk,y Rl, 1 -5 O, R-C3-6
16 , Rcy 17 c,lo Ra 1 l 8 k,y Rl, 1 -9 A, Rr4
2 a 0 ,n Rd 2 -1 H,e Rt4
6, 22 ;, R 23 , R 24 , R 31 , R 32 , R 33 35 R35 and R36 are each independently s r elected from–H, -halo, =O, -OH, -C1-6alkyl, -O R -C34
- 1 ,- 6 o a p l t k
Hio yl
,n ,
-aOll S y- -C a C
1n 1
-6d -6a
alk in lk
yd y
l,e l,
-pSe -C
-nCd 3- 1e 6c
-6n y
atlkl c y lo
yl s a
,u l
-Cb ky s l
3t ,
-6itcu - yt A
celd 6
oa w a
lki n tyh d
l, f -r
Ho H m et
et61 6;
, - tAo w
r63 he
a s r
nu e
db in s–tNit e u a
Re c
3n h
7Rts o
38 s f
;ele sa ct id ed - f C ro 1- m 6al k h y a l lo isO , -27- R R27 and R28
38,, a arree e eaacchh in inddeeppeennddeenntlytly se sleelcetcetded fro frmom–H–,H -,C -1h-6aallok,y -l,O -CH3,-6 -cCy1c-6laolalkyl and -Het2 37 and R : C1-6alkyl, -C3- 5 o6c kyl, -O-C1-6alkyl, -S- X1 is selected frmyc–loCa1lk-6yall,k -yAl-r,7– aOnd-C–1H-6aeltk7;yl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- X 6
A2r isa sleklyelc-,te adnd fro -NmR- ,–3
aO;
n-dC2 A-3ralkyl-,–S-C2-3alkyl-, -NR2-C2-3
1, Ar4, Ar5, Ar6 7 are each independently aalk 5y-l-, to -N 1R02--m, aend -O-;
optionally comprising 1 to 3 heteroatoms selected from O, N and Smbered aromatic cycle Ar5, Ar6, and Ar7 being optionally and independently substitute; each of said Ar1, Ar4, 10 s w u h b e s r t e it i u n e e n a ts ch se o l f e s c a te id d - f C ro 1- m 6al ky h l a i l s o, o -p O tio H n , a -l C ly 1- a 6a n l d ky in l, d -e O p-e C1-6alkyl, -S-C1d-6al wkyitlh, a fnrodm–N 1R1 t9oR203;
halo; ndently substituted with from 1 to 3 - Het1 h,a Hveint2g, H froemt4, 1 H teot53, H heett6e,r aoantdom Hest7 se alreect eeach independently a 3- to 10-membered heterocycle 15 H suebt4s,tit Hueetn5t,s H seetl6e,ct aendd fr Homet7– ihsal oop,t -ionalldy fr aonmd O in,d Nep aenndde Sn;t wlyh seurebisnti etuatcehd o wfi sthaid fro Hmet11, H toet23, 6a OH,–C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, =O, -
Figure imgf000029_0001
(C=O)-C1- sulbksytl,itu atendd w -iNthR f2r1oRm221; t woh 3er -ehin each of said -C1-6alkyl is optionally and indp d tly 20 Het8 a i n s a 3- to 10-membered hetearloo;cycle having from 1 to 3 heteroatoms selected fro
w sehd
leer S
ce; m O, N teind s faroidm H–eht8a ilso, o -pOtiHon,a–llCy1 a-6nadlky inl,de -Ope-Cnd1-e6anltklyyl, su -Sbs-Ctit1u-6taeldky wl,ith =O fr,om -
Figure imgf000029_0002
(C 1=O to)- 3C s1-u6ablsktyitlu,e -nCt1s- 6alkyl-O-C1-6alkyl and -NR21R22; wherein each of said
25 independently sub h -C1-6alkyl i pti lly and Z wherein when R1 isst–itHut,e tdhe wnit at fr leoamst 1 o tnoe 3 h -ehtaelroo;atom of Het8 is attached to X2
A1
1, a Zn2d, Z A3
2, a Zr4e a enadc Zh5 in adreep eeancdhe inntdlyep seenledcetendtly fr soemle Ccte adnd fro Nm. C and N; and
30 t More in particular the present invention provides a compound of Formula I or a
wautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or so s lv te a r t e e o t i h so e m re e o r f , , Rh1e isre
(C sin
=e,
Sle)c-Rte4d, - frSoOm2-–RH4,, -–ChNal,o, -N -ORH9-,S -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, - wherein each of said -C1- O2-R4, -C3-6cycloalkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1; 35 R5 is su abtstatictuhe
Nendts
R t sel1ected from6a–lhkayllo is, - oOpRti3o5n,a -NllyR a11nRd12 i,n -dOe-pCe1n-6daelknytlly, a snudbs -Stit-uCte1-d6a wlkiythl; from 1 to 3 6Ro7 Z, -( oCr= ZO5)- aRn8d, i -s(C s=eSle)c-Rte8d, f -rSoOm2-RH8,, -ChNal,o -,N -OR6H-S,O -C1-6
2-Ra8,lky -Cl,3 --6Oc-yCcl1o-6aallkkyyll,, - -OS--CC1- 6alkyl, - 3- -28- 6 scuy y nbcslotitaulkteydl, w -Aitrh5 f aronmd– 1H teot53; w suhbesrteitiune enatsch se olefc staeidd f -rCom1-6a–lhkyallo is, - oOpRtio36n,a -lNlyR a23nRd24 in,d -Oep-Cen1-d6aelnktyll 5 s a
is sed
olpe -S
tciot-eC6
2 i nd1- , R al flra
yolkmyl
an–;
dH i,n -dheapleo,n -dOeHnt,ly -C s1u-6baslktiytul,te adnd w -iCth3-6 frcoymclo 1alk toyl; 3 w shuebrsetinitu eeancth of said -C1-6alkyl 3 is ha
is selo
olpe, s selected from– R tc–
iotOendR27
al flryo,m an
an–d
dH -N
i,n -R
dh1
ea3
plR
eo,14
n -;
dOeHnt,ly -C s1u-6baslktiytul,te adnd w -C3-6cycloalkyl; wherein each of said -C1-6alkyl 10 halo, ith from 1 to 3 substituents selected from– R and y R–
l, 8O
-N aR
Rre28, e aancdh - iNnRde15pRe1n6
4 d;ently selected from–halo,–OH, -C1-6alkyl, -O-C1-6
6alk 17R18, -O-C3-6cy alkyl, -S-C1- R R 7 , R 9 , R 10 , R 11 , R 12 , R 13 , Rc 1 l 4 o,a Rlk 1 y 5 l,, R -C3-6
16 , Rcy 17 c,lo Ra 1 l 8 kyl, -Ar4 and -Het4
6, ;
R , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 31 , R 32 , R 33 , R 34 35 and R36 are each independently selected from–H, -halo, =O, -OH, -C1-6alkyl, -O-C1- 15 6 oa
pl
Otk
Hioyl
,n,
-a - OllSy- -C aC
1n1
-6d-6a
alk inlk
ydy
l,el,
-pSe -C
-nCd3- 1e6c
-6ny
atlklcylo
yl sa
,ul l,
-Cbkys3t-6itcu - ytA
cer
ld6
oa w a
lkintyhd
l, f -r–
HoHmet
et616;
, - tAo w
r63he sruebinstit euaecnhts o sfele sactided - fCro1-m6al–khyallo is, R R37 a anndd R R8
38,, a arree e eaacchh in inddeeppeennddeenntlytly se sleelcetcetded fro frmom–H–,H -,C -1h-6aallok a
,y n ,C N
-l d
O -
H3,- R37
6 -cCy R
1c-6l 3
ao 8
27 2 la ;
klykly,l - aOn-dC -1H-6et2: 20 C1-6alkyl, -C3-6cycloalkyl, -Ar7 an alkyl, -S- X s 6a s lk e y l l e -, ct -e N d R f 3 r-o , m an d C1 -O -6a -; lky w l- h , e r Od-C–1H-6aeltk7
1 i ;yl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- substituted with from 1 to 3 suebisntit each of said -C1-6alkyl- is optionally and independently S-C1-6alkyl, -phenyl, and -NR33R3 uents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, - 25 X 4
2 is selected from–C1-6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1- 6 saulbksytl-it,ut -eNdR w2-i,th a fnrdom -O 1-; to w 3he sruebinsti etuaecnhts o sfe sleacidted -C fr1o-6malk–yhl-al ios, o -OptHio,n -aCll1y-6a alknydl, i -nOd-eCp1e-6nadlkently S-C1-6
com4,p Aa
rris5l,ky
in Al
gr,6 - 1,p ah
tone yl, - Ar dny
3 Al
her a7n
te ad
rroe -N
a eR
toamc31
1, Ar hR
s i3
sn2
ed;
leepcetendde frnotmly O a, 5 N- t aon 1d0 S-m;e emacbhered aromatic cycle optionally 30 A fro r m– i h n a g lo o , p -O tio H n , a -ll C y 1- a 6a nd lky in l, d -e O p-e C n 1 d -6 e a n lk t y ly l, s -S ub -C st 1 i-t 6 u a t l e k d yl, w a it n h d fr o N m R1 1 of
9R t soa 3id s Aurb1,s Atitru4,e Antrs5, s Aerl6 7 be e,c atnedd C y and independently substituted with from 1 to230
1-6alkyl is optionall ; - wherein each of said - Het1, Het2, Het4, Het5, Het6, and Het7 are each independently a 3- to 10-mhaelmo;bered heterocycl 35 having from 1 to 3 heteroatoms selected from O, N e
H suebt and S; wherein each of said Het1, Het2 4s,tit Hueetn5 is , t,s H seetl6e,ct aendd fr Homet7–hal oop,t -ioOnHa,lly–C a1n-6dalk inydl,e -pOe-nCd1e-6natllkyyl s,u -bSs-Ctit1u-6teadlky wl,it =hO f,ro -(mC= 1O) t-oC13- 6 s a u l b k s y t l, itu a te n d d w -i N th R f 2 r 1 o R m 22 1 ; t w o h 3 er -e h i a n lo; each of said -C1-6alkyl is optionally and indp d tly -29- Het8 O is a bivalent 3- to 10-membered heterocycle having from 1 to 3 heteroatoms selected from we Nr
5 w h,
her e a
ein
ind
n a S
wt h l;
ee n as R t 1 o i n s e o H f , s t a h i e d n h a eteroatoms is attached to X1 or X2;
w sehleerceteind s faroidm H–e t least one heteroatom of Het8 is attached to X2; and
ht8a ilso, o -pOtiHon,a–llCy1 a-6nadlky inl,de -Ope-Cnd1-e6anltklyyl, su -Sbs-Ctit1u-6taeldky wl,ith =O fr,om -
Figure imgf000031_0001
(C 1=O to)- 3C s1-u6ablsktyitlu,e -nCt1s- 6 inadlkeypl-eOn-C1-6alkyl and -NR21R22; wherein each of said -C1-6alkyl i pti lly and 10 Z1, Z2, Z3, Z4d aenndtly Z s5u abrseti etuted with from 1 to 3 -halo;
A M1o aroend
m in A
er p2
,a a
rrr
ate
ciceu e
mlaac
irh
c, th in
med
e pe
tarp ach independently selected from C and N; and
ee
bsn
oed
litne
etn
, itly selected from C and N.
taut n prvoe-n otiro pnre pdroruvigd,e ssa alt, c hoymdrpaoteun,d N- oofx Fidoerm fourmla, I oar o sro alva stteer tehoeirseoomf,er,
15 Wh
Figure imgf000031_0002
I
R1 iesre
(C si h=en eSle
re )c- in Rte4d
e, a - fr
cSo
hOm
o2 f -–RH
s4 a ,, l,
id -–Ch
-C Na
1, -6 -a N -O
lk RH
y9 l -,S -OC1-6
2-R4l,ky -Cl,3 --O6c-yCc1lo-6allkkyyll,, - -SO--CC1-6
3-6clykcyllo,a -NlkRyl,9R -1A0r,1 -( aCn=dO)–-HRe4,t1 - w ; subst is optionally and independently substituted with from 1 to 3 R5 is attaictuheendts to se Zl1ec otred Z5 fro amnd– ihsa sloe,le -OctRed35, fr -oNmR1–1RH1,2,– -hO-C1-6alkyl, and -S-C1-6alkyl;
20 alo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- 6
6acylkcylol,a -lkNyRl, 6R -A 7 r,5 - a(Cnd=O)H-Ret 8
5,; - w(Ch=erSe)i-nR e 8,ac -ShO o 2 f-R sa 8,id -C -CN1,-6 -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3- subds -tSituted with from 1 to 3 substituents selected froma–lhkyallo is, - oOpRtio36n,a -lNlyR a23nRd24 in,d -Oep-Cen1-d6aelnktly an
25 i hsal oop,t–io t-eC On d1-6 Ral f
2l ra yl, R2 is selec
7y olkmyl
n -d h
, a an –;
dH i , e a p lo e , n -d O e H nt , ly -C s 1 u -6 b a s lk ti y tu l, te a d nd w -i C th 3-6 fr c o y m clo 1 alk to yl; 3 w s h u e b r s e t in itu e e a n c ts h o s f e s le a c id te -d C f 1 r-o 6a m lky l R3 is is se olpetciotendal flryomn R 4
an–d
dH -N
i,n -dh1
ea3
plR
eo,1
n -;
dOeHnt,ly -C s1u-6baslktiytul,
lo,–OR28, and -NR15R16; te adnd w -iCth3-6 frcoymclo 1alk toyl; 3 w shuebrsetinitu eeanctsh o sfe sleacidte -dC f1r-o6amlky–l ha -30- R4 and R8 are each independently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- R R 6alkyl, -NR17R18, -C3-6cycloalkyl, -O-C3-6
7, R 9 , R 10 , cycloalkyl, -Ar4 and -Het4
6, ; 5 R35 and R36 R 1 a1r , e R e12a , c R h13 in , d R e14p , e R n1d5e , n R tl1y6 , s R e1l7e , c R te1d8 , f R ro19m , R –2H0 , , R -h21a , l R o,22 = , O R ,23 - , O R H24, , - R C31
1-, 6a R lk32y , l, R -3O3 R -C34
1,- 6 oapltkioyln,a -llSy- aCn1d-6a inlkyl, -C3-6cycloalkyl, -Ar6 and–Het6; wherein each of said -C1-6alkyl is –OH, -O-C1-6alkydlependently substituted with from 1 to 3 substituents selected from–halo, R and R8, are each , in -S d-e C p 1 e -6 n a d lk e y n l t , -C3-6cycloalkyl, -Het6, -Ar6 and–NR37R38
27 2 ;
R and R8, are each independenlyt selected from–H, -C1-6alkyl, -C3-6cycloalkyl and -Het2
37 3 : 10 X1 isC1 s-6ealelkcytle,d -C f3r-o6cmyc–loCa1lk-6yal ly selected from–H, -halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S- l,k -yAl-r,7– aOnd-C–1H-6aeltk7;yl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 6 saulbksytl-it,ut -eNdR w3-i,th a fnrdom -O 1-; to w 3h seurebisntit euaecnhts o sfel seacitded -C fr1o-6malk–yhl-a ilos, o -OptHio,nally and independently 15 S-C1-6alkyl, -p -C1-6alkyl, -O-C1-6alkyl, - X is selected frohmen–yCl,1 a-6nadlk -yNl-R,3–3RO3-4
2 C;1-6alkyl-,–S-C1-6alkyl-, -C1-6
6a alkyl-NR3-C1-6alkyl-, -NR2-C1- sulbksytl-it,ut -eNdR w2-i, and -O-; wherein each of said -C1-6alkyl- is optionally and independently S-C th from 1 to 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6
1-6alkyl alkyl, - 20 Ar1, o A
Apr
r5t,i4o,n A
Aarlr
6l5
,y,,
c A -p aor
nm6h,e dpr an Aisny r7idl an
ng Ad be 1r7 -N in to aR y
g 3re31R o hpe e3 tiota2
ec; nrh
aola i
lytnodme
anspe
d sned
ileecntetld f arom 5- O to, N 10 a-nmde Sm;b eearcehd o afr soamidat Aicr1 c,y Acrl4e, subst ndependently substituted with from 1 to 3 wh ituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, and–NR19R20; 25 haerein each of said -C1-6alkyl is optionally and independently substituted with from 1 to 3 - Het1 h,a Hlo
ve;
int2g, H froemt4, 1 H teot53, H heett6e,r aoantdom Hest7 se alreect eeadch fro independently a 3- to 10-membered heterocycle Het4 m O, N and S; wherein each of said Het1, Het2, 6 subs,tit Hueetn5t,s H seetl6e,ct aendd fr Homet7– ihsal oop,t -ioOnHa,lly–C a1n-6dalk inydl,e -pOe-nCd1e-6natllkyyl s,u -bSs-Ctit1u-6teadlky wl,it =hO f,ro -
Figure imgf000032_0001
(mC= 1O) t-oC13- 30 Het8 saulbksytl,itu atendd w -iNthR f2r1R22; wherein each of said -C1-6alkyl is optionally and indp d tly a i n s d a 3- to 10-meommbe 1re tod 3 he -htearloo;cycle having from 1 to 3 heteroatoms selected from O, N w sehleer S
ce;
teind s faroidm H–eht8a ilso, o -pOtiHon,a–llCy1 a-6nadlky inl,de -Ope-Cnd1-e6anltklyyl, su -Sbs-Ctit1u-6taeldky wl,ith =O fr,om - 1 to 3 su
35
Figure imgf000032_0002
(C=O)-C1-6ablsktyitlu,e -nCt1s d- i 6
wnalkyl-O-C1-6alkyl and -NR21R22; wherein each of said -C1-6alkyl i pti lly an hd e e r p e e in nd w e h n e tl n y R su 1 b
ar is st
e it
eH ut
ac, e
h t d h ie w
nn ith
de apt fr
e le o
na m
dset 1
n o t
tln o
ye 3
s h - ee h
let a e lo;
Z ctreodat foromm o Cf H aentd8 i Ns. attached to X2
1, Z2, Z3, Z4 and Z5 -31- M taourtoem iner p,a rraticceumlairc, th mee ptarebsoelintet, in pvreon-t oiorn p prerodvruidge,s s aalt c,o hmypdorautned, N of-o Fxoidrmeu folarm Ia, o orr a so sltereoisomer, wherein vate thereof, 5 R1 is ( wC s
h= e
eS le
re) c -inR ted from
each of- R H,–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6
4, -SO2 s4a,id -C -CN1,-6 -aNlkRy9l- iSsO o2p-tRio4n,a -lCly3- a6cnydcl ionadlekpyel,n -O-C3-6 a c l y k c y l l o , a -N lk R yl, 9R -1 A 0 r , 1 -( a C n = d O) -H R e 4, t1 -; substituents selected from–halo, -OR35, -NR11R12, -O-Cdently substituted with from 1 to 3 R Z 1-6
5 is attached to 1 or Z5 and is selected from–H,–halo, -OalHky,l -,C a1n-6da -lkSy-lC,1 --O6a-lCky1-l6;alkyl, -S-C1- 10 6alkyl, -NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3- 6 scuybcslotitaulkteydl, w -Aitrh5 f aronmd– 1H teot53; w suhbesrteitiune enatsch se olefc staeidd f -C1-6alkyl is optionally and independently an rom–halo, -OR36, -NR23R24, -O-C1-6alkyl, R2 is sdel -eSc-tCe1d-6a frlokmyl;–H, -halo, -OH, -C1-6alkyl, and -C3-6cycloalkyl,; wherein each of said -C1- 15 6alkyl is optionally and i
R is–h ; stituted with from 1 to 3 substituents selected from 3 op sa
tel
io loe,
nc–
at l eO
ly dR
a f2
nro7,
dm an
in –d
dH - ep ,N
e -Rh n a1n3dependently sub dl e oR
n,14
t -ly O s H u , b -s C ti 1 t-u 6a te lk d y w l, i -t C h 3 f-r 6 o c m yc 1 loa to lk 3 yl s ; u w b h s e ti r t e u i e n n e ts a s ch el of said -C1-6alkyl is OR2 ected from–halo,– 20 R 8
4 and R,8 an adre -N eRa1c5hR1 in6;dependently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- R 6
6, Ra 7 l,ky Rl, 9 , -N RR17
10 ,R R18
11 ,, - RC3-6
12 ,c Ry 1 c 3 l,oa Rlk 14 y,l, R - 1 O 5 ,-C R3-6
16 c,y Rc 1 lo 7 ,a Rlk 1 y 8 l,, - RA 1 r4
9, a Rn 2 d 0 , - RH 2 e 1 t4;
R R re each independently selected from–H, -hal , o, R =2O2 , , R -O23H , R , -2C4 , 1- R 31
6alk , y R l,3 -2 34, 35 and R36 a O , R -C33
1,- 6alkyl, -S-C1-6alkyl, -C3-6cycloalkyl, -Ar6 and–Het6; wher
25 optionally and independently substituted with from 1 to 3 suebins each of said -C1-6alkyl is R27 a n O d H R , 2 -8 O ,- a C re 1-6 e a a lk c y h l, in -S d-e C p 1 e -6 n a d lk e y n l t , ly -C s 3 e -6 le c c y t c e lo d a f l r k o y m l, - H H e , t6 -C , - tituents selected from–halo,
1A -6 r a 6 lk a y n l d , - C N 3- R37R38;
R dependently selected from–H, -halo, -OH,6
37 and R38, are each in -cCy1cloalkyl and -Het2: C -6
1-6alkyl, -C3- alkyl, -O-C1-6alkyl, -S- 30 X o6
1 is selected frcmyc–loCa1lk-6yall,k -yAl-r,7– aOnd-C–1H-6aeltk7;yl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- X 6a - A2r1 i,s el o A slek prti4ly o,c-, n Ate a alrl5dnd y, fr
c Ao -N ormR m6,–3 pr aO; isn- idC2
ng A-3
1ra7lk
to ayl
3r-e,–
he eS
ta- ecC
rh2-3
oa ia
tnl
odky
mel
sp-,e - snN
edR
leecn2- tetCly2-3
d f aalk
rom 5y-l-,
O to -N
, N 1R02
a-- nm, a
den
Smd
;b - eeO
arce-;
hd o afr soamidat Aicr1 c,y Acrl4e, 35 A
w sur5
hb,
esrt A
eitiur6e,nt asnd sel Aerc7te bdei fnrgom op–thioanloa,lly -O aHn,d -C in1d-6eaplkeynld,e -nOtl-yC1 s-6uablksytilt,ut -eSd-C w1-i6tahlky frlo,m–N 1R1 t9oR203; halo; n each of said -C1-6alkyl is optionally and independently substituted with from 1 to 3 - -32- Het1 h,a Hveint2g, H froemt4, 1 H teot53, H heett6e,r aoantdom Hest7 se alreect eeadch fro inmde Op,e Nnd aenndtly S a; w 3h-e tore 1in0- emaechmb oefr seadid h Heteetr1o,c Hyecle Het4, Het5, Het6, and Het7 is optionally and independently substituted with from 1 to t2 3 , 5 substituents selected from–halo, -OH,–C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, =O, -
Figure imgf000034_0001
(C=O)-C1- 6alkyl, and -NR21R22; wherein each of said -C1-6alkyl is optionally and indp d tly Het8 su
a i n sb asti 3tu-te tod 1 w0it-hm ferommbe 1re tod 3 he -htearloo;cycle having from 1 to 3 heteroatoms selected from O, N 10 w sehd
leer S
ce;
teind s faroidm H–eht8a ilso, o -pOtiHon,a–llCy1 a-6nadlky inl,de -Ope-Cnd1-e6anltklyyl, su -Sbs-Ctit1u-6taeldky wl,ith =O fr,om -
Figure imgf000034_0002
(C 1=O to)- 3C s1-u6ablsktyitlu,e -nCt1s- 6 inadlkeypl-eO-C1-6alkyl and -NR21R22; wherein each of said -C1-6alkyl i pti lly and whe ndently substituted with from 1 to 3 -halo; 15 Z rein when R1r ise– eHac,h th iennde apte lenadsetn otlnye s heeletectreodat foromm o Cf H aentd8 i Ns. attached to X2
1, Z2, Z3, Z4 and Z5 a
I snter aeo fuisrothmeerr, em tabuotodmimeer,nt r,ac theemic p,re mseentatb ionlviteen,t piorn provides a compound of Formula Ia or a solvate thereof, whe o- or predrug, salt, hydrate, N-oxide form, or R1 is selected fromrein
20 ( wCh=eSre)-inR4 e,a -cShO o2f-–RH
s4a,,
id -–Ch
-CNal
1,o,
-6 -aN -O
lkRH
y9l-,
iS - sOC1-6
o2p-tRa
io4l
n,ky
a -lCl,
ly3 --O
a6c- nyC
dc1l io-6
naa
dll
ekk
pyy
ell,, - n -S
dO- e-C
nC1-6
tl3y-6a
scl
uykcy
bll
so,N
ta - itlukR
tyeld,9R -1
wA0
ir,
th1 -(
f aC rn= odO)- m– 1HR te4, ot1 - 3; R is su abtstatictuheendts to se Zl1ec otred Z5 fro amnd– ihsa sloe,le -OctRed35, fr -oNmR1–1RH1,2,– -hOa-loC,1- -6OalHky,l -,C a1n-6da -lkSy-lC,1 --O6
5 a-lCky1-l6;alkyl, -S-C1- 25 6alkyl, -NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3- 6 scuybcslotitaulkteydl, w -Aitrh5 f aronmd– 1H teot53; w suhbesrteitiune enatsch se olefc staeidd f -rCom1-6a–lhkyallo is, - oOpRtio36n,a -lNlyR a23nRd2 independently and
is ope - 4, -O-C1-6alkyl, R2 is selS
tciot-eC6
nd1- al flra
yolkmyl
an–;
dH i,n -dheapleo,n -dOeHnt,ly -C s1u-6baslktiytul,te adnd w -iCth3-6 frcoymclo 1alk toyl; 3 w shuebrsetinitu eeanctsh o sfe sleacidte -dC f1r-o6alkyl 30 R halo,–OR27, and -NR13 m– 3 is selecte R14;
is d from–H, -halo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1-6alkyl ha optionally and independently substituted with from 1 to 3 substituents selected from– 35 i R, Rlo,–OR28, and - RN1R15
2, RR16
6 7, R9, R10, R11, 13,; R14, R15, R16, R19, R20, R21, R22, R31
6n c d y e
bcl p o e a n lk d y e l, nt -ly Ar6 se a le n c d te d He fr t o 6; m wh e H r , ei -n ha e lo a , ch =O of , s -a O id H, -C -C1-6
1-6a alkyl, -O-,C R32
1-6a,l Rky3l3, a -nSd-C R34
1-6a alkryel, e -aCc3h- su-6sctyitculoteadlk wyli,th -H ferot6m, -A 1r t6o an 3d s–uNbsRti3t7uRe3n8t;s selected from–h l a k l y o l , i s O o H p , ti -o O n-a C ll 1 y -6a a l n ky d l, in -S d-e C p 1 e -6 n a d lk e y n l t , ly C3 - -33- R R27 and R28
38,, a arree e eaacchh in inddeeppeennddeenntlytly se sleelcetcetded fro frmom–H–,H -,C -1h-6aallok,y -l,O -CH3,-6 -cCy1c-6laolaklkyl and -Het2 37 and R : C1-6alkyl, -C3-6c
5 6a my yl, -O-C1-6alkyl, -S- X1 is selected fro c–lo k
dCa1l-6yall,k -yAl-r,7– aOnd-C–1H-6aeltk7;yl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- sulbksytl-it,ut -eNdR w3-i,th a fnrom -O 1-; to w 3h seurebisntit euaecnhts o sfel seacitded -C fr1o-6malk–yhl-a ilos, o -OptHio,n -aCll1y-6a alnkydl, independently S-C1-6alkyl, -phenyl, and -O-C1-6alkyl, - X -NR33R34
2 is 6a selected from–C1-6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR2-C1- 10 sulbksytl-it,ut -eNdR w2-i,th a fnrdom -O 1-; to w 3he sruebinsti etuaecnhts o sfe sleacidted -C fr1o-6malk–yhl-al ios, o -OptHio,n -aCll1y-6a alknydl, i -nOd-eCp1e-6nadlkeynlt,ly - Ar S-C
opr1-6
ti4o,a
n Al
alrk
l5y
y,l,
c A -p
orm6h,e
pr an
isny
idl an
ng Ad
1r7 -N
to aR
3re31
1, A R
he e3
ta2
ec;
rhoa itnodmespe snedleecntetlyd f ar 5- to 10-membered aromatic cycle 15 Ar5, Ar6, and Ar7 being optionally and independoemntl Oy, N and S; each of said Ar1, Ar4, s w u h b e s r t e it i u n e e n a ts ch se o l f e s c a te id d - f C rom–halo, -OH, -C 1-6 a n l d ky in l, d -e O p-e C n1d-6 substituted with from 1 to 3
1-6alkyl is optionally a e a n lk tl y y l, s -u S b-s C ti1tu-6t a e lk d y w l, it a h n f d ro m N 1 R 1 t9o R 20 ; t1h,a 3 - He Hloe;t2, Het4, Het5, Het6, and He
20 having from 1 to 3 heteroatomt7 are each independently a 3- to 10-membered heterocycle
H suebtstituetn5t,s H seetl6e,ct aendd fr Homet7– ihss
al o s
opelected from O, N and S; wherein each of said Het1, Het2 4, He ,
,t -ioOnHa,lly–C a1n-6dalk inydl,e -pOe-nCd1e-6natllkyyl s,u -bSs-Ctit1u-6teadlky wl,it =hO f,ro -
Figure imgf000035_0001
(mC= 1O) t-oC13- 6 saulbksytl,itu atendd w -iNthR f2r1oRm22; wherein each of said -C1-6alkyl is optionally and indp d tly 25 Het8 a ins a 3- to 10-membe 1re tod 3 he -htearloo;cycle having from 1 to 3 heteroatoms selected from O, N w wh d
her S
ere ;
ein at least one of said heteroatoms is attached to X1 or X2;
wehleercei
teinn w
d s fah
roiedn
m H R
e1 is–H, then at least one heteroatom of Het8 is attached to X2; and s ht8a ilso, o -pOtiHon,a–llCy1 a-6nadlky inl,de -Ope-Cnd1-e6anltklyyl, su -Sbs-Ctit1u-6taeldky wl,ith =O fr,om -
Figure imgf000035_0002
(C 1=O to)- 3C s1-u6ablsktyitlu,e -nCt1s 30 - 6 inadlkeyl-O-C1-6alkyl and -NR21R22; wherein each of said -C1-6alkyl i pti lly and Z1, Z2, Z3p,e Zn4d aenndtly Z s5u abrseti etuatcehd i wnditehp feronmde 1nt tloy 3 se -lheacltoe;d from C and N. 35 In a st f
soeu
lvrreth
aoe
teisro thm em
eererb,o
o tfad
,uim
wtoe
hmnt
ere,
eri, th
n rae
ecae p
cmre
hicse
o,f mnt
saeit in
davbe
Zon
1l,itteio
Z,n
2, pr p
Zor
3-o
, ov finitions and provisions as defined herein above Zrid a4 pe pp arse
lynd a .dru Zg c
5,o
i sm
sapl Cto,u
; hn
ayd
nddra o
wtfeh, F
e No
r-r
eom
inxuidla
thee f Ioa r frum o rt, o a her de r -34- In a st feurrethoeisrom emerb,o taduimtoemnte,r, th raece pmreicse, mntet inavbeonlitteio,n pr por-o ovrides a compound of Formula Ia or a solvate thereof, wherein said predrug, salt, hydrate, N-oxide form, or from 1 to 3 hetero Het8 is a saturated 3- to 10-membered heterocycle having 5 provisions as defin a e t d om he s re se in le a c b te o d ve fr a o p m pl O y. , N and S; and wherein the further definitions and I snter aeo fuisrothmeerr, em tabuotodmimeer,nt r,ac theemic p,re mseentatb ionlviteen,t piorno- p orrov pidreedsru ag, c soamltp,o huynddrat oef, F No-ormxiudlea f Ioarm or a solvate thereof , or
10 Wh
Figure imgf000036_0001
I
R1 ierein
R s–httalo 15 R2 i i l h;
tdd f troom Z1– and is selected from–H and -C1-6alkyl;
R3 is selected from H and -C1-6
1alkyl;
X X 1
2 is sel t e e d d f f r r o o m Cn lC k t is sel e e c c t m ––
OH
O- a
-C 1d-6
1-6 a - alk ky- yl6
l-a
-,l
, - -Ny
NRl;
R3
2--C C 1-6
1-6 a a l l k k y y l l--, , - -N N R R 3-, -O-;
He substitute-d t
, woith 101-m toe 3m sbuebresdtitu Nen-ctosn stealiencintegd h freotmer2
8 is a 3 o- –c,
hy -O
aclol-e;
,; -O wHh,e–reCin1-6a slakiydl, - HOe-tC8
1- i6salk oypl,tio -Sn-aCll1y 20 - Z 6
1, Z2 a , lk Z y 3 l , , Z = 4 O an -d (C Z =O)-C1-6al h ky C l, -C1-6alkyl-O-C1-6alkyl and -NR21R22
Figure imgf000036_0002
; and
-35- More in particular the present invention provides a compound selected from the list comprising: C
Figure imgf000037_0001
p d N1 E pl N1 Cp d N2 E pl N2
C
Figure imgf000037_0002
p d N3 E pl N3 Cp d N4 E pl N4
Cp d N5 E pl N5 Cp d N6 E pl N6
C
Figure imgf000037_0003
p d N7 E pl N7 Cp d N8 E pl N8 -36-
C
Figure imgf000038_0001
p d N9 E pl N9 Cp d N10 E pl N10
Cp d N11 E pl N11 Cp d N12 E pl N12
C
Figure imgf000038_0002
p d N13 E pl N13 Cp d N14 E pl N14
C
Figure imgf000038_0003
p d N15 E pl N15
I in n v a
ee nn fu
uti r
mo th n er
b,e w p
rinh a
ge r r t
ae ic
sin ula
p R r
ro5 e
v iis m
de l b idn o k d
ine im d e
Fo to nt
rm t , h t
ue he
la a Ir p y r
ol e
r o s
Iar en
. h t e i t n e v ro e a n r t y io l n m p o r i o e v ty id a e t s p a o c s o iti m on po Z u 1 n i d n a a c c c c o o r r d d i a n n g c t e o w th it i h s th -37- I tnhis ye intv ae fnutriothne,r w phaerrteiciunla srai edmbodiment, the present invention provides a compound according to In yet a further particular em cboomdpiound is the S-enantiomer.
thi ment, the present invention provides a compound according to 5 I cts
om is inv
pr aen
isin futi
grotnh,
ae wrh
co oe
mbrje
pei
ocnt sa
un oi
dfd
a t cho
cemp
co po
rdreu
insn
gedn i
tts t
o ihne
tvhe R
isn-tei ion
nnan
ven ttoiom
t preorv.ide (pharmaceutical) compositions compositions according to t ion. In particular, the compounds and The compounds and comphoissi itniovnesnti aocnco arrdein sguit taobl tehi fsor in uvseen atison a h auman or veterinary medicine. 10 activity of a kinase, in particula re suitable for inhibiting the p Inre ave finntaioln r LRRK2 kinase, and may be used for the treatment and/or ob ojefc nteivuero,l tohgeic parle dsiesnotrd inevresn stuiocnh p arso Alzheimer’s disease or Parkinson’s disease.
of a neurological disorder, such as Alzheimveidr’ses d aise maesteho odr f Porar thkiens porenv’sen dtiisoena asend/or treatment comprising administering to a subject in need there ; said method to this i of a compound or a composition according 15 nvention.
D T IN
ofhEeTA
the prIeL
insE
veD
ennt D
ti ionE
nvSeC
anrtR
eioIP
dnT
e wIO
fiinllN
e ndo O
iwF
n b T
meH
o fE
ruert dheeV
trE
a dN
il.eT
EscIO
arcibN
he ads.p Inec thte so fo dlleowing passages, different aspects 20 other aspect or aspects unless clea fined may be combined with any i fnedaitcuaretesd in adsica bteeidng as p breefienrgre pdre oferrr aeddv oar
rnly
atadg in
ved
aoic
nua
taste mda tyo b thee co cmonbtirnaeryd. w Inith pa arntiycu olathr,er an feyat fueraetu orer U mnolneos-s o ar c boivnatleexntt d riacdtaictaels d oetphiecrtwedise is, c aosntenreiscktesd ag
tre
oeo
t uu
hss
ee.
sdtr huecrteuirne t too i wndhiiccahte it r theelat peosin atn adt o wfh wichhic a 25 the radi
of Formacdayl f mo h As alre remnstio pnaertd. hereinbefore, in a first aspect the present invention provides compounds oxide fourmla, I o orr s aolv satetere tohiesroemoefr, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-
Wherein
Figure imgf000039_0001
I -38- R1 is
w(C s=eSle)c-Rte4d, - frSoOm2-–RH4,, -–ChNal,o, -N -ORH9-,S -OC1-6
2-Ra4l,ky -Cl,3 --O6c-yCc1lo-6aallkkyyll,, - -SO--CC1-6
3-6aclykcyllo,a -NlkRyl,9R -1A0r,1 -( aCn=dO)–-HRe4,t1 -; 5 suhbesrteiin each of said -C1-6alkyl is optionally and independently substituted with from 1 to 3 R5 is 6a alkttyal,ctuhe
-Nendts
R6 tRo se
7 Zl
,1ec
-( oted from–halo, -OR35, -NR11R12, -O-C1-6alkyl, and -S-C1-6alkyl;
Cr= ZO5)- aRn8d, i -s(C s=eSle)c-Rte8d, f -rSoOm2-RH8,, -ChNal,o -,N -OR6H-S,O -C1-6
2-Ra8,lky -Cl,3 --6Oc-yCcl1o-6aallkkyyll,, - -OS--CC1- 3- 6 scuybcslotitaulkteydl, w -Aitrh5 f aronmd– 1H teot53; w suhbesrteiin each of said -C1-6alkyl is optionally and independently 10 and -S-C1-6a tuents selected from–halo, -OR36, -NR23R24, -O-C1-6alkyl, R2 is is se olpetciotendal flryolkmyl
a–;H, -halo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1-6alkyl halo,–OR27, an n d d - i N nd R e 1 p 3R en 14 dently substituted with from 1 to 3 substituents selected from– R3 is
15 is se olpetciotendal flryom an–dH i,n -dheapleo,n -;
dOeHnt,ly -C s1u-6baslktiytul,te adnd -C3-6cycloalkyl; wherein each of said -C1-6alkyl R ahnadlo, R– with from 1 to 3 substituents selected from–
8O aRre28, e aancdh - iNnRde15pRe1n6
4 d;ently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- R, R 6a7l,ky Rl,9 -NR17R18, -C3-6cycloalkyl, -O-C3-6cycloalkyl, -Ar4 and -Het4
6 ; 20 R , R10, R11
6, a R re 12, ea R c 1 h 3, in R d 14 e , p R en 15 d , e R n 1 t 6 ly , R se 1 l 7 e , c R te 1 d 8, f R ro 1 m 9, R –H 20 , , - R ha 21 l , o, R = 2 O 2, , R -O 23 H , R , - 2 C 4, 1- R31
34, R35 and R3 6alk , y R l, 3 -2 O , R -C 33
1,- 6 oapltkioyln,a -llSy- aCn1d-6a inlkdyel,pe -Cnd3-e6cnycloalkyl, -Ar6 and–Het6; wherein each of said -C1-6alkyl isOH, -O-C1-6alkyl, -S-C1-6a t lk ly yl substituted with from 1 to 3 substituents selected from–halo, R and R28 are each independentl,y -C se3l-e6ccytecldoa frlokmyl,– -HHe,t -6, -Ar6 and–NR37R38
27 ;
R7 and R38 are each independently selected from–H, -Ch1a-6loa,lk -yl, -C3-6cycloalkyl and -Het2
3 : 25 OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- X 6alkyl, -C3-6
1 is selected c f y ro c m loa lk C y 1 l, -6 -a A lk r7 yl a -, nd –O -H C e 1 t7
-6 ; alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 6 saulbksytl-it,ut -eNdR w3-i,th and -O-; wherein each of said -C1-6alkyl- is optionally and independently S-C1-6alkyl, -phe f n r y om 1 to 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, - 30 X2 is 6a s lk e y l l e -, ct -e N d R f 2 r-o , m an d Cl,1 a
-O -6nad
-; lk -yN
wl-R
h,3
e–3R3
re O in -4C;
e1- a 6a ch lky o l- f , s a S id -C -1 C -6
1a -6 lk a y lk l- y , l- -C is 1-6 o a p lk ti y o l- n N a R lly 2-C an 1-6alkyl-, -NR2-C1- substituted with from 1 to 3 substituents selected from–halo, -OH, -C1-6alkydl, i -nOdependently S-C1-6alkyl, -phenyl and -NR31R32 -C1-6alkyl, - 35 Ar1, o Ar4, Ar5, Ar6, and Ar7 are eac;h independently
Apr5t,ion Aarl6l,y c aonmdpr Aisr7ing be 1in tog 3 o hpetiotenraolalytom ansd se ilnedcetepden f a rdoem 5- ntl O to
y, s N 10
ub a- sn m
td e
itu S m
te; bered aromatic cycle d ea wchith of f sroamid A 1r1, Ar4, substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, and–NR1 t9oR203 wherein each of said -C1-6alkyl is optionally an ; halo; d independently substituted with from 1 to 3 - -39- Het1 h,a Hveint2g, H froemt4, 1 H teot53, H heett6e,r aoantdom Hest7 se alreect eeadch fro inmde Opendently a 3- to 10-membered heterocycle Het4, He , N and S; wherein each of said Het1, Het2, 5 substituetn5t,s H seetl6e,ct aendd fr Homet7– ihsal oop,t -ioOnHa,lly–C a1n-6dalk inydl,e -pOe-nCd1e-6natllkyyl s,u -bSs-Ctit1u-6teadlky wl,it =hO f,ro -
Figure imgf000041_0001
(mC= 1 6a O) t-oC13- sulbksytl,itu atendd w -iNthR f2r1oRm221; t woh 3er -ein each of said -C1-6alkyl is optionally and indp d tly Het8 a insd a 3- to 10-membered hehtearloo;cycle having from 1 to 3 heteroatoms selected from O, N 10 w s e S -Oehl-ere; Cc1t-ein
6ad s
lk faryoid
l,m H
-S–e
-ht
Ca8 is
1l-o6a, o
l -kOpt
ylHio,n
, =O–aClly ln p e s
,1 --
Figure imgf000041_0002
(6 a
Can
=lkd
Oy i
),d
-C -Ce1-e6
1-6aan
lkldkyyl,lnet
-nly
Ce1-, su
6a -Cb
lk1y-t6i
l-atu
Olkte
-yd
Cl-1C w3i-t6h
-6alkcyy f
lcro
alom
nadlk 1
-y t
Nl,o - 3C3 s-6ucbysctliotuaelknytsl, each of said -C1-6alkyl is optio lly d idp dently substituted with from 1R t2o1R 322 -;ha wlherein wherein when R1–H, then at l t ht tom of Het8 is atached to X2 o; 15 Z1 t
A1, a Zn2d, Z A3
2, a Zr4e a enadc Zh5 in adreep eeancdhe inntdlyep seenledcetendtly fr soemle Ccte adnd fro Nm. C and N; and U X1nl iess -sN inRd3i-cCated otherwise, all of the above radicals can be read both ways. For example, when aryl or heter1o-6aalkyl-, the -C1-6alkyl- may be attached to Het8 and–NR3- attached to the Z1-Z5 20 h eexreate
fmro
erpa
alery
bl wl
y,h m
Xeonieryl moiety. Alternatively, the -C1-6alkyl- may be attached to the Z1-Z5 aryl or Xty1 is an -NdR–3N-CR3
1-6-al aktytal-c,h -NedR3 t-o, a Hnedt8 th.e W“rhigahtt is pa crta”ll iesd -C“1le-6ft part” of a radical is for P 1 is such as the left par alkyl-.
C1-6alkyl, -S from–S-C1-6alkyl, -N t of the possible values of X1 (i.e. in particular–O from–O- 25 heteroaryl moiety. Alternatively R3 from -NR3-C1-6alkyl, etc) is attached to the Z1-Z5 aryl or p Za1-rZti5cu alrayrl o (Cr1 h-6eatelkryola)- is
ry from–O-C,1 X1
-6alky sl,uc–hS- aCs1- t6haelky rilg ahntd pa -rNtR o3f- tCh1e-6a ploksysl,ib eletc) va islu aetsta ocfh Xed1 ( tio.e. th ine PCr1e-6faelrkaybl,ly, - XS2 is fr soumchl a m
so
S- tChieety
1-6 lae.
lfkty pla,rt - oNfR th2e possible values of X2 (i.e. in particular–O from–O- 30 pyrzolopyrimidine moiety. Alternatively, X2 i fsro smuch -N asR t2h-Ce1 r-i6gahlkty pl,art e otcf) the is pos astitbalceh veadlue tso of th Xe ( .a 2 toi.e the in p pyarartzicoulolapryr (iCm1i-d6ainlkey ml)-o fireotym.–O-C1-6alkyl,–S-C1-6alkyl and -NR2-C1-6alkyl, etc) is attached T Whhee snam dees pcrriibnicnipgle th aepp clioemsp toou anlld thse o rfad thiceals in ovef tnhtieon in,ve thnetion unless specified otherwise.
accordance with the following definitions, unless a context d teicrms used are to be construed in 35 T rahde
oic taelrsm. G "aelnkyelr"a bllyy, it asleklyfl o grr aosup psar otf o tfh aisno inthveernt siounbs ctiotumepnrtis reeftea
frrt
oses
m to ot
1 fhue
tlloyrw
6 sisae
ctu:
arated hydrocarbon grbuspcsrip mt iasy us beed l hineeraerin o froll borwainncghe ad ca arnbdon m aatoym b,e the su sbusbtistucrteipdt r aesfer isnd toica thteedrb
nu ho
menrbe a
einto r.m o Ws. f ch Alkyl su aernbo an -40- a sitxom casrb thoant t ahteom nas.m Eexda gmropuleps m oafy al ckoynlt garionu.p Tshu asr,e fo mre ethxaylm,p elteh,y Cl,1 n-6-aplrkoyply ml,e ia-pnrsop aynl, a blkuytly ol,f a one to isomers (e.g. n-butyl, i-butyl and t-butyl); pentyl and its isomers, hexyl and its isom nd its alkyl includes all linear, branched, or cyclic alkyl groups with between 1 and 6 carbers. C1-C6 5 a t-nbdut tyhl)u;s p iennctlyuld aensd m ietsth isyol,m etehrysl,, h ne-pxryolp aynl,d i- iptsro ipsoylm, beursty,l c ayncdlop itsro ipsyolm, ceyrsc (e.g. n-butyl, io-bnu atytlo amnsd, cycloh lobutyl, cyclopentyl, and T mhoere tee
srumxy
bs "l.otitputeionntasll (yfo sru ebxsatimtupteled 1 al tkoyl 3" r seufbesrstit tuoe an alkyl group optionally substituted with one or 10 s inucblusdtiteue–nhtasl)o, at -O aHny, p arvimailaarbyle an pdoin stec oofn adttaarcyhmenntst., N foorn e-xlimamitipnlge e 1x,a 2m oprle 3s s oufbs stuitcuhen stusb osrtit 1ue tont 2s and the like amides, -O-C1-6alkyl, -S-C1-6alkyl, heteroaryl, aryl, T sahye, te arm mo“c.
nyocvloaalelknyt,l” by itself or as part of another substituent is a cyclic alkyl group, that is to 15 C hyydcrlooacalkryblon inc glurodue saturated, or unsaturated hydrocarbyl group having a cyclic structure.
pss a hll saturated or partially saturated (containing 1 or 2 double bonds) carbon atoms in the rinagv ainngd a cyclic structure. Cycloalkyl groups may comprise 3 or more Examples of cycloalkyl grou generally, according to this invention comprise from 3 to 6 atoms. 20 cyclohe ps include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, W othheerre g axylkl.yl groups as defined are divalent, i.e., with two single bonds for attachment to two includeroups, they are termed "alkylene" groups. Non-limiting examples of alkylene groups ethyles methylene, ethylene, methylmethylene, trimethylene, propylene, tetramethylene, 25 Genertahlylyle,n aelk,y 1l,e2n-edim gethylethylene, pentamethylene and hexamethylene.
a cotonmnesc ativsity th teoir th aelk mylr
o coouupnste orpfa trhtiss. in Wvehnetiroen a pnre afelkryalbelnye c oorm cpyricsleoa tlhkeyle snaeme bir naudmicbaelr is of pr ceasrebnont, atom or different carbleocnular structure of which it forms part may be through a common carbon invention, a C3 alkylene atom. To illustrate this applying the asterisk nomenclature of this CH2CH(-CH3)-*. Likewise a gr Cou3p cy mcloa
*aylk byelen foer g eroxaumpp mleay *- bCeH2CH2CH2-*, *-CH(-CH2CH3)-*, or *-
30 * *
Tarhoem taetricm,s fu "llhye steartoucraycteled" o ars pa ursteiadl h
Figure imgf000042_0001
i by it lf prt of another group refer to noend- monoc ly t td yli g ps (for example, 3 to 6 member 35 contain y in cl g ic ring systems) which have at least one heteroatom in at least one carbon atom- 4 su hbestteitruoteadto rming. Each ring of the heterocyclic grouyp containing a heteroatom may have 1, 2, 3 or heste sreolceycctelicd r ferofemrs n tiotro age hnete artoomcysc,li ocx hagveinng at oopmtiosn aanlldy/o orn seu olfrur m aotroem ssu.b Asntitu oepntitosna (flolyr -41- e suxabmstiptulete 1d t aolk 4 substituents, or for example 1, 2, 3 or 4), selected from those defined above for E isxoexmazpolalry heytel.rocyclic groups include piperidinyl, azetidinyl, imidazolinyl, imidazolidinyl, 5 i pnydroroly inyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidyl, succinimidyl, 3H- lil, isoindolinyl, chromenyl, isochromanyl, xanthenyl, 2H-pyrrolyl, 1-pyrrolinyl, 2-pyrrolinyl, 3- homopniyple,raz pinyyrrl,oli 2d-inpyl, 4H-quinolizinyl, 4aH-carbazolyl, 2-oxopiperazinyl, piperazinyl, dihydro- 2H-pyranyl,yra pzhotlhinaylal,zin 3-pyrazolinyl, pyranyl, dihydro-2H-pyranyl, 4H-pyranyl, 3,4- 10 dioximidazolidinyl, 2,2,4-piperidoynly,l, ox 2e-toaxnoypl,i thietanyl, 3-dioxolanyl, 1,3-dioxanyl, 2,5- i tnedtroalhinyydl,roiso teqturainhoylidnryolp,y thraionmylo,rph toeltinrayhl,y tdhrioofmuroarnp
pye
hlo,ridin
liny ty
lel
st,ruelh 2
foyxd-o
irxopyrrolodinyl, 2-oxoazepinyl, doethienyl, tetrahydroquinolinyl, dioxolanyl, 1,4-oxathianyl, 1,4-dithianyl, 1,3,5-trioxanyl, 6H,-1 t,h2io,5m-tohripholinyl sulfone, 1,3- dithiazinyl, 2H-oxocinyl, 1H-pyrrolizinyl, tetrahydro- 1,1-dioxothienyl, N- foardmiayzlpinyl, 2H-1,5,2- morpholinyl; in particular pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidiniyple,ra dzioinxyl, and 15 d piyorxroalnyl, morpholinyl, thiomorpholinyl, piperazinyl, thiazolidinyl, tetrahydropyorlaannyyll,, azabicoypciploe[r2a.2zi.n1y]hl,eptanyl, 3-azab oicyclo[3.1.0]hexanyl, 2-azabicyclo[3.1.0]hexanyl, 2- a]pyrazinyl, 3,4-dihydro-2H-bencztaoh[6y]d[1ro,4p]yorxraozloin[1y,l2,-a] 2p-yorxaaz-in5y-al,zabicy occlota[4h.y1d.r0o]h-1eHp-tapnyryrlo,lo[11,,24-- 20 o Tx
si ha
nez
gl te
eepr r man
ing “yal,
(r i. y a
eln"d
. p a h s te
e utr
nsahydrofuranyl.
ye l) d . h A e ry re l i i n s r a efers to a polyunsaturated, aromatic hydrocarbyl group having a the carbocyclic systems enumelrsaote indte hnedreedin. to N include the partially hydrogenated derivatives of biphenylyl, biphenylenyl, 5- or 6-tetralinyl, 1-, 2-,o 3n-,-l 4im-,it 5in-,g examples of aryl comprise phenyl, 1-, 2-, or 3-indenyl, 1-, 2-, or 9-anthryl, 1- 2-, 3-, 4-, 6- o,r 7- 5,- oarc 8e-naazpuhletynleyl, 1- or 2-naphthyl, 25 a 5c-ienndaapnhytl,en 5y-,l, 61--,, 27--,, 3 o-r, 84--t,e otrra 1h0y-dprhoennaapnhtthhryyl,l, 11- or 2-pentalenyl, 1, 2-, 3-, onry 4l-,flu 3o-,re 4n-y,l, o 4r- 5 o-r di ,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl, Thbeen azroy[la,d ri]ncgycl coahnep otepntiyoln,a alnlyd 1 b-e, 2-, 3-, 4-, or 5-pyrenyl; in particular phenyl.
substituted aryl” refers to an aryl ha svuinbgst oitputtieodna bllyy o onnee or more substituents. An“optionally 30 s duebfisnteitdue anbtosv,e fo fror ex saumbsptilteut 1e,d 2 a,l 3 or 4) at any available p oori mnto oref a stutabcshtimtueenntt,s s (efolerc etexdam frpolme 1 th toose 5 W refheerrreed a to c haerbreoinn a asto am in an akryyll. group is replaced with a heteroatom, the resultant ring is 35 T
o tohe
xy 5 t
ge teorm
n, 6“
n ch
itae
rorbte
gor
eno
n-aar
otyol” a hse rm su alfr ute uosr rmeo aada toti hry mcel s rr r
iein .nigng. Ns b
on iyn it
-li wse o
mhl
itif
icnhr
g o a
ens
xe p
am oarrt
pl m of
eso ar oeno
f ct
saher group refers but is not limited urcbhon he atteormoasry cla,n in bcel replaced by furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazouldyel,: pyrrolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridinyl, pyrimidyl, p tyrriazolyl, pyridazinyl, oxazinyl, dioxinyl, thiazinyl, triazinyl, imidazo[2,1-b][1,3]thiazolyl, thienaoz[i3n,y2l-, -42- b te]fturarazonlyol,[1,5-a t]hpiyernidoi[n3y,2l,-b]t ihnidooplhyel,nyl i,ndoliz thinieynl,o[2 i,s3o-din]d[1o,3ly]lt,hiaz boelnyzl,ofura tnhyiel,no[ i2s,o3b-de]nimzoidfuarzaonlyyl, benziosthiophenyl, isobenzothiophenyl, indazol, benzimidazolyl, 1,3-benzoxazolyl, 1,2l benz ly -, 5 b beennzzooio
tsx
hoa
iathz
dio
ial
azyl, 2,1-benzisoxazolyl, 1,3-benzothiazolyl, 1,2-benzoisothiazolyl, 2,1- zoollyyl, benzotriazolyl, 1,2,3-benzoxadiazolyl, 2,1,3-benzoxadiazolyl, 1,2,3- oxo-pyridazi l, 2,1,3-benzothiadiazolyl, thienopyridinyl, purinyl, imidazo[1,2-a]pyridinyl, 6- 1,3-benzodionx-1o(ly6lH, q)-uyiln,o 2lin-oyxl,o ipsyorqiduiinn-o1li(n2yHl,)- cyiln,no 6l-ionxyol,- qpuyrinidaazzoinlin-1y(l,6H qu)-inylo,xa 2l-ionxyol,p 7y-raidziani-n1d(o2lHyl),-y 6l-, 10 a Az
sunai
bs“nod
titpo
utl
eiyol
nn,
ta 5
sl-l (yaz
fo sa
ruin
ebd
xso
atil
mtyul,
pte 4
led-a
1 hzeai
totned
4rooaly
suryl.
bl”sti rteufeenrsts, to for a e hxeatmerpoleary 1l, h 2a,v 3in ogr optionally one or more defined above for substitu 4), selected from those T
15 iohdeo, te arsm w“ehlall aos” a onry“h sauloitgaetne
le”d
i a a
sslk
ot ayl
op g.
ero tuhp or part of a group is generic for fluoro, chloro, bromo, or W orh men b
oe ereof.
reve hr the term“substituted” is used in the present invention, it is meant to indicate that one a selectionyd frroogmen ts on the atom indicated in the expression using“substituted” is replaced with exceeded, and thahte th inedi scuabted group, provided that the indicated atom’s normal valency is not that is sufficiently robust to ssutritvuition results in a chemically stable compound, i.e. a compound 20 a Wn
anhd
de f
proerm
re gferu
rola
aut
bpio
lysn
o m in
nato
cy a
e, b twe th
ic oe
eprat oipoe
rnu
that
rli v
lc e iy a i ce sn solation to a useful degree of purity from a reaction mixture, .ud
Sb/
uso
btrist dui
tita
teg
udn
e,o
nt ss
sut
mcich a
ay ggre
bon
eutp.
sesle mcateyd b freom su,b thstoitsuete ddef oinnecde a obro mvore, su
25 wsb ustsit e for A eudte hde arelkinyl. the terms such as“alkyl, aryl, or cycloalkyl, each being optiona
alikthy”l, o oprti“oanlkayllly, a surybl,st oiturte cydc aloalkyl, optionally substituted with” refers to optionallllyy s suubbssttiittuutteedd More ge ryl and optionally substituted cycloalkyl.
inventionne mraaylly e,x from the above, it will be clear to the skilled person that the compounds of the geometrical isomisetr isn the form of different isomers and/or tautomers, including but not limited to 30 e sunbasnttiitoumenetrss o annd di dffiears,
ete c
nrteo
pon
oifso
sormational isomers, E/Z-isomers, stereochemical isomers (i.e. itmioenrss) of an td isomers that correspond to the presence of the same such possible isomers, tautomers andhe m rixintugrses pre tsent in the compounds of the invention. All inventio hereof are included within the scope of the 35 t In additino.n, the invention includes isotopicall
hoav cionmgp aonu antdosm oicf f moramsusla or (I m),a bsust n fourm tbheer f daicy
fft- e tl
rha
eab
ntel
t oled compounds and salts, which are identical frnoem o trh meo arteom aitcom msa are replaced by an atom commonly found in nature. Examples of isotopes that can be incorposrsat oerd m inatoss c noummpber most formula (I) are isotopes of hydrogen, carbon, nitrogen, fluorine, such as 3H, 11C, 13N,o 1u4Cnd,s 15 oOf -43- a tisnsdu 1e8F d.is Sturicbhut iisoonto apsicsaalylys-.la Fboerlle edxa cmomplpeou 11nCds a onfd fo 1r8mFu ilsao (tIo)p aerse u arseefu pl in drug and/or substrate (Positron Emission Tomography). PET is useful in brain imaarticularly useful in PET compounds of formula (I) can generally be prepared by car ging. Isotopically labeled 5 b laebloewle,d b rey substituting a readily available non-isotopically larbyienlegd ou reta thgeen ptro wcitehdu arnes iso ditsocpliocsaelldy Whenevera ugseendt.
is mea in the present invention the term“compounds of the invention” or a similar term al nt to include the compounds of general Formula I and any subgroup thereof. This term 10 h pys
rodo
-rda re
rtuefe
gss,rs
, st t
eeo
sre th
teoe
riss c
,oomm
anep
driocu
m fnod
ertams
bs a
o,s
li rta d
ece
sep
,mic
ait
sced
w m i
einxllt Tu araeb
ssle ,
t,h t 1
eaiurt tohmeirer dicer fiovramtivse,s o,p Ntic-oaxli idseosm,e srasl,ts a,n saololvgauteess,, oxide forms of said compounds are meant to com quaternized nitrogen analogues. The N- nitrogen atoms are oxidized to the so-called N prise compounds wherein one or several 15 i As used in the specification and the appende-odxi cdlaei.ms, the singular forms "a",
cnocmlupdoeun pdlu"ra mle raenferents unless the context clearly dictates otherwise. By way " oafn e",xa amndple "t,he "a" Th s one compound or more than one compound.
thee a tret.rms described above and others used in the specification are well understood to those in 20 P Ar1e afenrdab Al2y, compounds of Formula I are defined as such that
is
Figure imgf000045_0001
C, the anre selected from C and N; wherein when A1 is C, then A2 is N; and wherein when A2 Mor p f b Aly1 is A N i; N and A2 is C. Alternatively, A2 is N and A1 is C;
25 Pre (fCer=aObl)y-R, R1
4, -( iCs= sSel)e-Rct4e,d -S frOo2m-R–4,H -,C–Nh,a -lNo,R -9O-SHO,2 --CR1-6
4,a -Clk3y-6l,cy -Ocl-oCa1l-k6yall,k -yOl,- -CS3--C6c1y-6calolkayll, -NR9R10, - –Het1; wherein each of said -C1-6alkyl is optionally and independently kyl, -Ar1 and to 3 substituents selected from–halo, -OR35, -NR11R12, -O-C substituted with from 1 30 More preferably, R 1-6
1 is selected from–H,–halo, and -C1 alkyl, and -S-C1-6alkyl.
o Rp1t iison–ahlalylo a,n edve innd mepoerned pernetfleyra subblys Rtit1u itsed -6alkyl; wherein each of said C1-6alkyl is –F w.ith from 1 to 3–halo or -C1-6alkyl. More preferably Preferably, R5 is attached to Z1 or Z5 and is selected from–H,–halo, -OH, -C1-6alkyl, -O-C1- 35 6alkyl, -S-C1-6alkyl, -NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8
6c ky , -CN, -NR6-SO2-R8, -C3- an y
Rd clo
23 iRn a d l
24e,p l
-Oe , n - -Cd O e- 1-n C
6at 3 ly -6c
lky s y
lu c
,b lo
as a
ntdi l t k u y
-Ste l,
-d -A
C1 w r
-6i 5
ath an
lky fr d
lo.m –H 1 et t 5 o ; 3 wh s e u r b e s in titu e e a n c t h s o s f el s e a c i t d ed -C fr 1 o -6 m alk y h l a is lo, op -O tio R n 3 a 6, lly N - -44- Mor oept piorenfaelrlyab alny,d R in5d iesp seenledcetnetdly f sroumbs–titHu,te–dha wlioth, a frnod -C1-6alkyl; wherein each of said C1-6alkyl is R5 is selected from–H,–F, and a m m 1 to 3–halo, or -C1-6alkyl. More preferably 5 Prreefferably R ethyl group. Even more preferably, R5 is–H.
P 5 is attached to Z1.
searaidbly -C,1 R2
-6al iksy sle islec otpedtio fnroamlly - aHn,d -h ianldoe,p -eOnHd,en -Ctly1-6a slukbysl,t and -C3-6cycloalkyl; wherein each of selected from–halo,–OR27, and -NR13R14 ituted with from 1 to 3 substituents Mor aend pr aef mereatbhlyyl, g Rro2u isp. s Perleefceteradb flyro,m R2 - iHs– aHnd. A -.Clte1r-6naalktiyvle;ly m,o Rre2 preferably R2 is selected from -H 10 is a methyl group.
Pref searaidbly -C,1 R3
-6a ilsky sle ilsec otepdtio fnroamlly– aH
nn,
dd -h ialo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of selected from–halo, ndependently substituted with from 1 to 3 substituents 15 Mor aend pr aef mereatbhlyyl, g Rro3u isp. s Pe–
rleeO
fcR
ete2
rad8,
b f a
lyro,m -N
R3 - iHR1
s– a5
HnRd16
. A -.Clte1r-6naalktiyvle;ly m,o Rre3 is pr aef mereatbhlyyl g Rr3ou isp s.elected from -H Pref -eSra-Cbly, R4 and R8 are each independently selected from–halo,–OH, -C1-6
1-6alkyl alkyl, -O-C1-6alkyl, 20 MorOeH p,r oefre -rCa1b-6ly,
a, - lk RN
y4R
l. i1s7R s1e8l,e -cCte3-d6c fyrocmloa–lkhyall,o -,O–-OCH3-6,c oyrcl -oCa1l-k6ayll,k -yAl;r4 an adnd R -8H iset s4.elected from–halo,– Pref Rer3a2,bl Ry,33 R,6 R,3 R7
4,, R R9
35, a Rn1d0, R R11
36, a Rre12 e,a Rc1h3, i Rnd14e,p Re1n5d,e Rn1t6l,y R s1e7,le Rct1e8,d R f1ro9,m R2–0H, R,2 -1h,a Rlo2,2, = RO2,3, -O R2H4,, R -C31
1,- 25 6
6aalkyl, -O-C1-6alkyl, -S-C1-6alkyl, -C3-6cycloalkyl, -Ar6 and–Het6; wherein each of said -C1-hlakylol, is–O opHti,o -nOa-lCly1- a6nadlky inl,d -eSp-eCn1d-6eanlktylyl, s -uCb3s-6tcituted with from 1 to 3 substituents selected from More preferably R6, R, R7,3 R9
5 a,n Rd1 R0,3 R11
6 ar,e R e1 ycloalkyl, -Het6, -Ar6 and–NR37R38.
R a2,ch R1 in3,d Rep14e,n Rd1e5n,t Rly16 s,e Rle1c7,te Rd18 f,ro Rm19,–H R,20 a,n Rd21 -,C R22
1-6a,lk Ry2l3,, R24 31, R32, R33, R34 , 30 Preferably, R27 and R28, are each independently selected from–H, -C1-6alkyl, -C3-6cycloalkyl and More He
pre pt
fr2
ee.
rfaebralybl Ry,27 R a2n7d a Rnd28 a Rr2e8 b aorteh e–aHc.h independently selected from–H and -C1-6alkyl, more 35 Preferably, R37 and R38, are each independently selected from–H, -halo, -OH, -C1-6alkyl, -O-C1- 6alkyl, -S-C1-6alkyl, -C3-6cycloalkyl, -Ar7 and–Het7. -45- More preferably, R37 and R38 are each independently selected from–H and -C1-6alkyl.
Pref
5 -eNraRbly, X1 is selected from–C1-6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6
3-C1-6alkyl-, -NR3-, -O alkyl-, s Su-Cbs1-t6it -; wherein each of said -C1-6alkyl- is optionally and independently aultkeydl, w -pithhe fnryolm, 1 to 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, - More preferably, X1 is se and -NR33R34.
said C1-6alkyl is optionallyle acntedd in frdoempe–nOde-Cnt1l-y6a slkuybl-s,ti NtuRte3d-C w1-i6tahlk fryol-m, - 1NR to3- 3, -–Oh-a;lo w,h -eOreHin, a enadch -C o1f- 10 6alkyl.
Pref -eNraRb2l-yC,1 X2
-6al iksy slelected from–C1-6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, substituted wit-h, - fNroRm2-, 1 - tOo- 3; w shuebrsetiitnue enatcsh s oefle scateidd - fCro1m-6a–lkhyal-lo is, - oOpHti,on -Ca1ll-y6 and independently 15 S-C1-6alkyl, alkyl, -O-C1-6alkyl, - M saoidre C p1r-6eafelkryalb ilsy -,p
o Xh
pt2en
io isyl
na s a
len
lyled
ac - ntNeddR3
in f1rR
doem32.
pe–nOde-Cnt1l-y6a slkuybl-s,ti NtuRte2d-C w1-i6tahlk fryol-m, - 1NR to2- 3, -–Oh-a;lo w,h -eOreHin, a enadch -C o1f- 6alkyl. 20 Pref cerably, Ar1, Ar4, Ar5, Ar6, and Ar7 ar
Ayrc4,le A orp5,tio Anra6lly comprising 1 to 3 heteer eoaactohm insd seepleecntdeedn ftrlyom a O 5-, N to a 1n0d-m Se;m eabcehre odf a saroidm Aatri1c, substituents, se alnedcte Adr7 f broeming– ohpatloio,na -OllyH, an -dC1 i-n6adlekpyle,nd -Oen-Ctly1-6a slukbysl,tit -uSte-Cd1- w6aitlhky from 1 to 3 wherein each of said -C1-6alkyl is optionally and independent l,–NR19R20; 25 moermeha ly substituted with from 1 to 3– M b plo
erre.
efder aarbolmy,a Aticr1 c,y Acrle4, o Aprt5io,n Aarl6ly, a conmdp Arris7in agre 1 e oarc 2h N in adteopmesn.dently selected from a 5- to 6- Preferably, Het1, Het2, Het4, Het5, Het
30 heterocycle having fr 6, and Het7 are each independently a 3- to 10-membered
H toe 3t1, su Hbest2ti,tu H om 1 to 3 heteroatoms selected from O, N and S; wherein each of said eent4ts, H seelte5,ct Heedt6 f,ro amnd– Hhaelto7, is -O oHpt,io–nCa1l-l6yal aknydl, i -nOd-eCp1e-6nadlkeyntly substituted with from 1 C1-6alkyl, and -NR21R22; wherein each of said l, -S-C1-6alkyl, =O, -(C=O)- substituted with from 1 to 3–hal -C1-6alkyl is optionally and independently 35 M 3-o troe 6 p-mreefemrabbelrye,d H heet1t,er Hoecty2c,l Hee hta4,vi Ho
ne.
gt5 fr,o Hmet 16, to an 3d N H aetto7m asre. each independently selected from a -46- Pref ferably, Het8 is a 3- to 10-membered heterocycle having from 1 to 3 heteroatoms selected wro
seh m
leerce O
tein , N
d s fa a
roid nd
m H S
e ;
ht8a ilso, o -pOtiHon,a–llCy1 a-6nadlky inl,de -Ope-Cnd1-e6anltklyyl, su -Sbs-Ctit1u-6taeldky wl,ith =O fr,om -
Figure imgf000048_0001
(C 1=O to)- 3C s1-u6ablstituents 5 6 kyl, -C1- inadlkeypl-eO-C1-6alkyl and -NR21R22; wherein each of said -C1-6alkyl i pti lly and More wh perreefeinnd
ra we
bhn
lyetl
,ny
H R su
e1b
t8 isst
is–itHut
a,e td
3h-e wnith
to a 1t fr
0 leo
-am
mset 1
m o tno
be 3
er h - eeh
dtael
hroo;
eatetoromcy ocfle He hta8v isin agtta frcohmed 1 to to X23 hete 10 selected from O roatoms w seher
nldece
intein
dd s
ep fra
eoid
nm H
de–e,
hta8 N
lo is an
,– od
Cp1t S
-i6o;
anlkayllly, - aOn-dC i1n-6daelkpyel,nd =eOn;tl wyh seurbesintit euatecdh w ofith from 1 to 3 substituents a R nt 1 l said -C1-6alkyl is optionally wherein when y is s u H bs , t t i h tu e t n ed at w le it a h s f t ro o m ne 1 h t e o te 3 ro -h a a to lo m ; of Het8 is attached to X2
15 M azoarbeic pyrcelfoe[r3a.b1l.y0,]h Heext8 is selected from piperazinyl, piperidinyl, pyrrolidinyl, pyrrolopiperazinyl, 3- octtraahhyyddrroopisyorrolo[1,2a-an]yply,razinyl, 2-a ozcatbaihcyydcrloo[-31.H1-.0p]yhreroxlaon[1y,l2,-a]pyraz 2i-nayzla,bic teyctrlaoh[2y.d2r.o1q]hueinpotalinnyyll, a te , sezalebcitceydcl foro[4quino
m.1 linyl, morpholinyl, 3,4-dihydro-2H-benzo[6][1,4]oxazinyl, 2-oxa-5- 20 p.0y]rhreoplidtainnyyll,, p 1ip,e4r-aozxianzyel,p aanndyl, pip heormidoinpyipl.erazinyl. Even more preferably, Het8 is
Vy pf bly Ht8 i l td f
Figure imgf000048_0002
h i h R i H th t l t d ht t ;
25 f Ht i tt hd t X -47-
More wh pr e e r f e e in ra w bl h y e , n He R t 1 8 is is s H e , le th ct e e n d a fr t o le m a
Figure imgf000049_0001
t ht t f Ht i tt h ; d to X2
Even wh m e o r r e e in p w re h fe e r n ab R l 1 y i Het8 is selected from
Figure imgf000049_0002
;
5 s–H, then at least on ht t f Ht i tt hd t X
Even wh meorreein p wrehfeernab Rl1y i Hse–tH8, is th
Figure imgf000049_0003
t l t ne ; heteroatom of Het8 is attached to X2
In all the examplified Het8 groups above and below, the arrows indicates the attachment point.
10 F grooru epx aanmdp tlhee, C
Figure imgf000049_0004
means that the nitrogen atom is directly attached to the X2 Prefer b t t to it is directly attached to the X1 group.
More parbelfye,r Za1b,ly Z,2 Z, Z1,3 Z, Z2,4 Z3,d Z4 Z a5nde Z e5a acrhe i enadcehpe Cn.dently selected from C and N. 15 I snter aeao p
teisarticular embodiment, the present invention provides compounds of Formula I or a solv tohmereero,f tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or -48-
Wherein one or more of the foll
Figure imgf000050_0001
ig I
R1 is selected from–H,–halo, -OH ppli 5 (C=S)-R4 , -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, - w suhbesrteitiune e ,
na - tsc S h O
se o 2 4
lef -R
c sta ,
eidd -C
f -rC N
om1 , -6 -a N
lhk R
ay 9 l- lo i S s O
, - o 2
Op- Rt R i3o 4
5n ,
,a - -l C ly 3- a 6c n y d cl i o n a d l e k p y e l, n -d O e-n C tl 3 y -6 s c u yc b loalkyl, -Ar1 and–Het1; oNmR1–1RH1,2 stituted with from 1 to 3 R5 is attached to Z1 or Z5 and is selected fr ,– -hOa-loC,1- -6OalHky,l -,C a1n-6da -lkSy-lC,1 --O6a-lCky1-l6;alkyl, -S-C1- 6alkyl, -NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3- 10 s 6cycl
aunbdsotitaulkteydl, w -Aitrh5 f aronmd– 1H teot53; w suhbesrteitiune enatsch se olefc staeidd f -rCom1-6a–lhkyallo is, - oOpRtio36n,a -lNlyR a23nRd24 in,d -Oep-Cen1-d6aelnktylyl, R2 is is se olpe -S
tciot-eC
nd1-6
al flra
yolkmyl
an–;
dH i,n -dheapleo,n -dOeHnt,ly -C s1u-6baslktiytul,te adnd w -iCth3-6 frcoymclo 1alk toyl; 3 w shuebrsetinitu eeanctsh o sf said -C1-6alkyl 15 sh salo,–OR27, and -N, -R13R elected from– R ise
al ol
ope
,tciotendal flryom an–dH indheapl14
3 i eo,n -;
dOeHnt,ly -C s1u-6baslktiytul,te adnd w -iCth3-6 frcoymclo 1alk toyl; 3 w shuebrsetinitu eeanctsh o sfe sleacidte -dC f1-6alkyl h R–8O aRre28, e a rom– R ancdh - iNnRde15pRe1n6
4 and d;ently selected from–halo,–
Rn OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- 20 R 6
6, Ralkyl, -NR17R18, -C3-6cy
R7
3, 4, R R 9
3, 5 R a 1 n 0 d , R R 11
36 , a R re 12, ea R c 1c
h3l,oak
in Rl
d14y
e,l,
p R - en 1O5 d ,-C
e R3-6
n1 t 6c
ly ,y Rc
se 1lo
l7 e ,a
c Rlk
te 1y
d8l,, - f RA
ro 1r4
m9, a
H 2d0 , , - - RH
ha 2e1t4;
l, o, R = 2 O 2, , R -O 23 H , R , - 2 C 4, 1- R31
6alk , y R l, 3 -2 O , R -C 33
1,- 6 oapltkioyln,a -llSy- aCn1d-6a inlkdyel,pe -Cnd3-e6cnytlcylo saulbkyslt,itu -tAerd6 w ainthd fr–oHmet 16; wherein each of said -C1-6alkyl is 5 R –OH, -O-C 1-6 alkyl, -S-C 1-6 alkyl, -C 3-6 to 3 substituents selected from–halo, 2 R27 anndd R R28 are eaacchh i innddeeppeennddeennttllyy s seelle c
ec y
ctte cl
ed oa
d f fr l
ro k
om yl,
m -H
H e
H, t
, -6
-C ,
h1 - a-A 6loa r 6
,lk a
-y n
Ol, d
H -,C
-3 N
C-6 R
1c-6y37
ac R
llko3
ya8 ;
ll,k -yOl- aCn1d-6 -aHlkeytl2 37 a 38 are e ,:
y -S-C1- X is 6al s k e y l l e , c -C te 3 d -6c fro c m loa lk C yl, -A k r7
1-6alyl a -, nd –O -H C e 1 t7
1 -6 ; alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 30 s 6alkyl-, -NR3-, and -O-; wherein eac n h ts o s f el s e a c i t d ed -C fr 1 o -6 m alk y h l- a i lo s , o -O pt H io , n -a C ll 1 y -6a a l n
Su-Cbs1-t6itaultkeydl, w -pithhe fnryolm, a 1nd to -N 3R s3u3bRs3t4i;tue ky d l, in -O d-e C p 1 e -6 n a d l e ky n l t , ly - -49- X2 is selected from–C1-6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2
6a -C1-6alkyl-, -NR2-C1- sulbksytl-it,ut -eNdR w2-i,th a fnrdom -O 1-; to w 3he sruebinsti etuaecnhts o sfe sleacidted -C fr1o-6malk–yhl- is optionally and independently 5 S-C1 alo, -OH, -C1-6alkyl, -O-C1-6alkyl, - Ar -6
1, o Aprti4o,a
n Al
alrkyl, -phenyl and -NR31R32;
l5y, c Ar6, and Ar7 are each independently a 5- to 10-membered aromatic cycle Ar5, Ar6, aonmdpr Aising 1 to 3 heteroatoms selected from O, N and S; each of said Ar1, Ar4, substituents selecr7t being optionally and independently substituted with from 1 to 3 wherein ea ed from–halo, -OH, -C 1-6 alkyl, -O-C 1-6 alkyl, -S-C 1-6 alkyl, and–NR 19 R 20 ; 10 Het1h
h,a
a Hlo ch of said -C1-6alkyl is optionally and independently substituted with from 1 to 3 - ve;
int2g, H froemt4, 1 H teot53, H heett6e,r aoantdom Hest7 se alreect eeadch fro inmde Op,e Nnd aenndtly S a; w 3h-e tore 1in0- emaechmb oefr seadid h Heteerocycle Het4, Het5, Het6, and Het7 is optionally and independently substituted with f t1, Het2, 15 substituents selected from–halo, -OH,–C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, =O,ro -
Figure imgf000051_0001
(mC= 1O) t-oC13- 6 saulbksytl,itu atendd w -iNthR f2r1oRm221; t woherein each of said -C1-6alkyl is optionally and indp d tly Het8 a insd a 3- to 10-membered 3 he -htearloo;cycle having from 1 to 3 heteroatoms selected from O, N 20 s wher Se;in said Het8 is optionall
-Oel-eCcted from–halo, -OH,–Cy1-6 aanlkdy iln,d -Cep1-e6anldkeylnetnlye, su -Cbs1-t6iatulkteydl-C w3i-t6hcy fcrolomalk 1y tl,o - 3C3 s-6ucbysctliotuaelknytsl, each1 o-6fa slkayidl, - -CS-C1-6alkyl, =O, -
Figure imgf000051_0002
(Clly=O)-dC i1-6dalkpyl,d -Cen1-t6laylk syulb-Ost-iCtu1t-e6adlk wyilth an frdom -N 1R t2o1R 322
1-6alkyl is optio -; wherein wherein when R1–H, then at l t ht tom of halo; 25 Z1, Z2, Z3, Z4 and Z5 are Het8 is attached to X2
A1 and A2 are each indep eeancdhe inntdlyep seenledcetendtly fr soemle Ccte adnd fro Nm. C and N; and I rn
baird p
aica
dart
iclsicu
als tolar
m w,
ayh Xic1,
bh a
e p tnhd
reesy X2
e anr a
tes
in a u
etts
iae
thcd
ehre h
oder
f b feoi
orn
tm, r
h d aep
ire mre
casce
tiorn
not
scy b
incirla
tihcdi
e pc
myarl
aas,
czo wlohpicyhrim taikdeinne to cogmetphoeurn wdi.th S tahied 30 a Rreefe prrreinfegrably present in the direction as described below: rocyclic pyrazolopyrimidine, but
6 X a 1 i tso f soerlmecutlead I: from the list comprising *–C1-6alkyl-, *–O-C1-6alkyl-, *–S-C1-6alkyl-, *-C1- attlakyclh-NedR t3o-C th1-e6a alkryyll- o,r *- hNeRte3r-oCa1r-6alkyl-, *-NR3-, *-O-; * wherein said biradical is preferably 35 X2 is selected from the list C c 1 o y m l m pr o is ie in ty g v * ia –C *; 1-6alkyl-, *–O-C1-6alkyl-, *–S-C1-6alkyl-, *-C1- 6 a a tt l a ky c l h -N ed R t 2 o -C th 1- e 6a p lk y y r l a -, zo *- lo N p R y 2 r-imid -6 i a n l e ky m l-, oi * e-t N y R v 2 ia -, * * ; -O-; * wherein said biradical is preferably -50- I snte a preferred embodiment, the present invention provides compounds of formula I or a s reoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or 5 Ro1lv isat
( wC se h= e t eS lhee re) cr
-inR teeodf, fr wohmer–e each ofR Hin,–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6
4, -SO2- s4a,id -C -CN, -NR9-SO2-R4, -C3-6cycloalkyl, -O-C3-6 alkyl, -NR9R10, -(C=O)-R4, - 1-6alkyl is optionally and independent cycloalkyl, -Ar1 and–Het1; substituents selected from–halo, -OR35, -NR11R12, -O-C1-6alkly substituted with from 1 to 3 R5 is attached to Z1 or Z5 and is selected from–H,–halo, -OH, -Cyl1,-6 aanlkdy -l,S --OCH1-6,a -lCky1-l6;alkyl, -O-C1- 10 6alkyl, -S-C1-6alkyl, -NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3- 6 acnydclo inadlkeyple,n -dOe-nCt3ly-6c syucblosatiltkuytel,d -A wri5th an frdom–H 1et t5o; 3 wh seurbesintitu eeancths o sfel seacitded -C f1-6alkyl is optionally NR23R24, -O-C1-6alkyl, and rom–halo, -OR36, - R2 is selected from–H, -halo, - -OS-C1-6alkyl;
is optionally and indepe H, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1-6alkyl 15 halo,–OR27, and -NR13R n 14 d ; ently substituted with from 1 to 3 substituents selected from– R3 is is se olpetciotendal flryom an–dH i,n -dheapleo,n -dOeHnt,ly -C s1u-6baslktiytul,te adnd w -iCth3-6 frcoymclo 1alk toyl; 3 w shuebrsetinitu eeanctsh o sfe sleacidte -dC f1r-o6alkyl halo,–OR28, and -N
20 nRde1 m– R R 5
4 and 8 are each i pRe1n6
od;
aently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- R 6
6, Ra
R7l,k Ryl9,, - RN1R17
R0, RR18
11,, R -C3-6
12, Rc1y3c,l R14lk,y Rl,1 -5O, R-C3-6
tl 1 y 6, s Rcy
e1 l 7c
e,lo
c Ra
te 1l
d8k,y
f Rl,
ro 1 -9A
m, Rr4
2 a
H0,n
, Rd
-h 2 -1H
a,e
l Rt4
o, 22;
=, O R , 23 -, O R H 24 , , - R C 31
35 and 36 are each independen 1- , 6a R lk 32 y , l, R -3 O 3 R -C 34
1,- 6 oapltkioyln,a -llSy- aCn1d-6a inlkdyel,pe -Cnd3-e6cnytlcylo saulbkyslt,itu -tAerd6 w ainthd fr–oHmet 16; to w 3he sruebinstit euaecnhts o sfele sactided - fCro1-m6al–kyl is 25 R –OH, -O-C1-6alkyl, -S-C1-6alkyl, -C3-6cycloalkyl, -Het6, -Ar6 and–NR37R38 halo, 27 an ;
R37 and R28, are each independently selected from–H, -C1-6alkyl, -C3-6cycloalkyl and -Het2:
C1d- R38, are each independently selected from–H, -halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S- 30 X s6
1 is ealelkcytle,d -C f3r-o6cmyc–loCa1lk-6yall,k -yAl-r,7– aOnd-C–1H-6aeltk7;yl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- X 6
2 is al s k e y l l e -, c -te N d R3 f-ro a m nd C O 1--6 ; alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1- Ar 6
1,a
o Al
prk
ti4y
o,l- n A, - alrN
l5y,R
c A2- or,
m6 a,n
pr ad
isn - idO- ng A;
1r7 to a 3re he etaecrhoa itnodmespe snedleecntetlyd f arom 5- O to, N 10 a-nmde Sm;b eearcehd o afr soamidat Aicr1 c,y Acle 35 A sur5b,st Aitr6, and Ar7 being optionally and independently substituted with from 1 to r4 3 , wheruents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, and–NR19R20; halo;ein each of said -C1-6alkyl is optionally and independently substituted with from 1 to 3 - -51- Het1 h,a Hveint2g, H froemt4, 1 H teot53, H heett6e,r aoantdom Hest7 se alreect eeadch fro independently a 3- to 10-membered heterocycle Het4 m O, N and S; wherein each of said Het1, Het2, 5 subs,tit Hueetn5t,s H seetl6e,ct aendd fr Homet7– ihsal oop,t -ioOnHa,lly–C a1n-6dalk inydl,e -pOe-nCd1e-6natllkyyl s,u -bSs-Ctit1u-6teadlky wl,it =hO f,ro -
Figure imgf000053_0001
(mC= 1O) t-o 6a C13- sulbksytl,itu atendd w -iNthR f2r1R22; wherein each of said -C1-6alkyl is optionally and indp d tly Het8 a insd a S 3;- to 10-meommbe 1re tod 3 he -htearloo;cycle having from 1 to 3 heteroatoms selected from O, N 10 w s e a s
-Oehl-er
Cce
1t-ein
6ad s
lk fryoid
l,m H
-S–e
-ht
Ca8
1l i
-os
6a, o
l -kOpt
ylHio p
,,n
=O–aClly
,1 --
Figure imgf000053_0002
(6 a
Can ln
=lkd
Oy i
),d
-C -Ce1-e6 e
1-6aan
lkldkyyl,lnet
-nly
Ce1-, su
6a -Cb
lk1y-t6i
l-atu
Olkte
-yd
Cl-C w3i-t6hcy fcrolomalk 1y tl,o - 3C3 s-6ucbysctliotuaelknytsl, each of said -C 1-6
1-6alkyl is optio lly d idp dently substituteadlk wyil and -NR21R22; wherein wherein when R1 is–H, then at t ht atom of Het8 is attacthhe fdro tmo X 12 to 3 -halo; 15 Z1 l
A1 , a Zn2d, Z A3
2, a Zr4e a enadc Zh5 in adreep eeancdhe inntdlyep seenledcetendtly fr soemle Ccte adnd fro Nm. C and N; and I snter aeo pisaortmiceurl,ar ta eumtobmoedri,m reanctem thice, p mreetsaebnotlit ien,ve pnroti-on or p prorevdidreusg, c soamlt,po huydnrdaste o,f N f-oorxmiduela f I or a 20 solvate thereof orm, or R1 is (C s
h=e
eSle
re)c-inRte4d, e,a - fr w cSoh hOmer o2f-–e
RHin s4a,,
id -–Ch
-CNal
1,o,
-6 -aN -O
lkRH
y9l-,
iS - sOC1-6
o2p-tRa
io4l
n,ky
a -lCl,
ly3 --O
a6c- nyC
dc1l io-6
naallkkyyll,, - -SO--CC1-6
3-6aclykcyllo,a -NlkRyl,9R -1A0r,1 -( aCn=dO)–-HRe4,t1 - w ; substituents selected from–halo, -OR35, -NR11R12, -dependently substituted with from 1 to 3 25 R is attached to Z1 or Z5 and is selected from–H,–hOa-loC,1- -6OalHky,l
O -,C a1n-6d
2-Ra - 8,lkSy- -ClC,1
3 -- -6O6
5 a
c-l
yCky
cl1o-l6;
aallkkyyll,, - -OS--CC1- 6alkyl, -NR6R7, -(C=O)-R8, - w(C=S)-R8, -SO2-R8, -CN, -NR6-S 3- 6 scuybcslotitaulkteydl, w -Aitrh5 f aronmd– 1H teot53; suhbesrteitiune enatsch se olefc staeidd f -rCom1-6a–lhkyal is optionally and independently and -S-C1- lo, -OR36, -NR23R24, -O-C1-6alkyl, 30 R s i kyl hs se
a olpetciote 6
2 i ndal flra
yolkmyl
an–;
dH i,n -dheaploe,n -dOeHnt,l -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1-6al
iselo
olpe,
tc–
iotOendR y substituted with from 1 to 3 substituents selected from– R 2
al f7 , -R 4
lryo,m an
an–d
dH -N
indh1
ea3
3 is s plR
eo,1
n -;
dOeHnt,ly -C s1u-6baslktiytul,te adnd -C3-6cycloalkyl; wherein each of said -C1-6alkyl 35 hal d with from 1 to 3 substituents selected from– R4 a 6 n a do,
lky R–
l, 8O
-N aR
Rre28,
17 e a
Ran
1c 8, h - -O iNnR
-d C e15
3pR
-6 e1
cy n6
cd;
le o n a t l l k y yl s , e -C le 3 c -6 te cy d cl f o ro a m lky l, h -A al r o 4 , a n O d H -H , -C1-6alkyl, -O-C1-6alkyl, -S-C1- R6, R R 7, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21,e Rt4
22;, R23, R24, R31, R32, R33, R34 35
6alky al,nd -S R-C36
1- a6arelky el,ac -hC3 in-6dceycpleonadlkeynl,tly -A sre6le acnteddfrHoemt6;–H w,h -ehraelion, e =aOc,h -O oHf, s -aCid1-6a -Clk1y-6l,al -kOy-lC i1s- -52- o–pOtHio,n -aOlly-C a1n-6dalk inydl,e -pSe-nCd1e-6natlklyyl s,u -Cbs3t-ituted with from 1 to 3 substituents selected from–halo, R 6cycloalkyl, -Het6, -Ar6 and–NR37
27 an R38; 5 R an d d R R 28
38 , , a a r r e e e e a a c c h h in in d d e e p p e e n n d d e e n n tly tly se s l e e l c e t c e t d ed fro fr m om –H , H -, C -1 h -6 a a l l o k , y -l, O -C H 3 , -6 -c C y 1 c -6 l a o l a k l y k l y , l - a O n-d C -1 H -6a e l t k 2 37 y : l, -S- X1 isC1 s-6ealelkcytle,d -C f3r-o6cmyc–loCa1lk-6yall,k -yAl-r,7– aOnd-C–1H-6aeltk7;yl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 6 saulbksytl-it,ut -eNdR w3-i,th a fnrdom -O 1-; to w 3h seurebisnt each of said -C1-6alkyl- is optionally and independently S-C1-6alkyl, -phenyl, and -N ituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, - 10 X R33R34
2 is selected from–C1-6a -; lky w l- h , e re O in -C e 1- a 6a ch lky o l- f , s a S id -C -1 C -6alkyl-, -C1-6alkyl-NR2-C1-6
6alkyl-, -NR2-, and -O 1-6alkyl- is optiona alkyl-, -NR2-C1- substituted with from 1 to 3 substituents selected from–halo, -OH, -Clly and independently S-C 1-6
1-6alkyl, -phe alkyl, -O-C1-6alkyl, - Ar r4, Ar5, Ar6, andny Alr a7n adre -NR31
1, A R32;
15 c Aormpriisnigng o 1pt tioon 3a hllyete arnoda etach independently a 5- to 10-membered aromatic cycle optionally ionmdes selected from O, N and S; each of said Ar1, Ar4
7 be , Ar5, Ar6, and from–halo, -OH, -C1-6alkyl, - pendently substituted with from 1 to 3 substituents selected C1-6alkyl is optionally and O-C1-6alkyl, -S-C1-6alkyl, and–NR19R20; wherein each of said - 20 Het1, Het2, Het4, Het5, Het6, an indd Hepeet7nd areent ely substituted with from 1 to 3 -halo;
h Haevt4in,g H ferot5m, H 1e tto6, 3 a hnedte Hroeat7tom iss o spetiloencatea
lldch
y fr ao independently a 3- to 10-membered heterocycle nmd O in, N and S; wherein each of said Het1, Het2, substituents selected from–halo, -OH,–C1-6alkydl,e -pOe-nCd1e-6natllkyyl s,u -bSs-Ctit1u-6teadlky wl,it =hO f,ro -
Figure imgf000054_0001
(mC= 1O) t-oC13- 6
25 saulbksytl,itu atnd -NR21R22; wherein each of said -C1-6alkyl is optionally and indp d tly Het8 is a bivaelden wti 3th- f troom 101-m toem 3
O b -hearelod; heterocycle having from 1 to 3 heteroatoms selected from wh,e Nre ainnd a St l;
wherein wheenas Rt1 o inse– oHf, s tahiedn h aette leroaastto omnes i hse atettached to X1 or X2; 30 wherein said Het8 is optionally and independeronatltyom sub osft Het8 is attached to X2; and
s -O el-e C c 1 t-e 6a d lk fr y o l, m -S -h C a 1 l-o 6a , l -k O yl H , , =O –C , 1 --( 6 C a = lk O yl ) , -C1-6alkylene, -C1-6iatulkteydl-C w3i-t6hcy fcrolomalk 1y tl,o - 3C3 s-6ucbysctliotuaelknytsl, , Z each of said -C
Figure imgf000054_0002
-C1-6alkyl, -C1-6alkyl-O-C1-6alkyl and -NR21
1-6
2, Z3, Z4 and Z5 aarelky ela icsh o ipntdio R22; wherein Z1 epllyd dtly idlptdde fntly substituted with from 1 to 3 -halo; A1 and A2 are each independently rom C and N; and
35 selected from C and N.
I snte a
lvre f
aou
teirsth
toe
hmr
ere p
era
o,r
f tt
,aicuutolamre erm,b raocdeimmeicn,t m theeta pbreoslieten,t p inrvoe-n otiron pr perdorvuigd,es sa clot,m hpyodurantdes, o Nf- fooxrimdeula fo Iram o,r o a so r -53-
Wh
Figure imgf000055_0001
Ia
R1 iesre 5 (C si
=en
Sle)c-Rte4d, - frSoOm2-–RH4,, -–ChNal,o, -N -ORH9-,S -OC1-6
2-alkyl, -O-C1-6alkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, - wherein each of said -C1-6alkyl is opt R io 4 n , a -l C ly 3- a 6c n y d cl i o n a d l e k p y e l, n -d O e-n C tl 3 y -6 s c u yc b l s o t a it l u k t y e l d , - w A i r th 1 f a r n o d m 1 H t e o t1 3 ; R5 is su abtstatictuheendts to se Zl1ec otred Z5 fro amnd– ihsa sloe,le -OctRed35, fr -oNmR1–1RH1,2,– -hOa-loC,1- -6OalHky,l -,C a1n-6da -lkSy-lC,1 --O6a-lCky1-l6;alkyl, -S-C1- 6alkyl, -NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3- 10 6 scuybcslotitaulkteydl, w -Aitrh5 f aronmd– 1H teot53; w suhbesrteitiune enatsch se olefc staeidd f -rCom1-6a–lhkyallo is, - oOpRtio36n,a -lNlyR a23nRd24 in,d -Oependently s an
is sed -C1-6alkyl, R2 i olpe -S
tciot-eC
nd1-6
al flra
yolkmyl
an–;H, -halo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1-6alkyl 15 ha 7 d independently substituted with from 1 to 3 substituents selected from– R s is selo
olpe,
tc–
iotOendR2
al flryo,m an
an–d
dH -N
i, -R
ndh1
ea3
3 i lRo,14 -;OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1-6alkyl R halo,–OR28 pendently substituted with from 1 to 3 substituents selected from– 4 and R8 are, e aancdh - iNnRde15pRe1n6d;ently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- 20 R 6
6, Ralkyl, -NR17R18, -C3-6cycloalkyl, -O
R7, R9, R10, R11, R12 a , c R h 13 in , d R e 14 p , e R n 1 d 5 e , n R-C3-6
tl 1 y 6, s Rcy
e1 l 7c
e,lo
c Ra
te 1l
d8k,y
f Rl,
ro 1 -9A
m, Rr4
2 a
H0,n
, Rd
-h 2 -1H
a,e
l Rt4
o, 22;
=, O R , 23 -, O R H 24
35 and R36 are e , , - R C 31
1-, 6a R lk 32 y , l, R -3 O 3 R -C 34
1,- 6 oapltkioyln,a -llSy- aCn1d-6a inlkdyel,pe -Cnd3-e6cnytlcylo saulbkyslt,itu -tAerd6 w ainthd fr–oHmet 16; to w 3he sruebins each of said -C1-6alkyl is 5 –OH, -O-C1-6alkyl, -S-C1-6alkyl, -C3-6cycl tituents selected from–halo, 2 R R37 a anndd R R28
38,, a arree e eaacchh independently selecte o d a f l r k o y m l, - H H e , t6 -C , - 1 A -6 r a 6 lk a y n l d , - C N 3- R37
27 6cy R cl 3 o 8 a ; lkyl and -Het2: C1-6alkyl, -C3-6cyclo ianldkeylp,e -And
l-r,7ently
a s–elected from–H, -halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S- X1 is selected from–C1-6alky Ond-C1H-6aeltk7;yl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 30 s 6alkyl-, -NR3-, and -O-; wherein eac n h ts o s f el s e a c i t d ed -C fr 1 o -6 m alk y h l- a i lo s , o -O pt H io , n -a C ll 1 y -6a a l n
Su-Cbs1-t6itaultkeydl, w -pithhe fnryolm, a 1nd to -N 3R s3u3bRs3t4itue ky d l, in -O d-e C p 1 e -6 n a d l e ky n l t , ly - -54- X2 is selected from–C1-6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR2-C1- 6 saulbksytl-it,ut -eNdR w2-i,th a fnrdom -O 1-; to w 3he sruebinsti etuaecnhts o sfe sleacidted -C f1-6alkyl- is optionally and independently 5 ,S-C1-6alkyl, -phe rom–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, - Ar nyl and -NR31R32
1 ;
o Apr4, Ar5, Ar6, and Ar7 are each independently a 5- to 10-membered aromatic cycle Ationally comprising 1 to 3 heteroatoms selected from O, N and S; each of said Ar1, Ar4, sur5b,st Aitur6e,nt asn sdele Acr7ted be frinogm o–phtaiolon,a -lOlyH a,n -Cd 1-6 inadlkeypl,en -Ode-Cn 1 tl-y 6 alk syulb,s -tSitu-Cte 1 d -6 al wkyitlh, a fnrodm–N 1R to 3 wherein each of said -C optionally and independently substitute 19
1-6alkyl is R 20 ; 10 Het1h
h,a
a Hlo d with from 1 to 3 - ve;
int2g, H froemt4, 1 H teot53, H heett6e,r aoantdom Hest7 se alreect eeadch fro inmde Op,e Nnd aenndtly S a 3- to 10-membered heterocycle Het4, Het5, Het6, and Het7 is optionally and indepen ; wherein each of said Het1, Het2, 15 substituents selected from–halo, -OH,–C1-6alkyl, -O-Cd1e-6natllkyyl s,u -bSs-Ctit1u-6teadlky wl,it =hO f,ro -
Figure imgf000056_0001
(mC= 1O) t-oC13- 6alkyl, and -NR21R22; wherein each o
8 substituted wit f said -C1-6alkyl is optionally and indp d tly Het h from 1 to 3 -halo;
a ins a 3- to 10-membered heterocycle having from 1 to 3 heteroatoms selected from O, N 20 w
- sOehd
ler S -eCce; 1t-ein
6ad s
lk faryoid
l,m H
-S–e
-ht
Ca8
1l i
-os
6a, o
l -kOpt
ylHio
,,n
=O–aClly
,1 --
Figure imgf000056_0002
(6 a
Can
=lkd
Oy iln
),d
-C -Cep1-e6
1-6aan
lkldkeylnetnlye, su -Cbs1-t6iatulkteydl-C w3i-t6hcy fcrolomalk 1y tl,o - 3C3 s-6ucbysctliotuaelknytsl, each of said -C1-6alkyl is optio l yl, -C1-6alkyl-O-C1-6alkyl and -NR21R22; wherein wherein when R1 is–H, then at llytd id hpt daetontly substituted with from 1 to 3 -halo; 25 Z m of Hetd8 i Ns. attached to X2
1, Z2, Z3, Z4 and Z5 are each independently selected from C an
P A r 1 e a fe n r d ab A l 2 y, a c re om se p l o e u c n t ds of Formula Ia are defined as such that
is
Figure imgf000056_0003
C p, thfen ed from C and N; wherein when A1 is C, then A2 is N; and wherein when A2 Mor b Aly1 is A N i;
30 N and A2 is C. Alternatively, A2 is N and A1 is C;
Pre(fCer=aObl)y-R, R1
4, - is selected from–H,–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, -NR9R10, - –oH 3et s1u;b wshteitur(eC
einn=S
ts e)a- scR
eh4,
le o - cfS
te sO
dai2
fd-R
ro -mC4,1 - –-C6haN
alk,
loy - ,lN
- isR
O o9- RpStiOon2-aRll4y, a -Cn3d-6 icnydcelopaelnkdyel,n -tOly-C su3-b6csytictulotalkyl, -Ar1 and 35 t a35, -NR11R12, -O-C1-6alkyl, ed with from 1 Mor oept pisorenf
ae
hlr
alyab
lo al
,ny,
ed R
ve in1
nd i
mesp s
oee
rnle
edc
pet
rne
etd
fley fr
ra soum
bblys–
RtiHt1u,
itse–dh
F wlo
.it,h a frnodm -C 11- t6oa 3lky–lh;a wlohe orrei -n a
C1 en
-ad
6aclh -S
ky o-C
l.f M s1-a6a
oirdlk
e Cyl p1.
r-e6afelkraylb ils R1 i y -55- Preferably, R5 is attached to Z1 or Z5 and is selected from–H,–halo, -OH, -C1-6alkyl, -O-C1- 6alkyl, -S-C1-6alkyl, -NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3- 6 acnydclo inadlkeyple,n -dOe-nCt3ly-6c syucblosatiltkuytel,d -A wri5th an frdo–Het5; wherein each of said -C1-6alkyl is optionally 5 Mor oeNR
pt pior2e3R
nfae2
lr4
lya,b -O
alny,-C
d R1-6
in5d ia
eslk
p sy
eel,
nle a
dcn
etned
td -S m 1 to 3 substituents selected from–halo, -OR36, - ly f sr-oC
um1-6
bs–a
titHlk
u,yl.
te–
ydha
l wl
griotoh, a
u fprnd -C1-6alkyl; wherein each of said C1-6alkyl is R5 is selected from–H,–F, and a meth o.m Ev 1en to m 3o–reha plroe,fe orra -bCly1-,6a Rlk5y isl.– MHo.re preferably 10 Preferably R5 is attached to Z1.
Pref searaidbly -C,1 R2
-6al iksy sle islec otpedtio fnroamlly - aHn,d -h ianldoe,p -eOnHd,en -Ctly1-6a slukbysl,tit auntedd -C w3i-t6hcy fcrloalkyl; wherein each of selected from–hal om 1 to 3 substituents More preferably, o,–OR27, and -NR13R14.
15 and a methyl g Rro2u isp. s Perleefceteradb flyro,m R2 - iHs– aHnd. A -Clte1r-6naalktiyvle;ly m,o Rre2 is pr aef mereatbhlyyl g Rr2ou isp s.elected from -H Pref searaidbly -C,1 R3
-6a ilsky sle ilsec otepdtio fnroamlly– aHn,d -h inadloe,p -eOnHd,en -Ctly1-6 saulkbysl,tit auntedd -C w3i-t6hcy fcrlooalkyl; wherein each of 20 selected from–halo m 1 to 3 substituents Mor aend pr aef mereatbhlyyl, g Rro3u is d
p. s,
Pe–
rleeO
fcR
ete2
rad8,
b f a
lyrno,m -N
R3 - iHR1
s– a5
HnRd16
. A -.Clte1r-6naalktiyvle;ly m,o Rre3 is pr aef mereatbhlyyl g Rr3ou isp s.elected from -H Preferably, R4 and R8 are each independently selected from–halo,–OH, -C1-6alkyl, -O-C 25 -S-C lkyl, -NR 1-6
1-6a 17R18, -C3-6cycloalkyl, -O-C3-6cycloalkyl, -Ar alkyl, Mor OeH p,r oefre -rCa1b-6lya,lk Ryl. ted from–halo,–OH, or -C 4
4 is selec 1-6alkyl; an adnd R -8H iset s4.elected from–halo,– Pref Rerably, R6, R7, R9, R10, R11, R12
32, R33, R34, R3 , R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R31,30 5 and R36 are each independently selected from–H,e -inha eloa,c =hO, -OH C1- 6 1- 6a
alkyl, -O-C1-6alkyl, -S-C1-6alkyl, -C3-6cycloalkyl, -Ar6 and–Het6; wher of said, - -C hlakylol, is–O opHti,o -nOa-lCly1- a6nadlky inl,d -eSp-eCn1d-6eanlktylyl, s -uCb3s-6tcityuctleodal wkith from 1 to 3 substituents selected from More preferably R6, R7, R9, R10, R11, R12, R13, R14, yl, -Het6, -Ar6 and–NR37R38.
R , R R15, R16, R17, R18, R19, R20, R21, R22, R23 1, R32, R33 34, R35 and R36 are e , R24 3 , 35 ach independently selected from–H, and -C1-6alkyl, Pref Hereatb2.ly, R27 and R28, are each independently selected from–H, -C1-6alkyl, -C3-6cycloalkyl and -56- More pre pfreerfaebralybl Ry,27 R a2n7d a Rnd28 a Rr2e8 b aorteh e–aHc.h independently selected from–H and -C1-6alkyl, more
5 Preferably, R37 and R38, are each independently selected from–H, -halo, -OH, -C1-6alkyl, -O-C1- More 6a plkryelf,e -rSa-bCly1,-6 Ral3k7y al,n -dC R3-6
38cy acreloa elakcyhl, i -nAdre7p aenndd–eHntelyt7 s.elected from–H and -C1-6alkyl.
Pref
10 -eNraRb3l-yC,1 X1
-6al iksy sl-e,le -NctRe3d-, fr -oOm-;– wCh1e-r6eailnky el-a,c–hO o-Cf1 s-a6aidlky -Cl-,1-–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, s Su-Cbs1-t6itaultkeyd with from 1 to 3 substituents selected from 6al k h y a l- lo is , - o O p H tio , n -C al 1 l-y 6a a lk n y d l, in -O d-e C p 1 e -6 n a d l e ky n l t , ly - M saoidre C p1r-6eafelkryalbl
il,
sy -,p
o Xh
pt1en
io isyl
na s,
le a
lylned
acnt -eN
ddR
in f3r3
doR
em34.
pe–nOde-Cnt1l-y6a slkuybl-s,ti NtuRte3d-C w1-i6tahlk fryol-m, - 1NR to3- 3, -–Oh-a;lo w,h -eOreHin, a enadch -C o1f- 15 6alkyl.
Pref -eNraRb2l-yC,1 X2
-6al iksy sl-e,le -NctRe2d-, fr -oOm-;– wCh1e-r6eailnky el-a,c–hO-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, substituted with from 1 of said -C1-6alkyl- is optionally and independently S-C to 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, - 20 M saoidre C pr1e-6fearlkaybll,y -,p Xh
pt2en
io isyl
na s a
len
lyled
ac - ntNeddR3
in f1rR
doem32.
pe–nOde-Cnt1l-y6
1-6alkyl is o a slkuybl-s,ti NtuRte2d-C w1-i6tahlk fryol-m, - 1NR to2- 3, -–Oh-a;lo w,h -eOreHin, a enadch -C o1f- 6alkyl. 25 Pref cerably, Ar1, Ar4, Ar5, Ar6, and Ar7 are each independently a 5- to
Ayrc4,le A orp5,tio Anra6,lly an codm Aprr7is binegin 1g to op 3ti hoentaellryoa atonms selected from O, N a 1n0d-m Se;m eabcehre odf a saroidm Aatri1c, substituents sele scatiedd -C f1r-o6amlky–lh isal d independently substituted with from 1 to 3 wherein each of oop,tio -OnaHl,ly - aCn1d-6a inlkdyelp,e -nOd-eCn1t-l6ya slkuybl,sti -tSut-eCd1-6 wailtkhy fl,rom–N 1R t1o9R20; 30 moerme ha 3– M b p lo
erre .
efder aarbolmy,a Aticr1 c,y Acrle4, o Aprt5io,n Aarl6ly, a conmdp Arris7in agre 1 e oarc 2h N in adteopmesn.dently selected from a 5- to 6- Preferably, Het1, Het2, Het4, Het5, Het6, and Het7 are each independ
35 heterocycle having from 1 to 3 heteroatoms selected ently a 3- to 10-membered
H toe 3t1, su Hbest2ti,tu Heent4ts, H seelte5,ct Heedt6 f,ro amnd– Hhaelto7, is -O oHpt from O, N and S; wherein each of said
,io–nCa1l-l6yal aknydl, i -nOd-eCp1e-6nadlkeynl,tl -yS s-Cub1-s6taitlukytel,d = wOit,h -( fCro=mO) 1- -57- C su1b-6salkyl, and -NR21R22; wherein each of said -C1-6alkyl is optionally and independe 3- to 6-met
efietu
mrate
bbd
elry w
e,i
d Hth om ntly More pr heet f1r
t,er Hoe 1
cty2 t
c,o
l H 3
ee ht–
a4h,a
vi Hlo
ne.
gt5 fr,o Hmet 16, to an 3d N H aetto7 are each independently selected from a 5 ms.
Pref ferroambly, Het8 is a 3- to 10-membered heterocycle having from 1 to 3 heteroatoms selec selece O
tein, ted wher N
d s fa a
roidnd
m H S
e;
ht8a ilso, o -pOtiHon,a–llCy1 a-6nadlky inl,de -Ope-Cnd1-e6anltklyyl, su -Sbs-Ctit1u-6taeldky wl,ith =O fr,om - 1 to 3 substituents 10 (C=O)-C1-6alkyl, -C1- 6 inadlkeypl-eOn-dCe1n-6talylk syulbs atnitdute -dN wRi2th1R22; wherein each of said -C1-6alkyl i pti lly and wherein when R1 is–H, then at fr leoamst 1 o tnoe 3
Figure imgf000059_0001
h -ehtaelroo;atom of Het8 is attached to X2 15 Maar
ozo
cta be
hic p
yyr
dce
ro lfoe3a
p[r
yr .b1l xt
ro .y0,
lo ]h H
[1 ee
,2 a8
-a n is
]yl s,elected 2 f-raozmab piicpyecrlaoz[3in.1y.l,0 p]hipeexraidniynl,yl, pyrrol 2id-ainzyal,bi pcyyrcrlool[o2p.2ip.e1r]hazeipntyaln,y 3l-, tetarahydro pyrazinyl, octahydro-1H-pyrrolo[1,2-a]pyrazinyl, tetrahydroquinolinyl, azebicy isoquinolinyl, morpholinyl, 3,4-dihydro-2H-benzo[6][1,4]oxazinyl, 2-oxa-5- sel clo[4.1.0]heptanyl, 1,4-oxazepanyl, homopiperazinyl. Even more preferably, Het8 is 20 wctheedre frionm w phyernro Rli1di insy–l,H p,ip theeranz ainty lel,a asntd on peip heeritdeirnoyal;tom of Het8 is attached to X2
Vy pf bly Ht8 i l td f
Figure imgf000059_0002
h i h R i H th t l t d ht t ;
25 f Ht i tt hd t X -58-
More wh p e re re fe in ra w bl h y e , n H R et 1 8 is is s H e , le th ct e e n d a fr t o le m a
Figure imgf000060_0001
t ht t f Ht i tt hd to X2
5 Even wh m e o r r e e in p w re h fe e r n a R bl 1 y i H s e t H 8 , is th s e e n le a c t t l e e d as fr t o o m n
Figure imgf000060_0002
ht t f Ht i tt hd t X ;
Even wh meorreein p wrehfeerna Rbl1y i Hse–tH8, is th
Figure imgf000060_0003
t l t ne ; heteroatom of Het8 is attached to X2
10 P Mroerfeer parbelfye,r Za1b,ly Z,2 Z, Z1,3 Z, Z2,4 Z a3n,d Z4 Z a5n adre Z e5a acrhe i enadcehp Cen.dently selected from C and N. I snte are fouirsthoemre pra,r ttaicuutolamre erm,b raocdeim
lvate thereof, meicn,t m theeta pbreoslieten,t p inrvoe-n otiron pr perdorvuigd,es sa clot,m hpyodurantdes, o Nf- fooxrimdeula fo Iram o,r o a 15 so r
Figure imgf000060_0004
Ia -59- W R1h iesre
(C si
=en
Sle o
)cn
-Rteed or fr momore–H of, t–h
Che
Na flo
,ol,lo
-N -wOin
RHg, a -Cp1p-l6iaelsk:yl, -O-C1-6alkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4 4, -SO2-R4, - 9-SO2-R4, -C3-6c , - 5 wherein each of said -C1-6alkyl is optionally an y d cloalkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1; R is su abtstatictuheendts to se Zl1ec otred Z5 fro amnd– ihsa sloe,le -OctRed35, fr -oNmR1–1RH1,2 i,n
-d
hOependently substituted with from 1 to 3 a-loC,1- -6OalHky,l -,C a1n-6da -lkSy-lC,1 --O6
5 a-lCky1-l6;alkyl, -S-C1- 6alkyl, -NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3- 6 scuybcslotitaulkteydl, w -Aitrh5 f aronmd– 1H teot53; w suhbesrteitiune enatsch se olefc staeidd f -rCom1-6a–lhkyallo is, - oOpRtio36n,a -lNlyR a23nRd independently 10 R2 is an
is sed
ol -S-C 24
1-6alkyl; , -O-C1-6alkyl, petciotendal flryom an–dH i,n -dheapleo,n -dOeHnt,ly -C s1u-6baslktiytul,te adnd w -iCth3-6 frcoycloalkyl; wherein each of said -C1-6alkyl ihalo,–OR27, m 1 to 3 substituents selected from– 15 R s i hs se
al ol
ope
,tc
iote
Ond
Ral flryom an
an–d
dH -N
i,n -R
dh1
ea3
plR
eo,14
3 n -;
dOeHnt,l -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1-6alkyl e28, y substituted with from 1 to 3 substituents selected from– R nd R e aancdh - iNnRde15pRe1n6
4 a 8 ar d;ently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- 20 R 6alkyl, -NR17R18
6, R7, R9, R10, R11,, R -C3-6
12, Rc1y3c,lo Ra14lk,y Rl,1 -5O,-C3-6cycloalkyl, -Ar4 and -Het4;
R 6alkyl, -S-C1-6alky e l, ac -h C3 in -6 d c e yc p l e o n a d lk e y n R
l, tl1y6,
-A s R
re1
6l7e , c R te1d8, f R ro19m , R 2H0, , R -h21a , l R o,22 = , O R ,23 -, O R H24, , - R C31
1-, 6a R lk32 35 and R36 are y , l, R -3O3 R -C34
1,- optionally and independently substituted w ainthd fr–oHmet6; wherein each of said -C1-6alkyl is –OH, -O-C1-6alkyl, -S-C1-6alkyl, -C3-6cycloalkyl, -He 1 to 3 substituents selected from–halo, R27 and R28, are each independently selected from–H, t6 -C , - 1 A -6 r a 6 lk a y n l d , - C N 3- R37
6cy R c 38;
25 R37 a Cn1d-6a Rlk3y8,l, a -Cre3-6 ecaycchlo ianldkeypendently selected from–H, -halo, -OH, -C1-6laolaklykly,l - aOn-dC -1H-6aeltk2y:l, -S- X1 is selected from–C1-6all,k -yAl-r,7– aOnd-C–1H-6aeltk7;yl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 6 saulbksytl-it,ut -eNdR w3-i,th a fnrdom -O 1-; to w 3h seurebisn each of said -C1-6alkyl- is optionally and independently 30 X2 isS- sCe1l-e6acltkeydl, f -rpohmen–yCl,1 a-6nadlk -yNl-R,3–3R tituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, - O3-4C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR2-C1- 6 saulbksytl-it,ut -eNdR w2-i,th a fnrdom -O 1-; to w 3he sruebinsti etuaecnhts o sfe sleacidted -C fr1o-6malk–yhl-al ios, o -OptHio,n -aCll1y-6a alknydl, i -nOd-eCp1e-6nadlently 35 S-C
op r1-6
ti4o ,a
n Al
al rk
l5y
y,l,
c A -p
or m6h kyl, - Ar ,e
pr an
is ny
idl an
ng Ad
1r7 -N
to aR
3re31
1, A R
he e3
ta2
ec;
rh oa i t n o d m e s pe s n e d le e c n te tly d f a rom 5- O to , N 10 a-n m d e S m ; b e e a red aromatic cycle Ar Ar6, and Ar7 being optionally and independently substituted wchith of f sroamid A 1r1 5, , to Ar4, substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, and–NR19R203; -60- whahleorein each of said -C1-6alkyl is optionally and independently substituted with from 1 to 3 - Het1 h , a H v e;
in t2 g , H fro e m t4, 1 H t e o t5 3 , H h e e t t 6 e , r a oa n t d om He s t7 se a l r e e ct e e a d ch fro in m de O p , e N nd a e n n d tly S a ; w 3 h-e to re 1 in 0- e m a e ch mb o e f r s e a d id h H et e e t r 1 o , c H y e cle 5 H suet4, Het5, Het6, and Het7 is optionally and independently substituted with from 1 tot23, bstituents selected from–halo, -OH,–C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, =O, -
Figure imgf000062_0001
(C=O)-C1- 6 saulbksytl,i and -NR21R22; wherein each of said -C1-6alkyl is optionally and indp d tly 10 Het8 a ins a 3tu-te tod 1 w0it-hm ferommbe 1re tod 3 he -htearloo;cycle having from 1 to 3 heteroatoms selected from O, N w sehd
leer S
ce;
teind s faroidm H–ehta8l ios, o -OptHio,n–aClly1-6 aanlkdy iln,d -Cep1-e6anldkeylnetnlye, su -Cbs1-t6iatulkted with from 1 to 3 substituents -O-C1-6alkyl, -S-C1-6alkyl, =O, -
Figure imgf000062_0002
(C=O)-C1-6alkyl yl-C3-6cycloalkyl, -C3-6cycloalkyl, 15 each of said -C1-6alkyl is optio lly d idp,d -Cen1-6alkyl-O-C1-6alkyl and -NR21R22; wherein Z wherein when R1 is–H, then at l t ht atomtly o sfu Hbestti8tu iste adtt wacithhe fdro tmo X 12 to 3 -halo; 1, Z2, Z3, Z4 and Z5 are each independently selected from C and N.
I snte arenooitshoemre pra,rt tiacuutlar embodiment the present invention provides compounds of formula Ia or a 20 s Ro1lv isat
(C se
=e t
Slhee
)cr
-Rteeodf, omer, racemic, metabolite, pro- or predrug, salt, hydrate, N-oxide form, or fr wohmer–eHin,–halo, -ORH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, -NR9
4, -SO2-R4, -CN, -N9-SO2-R4, -C3-6cycloalkyl, -O-C3-6cycloa R10, -(C=O)-R4, - wherein each of said -C1-6alkyl is optionally and independently substilkyl, -Ar1 and–Het1; 25 substituents selected from–halo, -OR35, -NR11R12, -O-C1-6alkyl, and -tuted with from 1 to 3 R5 is attyal,ch -NedR to Z1 or Z5 and i -s(C s=eSle)c-Rted from–H,–halo, -OH, -C1-6alkSy-lC,1 --O6a
c-l
yCky
cl1o-l6;
6alk 6R7, -(C=O)-R8, 8, -SO2-R8, -CN, -NR6-SO2-R8, -C3-6 aallkk
6c yyll,, - -OS--CC1- 3- suybcslotitaulkteydl, w -Aitrh5 f aronmd– 1H teot53; w suhbesrteitiune enatsch se olefc staeidd f -rCom1-6a–lhkyallo is, - oOpRtio36n,a -lNly and independently 30 s an
6a sd
lk e y l -eS
l i c- stCe1
od- R23R24, -O-C1-6alkyl, R 6
2 i a
pt f i rl
ook
nmyl;
ally –H a , nd -h i a n l d o e , p -e O n H d , en -C tly 1-6 s a u lk b y s l, and -C3-6cycloalkyl,; wherein each of said -C1-halo,–OR27, and - tituted with from 1 to 3 substituents selected from R is selected NR13R14
3 ; 35 option from–H, -halo, -OH, -C1-6alkyl, -C3-6cycloalkyl; wherein each of said -C1-6alky o l , i s R OR28 R,ally and independently substituted with from 1 to 3 substituents selected from–hal
8 an adre -N eRa1c5hR1 in6
4 and ;dependently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- R 6
6, Ralkyl, -NR17R18, -C3-6cycloalkyl, -O-C3-6cycloalk1yl, -Ar4 and -Het4;
R7
3, 4, R R 9
3, 5 R a 1 n 0 d , R R 11
36 , a R re 12, ea R c 1 h 3, in R d 14 e , p R en 15 d , e R n 1 t 6 ly , R se 1 l 7 e , c R ted 8, f R ro 1 m 9, R –H 20 , , - R ha 21 l , o, R = 2 O 2, , R -O 23 H , R , - 2 C 4, 1- R31
6alk , y R l, 3 -2 O , R -C 33
1,- -61- 6 oapltkioyln,a -llSy- aCn1d-6a inlkdyel,pe -Cnd3-e6cnytlcylo saulbkyslt,itu -tAerd6 w ainthd fr–oHmet 16; to w 3he sruebinstit euaecnhts o sfele sactided - fCr1-6alkyl is –OH, -O-C1-6alkyl, -S-C1-6alkyl, -C3-6cycloalkyl, -Het6, -Ar6 and–NR37R38; om–halo, 5 R R27
37 a and R28, are each independently selected from–H, -C1-6alkyl, -C3-6cycloalkyl and -He
Cn1d-6a Rlk3y8,l, a -Cre3-6 ecaycchlo ianldkeylp,e -Andently selected from–H, -halo, -OH, -C1-6alkyl, -O-C1-6altk2y:l, -S- X s selected from–C1-6alkyl-r,7– aOnd-C–1H-6aeltk7
1 i ;yl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 10 X 6
2 is al s k e y l l e -, c -te N d R3 f-ro a m nd C O 1--6 ; alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1- Ar 6
1,a
o Al
prk
ti4y
o,l- n A, - alrN
l5y,R
c A2- or,
m6 a,n
pr ad
isn - idO- ng A;
1r7 to a 3re he etaecrhoa itnodmespe snedleecnttly a 5- to 10-membered aromatic cycle Ar5, Ar6, and Ar7 being optionally and indeepden frdoemntl O, N and S; each of said Ar1, Ar4, substituents selected from–halo, -OH, -C1-6alkyl, -O-yC1 s-6uabstituted with from 1 to 3 15 wherein each of said -C1-6alkyl is optionally and indepen lkyl, -S-C1-6alkyl,–NR19R20; et1 h dently substituted with from 1 to 3 - H h,a
a Hlo
ve;
int2g, H froemt4, 1 H teot53, H heett6e,r aoantdom Hest7 se alreect eeadch fro inmde Opendently a 3- to 10-membered heterocycle Het4, Het5, Het6, and Het7 is optionally and in,d Nep aend S; wherein each of said Het1, Het2, 20 s 6a u l b k s y t l, itu a e n n d ts - s N e R le 2 c 1 t R e 2 d 2; fro w m he re h i a n lo e , a -O ch H, o f C s 1 a -6 i a d lky -l, -O-nCd1e-6natllkyyl s,u -bSs-Ctit1u-6taedlky wl,it =hO f,ro -
Figure imgf000063_0001
(mC= 1O) t-oC13- substi C1-6alkyl is optionally and indp d tly Het8 is a 3tu-te tod 1 w0it-hm from 1 to 3 -halo; 25 and S embered heterocycle having from 1 to 3 heteroatoms selected from O, N w sehleerce;
tein
-O d s faroidm H–ehta8l ios, o -OptHio,n–aClly1-6 aanlkdy iln,d -Cep1-e6anldkeylnetnlye, su -Cbs1-t6iatulkteydl-C w3i-t6hcy fcrolomalk 1y tl,o - 3C3 s-6ucbysctliotuaelknyts ea-C1-6alkyl, -S-C1-6alkyl, =O, -(C=O)-C1-6alkyl, -C1-6alkyl-O-C1-6alkyl and -NR2 l, whcehre oinf s wahiden -C R o
Figure imgf000063_0002
1 is–H lly d idp dently substituted with from 1 to1
1-6alkyl is opti R 322 -;h wherein 30 ac , h th i e n n de a p t e l nde t ntly s h ele t cted at f o ro m m o C f alo;
Z H a e n t d 8 i N s . attached to X2
1, Z2, Z3, Z4 and Z5 are e
I snte arenooitshoemre pra,rt ti
,acu
wuhtlaor
em e
reem
inr,b roadciemmeinct, t mheet parbeosleitnt invention provides compounds of formula Ia or a 35 solvate thereof e, pro- or predrug, salt, hydrate, N-oxide form, or R1 is (C s=eSle)c-Rte4d, - frSoOm2-–RH4,, -–ChNal,o, -N -ORH9-,S -OC1-6
2-Ra4l,ky -Cl,3 --O6c-yCc1lo-6aallkkyyll,, - -SO--CC1-6
3-6aclykcyllo,a -NlkRyl,9R -1A0r,1 -( aCn=dO)–-HRe4,t - whbesrteitiune enatsch se olefc staeidd f -rCom–halo, -OR35, -NllyR a11nRd12 i,n -dOe-pCe1n-6daelknytlly, a snudbs -Stit-uCte1-d6a wlkiythl; from 1 to1
1-6alkyl is optiona 3; su -62- R5 is attached to Z1 or Z5 and is selected from–H,–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- 6alkyl, -NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3- 6
5 scuycloalkyl, -Ar5 and–Het5; wherein each of said -C1-6alkyl is optionally and independently R2 is anbdstituted with from 1 to 3 substituents selected from–halo, -OR36, -NR23R24, -O-C1-6alkyl, is se olpe -S
tciot-eC6
nd1- al flra
yolkmyl
an–;
dH i,n -dheapleo,n -dOeHnt,ly -C s1u-6baslktiytul,te adnd w -iCth3-6 frcoymclo 1alk toyl; 3 w shuebrsetinitu eeanctsh o sf said -C1-6alkyl halo
10 i hsal ol
ope, ,tc– –iotOe
OndR elected from– R 2
al f7
lryo,m an
an–d
dH -N
i,n -R
dh1
ea3
3 is se plR -;
eo,14
ndOeHnt,ly -C s1u-6baslktiytul,te adnd w -iCth3-6 frcoymclo 1alk toyl; 3 w shuebrsetinitu eeanctsh o sfe sleacidte -dC f1r-o6amlky–l R 7, R9, RR28
10,, R a1n1d, - RN1R15
6, R 2, RR16
13,;
independently selected from R–H14,, R -h1a5,lo R,1 =6,O R,19 -,O RH2,0, - RC21
1-6,a Rlk2y2l,, R -O31-,C R32
1-6a,l Rky3l3, a -nSd-C R34
1-6a alkryel, e -aCc3h- 15 6 sc
Cuybcslotitaulk
otey
adl,
lk w -A
yli,thr6
-H f a
eron
tmd 1–H toet 36; s wuhbesrtietuinen etsac shele ocfte sadid fro -mC1-–6halaklyol, i–sO oHp,ti -oOn-aCll1y-6a alnkydl, in -Sd-eCp1e-6ndently 3-6cycl 6, -Ar6 and– alkyl, - R R7
37 a anndd R R28
38,, a arree e eaacchh in inddeep R
peennd N
deen R
nt 3 ly 7
tly s 3 e 8
2 sl ;
eelcetcetded fro frmom–H–,H -,C -1h-6aallok,y -l,O -CH3,-6 -cCy1c-6laolaklykly,l - aOn-dC -1H-6aeltk2: 20 C1-6alkyl, -C3-6cycloalkyl, -Ar7 and–H yl, -S- X1 is selected from–C1-6alkyl-,–O-C1-6aeltk7;yl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 6 saulbksytl-it,ut -eNdR w3-i,th a fnrdom -O 1-; to w 3h seurebisntit euaecnh of said -C1-6alkyl- is optionally and independently S-C ts selected from–halo, -OH, -C1-6alkyl, -O-C1-6
1-6alkyl, alkyl, - 25 X -phenyl, and -NR33R34
2 is selected from–C1-6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR2-C1- 6 saulbksytl-it,ut -eNdR w2-i,th a fnrdom -O 1-; to w 3he sruebinsti etuaecnhts o sfe sleacidted -C fr1o-6malk–yhl-al ios, o -OptHio,n -aCll1y-6a alknydl, i -nOd-eCp1e-6nadlkeyntly S-C1
optio,-6a
n Al
alrk
l5y
y,l,
c A -p
orm6h,e
pr an l, - Ar1, Ar4 isny
idl an
ng Ad
1r7 -N
to aR
3re31R
he e3
ta2
ec;
rhoa itnodmespe snedleecntetlyd f arom 5- O to, N 10 a-nmde Sm;b eearcehd o aromatic cycle 30 A sur5b,st Aitur6e,nt asn sdele Acr7ted be frinogm o–phtaiolon,a -lOlyH a,n -Cd1-6 inadlkeypl,en -Ode-Cn1tl-y6alk syulb,s -tSitu-Cte1d-6al wkyitlhf
, a f s
nroa dmid A –N 1r1, R1 t9o Ar4 R23, wherein each of said -C 0
1-6alkyl is optionally ; h and independently substituted with from 1 to 3 - 35 Het1 h,a Hloe;t2, Het4, Het5, Het6, and Het7 are each independently a 3- to 10-membered heterocycle
Haevt4in,g H ferotm 1 to 3 heteroatoms selected from O, N and S; wherein each of said Het1, Het2, substituen5t,s H seetl6e,ct aendd fr Homet7– ihsal oop,t -ioOnHa,lly–C a1n-6dalk inydl,e -pOe-nCd1e-6natllkyyl s,u -bSs-Ctit1u-6teadlky wl,it =hO f,ro -(mC= 1O) t-oC13- 6 s a u l b k s y t l, itu a te n d d w -i N th R f 2 r 1 o R m 22 1 ; t w o h 3 er -e h i a n lo; each of said -C1-6alkyl is optionally and ind
Figure imgf000064_0001
p d tly -63- Het8 a is a 3- to 10-membered heterocycle having from 1 to 3 heteroatoms selected from O, N wnhder Se;in at least one of said heteroatoms is attached
5 w wh ein
seher
leercetein w
d s fah
roiedn
m H R
e1
hta8 is
l ios–H
, o -Op,t t
Hihoe n o
,nn
a a
Cllyt
1-6 a le
ana
lkdst
y il,dn
-Ceep h
1eentdeeronatltyom t
sub oo
sf X
t H1
itue o
tte8r
d i Xs2
w a;
ittthac fhroemd t 1o t Xo2; 3 a snudbstituents -O-C -6
1-6alk alkylene, -C1-6alkyl-C3-6cycloalkyl, -C3-6cycloalkyl, each of sayidl, - -CS-1C1-6
-6alkayllk iysl, o =pOtio, -
Figure imgf000065_0001
(Clly=O)-dC i1-6dalkpyl,d -Cen1-t6laylk syulb-Ost-iCtu1t-e6alkyl and -NR21R22; wherein 10 Z1, Z2, Z3, Z4 and Z5 are each indep d tly l td from C and Nd with from 1 to 3 -halo;
In a st sepreeociisfiocm eemr,b toaduitmomenetr, t rhaece pmreics,e mntet ianbvoelnitteio,n pro p-ro ovrid peresdr a com.pound of formula Ia or a solvate thereof as defined in anyone of c ug, salt, hydrate, N-oxide form, or and Z and wherein the further deflianiimtiosns 1 a tond 6, p wrohveisreioinns ea acsh d oeffi snaeidd h Ze1,re Zin2
5 is C; , a Zb3,ov Z4 5 app e 1 ly.
In a st s
oe p
lvre e
ao c
tei i s fi
to c
hm e
ere m
ero, b
f t o a d
au i
st m o dm en
efe t
inr, t
e r h
da e c ine p m re
anic s
y, e
o m nt
neet i
oa n
fb v
co e
ll n
ait t
ie io
m, n
s pr 1o p-ro
to o v r id
7 p e
,re s dr a ug c , o s m al p t, o h u y n d d ra o te f , f N or-m ox u id la e f I o a rm or , o a s r 10-membered heterocycle having from wherein said Het8 is a saturated 3- to 20 wherein the further definitions and provis 1io tnos 3 as he dteefrionaetdom hesre sienle acbtoevde fr aopmply O., N and S; and I snter aeo sispoemcieficr, t eamutboomdeimr,e rnatce thmeic p,r meseetanbto ilnitvee,n ptiroon- o prro pvrieddersug a, s caoltm,p hoyudnradte o,f N f-oorxmiduela f I or a 25 solva i
R1 isnt
sde
e A th orm, or A1 a le2e
c ar
tereeof
d e,
fra w
och
mhere
inHdne
H, ap
-nendently selected from C and N;
R5 i iss s seelleecctteedd f frroomm––H hdal–oh aanlod;
R2 -C1-6alkyl; 30 R3 is selected from–H and -C1-6alkyl;
X X1 is selleecctteedd f frroomm– -OC-C a1n-l6d
ka - yllkC
-y1
,l- –-6,a
O -l
-Nky
CRl;3-C1-6alkyl-, -NR3
2 is se 1-6a 1-6alkyl-, -NR2-C1-6-a,l -kO-;
Het8 isb ast 3it-u to 10-membered heterocycle; wherein said Hyel-t,8 - iNR2-, -O-;
su k e y n l t , s - selected from–halo, -OH,–C1-6alkyl, -C1-6alksyle onpetio,n -Cal3l-y6c syucblosatiltkuytel,d -C w1i-t6hal 1ky tloC33- 35 Z 6cycloal
Figure imgf000065_0002
(C=O)-C1-6ahlk Cyl, and -(C=O)-C3-6
1, Z2, Z3, Z4 and Z cycloalkyl ; and M A1o arend pr Ae2fe arraebl eya,ch independently selected from C and N; -64- R R1
5 i iss s seelleecctteedd from–H and–halo;
R2 is selected f frroomm––HH, a -nhdalo and -C1-6alkyl; 5 R3 is selected from–H and - -CC1-6
1-6aallkkyyl;
X X 1
2 i i s s s s e e l l e e c c t t e e d d f f r r o o m m O O--C C 1-6
1-6 a a l l k k y y l l -, -NRl;3-C1-6alkyl-, -NR3-, -O-;
Het8 is a 3- to 10-me -, -NR2-C1-6alkyl-, -NR2-, -O-;
substituents selemctbeedre frdom het–ehroacloy,cl -eO;H w,he–rCe1in-6a slakiydl, H -eCt8
1-6 iaslk oyplteionnea,ll -yC s3-u6cbysctiltouatelkdyl w kylC3-6 ,i athnd 1 t -oC13- 10 Z 6
1 al
Ev,e Zn2, cycloalkyl; and
m Zo3r,e Z p4r aenfedra Zb5l ay,re A e1a isch N C a.nd A2 is C.
I snter aeo sipsoemcifeicr, e tamubtoomdiemr,en ratc tehmeic p,re mseetnatbo inlivtee,nt pioron- p orro pvirdes a compound of formula Ia or a 15 solvate thereof, wherein edrug, salt, hydrate, N-oxide form, or R R 1
5 i i s s selected from–H and–halo; 20 R2 is a settlaecchteedd f troom Z1– aHnd an is selected from–H and -C1-6alkyl;
R X3
1 i iss s seelleecctt d -C1-6alkyl;
eedd f frroomm––OH- aCnd -C1-6alkyl;
X 1-6
2 is sele alkyl-, -NR3-C1-6alkyl-, -NR3-, -O-;
Het8 is acte 3d- fr toom 1–0O-m-Ce1m-6ablekryel-d, -N NR-c2o-Cnt1a-6inailnkgyl-, h -eNteRr2-, -O-;
substituted with 1 to 3 substituents selected fromo–chyaclloe,; -O wHhe,r–ein said Het8 is optionally 25 C1-6alkyl, -C1-6alkylene, -C3- 6 NcRycloalkyl, -O-C1-6alkyl, -S-C1-6alkyl, =O, -
Figure imgf000066_0001
(C=O)-C1-6alkyl, - Z21
3R, Z2 C1-6alkyl-O-C1-6alkyl and - Z 2
1, Z2, 4 ; a anndd Z5 are each C. 30 s Inte yet another particular emb
solvreaoteis tohmereero,f t,a suetolemcteerd, f rraocmemo
thice,di
li mm
stee
ctn
oatb,
mo t
plhirtiee
s, p present invention provides a compound or a ingr:o- or predrug, salt, hydrate, N-oxide form, or -65- C
Figure imgf000067_0001
p d N1 E pl N1 Cp d N2 E pl N2 C
Figure imgf000067_0002
p d N3 E pl N3 Cp d N4 E pl N4 Cp d N5 E pl N5 Cp d N6 E pl N6 C
Figure imgf000067_0003
p d N7 E pl N7 Cp d N8 E pl N8 -66- C
Figure imgf000068_0001
p d N9 E pl N9 Cp d N10 E pl N10 C
Figure imgf000068_0002
p d N11 E pl N11 Cp d N12 E pl N12 C
Figure imgf000068_0003
p d N13 E pl N13 Cp d N14 E pl N14
Co
Figure imgf000068_0004
p d N15 E pl N15 Cp d N16 E pl N16 -67- C
Figure imgf000069_0001
p d N17, E pl N17 Cp d N18, E pl N18 C
Figure imgf000069_0002
p d N19 E pl N19 Cp d N20 E pl N20 C
Figure imgf000069_0003
p d N21, E pl N21 Cp d N22, E pl N22 C
Figure imgf000069_0004
p d N23 E pl N23 Cp d N24 E pl N24 -68- Co
Figure imgf000070_0001
p d N25 E pl N25 Cp d N26 E pl N26 Cp d N27 E pl N27 Cp d N28 E pl N28 C p d N29 E pl N29 Cp d N30 E pl N30 Co
Figure imgf000070_0003
p d N31 E pl N31 Cp d N32 E ple N32 -69- Comp
Figure imgf000071_0001
d N33 E pl N33 Cp d N34 E pl N34 Co
Figure imgf000071_0002
p d N35 E pl N35 Cp d N36 E pl N36 Co
Figure imgf000071_0003
p d N37, E pl N37 Cp d N38, E pl N38 Co
Figure imgf000071_0004
p d N39 E pl N39 Cp d N40 E pl N40 -70- Co
Figure imgf000072_0001
p d N41, E pl N41 Cp d N42, E pl N42 Comp
Figure imgf000072_0002
d N43 E pl N43 Cp d N44 E pl N44 Co
Figure imgf000072_0003
p d N45 E pl N45 Cp d N46 E pl N46 C
Figure imgf000072_0004
p d N47 E pl N47 Cp d N48 E pl N48 -71- C
Figure imgf000073_0001
p d N49, E pl N49 Cp d N50, E pl N50 Cp d N51 E pl N51 Cp d N52 E pl N52 C
Figure imgf000073_0002
p d N53 E pl N53 Cp d N54 E pl N54 C
Figure imgf000073_0003
p d N55, E pl N55 Cp d N56, E pl N56 -72-
C
Figure imgf000074_0001
p d N57 E pl N57 Cp d N58 E pl N58
C
Figure imgf000074_0002
p d N59, E pl N59 Cp d N60, E pl N60
C
Figure imgf000074_0003
p d N61, E pl N61 Cp d N62, E pl N62
Figure imgf000074_0004
In a Cp d N63, E pl N
c pormefperrirseindg e:mbodiment, the pre 6 se 3 nt invention provides a compound selected from the list -73-
Comp
Figure imgf000075_0001
d N27 E pl N27
Cp d N59 E pl N59 Cop d N43 E pl N43
Cp d N60 E pl N60 Cop d N44 E pl N44 Cp d N62 E pl N62 Cop d N45 E pl N45
Figure imgf000075_0002
Cdp d N63 E pl N63 Preferably the present invention provides a compound which is -74-
and Co
Figure imgf000076_0001
p d N60 E pl N60 Cp d N45, E pl N45. I h n et p e a ro rt a ic ry u l la m r o in iet t y he at c p o o m si p ti o o u n n Z d 1 s in a a cc cc o
a. o rd rd in a g nc to e w th it is h t i h n e ve n n u ti m on b , er t i h n e g a R s 5 p is ro l v in id k e e d d in to F t o h r e mu a l r a yl I o o r r 5 I
-75- F sauirdth ceormmpooreu,n tdhe is p threes Sen-etn invention provides a compound according to this invention, wherein F sauirdth ceormmpooreu,n tdhe is p threesent inavnetinotmioenr. provides a compound according to this invention, wherein 5 T prhoevi cdoemdp inou thneds ex oaf the R p-erensaenntitom inveer.ntion can be prepared according to the reaction schemes only illustrative for tmhepl iensve hnetrioeinna afntedr, th bautt t thhose skilled in the art will appreciate that these are any of several standard synthetic processees co cmompomuonndlsy o ufs tehdis b inyve thnotisoen s ckainlle bde i prepared by 10 organic chemistry. n the art of I vnet ae preferred embodiment, the compounds of the present invention are useful in human or inhibrinary medicine, in particular for use as kinase inhibitors, more in particular for the The pitiroense of LRRK2 kinase.
use of a cnotm inpveonsittiioonn fu crotmheprri psrinogvid seasid th ceo umspeo ouf a compound as defined hereinbefore or the 15 p toar Ptiacruklianrs foonr’s th deis peraesveen atniodn A alnzhde/oimr terer’ast dmiseenat of n n e d u , ro a l s og a ica h l u d m is a o n rd o e r rs v s e u te c r h in a a s ry bu m t e n d o i t ci l n im e i , te in d I hner aein pbreeffoerrere odr t ehmeb uosdeim oefn at, co thmepo insviteionntions pero.vides the use of a compound as defined treatment o comprising said compound in the prevention and/or 20 A f neurological disorders such as but not limited to Parkinson’
T cohlz
mehe
p pi
rrm
iesse
iner’
gnst d
s inis
ave s disease and ideans
cteioo.
mnp fuoruthnedr p fororv uidsees a in co thmepo purnedve anstio dnefin aendd/ hoereinbefore or a composition disorders such as but not limited to Parkinson’s disease and Alzhreim treear’tsm deisneta osfe. neurological 25 F nuumrthbeerre edm sbtaotdeimmeennttss: of the present invention are detailed herein below in the form of 1 p.redrug, A sa clot,m hpyodurantde, o Nf- Fooxirdmeu floarm I o,r or a s sotlevareteoi tshoemreeor,f, tautomer, racemic, metabolite, pro- or
30 Wherein
Figure imgf000077_0001
I -76- R1 is( te
wC s=eSle)c-R4d, f -rSoOm2-–RH4,,– -ChaNl,o, -N -ORH9-,S -OC1-6
2-Ra4lk,y -lC,3 --O6c-yCc1l-o6aallkkyyll,, - -SO--CC1-6
3-6aclykcyllo,a -NlkRyl9,R -1A0,r1 -( aCn=dO–)-HRe4,t1 -; 5 su h b e s r t e i in each of said -C 1-6 alkyl is optionally and independently substituted with from 1 to 3 R5 is 6a alkttyalct
,hu
-Neednts
R6 to s
R7 Ze
,1le
-( octed from–halo, -OR35, -NR11R12, -O-C1-6alkyl, and -S-C1-6alkyl;
Cr= ZO5) a-Rnd8, i -s(C se=lSe)c-tRe8d, f -rSoOm2-RH8,, -ChNal,o, -N -ORH6-,S -OC1-6
2-Ra8l,ky -Cl,3 --6Oc-yCc1lo-6aallkkyyll,, - -OS--CC1- 3- 6 s c u y b c s lo tit a u lk te y d l, - w A i r th 5 a f n ro d m –H 1 et t 5 o ; w 3 h s e u re b i s n tit e u a e c n h ts of s s e a le id ct -e C d 1-6 fr a o lk m yl is ha o l p o t , io -n O a R lly 36 a , n -N d R in 2 d 3R ep 24 e , n -d O e-n C tl 1 y-10 R 6
2 is a
6a s lk
lk e y
yle l,
lc a
is te n
od d - p f t r S
io- o m C1
nal -6alkyl;
ly H, a -halo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1- from–halo,–OR 27 , anndd - inNdRe 1 p 3 eRn 14 dently substituted with from 1 to 3 substituents selected R3 is 6 selected from–H, -halo, -OH, ; -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1- 15 R a fnr a o lk
dm yl
R i
8h s
aa o ionally and i
rleo p , t
e ndependently substituted with from 1 to 3 substituents selected aOcRh2 i8n,d aenpde -nNdRen15tRly16
4 s;elected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- R, R 6a7l,k Ryl9, -NR17R18, -C3-6cycloalkyl, -O-C3-6cycloalkyl, -Ar4 and -Het4
6 ; 20 R , R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R31
34, R35 and R3 , R32, R33, C 6
op1-t6ioanlkaylll,y - aSn-Cd1- i6na a
dlr
ekeypl each independently selected from–H, -halo, =O, -OH, -C1-6alkyl, -O- e,n -dCe3n-6cycloalkyl, -Ar6 and–Het6; wherein each of said -C1-6alkyl is halo,–OH, -O-C1-6alkyl, -S- t C ly 1-6 s a u lk b y s l tituted with from 1 to 3 substituents selected from– R and R28 are each independently sele,c -tCe3d-6 fcryocmlo–aHlk,y -l, -Het6, -Ar6 and–NR37R38
27 ;
R7 and R38 are each independently selected from–H,C -h1a-6laol,k -yl, -C3-6cycloalkyl and -Het2 3 : 25 X C1-6alkyl, -Cr3o-6 OH, -C1-6alkyl, -O-C1-6alkyl, -S- 1 is selected f mcy–cClo1a-6lkaylkl,y -l-A,r–7O an-Cd1–-6Halekty7l;-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 6 saulbksytl-it,u -tNedR w3-i,th and -O-; wherein each of said -C1-6alkyl- is optionally and independently -S-C1-6alkyl, -phe fr n o y m 1 to 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, 30 X2 is 6a s lk e y le l- c , te -N d R fr 2 o -, m a n C d 1l
--,6 O a a
-ln
;kdy w l --N
h, e –R
rO33
ei -R
nC34
1 e -;6 a a c l h ky o l- f , s a S i-d C -1 C -6a 1- l 6 k a y lk l- y , l --C is 1-6 o a p lk t y io l- n N a R lly 2-C an 1-6alkyl-, -NR2-C1- substituted with from 1 to 3 substituents selected from–halo, -OH, -C1-6aldky iln,d -Oependently -S-C1-6alkyl, -phenyl and -NR31R32 -C1-6alkyl, 35 Ar1, o Ar4, Ar5, Ar6, and Ar7 are each; independently
Apr5t,ion Aarl6l,y c aonmdp Arirs7ing be 1in tgo 3 op hteiotenraolalytom ansd se inledcetpeed a
n fdro 5
em- ntl O to
y, s N 10
ub a- sn m
td em
itu Ste; bered aromatic cycle d ea wchith of f sroamid A 1r1, Ar4, substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, and–NR19 toR203 wherein each of said -C1-6alkyl is optionally an ; -halo; d independently substituted with from 1 to 3 -77- Het1 h,e Hteerot2c,y Het4, Het5, Het6, and Het7 are each independently a 3- to 10-membered said Het1c,le He hta2,vi Hnegt4 f,ro Hm 1 to 3 heteroatoms selected from O, N and S; wherein each of 5 from 1 to 3 substituentest5 s,e Het6, and Het7 is optionally and independently substituted with = inOde,p -
Figure imgf000079_0001
(C=dO)t-lCy1-6ablkytilt,t aendd w -lNected from–halo, -OH,–C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, ithR fr2o1Rm221; t woh 3e -rein each of said -C1-6alkyl is optionally and Het8 is a 3- t 10- b ed heterocycle havinhga flro;
and om 1 to 3 heteroatoms selected from O, N wher S;
10 s Cu3b-6scte
yiti
cun
loean s
lta
ksid sel Hecette8d i fsrom op–tihoanlaol,ly -O aHn,d–C in1-d6aelpkeynl,d -eCn1t-6lyalk syulebnseti,tu -tCe1d-6a wlkiythl-C f3r-o6cmyclo 1al tkoyl, 3 - NR yl, -O-C1-6alkyl, -S-C1-6alkyl, =O, -
Figure imgf000079_0002
(C=O)-C1-6
21R alkyl, -C1-6alkyl-O-C1-6alkyl and - from 22; wherein each of said -C1-6alkyl is opti lly d idpendently substituted with w 1 to 3 -halo;
15 Z herein when R1–H, then at least one heteroatom of Het8 is attached to X2
A1
1, a Zn2d, Z A3
2, a Zr4e a enadc Zh5 in adreep eeancdhe inntdlyep seenledcetendtly fr soemle Ccte adnd fro Nm. C and N; and 2
20 R.1 is sel Aec cteodmp frooumnd–H as,– dheafilnoe,d -O inH s,t -aCte1-m6aelknytl 1, wherein
( wCh=eSre)-inR4 e,a -cShO o2f-R sa4,id -C -CN, -NR9-SO2-R4, -C,3 --O6-C1-6alkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, - 1-6alkyl is optio cycloalkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1; s su abttsatcithueednts to s Ze1le ocrte Zd5 f aronmd i–sh saelole,c -tOeRd3n
f5r,a
o -lly and independently substituted with from 1 to 3 R mNR–1H1R,–12h,a -O-C1-6alkyl, and -S-C1-6
5 i alkyl;
C1-6alkyl, -S-C1-6alkyl, -NR6R7, -(C=O)-R8, -(C=Slo, -OH, -C1-6alkyl, -OH, -C1-6alkyl, -O- 25 )-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3- 6 acnydcl ionadlekpyle,n -dOe-nCt3ly-6c syucblosatitlkuytel,d -A wri5th an frdom–H 1e tto5; 3 w shuebresitni each of said -C1-6alkyl is optionally NR23R24, - tuents selected from–halo, -OR36, - R is selectedO fr-oCm1-6–aHlk,yl -,h aanlod, - -SO-CH1,-6
2 -aClk1-y6la;lkyl, and -C3-6cycloalkyl; wherein each of said -C1- 30 6alkyl is optio
R3 is fro smele–chtealdo, fr–oO n
mR al
2 ly 7H, a
, a n n d independently substituted with from 1 to 3 substituents selected -hda -loN,R -1O3RH1,4; -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1- 6 f alkyl is optionally and independently substituted with from 1 to 3 substituent 35 nrodm R–8h aarleo, e– s selected R aOcRh2 i8n,d aenpde -nNdRen15tRly16
4 a s;elected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- R 6
6, Ra
R7l,k Ryl9,, -N RR17
10, RR18
11,, R -C3-6
12,c Ry1c3l,o Ra1lk4,yl R, -1O5,- RC3-6
16,c Ryc17lo,a Rlk18y,l, R -A19r,4 R a2n0d, R -H21e,t R4;22, R23, R24, R31, R32, R33 C34
1-6 , a R lk 3 y 5 l, an -S d- R C 36
1-6a a l r k e yl e , a -c C h 3- i 6 n c d y e c p lo e a n lk d y e l n , t -ly Ar s 6 e a le n c d te d H f e ro t6 m ; w –H he , r -e h i a n lo e , a = c O h , o -O f s H a , i -C1-6alkyl, -O- ohpatloio,n–aOllyH, a -nOd-C in1d-6eaplkeynl,d -eSn-tCly1-6 saulkbyslt,it -uCte3-d6c wycitlhoa flrkoyml, - 1He tot6, 3 -A sru6b asntditu–eNnRts37 sRed
3l8e;c -Cte1d-6a frlkoyml i–s 40 -78- R R27
7 a anndd R R28
38,, a arree e eaacchh i innddeeppeennddeennttllyy s seelleecctteedd f frroomm––HH,, - -Ch1a-6loa,lk -yOl,H -,C -3C-6
1c-y6acllkoyall,k -yOl a-Cnd -Het2 3 : C yl, -C 1-6
1-6alk 3-6cycloalkyl, alkyl, -S- 5 X1 is selected from–C1-6alky -l-A,r–7O an-Cd1–-6Halekty7l;-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- X 6
2 is a s lk e y le l- al c , t -e N d R f 3 r-om and –C 1 O -6-a ; lkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1- Ar 6
1,
10 o Aprk
t4y
io,l- n A,
ar - ll5N
y,R
c A2
or- m6,, an
p ad
rinsd -O
ing A-;
1r7 to ar 3e h eeatecrhoa intodmepse snedleecnttelyd a 5- to 10-membered aromatic cycle A sur5b,st Aitur6e,n atsn sdel Aecr7ted be frinogm o–phtaiolon,a -lOlyH a,n -Cd1-6 inadlkeypl,e -n f
Odro
-em
Cn1t-l O
6y,
alk s Nub asntditu Ste;d ea wchith of f sroaimd A 1r1, to Ar43, wherein each of said -C1-6alkyl is optionally and indepen yl, -S-C1-6alkyl, and–NR19R20;
15 1 - h,ha n y
sae Hl dently substituted with from 1 to 3 Het o itdee;
r Hot2c,
eyt1c H
,leet4
He h,
ta2,v Hi Hne
egt5,
t4 f,ro H
Hmet6
et51,
, t Ho an
e 3d
t6, h ae H
nteet
dr7o Ha a
ettore
7m iss ea
o sc
peh
tiloenc itaed
lldep
y f are
non
dmde
in On
d,tl
e Npe a a 3- to 10-membered nnd S; wherein each of from 1 to 3 substituents selected from–halo, -OH,–C1-6alkyl, -O-dCently substituted with =O, -
Figure imgf000080_0001
(C=O)-C kyl, and -NR 1-6
1-6al 21R22; wherein each of said -C1-6a alkyl, -S-C1-6alkyl, 20 indep d tly btitted with lkyl is optionally and Het8 a insd a 3- t 10- b ed hetero frcoymcle 1 h toav 3in -hga flroo;m 1 to 3 heteroatoms selected from O, N w suhbesr S
te ;
itiunen stasid sel Hecette8d i fsrom op–tihoanlaol,ly -O aHn,d–C in1-d6ependently substituted with from 1 to 3 25 C3-6cycloalkyl, -O-C1-6alkyl, -S alkyl, -C1-6alkylene, -C1-6alkyl-C3-6cycloalkyl, - N froRm21R 122; wherein each of said-C -C1-6
1a-6laklykly,l = iOs, o -p
Figure imgf000080_0002
(tCi=Ol)l-yC1-6adlk iydl, -pCe1n-6daelknytll-yO s-uCb1s-6taitluktyeld an wdith - wherein to w 3h -ehnalo;
Z R1 is–H, then at least one heteroatom of Het8 is attached to X2
A1
1, a Zn2d, Z A3
2, a Z4 and Z5 are each independently selected from C and N; and
30 re each independently selected from C and N.
3 R.1 is s=eSl Ae)c c
-tReo
4dmp
, f -ro
Sou
Omnd
2-–RH as
4,,– d
-Cheafi
Nln
,oe,d
-N -O in
RH s
9-,t
S -a
OCte1-m6
2-aelknytl, 1, -O w-hCe1r-e6ain
(C lkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, - wherein each of said -C1-6alkyl i R4, -C3-6cycloalkyl, -O-C3-6cycloalkyl, -Ar1 andm– 1H teot13; 35 in
R5 is su abttsatcithueednts to s Ze1le ocrte Zd5 f aronmd– ish saelos
le, o
c -Opt
teRio
d3n
f5r,a
o -ll
mNyR a
1n
H1dR,1–2h,d
a -eOp
lo-e
,Cn
-O1d-6e
Han
,lktl
-yy
Cl, s
1 au
-6nb
adst
lky -itSu
l,-t
-Ced
O1--6 with fro
Ca1lk-6yall;kyl, -S-C1- 6alkyl, -NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3- 6 s c u y
lb c
ks lo
ytl,it a u lk
atne y
dd l, - -S w A
-i r
Cth 5 a
1-6 f n rao d
lkm –H
yl; 1 et t 5 o ; w 3 h s e u re b i s n tit e u a e c n h ts of s s e a le id ct -e C d 1-6 fr a o lk m yl is ha o l p o t , io -n O a R lly 36 a , n -N d R in 2 d 3R ep 24 e , n -d O e-n C tl 1 y 40 - 6a -79- R2 is selected from–H, -halo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1- 6 fr a o lk m yl is optionally and independently substituted with from 1 to 3 substituents selected 5 R is selechtealdo, fr–oOmR–27H,, an -hda -loN,R -1O3RH1,4
3 ; -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1- 6 fr a o lk m yl i h s a o lo p , ti o O n R al 2 ly 8, a a n n d d - in N d R e 1 p 5 e R n 1 dently substituted with from 1 to 3 substituents selected R nd R re each independently6
4 a 8 a s;elected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- 10 R 6
6, Ralk Ryl, -NR17R18, -O-C3-6cycloalkyl, -C3-6cyclo
R7, R -H ; C1-6 R9
al3,
k5 R
y a1
l,n0
-d, R
S- R11
C36,
1-6 a R
ar1
le2,
ky e R
l,a1
-c3
Ch, R
3 i-n1
6cd4
ye,
cp R
loe1
an5,
ld R
keyln16 1
,t,l -y R
A sr6e7,
ale Ral nc1k dte8y,l, –d R - H f1A
r9
eo,r4 tm R a2n 6; w–0H,d he,r -2
eh1e,t ia R4 nlo2
e,2
a =,
cO R2
h,3
o -,O R4
f sH2
a,,
id -C R31
-1C-6,
1a R32, R33 34 ,
-lkyl, -O- optionally and independently substit 6alkyl is h uted with from 1 to 3 substituents selected from– 15 R27 anadlo R,–28O,H a, -O-C1-6alkyl, -S-C1-6alkyl, -C3-6cycloalkyl, -Het6, -Ar6 and–NR37R38;
R a Cn1d-6a Rlk38y,l, ar
-re
Ce e
3 eaacchh i innddeeppeennddeennttllyy s seelleecctteedd f frroomm––HH,, - -Ch1a-6loa,lk -yOl,H -,C -3C-6
1c-y6acllkoyall,k -yOl a-Cn1d-6 -aHlkeytl2 37 ,: -S- X -6
1 is selected fromcy–cClo1a-6lkaylkl,y -l-A,r–7O an-Cd1–-6Halekty7l;-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 6 saulbksytl-it,u -tNedR w3-i,th an frdom -O 1-; to w 3he sruebinsti etuaecnhts o sfe slaeicdte -dC f1r-o6amlky–l-ha islo o,p -OtioHnally and independently 20 X -S-C1-6alkyl, -phenyl, and -NR33R34 , -C1-6alkyl, -O-C1-6alkyl, 2 is selected from–C1-6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2 6a -C1- sulbksytl-it,u -tNedR w2-,ith an frdom -O 1-; to w 3herein each of said -C1-6alkyl- is optionally and independently -S-C1-6alkyl, -phenyl and -N substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, 25 Ar, o Aprt4, Ar5, Ar6, and Ar7 areR3 e1Rac32
1 h; independently a 5- to 10-membered aromatic cycle Ar5,ion Aarl6l,y c aonmdp Arisring 1 to 3 heteroatoms selected from O, N and S; each of said Ar1, Ar4, substituents selec7ted be frinogm o–phtaiolnally and independently substituted with from 1 to 3 wherein each of said -C1-6alkyl io, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, and–NR19R20; 30 s optionally and independently substituted wit
Het1 -halo; h from 1 to 3 h,e Hteerot2c,yc Hleet4 h,av Hinegt5, fro Hmet61, to an 3d he Hteetr7oa atorems ea scehle independently a 3- to 10-membered said Het1, Het2, Het4, Het5, Het6, and Het7 is optionctaelldy f arnodm in Od, N and S; wherein each of from 1 to 3 substituents selected from–halo, -OH,–C1-6alkyel,p -eOn-dCe1ntly substituted with 35 = inOde,p -
Figure imgf000081_0001
(C=dO)t-lCy btitt aendd w -iNthR -6
1-6alkyl, fr2o1Rm221; t woherein each of said -C1-6alkyla islky ol,pt -iSo-nCa1ll-y6al aknydl, Het8r iosm a O b,i Nl t 3- t 10-membered hetero 3c -yhcalelo;
f having from 1 to 3 heteroatoms selected 40 w whheerreeiinn a wt a
h leen
nads S
Rt;
1 o inse– oHf, s tahiedn h aette leroaastto omnes i hse atettraocahtoemd t oof X H1e ot8r i Xs2 a;ttached to X2; and -80- w suhbesrteitiunen stasid sel Hecette8d i fsrom op–tihoanlaol,ly -O aHn,d–C in1-d6aelpkeynl,d -eCn1t-6lyal substituted with from 1 to 3 C3-6cycloalkyl, -O-C1-6alkyl kylene, -C1-6alkyl-C3-6cycloalkyl, - NR , -S-C1-6alkyl, =O, -
Figure imgf000082_0001
(C=O)-C1-6alkyl, -C1-6alkyl-O-C1-6alkyl and - 5 21R22; wherein each of said -C1-6alkyl is opti lly d idpendently substit
Z A1
1, a Z fr
n2 o
d, m Z 1 to 3 -halo; uted with A3
2, a Zr4e a enadc Zh5 in adreep eeancdhe inntdlyep seenledcetendtly fr soemle Ccte adnd fro Nm. C and N; and
10 4 p.redrug, A sa clot,m hpyodurantde, o Nf- Fooxrimdeul faor Ima, o orr a so sltvearteeo tishoemreeorf,, tautomer, racemic, metabolite, pro- or
Wh
Figure imgf000082_0002
I
R1 iesre te
15 (C s=ein
Sle)c-R4d, f -rSoOm2-–RH4,,– -ChaNl,, -N -ORH9-,S -OC- 2-R4lk,y -lC, -O-C- lkyl, -S-C- lkyl, -NR9R10, -(C=O)-R4, - w suhbesrteitiune enatsch se olfe scateid 3-6cycloalkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1;
d - fCro1m-6a–lkhyall ios, o -OptRio3n5,a -llNyR a1n1dR i1n2,d -eOp-eCn1d-6eanlktlyyl, s aunbstituted with from 1 to 3 R5 is attached to Z1 or Z5 and is selec-tRe8d, f -rSoOm2-RH8,, -ChNal,o, -N -ORH6-,S -OC1-6
2-Rad
8l,ky -S
-Cl,- 3 -C
-6O1--6Ca1lk-6yall;kyl, -S-C1- 6
6acylkcylol,a -lNR6R7, -(C=O)-R8, -(C=S) cycloalkyl, -O-C3- 20 s kyl, -Ar5 and–Het5; wherein each of said -C1-6alkyl is optionally and inde
6a u l b k s y t l, ituted with from 1 to 3 substituents selected from–halo, -OR36, -NR23R p 24 e , n -d O e-n C tl 1 y- R2 is selec a te n d d - fr S o-m C1 -6 H al , ky
6 -h l; alo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1- 25 fr a o lk m yl i h s a o lo p , ti onally and independently substituted with from 1 to 3 substituents selected R is 6 selected froOmR–27H,, an -hda -loN,R -1O3RH1,4
3 ; -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1- fr a o lk m yl i h s a o l ptionally and independently substituted with from 1 to 3 substituents selected R nd R o,–aOcRh2 i8n,d aenpde -nNdRen15
4 a 8 are e tRly16 s;elected from–hal A o r , 4 a OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- 30 R 6
6, Ralkyl, -NR17R18, -C3-6cycloalkyl, -O-C3-6cycloalkyl, - R7
C3 , R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R2n0d, R -H21e,t R4;22, R23, R24, R31, R32, R33 4, R35, an -Sd- RC36
1-6a alrkeyl e,a -cCh3- i6ncdyecploeanlkdyeln,t -lyAr s6e alencdte–dH ferot6m; w–Hhe,r -ehianlo e,a =cOh, o -Of sHa,id -C -1C-6
1-6alkyl 1a-6lkaylkl,y -lO is- -81- ohpationally and independently substituted with from 1 to 3 substituents selected from– R27 andlo R,–28O,H, -O-C1-6alkyl, -S-C1-6alkyl, -C3-6cycloalkyl, -Het6, -Ar6 and–NR37R38; 5 R37 and R38, are each independently selected from–H, -C1-6alkyl, -C3-6cycloalkyl and -Het2: X C are each independently selected from–H, -halo, -OH, -C1-6alkyl, -O-C1-6
1-6alkytel, alkyl, -S- Nd -C fr3o-6mcy–cClo1a-6lkaylkl,y -l-A,r–7
1 is selec O an-Cd1–-6Halekty7l;-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 6 saulbksytl-it,u -tedR w3-i,th an frdom -O 1-; to w 3he sruebinsti etuaecnhts o sfe slaeicdte -dC1-6alkyl- is optionally and independently 10 -S from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, X2 is s-eCle1-c6atelkdyl f,ro -pmhe–nCy1l-,6a alnkdyl --N,–RO33-RC34
1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR2-C1- 6 saulbkyl-, -NR2-, and -O-; wherein each of said -C1-6alkyl- is optionally and independently -Sstitutlekd with from 1 to 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, 15 Ar1, o A-rC1-6
4, Aar5,y Al,r -6p,h aenndyl A anr 2
7d - aNreR3 e1Rac3h; independently a 5- to 10-m
Apr5t,ion Aarl6l,y c aonmdp Arirs7ing be 1in tgo 3 op hteiotenraolalytom ansd se inledcetpeedn fdroemntl Oy, s Nub a m
sntde
itu Ste;b
d eeare
wcdhith o afromatic cycle f sroamid A 1r1, t Ar4, substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, and–NR19o 3 wherein each of said -C1-6alkyl is optionally and independently substituted with from 1R to20; 20 1 - h,ha
e Hl 3 Het o
te;t2, Het4, Het5, Het6, and Het7 are each independently a 3- to 10-membered saider Hoceyt1c,le He hta2,vi Hng from 1 to 3 heteroatoms selected from O, N and S; wherein each of from 1 to 3 substeittu4, Het5, Het6, and Het7 is optionally and independently substituted with =O, -
Figure imgf000083_0001
(C=O)-C1-6alkyents selected from–halo, -OH,–C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, 25 Het8 in isde ap 3-d t 1t0ly- bbtilt,
et aen
ddd
h w -N
eittehR
ro fr2
co1R
ym22; wherein each of said -C1-6alkyl is optionally and cle 1 h to 3 -halo;
an aving from 1 to 3 heteroatoms selected from O, N w
30 suhd
besr S
te;
itiunen staid sel Hecette8d i fsrom op–tihoanlaol,ly -O aHn,d–C in1-d6aelpkeynl,d -eCn1t-6lyalk syulebnseti,tu -tCe1d-6a wlkiythl-C f3r-o6m 1l tkoyl, 3 C3 s - NR-6
2c1yRc cycloa 2l2o;a wlkhyel,re -Oin-C ea1-c6ahlk oyfl, sa -Sid-C -C1-6
1a-6laklykly,l = iOs, -
Figure imgf000083_0002
(C=O)-C1-6alkyl, -C1-6alkyl-O-C1-6alkyl and - from 1 to opti lly d idpendently substituted with
35 Z wherein w 3 - ahneh
dna
Z Rlo1;
5 ar ise– eHac,h th iennde apte lenadsetn otlnye s heeletectreodat foromm o Cf H aentd8 i Ns. attached to X2
1, Z2, Z3, Z4
5 R.1 is A compound as defined in statement 4, whe
(C s=eSle)c-tRe4d, f -rSoOm2-–RH4,,– -ChaNl,o, -N -ORH9-,S -OC1-6
2-Ra4lk,y -lC,3 --O6c-yCc1r
l-e
o6ain
allkkyyll,, - -SO--CC1-6
3-6aclykcyllo,a -NlkRyl9,R -1A0,r1 -( aC=O)-R4, - w suhbesrteitiune enatsch se olfe scateidd - fCro1m-6a–lkhyall ios, o -OptRio3n5,a -llNyR a1n1dR i1n2,d -eOp-eCn1d-6eanlktlyyl, s aunbdst -itSu-tCed1-6 wailtkhyl f;rnodm– 1H teot13; 40 -82- R5 is attached to Z1 or Z5 and is selected from–H,–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- 6alkyl, -NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3- 6 s c u y b c s lo tit a u lk te y d l, - w A i r th 5 a f n ro d m –H 1 et t 5 o ; w 3 h s e u re b i s n tit e u a e c n h ts of s s e a le id ct -e C d 1-6 fr a o lk m yl is ha o l p o t , io -n O a R lly 36 a , n -N d R in 2 d 3R ep 24 e , n -d O e-ntly 5 C1- R is 6a s lk e y le l, c a te n d d f -r S o-m C1 -6
2 H al , k -y h l; alo, -OH, -C1-6alkyl, and -C3-6cycloalkyl,; wherein each of said -C1- 6 fraolkmyl– ihsa olop,ti–onally and independently substituted with from 1 to 3 substituents selected 10 R s selected fromOR–2H7,, a -hnadl -NR13R14
3 i ;
o hpatloio,n–aOllyR2 a8,n adn idnd -Nep o, -OH, -C1-6alkyl, -C3-6cycloalkyl; wherein each of said -C1-6alkyl is
Re1n5dently substituted with from 1 to 3 substituents selected from– R4 and R8 are each indepeRn1d6;ently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- 15 R, R 6a7l,k Ryl9,, -N RR17
10R18, -C3-6cycloalkyl, -O-C3-6cycloalkyl, -Ar4 and -Het4
6 , R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R;
R 22, R23, R24, R31
C34
1-6,a Rlk3y5l, an -d R36 are each independently selected from–H, -halo, =O, -OH, -C1-6,a Rlk3y2l,, R -O33-, optionall S-C1-6alkyl, -C3-6cycloalkyl, -Ar6 and–Het6; wherein each of said -C1-6alkyl is halo,–O y H, a -n O d -C in 1 dependently substituted with from 1 to 3 substituents selected from– R -6
27 and R28, are each ianldkyl, -S-C1-6alkyl, -C3-6cycloalkyl, -Het6, -Ar6 and–NR37R38;
20 R a Cnd R ndeeppeennddeennttllyy s seelleecctteedd f frroomm––HH,, - -Ch1a-6loa,lk -yOl,H -,C -3C-6
1c-y6cloalkyl and -Het2 37 38
1-6alky,l, a -rCe3 each i alkyl, -O-C1-6alkyl,: -S- X s selected fro-6mcy–cClo1a-6lkaylkl,y -l-A,r–7O an-Cd1–-6Halekty7
1 i l;-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- X 6
2 is a s lk e y le l- c , t -e N d R f 3 r-om and –C 1 O -6-a ;
25 lkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1- Ar 6
1,a
o Al
prk
t4y
io,l- n A,
ar - ll5N
y,R
c A2
or- m6,, an
p ad
rinsd -O
ing A-;
1r7 to ar 3e h eeatecrhoa intodmependently a 5- to 10-membered aromatic cycle A s selected from O, N and S; each of said Ar1, Ar4, sur5b,st Aitur6e,n atsnd Ar7 being optionally and independently substituted with from 1 to 3 30 wherein each s oefle scatiedd -C fr1o-6malk–ylh iaslo o,pt -iOonHa,lly -C a1n-6dal iknydle,p -eOn-dCe1n-6talylk syul,bs -Stit-uCte1-d6a wlkiythl, fr–oNmR 119R to203; Het1 -halo;
h,e Hteerot2c,yc Hleet4 h,av Het5, Het6, and Het7 are each independently a 3- to 10-membered said Het1, Het2,i Hnegt4 f,ro Hmet51, to 3 heteroatoms selected from O, N and S; wherein each of 35 f =rOom, - 1(C t=oO 3)-C su1-b6satliktuyle,n atsn se Hleect6t,e adn fdro Hmet–7h isal oop,t -ioOnHa,lly–C an1-d6a ilnkdyel,p -eOn-dCe1n-6talylk syul,bs -Stit-uCt1e-6da wlkiythl, indep d tly btittedd w -iNthR fr2o1Rm221; t woherein each of said -C1-6alkyl is optionally and Het
Figure imgf000084_0001
8 insd a S 3;- t 10- b ed heterocycle hav 3in -hga flroo;
a m 1 to 3 heteroatoms selected from O, N -83- w suhbesrteitiunen stasid Het8 is optionally and independently substituted with from 1 to 3 C3-6cyclo selected from–halo, -OH,–C1-6alkyl, -C1-6alkylene, -C1-6alkyl-C3-6cycloalkyl, - NR21 alkyl, -O-C1-6alkyl, -S-C1-6alkyl, =O, -
Figure imgf000085_0001
(C=O)-C1-6alkyl, -C1-6alkyl-O-C1-6alkyl and - 5 f R22; wherein each of said -C1-6alkyl is opti lly d idpendently substitute
wrom 1 to 3 -halo; d with Z1, Z2,h Zer3e,i Zn4 w ahnedn Z R1
5 ar ise– eHac,h th iennde apte lenadsetn otlnye s heeletectreodat foromm o Cf H aentd8 i Ns. attached to X2 10 6 R.1 is (C s=eSl Ae)c c
-teodmp frooumnd–H as,– dheafilnoe,d -O inH s,t -aCte1-m6aelknytl, 4 - wOh-Cer1e-6ianlkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, - whereinR4 e,a -SO2-R4, -CN, -NR9-SO2-R4, -C3-6cycloalkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1; substituentsch s of said -C1-6alkyl is optionally and independently substituted with from 1 to 3 R5 is attached to Ze1le ocrte Zd5 f aronm–halo, -OR35, -NR11R12, -O-C1-6alkyl, and -S-C1-6alkyl;
15 d is selected from–H,–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- 6
6acylkcylol,a -lNkyRl, 6R -A 7 r,5 - a(Cn=dO)H-Ret 8
5,; -(C=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3- substituted with from 1 to w 3 h s e u re b i s n tit e u a e c n h ts of s s e a le id ct -e C d 1-6 fr a o lk m yl is ha o l p o t , io -n O a R lly 36 a , n -N d R in 2 d 3R ep 24 e , n -d O e-n C tl 1 y- R is 6a s lk e y le l, c a te n d d - f S-C1-6
2 alkyl;
20 6 r i o o m–H, -halo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1- is fr a o lk
sm yl
ele– i
ch s
tea o ldo p , t
fr–oO n
mR al
2 ly 7H, a
, a n n d
-hda - independently substituted with from 1 to 3 substituents selected R loN,R -1O3RH1,4
3 ; -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1- 6alkyl is optionally and independently substituted with from 1 to 3 substituents selected 25 R ind,e R fro
p7e, m
n R
de9, h
n R al
tly1 o 0 , ,
s R O
el1e1 R
c, 2
t R 8,
ed12 a , n
fr R d
o1 - m3 N , R R 15
H14 R
,, R 16
6 -h1 ;
a5,lo R,1 =6,O R,19 -O, RH2,0, -C R21, R22, R31
1-6alkyl, -O-,C R32
1-6a,l Rky3l3, a -nSd-C R34
1-6a alkryel, e -aCc3h- 6 scuybcslotitaulkteydl, w -Aithr6 f aronmd 1–H toet 36; s wubhsetrietuinen etsac shele ocfte sadid fro -mC1-–6haalklyol, i–sO oHp,ti -oOn-aClly and independently 30 C 1-6
3-6cycloalkyl, -He alkyl, -S-C1-6alkyl, - R R7
37 a annd
1d R
-6a R28
lk38,
y, a
l, ar
-re
Ce e
3 ea t6 h -A -6ac , ccyh i
clo in r
nd 6 ade a lkep n ype d–NR37R38
2 ;
ennddeennttllyy s seelleecctteedd f frroomm––HH,, - -Ch1a-6loa,lk -yOl,H -,C -3C-6
1c-y6acllkoyall,k -yOl a-Cn1d-6 -aHlkeytl2,: C -S- X1 is selected from–C1-6alkl,y -l-A,r–7O an-Cd1–-6Halekty7l;-,–S-C1-6alkyl-, -C1-6alkyl-NR ly 3-C1-6alkyl-, -NR3-C1- 35 6 sa
-S ul
-bk
Csy 1- a6
1tl-i N
-t,
6u - at l edR
kyl, w3- -i,
pth an
he frd
no y m -O
l, a 1-;
n t d o w 3he sruebinsti etuaecnhts o sfe slaeicdte -dC f1r-o6amlky–l-ha islo o,p -OtioHn,a -lC anldky iln,d -Oep-Cen1-d6aelnktylyl, X -NR33R34
2 is a selected fro , m–C1-6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR2-C1- s 6
0 -Su l
-b k
Cs y t l- i-t ,
6u - at N
lekd R
yl, w 2- -ipth an
he fr d
noym -O
l a 1 -;
nd to w e
-N 3 he
R s r
3u e
1b in
Rs3t2i;tu a e ch nts of se s l a e i c d te -C d 1 f-r 6 o a m lky l- ha is lo o , p -O tio H n , a -l C ly 1- a 6a n l d ky i l n , d -O ep -C en 1- d 6 ently 4 1 alkyl, -84- Ar1, o Aprt4io,n Aarll5y, c Aorm6,p arinsding A 1r7 to ar 3e h eeatecrhoa intodmepse snedleecnttelyd a fro 5m- O to, N 10 a-nmdem S;b eearecdh o afro smaidatic cycle Ar5, Ar6, and Ar7 being optionally and independently substituted with fr Ar1, Ar4, substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- om 1 to 3 5 wherein each of said -C 6
1-6alkyl is optionally and independe alkyl, and–NR19R20; et1 - h,h ntly substituted with from 1 to 3 H a
e Hlo
tee;
rot2c,yc Hleet4 h,av Hinegt5, fro Hmet61, to an 3d he Hteetr7oa atorems ea sceh independently a 3- to 10-membered said Het1, Het2, Het4, Het5, Het6, and Het7 is o lected from O, N and S; wherein each of 10 f =rOom, - 1 u
Figure imgf000086_0001
(C t=oO 3)-C su1-b6satliktylents selected from–halop,t -ioOnHa,lly–C an1-d6a ilnkdyel,p -eOn-dCe1n-6talylk syul,bs -Stit-uCt1e-6da wlkiythl, indep d tly btit,t aend -NR21R22; wherein each of said -C1-6alkyl is optionally and Het8 is a 3- t 10- b edd h weittehro frcoymcle 1 h toav 3in -hga flroo;m 1 to 3 heteroatom
15 ad s selected from O, N wn
whe
whher S
re;
eiinn a wth leenas Rt1 o inse– oHf, s tahiedn h aette leroaastto omnes i hse atettraocahtoemd t oof X H1e ot8r i Xs2 a;ttached to X2; a Cbesrteitiunen stasid sel Hecette8d i fsrom op–tihoanlaol,ly -O aHn,d–C in1-d nd su 6aelpkeynl,d -eCn1t-6lyalk syulebnseti,tu -tCe1d-6a wlkiythl-C f3r-o6m 1 to 3 20 3-6cycloalkyl, -O-C1-6alkyl, -S-C1-6alkyl, =O, -
Figure imgf000086_0002
(C=O)-C1-6a cycloalkyl, - N fR21R22; wherein each of said -C1-6alkyl is opti lly dlk iydl, -pCe1n-6daelknytll-yO s-uCb1s-6taitluktyeld an wdith - Z1, Zr2o,m Z3, 1 Z to4 a 3n -dha Zl5o a;re each independently selected from C and N. 25 7. A p compound of Formula Ia or Formula I or a ste
straot-e omre pnrtesd 1ru tog, 6 s,a wlth,e hryedinra etea,ch N-oxide form, orre sooislvoamteer t,h tearuetoofm aesr, d reafcineemdic i,n m aentyaobnoelite o,f definitions and provisions as defin oefd sa inid s Zta1,te Zm2,e Zn3ts, Z 14 t aon 6d a Zp5p ilsy. C; and wherein the further
30 A 8.
R1 A compound as defined in one of statements 1 t
1 a isn sde Ale2c atered e frach independently selected from Co an 3d w Nh;erein R5 is selected froomm––HH, a -nhda–halo;
R2 is selected from–H a lo and -C1-6alkyl; 35 R3 is selected from–H anndd - -C1-6alkyl;
X X1
2 i iss sel
8 i sse aleec
3ctted
-e td f
o from -C1-6
1ro0m–
-m -O
eCm1-b6aelrka
eylC1-6alkyl; dlk-y,l
h–-,
eO - te-N
rCR3
oc1-y6-aC
cll1-6alkyl-, -NR3-, -O-;
Het eky
,;l
- w-,
Oh - HeN
,rRe2-C1-6alkyl-, -NR2-, -On-;
3 substituents selected from–halo –inC s1-a6aidlk Hyle,t8 -C is1-6 oapltkioyleanlely, s -uCb3s-6tcityuctelodal wkyitlh, 1 -C t1o- 40 Z 6
1, Z2 a , lk Z y 3 l , -C Z 3-6
4 a c n y d cl Z o 5 al a k r y e l, e -(C= h O C )-C1-6alkyl, and -(C=O)-C3-6
Figure imgf000086_0003
cycloalkyl ; and -85- 9 A.1 A an cdom A2po aurend ea acsh d ienfdineepden inde sntatltyem seelnetct 8ed wh ferein 5 R1 is select rom–H and–h rom C and N;
R R5
2 i ed f
is sele alo;
s cted from–H, -halo and -C1-6alkyl;
R selected from–H and -C1-6
3 is selecte alkyl;
X1 is selected d f f r r o o m m O H- and -C1-6alkyl;
X is selected from–O-CC1-6
1-6aallkkyyll--,, - -NNRR3
2--CC1-6
2 1-6aallkkyl-, -NR3-, -O-;
10 Het8 r- 3 is su ab 3s-tit tuoe 1n0ts-m seemlecbteerded fro hmete–rhoaclyoc,le -O;H w,hy
el
Ce,
1i - -nN
6a sR
lka2
yi-d, - l, HO
-Ce- 1t;8
-6a islk oypletnioen,a -lCly3- s6ucybcsltoitaultkeydl, w ainthd 1 -C t1o- Z 6
1, Z2a,lk Zy3l,-C Z3-6
4 acnydcl Zo5al akryel; e aancdh C.
15 10. A compound as defined in statement 8 or 9 wherein A1 is N and A2 is C.
11.A pr ceodmrupgo,u snadlt, o hfyd Froartme,u Nla-o Ixaide or fo arm s,te orre sooislvoamteer th,e traeuotof,mer, racemic, metabolite, pro- or
20 W in
Figure imgf000087_0001
I
R R1h R5 iesr 2 i is se s ae
settl
lae
ecc
chte
teed
dd f
f tr
room
om Z1–
aH
Hnd an
a isd s–ehleclte;d from–H and -C1-6alkyl;
R3 is selected from–H anndd - -CC1-6
1-6aalkyl;
25 X X1
2 is se om
t is 8 s is elleec d
acttee 3 d f
- fr
tr o om–O-C1-6alkyl-,l -kNyRl;3-C1-6alkyl-, -NR3-, -O-;
He 10 -O m-e C m1-b6 a e l r k e y d l-, N -N -c R o2n -C ta1i-n6 a in lk g yl h -, e -t N er R 2 -, -O-;
sub-6sctyitculoteadlk wyli,th -O 1-C to1- 36a slkuybl,st -iStu-eCn1-t6sal skeylle,c =teOd, f -r(oCmoc
=O–y
)hcle; wherein said Het8 is optionally C3 -aCl1o-6,a -lOkyHl,, -–CC1-6
1-6aalklkyyl-l,O --CC1-6
1-6aallkkyyllen aen, - 30 Z1, ZN2R21
3R, Z22
4 ; a anndd d - , Z Z5 are each C.
Figure imgf000087_0002
-86- 12. A compound selected from the list comprising:
Cp d N1 E pl N1 Cp d N2 E pl N2 Cp d N3 E pl N3 Cp d N4 E pl N4 Cp d N5 E pl N5 Cp d N6 E pl N6 C
Figure imgf000088_0001
p d N7 E pl N7 Cp d N8 E pl N8 -87- C
Figure imgf000089_0001
p d N9 E pl N9 Cp d N10 E pl N10 Cp d N11 E pl N11 Cp d N12 E pl N12 C
Figure imgf000089_0002
p d N13 E pl N13 Cp d N14 E pl N14
Co
Figure imgf000089_0003
p d N15 E pl N15 Cp d N16 E pl N16 -88- C
Figure imgf000090_0001
p d N17, E pl N17 Cp d N18, E pl N18 C
Figure imgf000090_0002
p d N19 E pl N19 Cp d N20 E pl N20 C
Figure imgf000090_0003
p d N21, E pl N21 Cp d N22, E pl N22 C
Figure imgf000090_0004
p d N23 E pl N23 Cp d N24 E pl N24 -89- Co
Figure imgf000091_0001
p d N25 E pl N25 Cp d N26 E pl N26 Cp d N27 E pl N27 Cp d N28 E pl N28 C
Figure imgf000091_0002
p d N29 E pl N29 Cp d N30 E pl N30 Co
Figure imgf000091_0003
p d N31 E pl N31 Cp d N32 E ple N32 -90- Comp
Figure imgf000092_0001
d N33 E pl N33 Cp d N34 E pl N34 Co
Figure imgf000092_0002
p d N35 E pl N35 Cp d N36 E pl N36 Co
Figure imgf000092_0003
p d N37, E pl N37 Cp d N38, E pl N38 Co
Figure imgf000092_0004
p d N39 E pl N39 Cp d N40 E pl N40 -91- Co
Figure imgf000093_0001
p d N41, E pl N41 Cp d N42, E pl N42 Comp
Figure imgf000093_0002
d N43 E pl N43 Cp d N44 E pl N44 Co
Figure imgf000093_0003
p d N45 E pl N45 Cp d N46 E pl N46 C
Figure imgf000093_0004
p d N47 E pl N47 Cp d N48 E pl N48 -92- C
Figure imgf000094_0001
p d N49 E pl N49 Cp d N50 E pl N50 Co
Figure imgf000094_0002
p d N51 E pl N51 Cp d N52 E pl N52 C
Figure imgf000094_0003
p d N53 E pl N53 Cp d N54 E pl N54 C p d N55, E pl N55 Cp d N56, E pl N56 -93-
Cp d N57 E pl N57 Cp d N58 E pl N58 C
Figure imgf000095_0001
p d N59, E pl N59 Cp d N60, E pl N60 C
Figure imgf000095_0002
p d N61, E pl N61 Cp d N62, E pl N62 C
Figure imgf000095_0003
p d N63, E pl N63
5 -94- 13. A compound as defined in statement 11 which is selected from
Comp
Figure imgf000096_0001
d N46 E pl N46 Cp d N27 E pl N27
Comp d N47 E pl N47
Figure imgf000096_0002
Cp d N43, E pl N43
Cop d N48 E pl N48
Cp d N44 E pl N44
Cop d N50 E pl N50
Figure imgf000096_0003
Cp d N45 E pl N45
Co
Figure imgf000096_0004
p d N49, E pl N49 -95- C
Figure imgf000097_0001
p d N59, E pl N59 Cp d N63 E pl N63 Comp
Figure imgf000097_0002
d N62 E pl N62d Cp d N60, E pl N60 14. A compound as defined in statement 13 which is selected from .
Cp d N27 E pl N27 Cp d N44 E pl N44 C
Figure imgf000097_0003
p d N43 E pl N43 Cp d N45 E pl N45 -96-
C
Figure imgf000098_0001
p d N59, E pl N59 Cp d N62 E pl N62
C
Figure imgf000098_0002
p d N60, E pl N60 Cdp d N63 E pl N63 15. A compound as defined in statement 12 which is selected from
Comp
Figure imgf000098_0003
d N60 E pl N60 and
Co
Figure imgf000098_0004
p d N45, E pl N45. -97- 16. h Aet ceoromaproylu mndoi aectyco artdi pnogsi ttoio ann Zy1 o inne a occfo srtdaatenmceen wtsith 1 t thoe 1 n1u;m whbeerrienign R as5 i psro linvikdeedd t ion t Fheor amruylla or I 5 or Ia.
17. Aen caonmtiopmouenr.d according to any one of statements 1 to 12; wherein said compound is the S-
10 18. Aen caonmtiopmouenr.d according to any one of statements 1 to 12; wherein said compound is the R- 19. A to p 1h8a.rmaceutical composition comprising a compound according to anyone of statements 1 15 20. s Ata cteommepnotu 1n9d f aocrc uosredi ansg a to me adniycoinnee. of statements 1 to 18 or a composition according to 21. s Atat ceommepnotu 1n9d f aocrco ursdein ign t tohe an dyioangeno osfis s,ta ptreemveennttison 1 a tnod 1/o8r o trrea atm coemntpo osfit aion LR according to 20 associated disease. RK2-kinase 22. s Atat ceommepnotu 1n9d f aocrco ursdein ign t tohe an dyioangeno osfis s
e; ,ta ptreemveennts 1 to 18 or a composition accordings teo 25 d aisssoorcdieartse,d su dci tion and/or treatment of a LRRK2-kina hse aass Par wkihnesorenin’s d thiseea LseRR orK A2l-zkhineaimseer’ ass dsioseciaasteed. disease is a neurological 23. d Use of a compound as defined in any one of statements 1 to 18, or a composition as kefined in statement 19, suitable for inhibiting the activity of a kinase; in particular a LRRK2 30 inase.
24. s Utasteem ofe ant c 1o9m,p foorun thde a dcicaording to anyone of statement 1 to 18 or a composition according to disease. gnosis, prevention and/or treatment of a LRRK2-kinase associated 35 25. m Ae mtheotdho cdom foprri tshineg p aredvmeinntiisotner ainngd/ toor a tre suabtmjeecntt in of a LRRK2-kinase associated disease; said one of statements 1 to 19 or a composition accord nienegd to th setraeteomf aen cto 1m2p.ound according to any
40 M H
proE
emT
drpuoO
guD
,n sd O -98- C asF
lt, o T
hfR
y fdoE
rrA
amT
teuM
,laEN
N- (oI)T
xid aend for (mIa,) o ar s sotelvraetoeis tohmereero,f, ta aurteom inehrib,it roarcse omfic L,R mRKet2ab koinliates,e p arcot- or 5 and are thus believed to be of potential use in t treatment of neurological disorders includivinitgy P he
vaasrkciunlsaorn d'sem deisnease, Alzheimer's disease, dementia (including Lewy body dementia and grain disease,t Piaic),k's age related memory dysfunction, mild cognitive impairment, argyrophilic inherited frontotempora dlis deeamse, corticobasal degeneration, progressive supranuclear palsy, 10 withdrawal symptoms/relapsee anstsiaoc aiantded p warikinsonism linked to chromosome 17 (FTDP-17), r Inen thale, b croenatestx,t lu onfg th,e pr porsetsaetent ca innvceenrtsio ans, t wreeallth
t amse a dr
ncu
tug
ot addiction, L-Dopa induced dyskinesia, and fe P mayrkeilnosgoenn'sou dsis leeukemia (AML).
of idiopathic Parkinson's disease and familial Parkinson's disease. Inas oene refers to the treatment Parkinson's disease includes patients expressing LRRK2 kinase bearing th eem Gbo2d0i1ment, familial 15 or the R1441G mutation. Treatment of Par 9S mutation d triesaetams kinson's disease may be symptomatic or may be een mt.o Cdifying. In one embodiment, treatment of Parkinson's disease refers to symptomatic as susceptibloem topo punds of the present invention may also be useful in treating patients identified associated with dirsoegarseess piornog tro severe Parkinsonism by means of one of more subtle features cognitive defects, gait or biologeiscsaion such as family history, olfaction deficits, constipation, 20 b syiomchpemical, immunological or Im l a in g d in ic g at t o e r c s h o n f ol d o i g s i e e a s s . e In pro th g i r s es c s o io n n te g x a t, ine tr d ea f t r m om ent mo m le a c y ula b r e , In theto cmonatteicxt o orf d tisheea pse modifying.
of idiopathic Alzheimerre'ssent invention, treatment of Alzheimer's disease refers to the treatment disease may be symptom daitsicea osre m aanyd b familial Alzheimer's disease. Treatment of Alzheimer's 25 A Slizmhielaimrlye,r' tsre daistmeaesnet o reffe dresm toen styiam (pintocmluadte
iinc d triseeaatmseen mt.odifying. In one embodiment, treatment of rel g Lewy body dementia and vascular dementia), age disaetaesde, m ceomrtory dysfunction, mild cognitive impairment argyrophilic grain disease, Pick's dementia andico pbaarskal degeneration, progressive supranuclear palsy, inherited frontotemporal 30 p drisoesatastee m coadnicfyeirnsg. a Isins
n wo
onen
elilsm
e ams li
b an
ock
due o
imtde t
en mt,y c
tehromosome 17 (FTDP- 7) and renal, breast, lung, rleoagtemneonuts of le duekmemia (AML) may be symptomatic or and vascular dementia), age related memory dysfuenncttiiaon (,inc mluildding co Lgenwy body dementia argyrophilic grain disease, Pick's disease, corticobasal degeneration, progressitive impairment, palsy, inherited frontotemporal dementia and parkinsonism linked to chromosioveme su 1p7ran (uclear 35 1 re7f)e,r and renal, breast, lung, prostate cancers as well as acute myelogenous leukemiaFT (ADP L-) I wnith ths
de t
ru co
go sny
atdem
dxptto
ic om
tiofn taht
aeic
n p tr
dre
Lea
-st
Dem
one
ptn
a int.
ivnednutcioend, d tryesaktimneesniat o reffe wristh tdora swymalp stoymmapttiocm trse/aretmlaepnste. associated Accordingly, the present invention further prov -99- of neu ides a method for the prevention and/or treatment diseasero,lo sgaiicdal m deitshoordde crsom spuch as but not limited to Parkinson’s disease and Alzheimer’s 5 effective amount of a comproisuinndg o ardm ain ciosmteprionsgiti too a subject in need thereof a therapeutic p orpetismeanlt t inrevaetnmtieonnt c caonur bsee u fotirliz aed pa intie ant v,a inrie ptyre odfic steintgtinn tg a
hss
e, l iin d
kce
ellufin
ihde
oind
ogd, h
o feorein. The methods of the fr s euxcacmespsle, in selecting the individual patient with a particular treatment regimen, in assessing disease wh perong trreesastiionng, an monitoring treatment efficacy, in determining pro in 10 predis gnosis for individual patients and in assessing I tnhe trheep
of ions
thvi
aeti
tno
itn
nio o
tnf
h, a
e pn
ina i
hrntiid
bci
iuv
tili
oad
nrua
a pl
sre to
sfae b
yreen
fone
rcefit
LR i fsro
RK gm
2iv ae particular therapy.
dnes tcorib ceodm bpeoluonwds in of Formula I or any subgroup value of less than 10 µM, preferably less than 1 µM, most preferahbiblyit le ksinsa tshean activity with an IC50 Said inhibition may be effected in vitro and/or 100 nM. 15 effect in vivo, and when effected in vivo, is preferably T orhe ot thee
erdm in
r d "eL a
lR s
etRe
eKle
rio2ct
u kiv
sine
ca m
osnea
d-nmn
itioee
ndr,ia a
intsed de
wh cf
ioin
cne
hddi tthi aob"v
eno
LR oer.
K "Kd2ise kainsaes"e, a iss u ksneodwn he troein p,la mye aan rosle a.ny Th deise tase "LRRK2 kinase-mediated condition" or "disease" a erm are allevia lso means those diseases or conditions that 20 the presentted inv beyn ttrieoantm reelnt with a LRRK2 kinase inhibitor. Accordingly, another embodiment of which the LRRK2 kinase a is te k s no to wn tre to at p in la g y o a r r l o e l s e sening the severity of one or more diseases in F anodr/ pohra inrm thaece fourtmica ol use, the compounds of the. invention may be used as a free acid or base, obtained with non-tfox aic ph oarrgmaceutically acceptable acid-addition and/or base-addition salt (e.g. 25 and/or complex, and/or in thaen fiocrm or o inro arg paron-icdru acid or base), in the form of a hydrate, solvate a bnyd a un colemsspo outhnedrw oifse th sista itnevde,n thtioen te wrmith“s aol svauittea”g
b iln o
eclr
iu p
ndr
oee
rgs-d
a ar
nnu
icyg,
s c s
oou
lmc
vebh as an ester. As used herein ninta (teio.gn. w hhyidcrhat mesay be formed solvent, such as but not limited to alcohol ) or organic s s, ketones, esters and the like. Such salts, hydrates, 30 inoslvtaanteces, m etac.de an td the preparation thereof will be clear to the skilled person; reference is for 6,369,086, US-A-o6,3 t6h9e,0 s8a7lts a,nd h UydSra-Ates, solvates, etc. described in US-A-6,372,778, US-A- T fohrem p ohfa wrmaatecre-,ut oicila-slloylu abclcee,p otrab dliesp searlsts-6
ib o,3
lef7 t ph2
re,73
od cuo3
cm.
tpounds according to the invention, i.e. in the the quat s, include the conventional non-toxic salts or 35 bases. Eexranmarpyle asm omfo snuiucmh a sacildts a which are formed, e.g., from inorganic or organic acids or b cyecnlzoopaetnet,an beepnrozpeinoensautelf,onate d,igl buicsd
oud
nlfi
aati
tto
een
,, s baul
dttys include acetate, adipate, alginate, aspartate, ordaetec,yls cuitlrfaattee,, camphorate, camphorsulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate e,tha hneexasunlofoantea,te, hy fumarate, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesdurlfoocnhalotride, naphthalene-sulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionea,t 2e-, picrate, pivalate, propionate, succinate, tartr -100- salt ate, thiocyanate, tosylate, and undecanoate. Base eartsh in mcelutadle s aamltsmo snuicuhm a salts, alkali mdetal salts such as sodium and potassium salts, alkaline 5 dicyclohexylamine salts, Ns-m caelcthiuyml-D a-gnluc mamaginneesium salts, salts with organic bases such as l syuscinhe a,g aenndts so as fo lrotwh.e Irn a alkdydli htioanlid,e thse, s buacshic a nsit mroeg,
te a
hnn
y-l,cdo s
ena
thtalt
yis
ln,i pn w
rgith
op gyr aomino acids such as arginine, l,u apnsd m bauyty ble ch qlouraidternized with and iodides; dialkyl sulfates like dimethyl e, bromides hali , diethyl, dibutyl; and diamyl sulfates, long chain 10 haliddeess l sikuech be anszy dlec aynld, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl s Gaeltnse irnaclllyu,de fo trh peh saurlmfaatece sua p
tlh
ite
c en
atlhe
uath
sny
eol
,l–ab
ttero amnidde ssulf aanted s oatlhtse.rs. Other pharmaceutically acceptable phar he compounds of the inventions may be formulated as a of them iancveeunttiicoanl a pnredp aatra ltion or pharmaceutical composition comprising at least one compound 15 adjuvant, and optionallye oanset o onre m pohrearmaceutically acceptable carrier, diluent or excipient and/or B adym mineisatnrastio onf, no fonr-lim piatirnegnte erxaalmp aldems, fu
in srt
isuh
tce
rahr p
tio aha
n form
(rsma
uuc
cle
hautitoic
anal
s mly
ba a
yyct
i biv
nee c
tra ivnom
en ap
o fo
uou
srnds.
,m in sturaitambulesc fuolarr or oarl s buyb acnut iamnpeloaus injection or intravenous infusion), for administration by inhalation, by a skin patch, 20 semi-solid onrt, li bqyui ad, su dpeppoesnidtory, etc.. Such suitable administration forms– which may be solid, c p a e r r r s ie o r n s ; , r d e il f u e e re n n ts ce an is d e a x g c a i i p s o
nieinng
mt ad f e onr t
t uh
osee m
fo i r nan
in thn
seer
ta p n r o
cef
ep aad
Uramionnistration– as well as methods and St-i A-6 t , h 3 e 7 r 2 e , o 77 f, 8 w , il U l S be -A clear to the skilled 6,369,087 and US-A-6,372,733, as well as to the standard handbooks, such a-s6, t3h6e9 l,a0t8e6s,t e UdSit-ioAn- o Sf c
25 l ooo R izme netmnem
gee pin nsreg ts,fteo , srn care’s recd P ah,h me ba
tssur ,,tm na lo coc
ane tioch-lu neimti s,tsita s,inl of eg Sc tli ei
xxeceps ainran
sm
d, h sl
aue. rss
dp oef
gn ssuiocnhs, pre epmaurlastiioonnss, in scoluludteion tasb,le stsy,ru ppilsls,, p aeowrodseorlss,, inj elatin capsules, suppositories, eye drops, sterile fore acdtambilneis storalutitions and sterile packaged powders (which are usually reconstituted prior to use) 30 carriers, excipieonnts a,s a and bo dluiluse and/or for continuous administration, which may be formulated with d treaxgtarocsaen,th s,uc groeslaet,in s,orb ciatolcl,n
iu mts
man thna
siitt
lo a
icl,re
at set s
,aurcitable per se for such formulations, such as lactose, mheicsr,oc gruymsta allicnaecia, ce calcium phosphate, alginates, polyethylene glycol, cellulose, (sterile) water, methllyulcloeslleu,lose p,olyvi mnyeltphyyrlr-olidone, propylhydroxybenzoates, talc, magnesium stearate and 35 or suitabl , edible oils, vegetable oils and mineral oils a incvteivnetio sunbe
)s atna m
dnixct
oeu
tsre
he (swrh th ormulations can optionally c
suice
bhre
s mof. The f
taany ontain other pharmaceutically ce osr t mhaaty a nroet c leoamdm too a synergistic effect with the compounds of the as lubricating agents, wetting agents, emulsifyinngly an udse sdu isnpe pnhdairmaceutical formulations, such desintegrants, bulking agents, fillers, preserving agents, sweetennging ag aegnetns,ts d,ispersing agents, flow regulators, release agents, etc.. The compositions may also be formulated fl saovo arsin tgo a pgroevnidtse, rapid, sustained or delayed release of the ac -101- u tive compound(s) contained therein, for example Insin ogrd leiposomesa or hydrophilic polymeric matrices based on natural gels or synthetic polymers. 5 composriti toon en ahcconce tghe solubility and/or the stability of the compounds of a pharmaceutical c cyocmlobdineaxttiroinns wi othrrhi
a td
cen
yicrlo d to
deerxi tvh
trae
intiv i
oen
rsvention, it can be advantageous to employ α-, β- or γ- a. d Aenriv ianttievrees tting way of formulating the compounds in particular, the present invention encompassesh aere pohfa hrmasa been described in EP-A-721,331. In effective amount of a compound according to the inventionc weuitthica al p chompaocseitiuotnica clolym apcrciseipntgab alen 10 I cnyc aloddde
compoiutx arm
inotr
dnin
s,.
. c Ion-s thoelve pnretspa sruactihon as of a alcqouheoolsus m caoym ipmopsriotiovens t,h aed sdoilubility and/or the stability of the the invention can be more suitable due to their increased waterti soonlu obfil salts of the compounds of For local administration, the compounds may a ity. 15 ointmen dvantageously be used in the form of a spray, intradermta olr ad tmrainnsisdtermal patch or another suitable form for topical, transdermal and/or M coomre in particular,ra thtieon c.ompositions may be formulated in a pharmaceutical formulation compproising a therapeutically effective amount of particles consisting of a solid dispersion of the 20 polymeurnds of the invention and one or more pharmaceutically acceptable water-soluble T ga h s e eo te u r s ms.
st " a a te s ) o c li o d m d p i r s is p i ersion" defines a system in a solid state (as opposed to a liquid or or less evenly throughonugt a thte le oatshte two components, wherein one component is dispersed more components is such that the systrem com ispo chneemntic oarlly components. When said dispersion of the 25 throughout or consists of one phase as defined in the armndod pyhnyasmiciacslly uniform or homogenous r ceofmerpreodne tnots as th "eare sinolid ar seol uustiuoanl"l.y S roelaiddil syolu btiiooanvsai alareble pre tofer trheed o prhgyas,
ni scu
isac
mlh
s sy as solid dispersion is totem wshic bheca thuse the admain ey are It myis ftuerrtehde.r be convenient to formulate the compounds in the form of nanoparticl 30 have a surface modifier adsorbed on the surace thereof in an amount sufficient to maeinsta wihich e f
bf tive average n an efec se particle size of less than 1000 nm. Suitable surface modifiers can preferably includelec vtaerdiou frsom known organic and inorganic pharmaceutical excipients. Such excipients Preferred surface po mlyomdiers, low molecular weight oligomers, natural products and surfactants. 35 Yet another interestingfi wearsy i oncfl fuodrmeu nloantiinogni tch aen cdo amnpioonic surfactants.
p ahnadr ampapclyeiuntgic tahlis co mmixptousreiti aosn a w choearetb fiylm th oeve cro mmapnoyun sdmsun
a ad
llr bes a
e ianc
dcc
soording to the invention involves a ,rp thourasted in hydrophilic polymers good bio-availability which can conveniently be manufactured a yniedld winhgic ah co imposition with preparing pharmaceutical dosage forms for oral administration. Materials suitabsle su foitable for cores in the beads are manifold, provided that said materials are pharmaceutically acrce upsteab ales and have appropriate dimensions and firmn -1e0ss2- inorgani . Examples of such materials are polymers, The prepca sruabtisotnasnc measy, o brega pnric substances, and saccharides and derivatives thereof. 5 least one compound accoerdpianrged to in t ahe ma innvneer known per se, which usually involves mixing at a coccmeppotaubnldes, c wahrreienrs n,ec aensds,ar iyf u dnedseirred a,se ipntic c con
omtio
nbn
diintia w
otniioth
sn th
. R we
eifteh on
ren oe
cth or more pharmaceutically eer is p ahgaarimna mceautical active 6,372,778, US-A-6,369,086, US-A-6,369 de to US-A- men ,087 and US-A-6,372,733 and the further prior art 10 Remtiinognteodn’s a Pbohvaerm,a acseu wtell as to the standard handbooks, such as the latest edition of T behe su pihtaabrmlya pcaecuktaicgaeld p,re fopraic
eraal
xtai Somnci
psen
le ocfe
in ths
ae.
b inovxe,n r
s btliiosnte ar,re vi pal,e bfeortatlbel,y s ianc ahe utn,i atm dopsoauglee o forr imn, a annyd o mthaeyr oupittiaobnlaelly si wnigle-doese or o mro mreu lleti-adfloestse c hoonltdaeinr or container (which may be properly labeled); 15 Generally, suthch on un ing product information and/or instructions for use.
540000 m mgg, p oefr t uhneit a dto leit
sa d
aso
gts
e oa
.ngee cso wmilplo cuonndta oinf t bheetw ineveennt 1io ann,d e.1g0.0 a0bo mugt, 1 a0n,d 25 u,s 5u0a,lly 10 b0e,tw 20e0e,n 3500 an odr T trhaens cdoemrmpaolu,n sdusbc cuatnan beeou asd,m inintriastveerned by a variety of routes including the oral, rectal, ocular, 20 on the specific preparation used ando thues, c ionntramuscular or intranasal routes, depending mainly i wnitlrla gveenneoruaslly ad bmein aisdtmraintioisnte uresdua ilnly a bnein“egff percetif d
ve i
er t r io e n
ad to be treated or prevented, and with oral and m.o Tuhnet” a,t b least one compound of the invention compound of Formula or any subgroup thereof that, upon suyit wabhliech ad ism miniesatrnt any amount of a achieve the desired therapeutic or prophylactic effect in the individuaatilon t,o is w suhfificient to 25 administered. Usually, depending on the con ch it is a bdomdyin dition to be prevented or treated and the route of wisetrigahtito dn, such an effective amount will usually be between 0.01 to 1000 mg per kilogram and 250 mg,a foyr o efx thaem ppaletie anbto puetr 5 d,ay, more often between 0.1 and 500 mg, such as between 1 weight day of the patient per day, w 1h0ic,h 20 m,a 5y0 b,e 10 a0d,m 1in5i0s, 200 or 250 mg, per kilogram body over one or more daily doses, or essentially continuoutselyre,d e a.gs. a us siinngle daily dose, divided 30 a bmeo duentet(rsm)i tnoe bde b aydm thineis ttreeraetdin,g th celi rnoicuitaen o,f d aedpmenindisintrgat oionn f aancdto trhse s fuurcthhe arg
s tre a
thaetm dr
aeip infusion. The gnet, re ggeinmdeenr m anady g treenaeteradl. R coenfedition of the patient and the nature and severity of the disease/symptoms to be A-6,372,733r aenndce th ies a fugratin made to US-A-6,372,778,US-A-6,369,086, US-A-6,369,087 and US- 35 s I t
bnuc
e ah
acdc a
mosrid th
nae
isntec laete
red wsit sh ed
ep tihti
aeonh ra m oe teefr lyth R p aoer tdmio d oirn a iffgr fe ttt mentioned above, as well as to the standard handbooks, ho
reen’
nt psr P
teimshea
enrm
st d ianc
uve
rieu
nnt
gtiicoa
thnl
e, S sc
caienc
oidurs pe
ehsa.
ormf tahceeruapticya olr co cmonposition can divided or single combination forms. The present invention is therefore to be undceurrsrteonotdly a ins e "amdbmraincisintegrin agl"l is su toch regimes of simultan -e1o0u3s- or alternating treatment and the term F suoirta abnle o ardadli atidvmesin,i ssut brcae
hti ion
anter
s e fpor
xre
cmte
ip,d
ie th a
necc
ts, co
sor
tmdi
abpn
iog
lisly
ziet.irosn,s or o ifne thret d pilrueesnetnst, a innvden btriooung chatn by b mee mainxsed of w tith 5 c cuasptsoumleasry methods into the suitable administration forms, such as tablets, coated tablets, hahrde arabic, m,a agqnueesioau,s m,a aglcnoeholic, or oily solutions. Examples of suitable inert carriers are gum particular, corn starch. Ins thiuism ca csaerb,o tnate, potassium phosphate, lactose, glucose, or starch, in 10 granules. Suitable oily excipients or shoelv pernetpsa araretio vne can be carried out both as dry and as moist o sorl cuotidon lsiv,e orr o mili.x Stuureitasb thleer seoolvf.e Pnotsly feotrhy alqeuneeo gulsyc oorls ag
alce
not
dha
pob
olliec o
lyp sr
ro a
olun
ptimal oils, such as sunflower oil yiolennse a grle water, ethanol, sugar further auxiliaries for other administration forms. As immediate ryecloelass aere ta ablsloet us,se tful as compositions may contain microcrystalline cell hese 15 steara ulose, dicalcium phosphate, starch, magnesium lubricatnets a knndow lanct ionse and/or other excipients, binders, extenders, disintegrants, diluents and W achceonrdi andgm tionistered th bey ar nt.asal aerosol or inhalation, these compositions may be prepared prepared as s teocluhtnioiqnuses in w seallli-nken,ow emnp in the art of pharmaceutical formulation and may be 20 absorption promoters to enhance bioalovyainilagbi blietyn,zy fl alcohol or other suitable preservatives, d th is e pe fo r r s m ing of ag a e e n ro ts so k ls no o w r n s i p n ra t y h s e a a r r e t. , S fo u r ita e b x l a e m p p h le a , rml
sau
oco
lu ero ns
tuc
io t n iac s arb
,lo
s fo u r s m, and/or other solubilizing or pe u n la s t i i o o n n s s f o o r r e administration in compounds of the invention or their phy mulsions of the ac siologically tolerable salts in a pharmaceutically 25 forcmeupltaatbiolen s coalnve anlst, such as ethanol or water, or a mixture of such solvents. If required, the emulsifiers and staboiliz aedrdsit aionally contain other pharmaceutical auxiliaries such as surfactants, F suobrs stuabnccuetsan ceuosutosm aadrmyin thisetrs s
ra w
etfiooe
rnll
e, a t shue a
ch c poromp
aspeoll
sua
onn
ludt. according to the invention, if desired with the brou bilizers, emulsifiers or further auxiliaries are 30 lyophgihlizte indto an sdolu thteion ly,o suspension, or emulsion. The compounds of the invention can also be i anlfcuoshioonls, pr ee.gp.ar eatthioannso.l, Sp
puh
rii
otlaiz
pba
alnetes
o sl,o olbtained used, for example, for the production of injection or gvleynctes are, for example, water, physiological saline solution or mannitol solutions, or alternatively mixrtoulr,e isn o afd tdhietio vn also sugar solutions such as glucose or solutions or suspensions may be formulated accordianrgio tuos k snoolvwennt asrt mentioned. The injectable parenterally-acceptable diluents or solvents, such as mannitol, 1,3-b,u utasninegdio suitable non-toxic, 35 s aogleuntitosn, s ourc ihso atosni scte sroiled,iu bmla cnhdl,or fiixdeed so oliulst,io inn, or suitable dispersing or wettingl, a wndate sru,s Rpeinngdeinr'gs aci cluding synthetic mono- or diglycerides, and fatty W mihd
xes
inn, i
g rn
tec
hcl
etuad
clli
oyng
m apd o
omle
uii
nnc
dis a
stcei
ard
ce.
cdo irndi tnhge t foor tmhe o infv seunptpioonsit woirtihes a, s thueitsaebl feor nmounl-airtriiotantsin mga eyxc biepie pnret,p saurecdh b ays cocoa butter, synthetic glyceride esters or - p1o0ly4- temperatu ethylene glycols, which are solid at ordinary In preferrerdes e,m bbuotd liqimueenfyts a,n thde/or co dmisspooluvne in the rectal cavity to release the drug. 5 p ds and compositions of the invention are used orally or Ta
exhr
aeen
m it
pne
lvr
eea
snlly
,t wi.ohnich w dillo n noowt lim beit th ilelus stcroapteed of b tyhe m inevaennstio onf in th aeny fo wllaoyw.ing synthetic and biological
EXAMPLES -105- A. Compound synthesis and physicochemical properties
5 T prhoece csosmespo cuonmdmso onfly t uhsised in bvyen thtioosne c saknille bde i prepared by any of several standard synthetic generally prepared from starting materials wnhi tchhe art of organic chemistry. The compounds are by standard means obvious to those skilled in the a arret either commercially available or prepared 10 F
p cho
rorrom s
cedao
utmoreger waip co
thhmypounds that were purified by r.eversed phase high-performance liquid HP (HLCPL mCe)th thoed A used method is described below (indicated in the compound person skilled in the art to obtain). a W mhoerne n oepctiemsasal rrey,su thlte fsoer m theet sheopdasr caatinon b.e slightly adjusted by a
15 H
H Th P
Pe LC
LC cr m
suyd e
se tho p d ro A duct was purified by reversed phase HPLC, using a Gilson semi-preparative The pur tem operated by Gilson UNIPOINT software.
5µm paritfiiccaletsio)n at w raos carried out on a Phenomenex Luna column (100 mm long x 21.2 mm i.d.; 20 was performed fromom 32 te%mp (erature, with a constant flow rate of 20.0 mL/min. A gradient elution 1 m:1in)ut teos.4 T%he (2 U5V m deMtec NtoHr4 wH2
aC5
sO m
s3M
et a toq NuH
2e4
2oH
6unsCO
m, s3
wolhu aqueous solution) / 68% (Acetonitrile-Methanol itciohn c)o /r 96% (Acetonitrile-Methanol 1:1) in 20 absorbance observed for the compound. responds to the wavelength of maximum
25 A G
fosen
rm ineral schemes:
udlicated herein before, the present invention in general provides compounds according to diseasaes I:, for use in the diagnosis, prevention and/or treatment of LRRK2-kinase associated
Figure imgf000107_0001
(I) W co i m th p r o e u fe n r d e s n c c a e n to be th r e ep g r e e n s e e r n a te l d re b a y ct f i o o r n m s u c la h s em -1
Ia e0
os6
r s- Iu b it r a e b s l p e e f c o t r iv p e r ly e , p f a o r r ing said compounds, these schemes can be found herein below. which the general reaction
5
Figure imgf000108_0001
(I) (Ib)
G
10 In generl h
a ompounds of formula (I) can be prepared as shown in scheme 1 below wherein whi p th yr al t
aaz c o o l m o[1he c
po ,5 u-n a d ]py o r f im fo i r d m in u e la or (II a I) im in i t d o a a zo c [ o 2 m ,1 p -f o ]p u y n r d ida o z f i f n o e rm o u f l f a or ( m IV u ) l , a w (I h I) is converted by reaction (aente breo- c)yacrylilze odf f toorm fourmla a (V c)o tmop foourmnd a o cfo fomrmpouuland (I) o.f formula (VI). The cicohm ipso tuhnedn o refa focrtemdul wait (hVI a c ) 15
Scheme 1 -107-
Figure imgf000109_0001
In the above scheme:
5 L XG1
3 a anndd L XG2
4 t eoagcehth ienrde wpiethnd tehnetly fu renpctrieosneanlt m suoitiaebtyle t loea wving or functional groups; unprotected or a protected functional group wh hich they are attached represent an together X1 as defined in formula I ich upon reaction (after deprotection) produce 10 E (he reteprroe-s)aernytls g aro suupit aanbdle th fuen scctiaofnfoall;
d. group that can be used to form a direct bond between the I lena tvhineg a gbroovueps re LaGct1io annd of LG th2e a compound of formula (II) with the compound of formula (III) the 5 group. The reaction ca re advantageously a halo group such as a chlorine or a bromine 1 f aoprpmruolpari (aItIe) w biathse th seu ccohmn
ap b
soeu a
fonf
rdfe
e oc
xfte
a fmodrpm by
leul aa s
tri (eIu
tIIb
h)s
y ilntitu
am atnio
ine onrg fo
aar
tn e
aicxam
n s eolelvp
vele
antet b
d syu t
tcre
eha
m ati
psng
er ahe
ac t
teutroen ciotrmilepo wuinthd a onf under re for example Compoufnludxs. of formula (III) can be obtained through vario
20 standard m us selective reaction steps by T ahe reactioenans of ob tvhieous co tom tphoousned ski (lIlVed) in w tithhe a art. (hetero-)aryl compound of formula (V) is odfvan thtaegeo (uhseltyer eoff-e)acrtyeld th croomugphou thned cou upnldinegr of S au bzourkoinic c aocniddi Etio onrs bor uosniincg este forr E d eexriavmatpivlee t (eXtprahkoiss)(tr aipndhe pnoytlapshsoiuspmhi pnheo)psaplhlaadteiu tmrib(0a)s,ic i 2- -d1i0c8y-clohexylphosphino-2’,4’,6’-triisopropylbiphenyl elevated temperature for exa n a solvent mixture such as 1,4-dioxane/water at an 5 c The cyclisation of the compomunpdle o ufn fdoermr ruelfalu (xV.I) can be effecte
moixntduitrieon ssuc uhsi ansg 2 f-omre etxhayml-1p,l4e-d diisopropyl azodicarboxylate andd tri fpohre enxyalpmhpolsep uhnindeer in M aits suonlvoebnut The res l u ky lt l in g g ro c u o p m . pou ioxane and toluene at an elevated temperature such as 90°C. as an a nd of formula (I) can optionally be treated to introduce substituents such 10 I an p gyernaezoralol[ t1h,e5- cao]pmypriomuinddinse o ofr fo arm imuildaa (zI)o[ c2a,1n-f b]epy prirdeapzared as shown in scheme 2 below wherein with a compound of formula (VII) into ine of formula (II) is converted by reaction into a compound of formul a compound of formula (VIII), which is then transformed 15 compound oI)f. formul a (Iv) and reacted with a (hetero-)aryl of formula (V) to form a of formula ( a (VI). The compound of formula (VI) can be cyclized to form a compound Scheme 2
Figure imgf000110_0001
20 In the above scheme:
L XG1
5 is a cnodn LveGr2te eda icnhto in ade fupnecntidoennatlly gr roeuppre Xse3;nt suitable leaving or functional groups; X un3p arontdec Xte4d t oorge ath perrote wcitthed th fuenc ftuionctional mo -1ie0t9y- to which they are attached represent an to nal group which upon reaction (after deprotection) produce Eg reetphreerse Xn1t ass a de sufinitaebdle in f fuonrmctula I;
5 (hetero-)aryl group and the scaiofnfoalld. group that can be used to form a direct bond between the I lena tvhineg a gbroovueps re LaGct1io annd of L tGhe2 a croem apdovuanndta ogfeo foursmlyul aa h (IaI)lo w gitrhou tphe su ccompound of formula (VII) the 10 group. The reaction can be affected b h as a chlorine or a bromine f aoprpmruolpa y a substitution for example by treating the compound of ri (aIIte) w biathse the su ccohm apsou fondr e oxfa fomrmula (VII) in an organic solvent such as acetonitrile with an unde ple triethylamine at an elevated temperature for example C
15 stoamndpr
ao re
ruf
dnlu
mdxs.
ea onfs f oobrmviouulas t (oV tIhI) can be obtained through various selective reaction steps by C suoimtapboleu pnds of formula (VII) c o a s n e b s e kil c le o d nv in er t t h e e d a to rt. compounds of formula (IV) by reaction with a The reacrtoiotencte odf o thre unp croomtepcted linker group.
advantageously effected throuoguhnd the (IV co)up wliitnhg o af a (h beoteroron-ic)a aryclid c Eom orpo bund of formula (V) is 20 of the (hetero-)arpyl compound under tionsor uosniincg este forr E d eexriavmatpivle t e (eXtprahkoiss)(tr aipndhe pnoytlapshsoius Suzuki condi
mhi pnheo)psaplhlaadteiu tmrib(0), 2-dicyclohexylphosphino-2’,4’,6’-triisopropylbiphenyl eleva asic in a solvent mixture such as 1,4-dioxane/water at an The ctyecdlis teamtiopner oaftu tre for example under reflux.
conditions using forhe ex caommppleou dnidiso opfr fooprmylu alazo (dViIc)a crbaon be effected for example under Mitsunobu 25 m Thixetu rreesu sluticnhg a cso 2m-pmoeutnhdyl- o1f,4 fo-drmiouxalane (I) a cnadn to olupetinonea altx aynla etelev aantded tr tipehmepneyrlapthuoresp shuinche a ins a 90 s°oClv.ent as an alkyl group. ly be treated to introduce substituents such
Example N1 -110- E Pxreapmapraletio Nn1 o isf i pnrteeprmareeddia ftoello 1wing general scheme 1.
5 Apyr mroixlitduinre-2 o-yfl] 2m-(ettehrat-nboultoxycarbonylami
Figure imgf000112_0001
)thyl th ulfonate (1.20 g, 5.01 mmol), [(2S)- potassium iodide (0.99 g, 10.02 l), di arbonate (1.593 g, 15.03 mmol) and overnight. The sol (v1e.n0t8 w1a gs, r 6e.m51ov memdo uln)d iner N re,Nd-udciemdet phryelsfosrumrea,m diidcehlo (3ro2 ml) was stirred at 60ºC 10 t thhe
ieel r m
de:sixi 5dtu
1ur
3ee
m w w
gaass
of p f
iuilt
nreifrieedd b oyve rerv Ceerslieted® p.h Tahsee c soolluvmennt c wharosm reamtoogvrae
Y pdh uyn (dHe m
Pr e
L r t
Ce h d a
mu n
ec e ethd wa
od p s r Ae a
)s d .s d u e re d a an nd d LCMS method 2: MtHe+rm =e 2d4ia5t,e R 1T ( =421%.1)65 min
15 Preparation of intermediate 2
I mntl)e.rm Theedia mteixt 1ur (e51 w3as mg st,ir 2re.1d0 a mtm rooolm) w taes
Figure imgf000112_0002
dpi tl d i 4rN hydrochloric acid in 1,4-dioxane (6.3 20 reduced pressure, toluene was add night. The solvent was removed under p LrCoMduSct m weathso odb 1ta:i ed twice and remo f v u e rt d he tw r p ic u e ri u fic n a d t e io r n re in du th c e ed ne p x r t e s s t s e u p r . e. The
MneHd+ a =s 1 th4e5, H RCTl = sa 0lt.1 a2n8d m usined without Preparation of intermediate 3 -111-
T acoe ato mniitxritluere (6 o.f2 i7nte mrml)e wdaiaste a 2dd (3e0d03
Figure imgf000113_0001
g 210 l) d tithylamine (1.162 ml, 8.36 mmol) in mmol). The reaction mixture was stirre-bd at 80-5°C-h olvern-pigyht. Thloe[1 re,5a-cat]ipoynri mmidine (485 mg, 2.09 5 t c h h e ro s m o a lv t e o nt was removed under reduced pressure. The residue was puriixfiteudre b wya fsla csohol ceodlu amndn as eluentsgr (agprahdyie onvte erl suitliiocna f groeml u 2sin %g t dichloromethane and a 7N ammonia solution in methanol fractions were collected and the solvenot 1 w0as % re omf 7oNve adm umndoenria re sdoulucteion in methanol). The product LCMS method 2: MH+ d pressure.
10 = 340, RT = 1.548 min
Preparation of intermediate 4
Idnicteyrcmloehdeiaxytelph 3osp (h1i.n7o1-2’ m,4m’,6o’l-)t,riis 3
Figure imgf000113_0002
phydpylbyipphh yyll) (bXphi) (33id mg (,3050.07 m mgm,o 2l).5 a6nd m pomtaosl)s,iu 2m- 15 p 1h0o
e,t3sp
rak mha
isl()te
tri a t
pnri
hdba
en ts
yhic
lpe (
ho m1.
si0
px8 g
htuinre, 3
e)p w e
aaq.) were dissolved in a mixture of 1,4-dioxane and water (3:1, T llsad diuemg(a0s)se (3d5 b myg, b 0u.b0b3lin mgm noitrogen gas through the mixture. stirred under nitrogen gas at 80°C for 5 hours. More 3-hydl)ro wxaypsh aedndyel)dbo arnodnic the ac midix (t1u7re5 w mags 20 1.28 mmol), tetrakis(triphenylphosphine)palladium(0) , d pihcoy
8sc
0plo
°hh
Caetexy
ov tlrp
eibh
rnao
iss
gip
hch
t. (i5n
T4o
h0-2
e m’,4
rg’
e,,6
a 1’
c.- t5tri (17 mg, 0.015 mmol), 2- io eis
nqo.p
m)r wo
ixep
turyelb
re aipdh
wde
aen
sdy
c al
on (X
odp
le thho
des) (16 mg, 0.035 mmol) and potassium at a mnidxtu three w saoslv setnirtre wda usnd reerm noitvreodge unn gdas reduced pressure. The residue was purified by flash colum er using dichloromethane and n chromatography over silica gel 25 f arnodm th 2e % so tlove 1n0t w %as of re 7mNov aemdm a
uo 7nNia a smolmutoionnia in so mluetitohnan ionl) m. Tehthean proold ausct e flruaecntitosns (g wraedrieen cto ellelucttieond Yield: 239 mg of intermediate 4n (d4e0r% re)duced pressure. LCMS method 2: MH+ = 354, RT = 1.718 min -112- Preparation of example N1
5 A
Figure imgf000114_0001
de sgoalsustieodn o bfy inte brumbebdliinagte 4 ni (tr2o3g9eng, ga 0s.68 thro l) i 2- thyltetrahydrofuran (20 ml/mmol) was azodicarboxylate (400 mg, 2.04 mmol) in toluugehne t (h2e0 m mlixture. A solution of diisopropyl nitrogen gas through the mixture. Both solutions were adde/dm dmroopl)w was degassed by bubbling 10 a in p teorluioedne of ( 27.55 m hol/umrsm aotl) 9.0 T°hCe t moi axt duerega wsassed st sirorleudtio ant o 9f0 t°rCiph foern 1ylp hhoousis
r.peh and simultaneously over Tihnee r (e535 mg, 2.04 mmol) cooled and the solvent was removed under reduced pressure. The residue waacsti pounr mixture was column chromatography over silica gel using dichloromethane and a 7N ammoniaifie sdol buyt flash 15 methanol as eluents (gradient elution fro o 10 % of 7N ammonia solution in methiao Th m 2 % t nn in The ol). e r persoduct fractions were collected and the solvent was removed under reduced pressure. Yield: 56idu meg w oafs ex paumrifpield by reversed phase column chromatography (HPLC method A).
LC
20 ( aMmSp mlee Nth1od (420: e N1 (12%)
Ex m MgH,+ 0 =.13236 m,m RoTl) = w 2a.1s3 d2is msoinlved in a mixtu
a4t:1 ro,o 0m.5 t meml)p aenrdat 4uNre h fyodrro 1ch hloourirc. a Tchied i sno 1lv,e4n-dtio wxaasne re (m10ov µel)re
d w of dichloromethane and methanol uansde ardd reed. The mixture was stirred w saith diisopropyl ether and dried under reduced pressure. The productdu wcaesd o pbrteasinseudre a,s tr tithuera HteCdl 25 Y LCielt
Ml.dS: 6 m megth oofd e 2x:a MmHp+le = N 3136 (1,5 R%T) = 2.127 min Example N2 -113- E Pxreapmapraletio Nn2 o isf i pnrteeprmareeddia ftoello 5wing general scheme 1.
5 t inetret-rBmuetydli-acthelo 3ro (1d.im70et gh,y 5ls.0ila mnemo (0l).9 a0
Figure imgf000115_0001
d g 60 l) dded portionwise to a mixture of ml). The reaction was tithyl i (1.21 g, 12.0 mmol) in dichloromethane (15 aqeuous layer was extr s a t c ir t r e e d d w a i t th ro d o ic m hlo te ro m m p e e t r h a a tu n r e e . T fo h r e 2 s 4 ol h v o e u n r t s w . a W s a r t e e m r o w v a e s d a u d n d d ed and the 10 p Yrieeslds:u 2re,2 a4n gd o the product was used in the next step without further purification. er reduced LCMS methodf 2 in:t MerHm+e =di 3a5te4, 5 R (T99 =% 2).625 min
Preparation of intermediate 6
15 t (e2r.t2-4Bu gt,ox 4ycarbonyl anhydride (1
Figure imgf000115_0002
18 g 542 l) ddd to a mixture of Intermediate 5 T pr h e e ss s u o r l e u . ti.o9
Wn3
a w m
te am
rso
w sl)
at,i s r 4re-(
addim
dd u e ne
ddthey
arl
nd ref t li
hux) fpoyri 2di hou (3rs1. Thge, 0 s.2ol5venmto wla)s in re temtrahydrofuran (15 ml). 20 de aqueous layer was ex oved under reduced o rergsiadnuiec w laayser p wuraifsie ddri beyd, fl failstehre cdolu amnn t ch tracted with ethyl acetate. The hero smoalvteongtra wpahsy r oevmerov seilidca un gdeelr us reindguc heedpt parneess aunrde. e Tthhyel a wceerteat ceol alesct eelude anntsd ( thgera sdoielvnetn etlu wtaiosn re frmomov 0 % -1 to141-00 % of ethyl acetate). The product fractions Yield: 1.7 g of inter ed under reduced pressure. 5 LCMS method 2: MmHe+d =ia 5te546, ( R6T2% =) 3.094 min
Preparation of intermediate 7
A thro muixgthur tehe o mfi 1x,t4u-rdei.o Ixnatneerm aenddi
Figure imgf000116_0001
t 6t (1. (3181 l) dg d by bubbling nitrogen gas 10 ( d5ic0y0clo mhge,xy 3lp.2h4osp mhminool-)2,’,4 te’,t6ra’-ktriisis(toriphe5n0yl gp,ho 2s.7p0hine)pal)l,la (d5i-um(i0)-2 (5-f3lu3or mo-gp,he 0n.y4l6)bo mromnoicl), ac 2id- phosphate tribasic (1.7 g, 3 eq.) wepropylbiphenyl (Xphos) (872 mg, 1.83 mmol) and potassium 85°C overnight. More (r5e-a amdidneod-2 a-fnlud the mixture was stirred under nitrogen gas at 15 tetrakis(triphenylphosphine)palladium(0) (0.02oro e-qp.henyl)boronic acid (1.2 eq.), t graiisso aptro 8p5y°lbCip ohveenrynlig (Xhtp.h Tohse) ( r0e.0a8cti eoqn.) m wixetruere ad wdae ), 2-dicyclohexylphosphino-2’,4’,6’- sd and the mixture was stirred under nitrogen oergdaunceicd la pyreesrsu wraes. T whaesh reesdid wueith w wasate pru,rif dierided b,y fi fltlae c
sroeoled and diluted with ethyl acetate. The r hd co alnudmn the solvent was removed under 0 using heptane and ethyl acetate as eluents (gradient elution f chromatography over silica gel 2 p Yrioedldu:c 1t. f3r0ac gtio onfs in wteermree cdoiallteect 7ed (8 a2n%d) the solvent was removedro umnd 0e%r r teod 6u0ce%d e ptrheysls aucreet.ate). The
Preparation of intermediate 8 -115-
2 (1-N.3i0tro gb,e 2n.z2e2n mesmuolfol)n,y ply crihdlionreid
Figure imgf000117_0001
(23 (065 µ9l, g 2.62666 l)l)d 4-(ddiddth tyla am solution of intermediate 7 5 mmol) in dichloromethane (6.66 ml). The react ino)pyridine (13 mg, 0.11 o hvyedrrnoicghhlot.ri Dcic ahcliodro smoleutthioann.e ion mixture was stirred at room temperature
T wheas or agdadneidc l aanyder th wea osrg darineidc, l failyteerre wda asn wda thshee sdol wveithnt a w 1aNs aqueous under reduced pressure. The residue was purified by flash colum removed gecelta utsein).g T hheept parnoedu acntd fra ectthioyl acetate as eluents (gradient elutinon ch frroommat 0o%gra tpohy 10 o0v%er s eitlihcya a l 10 Y pressure. ns were collected and the solvent was removed under reduced LCieMldS: 1 m.0e3t3ho gd o 1f: in MteHr+m =ed 7i7a0te, R 8T (6 =0% 1.1)76 min 15 Preparation of intermediate 9
I 3n.t1e2rm mel)di aanted 8 th (e80 m0ix mtugre, 1 w.0a4s
Figure imgf000117_0002
ti dl) t di tlpd i ti id/water/tetrahydrofuran (3:1:1, c uonndceern rterdautecded un pdreerss reudreu.ce Tdhe pr reesssiduuree a wnad t ight. The reaction mixture was 20 s to pluureifnieed w bays fl aadsdhe cdo 3lu tmimne csh arnodm caotongcreanpthrayte odve 3r t similiecas g soellv uesnitn wga hse rpetmanoeve adnd un edtehryl re adcuectaetde p aress elue -n1ts1.6- The product fractions were collected and the Yield: 580 mg of intermediat sure.
LCMS method 1: MH+ = 656e, R 9T (85%)
5 = 0.830 min
Preparation of intermediate 10
A solution of intermedia
Figure imgf000118_0001
10 degassed by bub te 9 (580 g 088 l) i 2 thyltt hydrofuran (20 ml/mmol) was a nz
pietorrod
iogic
deanrb
of go
3axsy
ho tlha
urte bling nitrg g th gh th it . A solution of diisopropyl rosu (
ag1
th80
9 t0h°e m
C mg,
tiox 0t l i
au.8r de8
e.g B m
aom
stsho
e sl)
do sun
otiluo tonlu
t weenree ( a2d0de mdl/ smimmuoltla)n weaosus dlyeg aansds derdop bwyis beu obvbelirng a toluene (75 ml/mmol ion of triphenylphosphine (231 mg, 0.88 mmol) in 5 cooled and the solven).t w Thaes r memixtouvreed w uansde srti rreredduc aetd 9 p0r°eCss fuorre 1. T hhoeur r.es Tidhe reaction mixture was 1 c froalcutmionns ch wreormea ctography over silica gel using heptane and ethyl acetateu aes e wlausen ptusr.if Tiehde b pyro fdlauscht YCieMldS: 4 ollected and the solvent was removed under reduced pressure.
L m70et mhogd o 1f: in MteHr+m =ed 6i3a8te, R 1T0 ( =840%.95)7 min
20 Preparation of intermediate 11 -117-
T adod aed so cleustiiounm o cfa inrbteornmaetedi (a4t1e11
Figure imgf000119_0001
0g (4,010.26g 06l)3 d thl) i NNdi thylformamide (2.0 ml) were 5 m thiixotpuhreen wolas (0 s.1tirr eeqd.) at w reoroem ad tedmedperature for 17 houris.ph Morel c (8e0siu µml, 0 c.7a6rb monmaotel). (0 T.h5e e rqe.a)c ationdn aqueous sodium hydroxid and the reaction was stirred at room temperature. A 1N acetate. The or e solution was added and the water layer was extracted with ethyl 0 pressure. The rgeasnidicue lay wears w pausrif dierided b,y fil ftlearsehd c aonldum thne c shorolvmenatto wgraasph reym oovveerd s uilincdaer ge reld uusced 1 h peropdtauncet fr aancdtio entshy wle arcee ctaotlleec atesd e alunedn tthse (g sroalvdeienntt w ealsut rioenmo frvoemd 0% to 100% ethyl acetate). Tihneg LCMS method 1: MH+ = 453, RT = 0.771 min under reduced pressure. Preparation of example N2
15 I mntl)e.rm Theedia mteixt 1u1re (3 w5a8s m sgti,rr 0e.d79 a mt r
Figure imgf000119_0002
l) t dpi tl d i 4Nig hhytd. Tchhelo sroiclv aecnitd w ina 1s,4 re-dmiooxvaende u (n3.16 red e u ss c u e r d e. p T re h s e su c r o e m . p D o ie u t n h d yl w et a h s er ob w t a a s in a e d d d a e s d, th th e e hy c d o r m o p ch o l u o n ri d c w ac a i s d f s il a te lt r . ed and dried under reducdeedr 20 Y pr
LCieMldS: 1 m00et mhogd o 2f: e MxaHm+p =le 35 N32, R (3T6% =) 1.952 min
25 Exammpl -118- E ill x u a stra p t le
ee N
d N3
fo 3 r t m he ay pr b e e pa p r r a e t p io a n re o d f e fo xa llo m w p i l n e g N g 2 e . n T e h r e al p s ro c d h u e c m t e wa 1 s a o n b d ta a in c e c d or a d s in t g he to HC th l e sa p lt r . ocedures
5 E
Figure imgf000120_0001
Exa ple
ill x u am
sm tra p t l e e N
d N4
fo 4 r t m he ay pr b e e pa p r r a e t p io a n re o d f e fo xa llo m w p i l n e g N g 2 e . n T e h r e al p s ro c d h u e c m t e wa 1 s a o n b d ta a in c e c d or a d s in t g he to HC th l e sa p l r t. ocedures
10
Figure imgf000120_0002
Exa -119- E P x re am
pmple N
ap ra le tio N5
n5 o m f a in y te b r e m p e r d e ia p t a e re 1 d 2 following general scheme 2.
5 A am minioxetuthreyl) opfyr 3ro-blirdoinmeo-1-5-c-cahrbloorxoy-playtr
Figure imgf000121_0001
(1l.0[115 g,] 4p.y73i idi l) (10 g, 4.30 mmol), tert-butyl 2-(2- mmol) in acetonitrile (12.9 ml) was stirred unde nd triethylamine (0.878 ml, 5.16 cooled and ethyl acetate was added. r reflux for 16 hours. The reaction mixture was and the solvent was remov The organic layer was washed with water, dried, filtered 10 c eo
olulu
ltimonn f crohmrom 0a %tog troap 1h0y0 o %ver ed
o sfil u
eic ne
ta d
hy g r
le al re
c u d
es u
tain c
teg ed
). he p
Tp r
ht e
ea s n s
pe ur
ro a e
dn .
ud T
ct e h
ft e
rhay r
cl e
ti a si s s oc d
ne ue
sta wte wa
er aes c e p
ol u
lu r
lee if
cn ie ttes d
d ( b g y a arnadd fl ie s thn h et Yievlde:n 1t. w6a5s4 r gem ofo inved under reduced pressure.
L termediate 12 (94%)
15 CMS method 1: MH+ = 410, RT = 1.000 min
Preparation of intermediate 13
I mntl)e.rm Theedi matiex 12 (1.654 g, 4.03 mm
Figure imgf000121_0002
l) di l d i 4N hydrochloric acid in methanol (12.09 20 r c e o d m u
xtp c
so e u d n p u
dre w st
as s urer o e w
b.a
ta Ts
io n l s
eut
deirnre
aed
s w a
th at
es ro
h ao
yd d d ro e t
cd hl t o wp
ri i c c et
a a ci n f
dd s r a e lt m 2
ao n v h
ded us t e w.
dic T
wehe
it u h n s
odo
uelv
tre
fu rnd w
ret
th u e ca
res
pd re
ur pm
if r ic eo
asv tse io ud nre u i.n n Td th he eer
L ne
PCreMpaSte
ra mp
tie.
otnho odf i 1n:te MrmHe+d =ia 3t4e71,4 RT = 0.287 min -120-
21-2b.0ro9mo memthoolx)y-t weretr-ebuty ald-ddiemdeth ty
Figure imgf000122_0001
lil (l88ti0 µlf 40 I3t dl)itnd 1 c3esi (u4m.0c3arb monate (3.939 g, dimethylformamide (12,09 ml). T mol) in N,N- 5 a ddicdhelodrom anetdhan thee/me athqauneoolus (9:1 la).yhee
Tr rea
he wc
oation mixture was stirred at 60°C for 6 hours. Water was rsgan extracted with ethyl acetate and a mixture removed under reduced pressure. The resid ic layer was dried, filtered and the solvent was over silica gel using dichloromethane and ue was purified by flash column chromatography % of methanol). The product fractions w methanol as eluents (gradient elution from 0 % to 10 10 redu ere collected and the solvent was removed und Y LCieMldc
S:e 1d
m.2 p
e2r
t7es
ho gsu
d or
1fe
: in. er MteHr+m =ed 4i6a9te, R 1T4 ( =650%.77)9 min
Preparation of intermediate 15
15 t (e1r.t2-2B7ut go,xy 2c.arbonyl anhydride (0
Figure imgf000122_0002
90 l 393 l) ddd to a mixture of Intermediate 14 ml). The sol6u2tio mmol), 4-(dimethyl i )pyidi (16 g, 0.13 mmol) in tetrahydrofuran (7.86 0 3 a.93 mmo n was st a irred under reflux for 16 , hours. tert-Butoxycarbonyl anhydride (0.90 ml, 2 added andl) t,h 4e-( mdiimxtuerthey wlamsin sotir)rpeydrid aitn 7e0 (°1C6 fo mrg 200 h.1o3ur ms.m Tohl)e a renadc ttrioienth myliaxtmurinee w (a0s.5 c0o2ol medl), w etehr dc yel rieetda,te filt weraesd a adndded the an sdolv theent o wrgaasn ricem laoyveerd w uansde erxt rreadcutecded w pitrhes wsautreer.. Th Tehe res oirdguaeni wca lasy peurri wfieads b (gyra fldaisehnt co elluumtionn c fhroromma 0to %gr taoph 7y % ov oefr m sileicthaa g - ne1
ol2
l) u1
.s- Tinhge d picrohdlouroctm ferathcatinoens and methanol as eluents solvent was remove were collected and the Yield: 1.387 g of d under reduced pressure.
5 LCMS method 1: in MteHr+m =ed 5i6a9te, R 1T5 ( =931%.09)5 min
Preparation of intermediate 16
10 A t
Figure imgf000123_0001
s ah
dcr mouixgthur tehe of m 1ix,4tu-dreio.x Iannteerm andditt 15 ( (311.38773 g2, 2.l4)4 dl),g (5-mdin boy-2 b-uflubobrlion-gph neitnryolg)beonro gnaic pihcid
oyscpl (o6
hh9
ae0
texy m
tlrpg
ibh,
ao 2
ssip.9
ch3
(i1n.o m
5-52m
3’,o4l)
g’,,
,63’ t-et ertir
qiask
.oi
)ps
wr(
eotr
rpip
eyhl abe
dinpy
dhl
eep
dnhyo
als
n (p
dXh
tpin
hhe
eo)
msp)a
ix (ll
t4a
u8di
r mumg(,00).1 (058 m mmgo,l) 0 a.0n5d p momtaosls),iu 2m- at 85°C for 16 hours. The reaction mixture was cooled e was stirred under nitrogen gas 15 o rerg
sda
inun
gceic a
dd l
ic pry
hloee
rsr
osmu wra
ees
t.ha T w
nha
eesh
a rnee
dsdid w
mueeith
th w w
aansate
ol pru,rif dierided b,y fi fltlaesrehd co aln a
ud nd
mn the dil
ch s u
roo te
mlv d eatn w
ot ith
gr waa e
ps th
hy r y e l e
om a veo c
rve ta sd te ilic u . an T d h ge e er u l The product fractions were co as eluents (gradient elution from 0% to 10% methanol). 0 Y LCieMldS: 0 m.9e9th go odf 1 in:t MerHm+e llected% and the solvent was removed under reduced pressure. 2 =di 5a9te9, 1 R6T (6 =81.0)53 min
Preparation of intermediate 17 -122-
2 (0-N.9i9tro gb,e 1n.z6e7n mesmuolfol)n,y ply crihdlionreid
Figure imgf000124_0001
(1 (4084 µ4l, g 1.26700 l)l)d 4-(ddiddth tyla am sionlout)ipoynri odfin iente (rmediate 17 5 mmol) in dichloromethane (5.0 ml). The reaction mixture was stirred a 10 mg, 0.08 h woausrs s.tir Mreodre at 2 r-onoitrmob teenmzpeenreastuurlfeon foyrl 1 ch hlooruidr.e D (i0c.088 g, 0.4 mmol) wast r aododmed te amnpde trhaetur meix foturr 4e was washed with a 1N aqueous hydrochl hloromethane was added and the organic layer and the solvent was rem oric acid solution. The organic layer was dried, filtered 0 column chromatogr oved under reduced pressure. The residue was purified by flash 1 ( wgarasd rieemnto evleudtio unnd freormap
re 0h
d%y
uc teo ov
d 7e
p%r
re m sil
sseic
utrha
ea.n goell). u Tshieng pro ddicuhclto frroamcteiothnasn weer aen cdol mlecettehdan aonld a thse e sloulevenntst Y LCieMldS: 0 m.9e7t5ho gd o 1f: in MteHr+m =ed 7i8a4te, R 1T7 ( =741%.16)8 min
15 Preparation of intermediate 18
T (9e2tr5ab mugty,la 1m.1m8o mnimumo fluoride
Figure imgf000124_0002
(189 g 189 l) ddd t solution of intermediate 17 0 t aenmdp aer saattuurreat feodr a 2q4u h l)
eoou in
urss. tetrhyd f (3.54 l). Th ti mixture was stirred at room 2 so Tdhieum m bixictuarrebo wnaaste d siloultuetdion w.it Thh eeth oyrgla anciecta latyee arn wdas w dasriheedd, fi wlteithred wa atnedr t ahned s dorliveedn utn wdaesr r reemduocveedd p urnedser reduced pres -s1u2r3e-. Acetonitrile was added, the solid was filtered Yield: 680 mg of intermedi sure.
LCMS method 1: MH+ = 67ate 18 (86%)
5 0, RT = 0.804 min
Preparation of intermediate 19
A in s dorlyut Nio,nN o-dfi imnteetrhmylefodriamteam 1i8d (
Figure imgf000125_0001
5 (820 lg) 08d7 llt)i i 2f ditihyplttpyhly adzroofduicraanrb (o2x0yl matle/mmol) and 10 2 h.o6
hu1
ers m
m am
ixto
t 9l
u0)
re° iCn t
w to
aolu
s ae
s sn
toe
irlru (20
etdion m
at ol/fm
9 tmol) were added simultaneously and dropwise over a pe (5ri2o0d m ofg 2, T 0ri°pChe fnoyrlp 3h0os mpihniuntees (.68 T5he mg re,a 2c.6ti1on mm moixlt)u irn toluene (75 ml/mmol). solvent was removed under reduced pressure. T e was cooled and the 5 c ehromatography over silic he residue was purified by flash column 1 l tu
relumtioovned from 0% to 3% meatha gneoll) u.s Tinhge d pircohdlourcotm freatchtaionnes a wnedre m ceotlhleacnteodl a asnd eheen stsolv (gernatd wieanst YCieMldS: 57 under reduced pressure.
L m4et mhogd o 1f: in MteHr+m =ed 6i5a2te, R 1T9 ( =960%.92)9 min
Preparation of intermediate 20 -124-
Figure imgf000126_0001
5 T
m ado
ixd a
teud so
re cleu
wsti
aioun
sm o
st cf
ira in
rerbte
dor
anmediate 19 (546 g, 0.84 l) i N,N-di thylformamide (2.52 ml) were ta rtoeo (m54 t7em mpge,r 1a.6tu8re m fmoro 3l) a hnodur tsh.io Epthhyeln aocle (1ta0t0e µ wl,a 1s.01 mmol). The reaction layer was washed with a 1N aqueous sodium hydroxid added and the organic filtered and the solvent was re e solution. The organic layer was dried, 0 column chromatography ove m r o s v il e ic d a un g d e e l r u re si d n u g ce d d ic p h r l e o s r s o u m re e . th T a h n e e re a s n id d ue m w e a th s a p n u o r l ifi a e s d by flash 1 ( sgorlavdeinetn wta eslu rteiomnov freodm un 0d%er t roed 1u0c%ed m preetshsaunrol). The product fractions were collected a enlude tnhtes Yield: 206 mg of intermediate 20 ( e.
LCMS method 1: MH+ = 467, RT =532%.36)7 min
15 Preparation of example N5
I mntl)e.rm Tehdeiat meix 2t0ur (e20 w6a msg s,t 0ir.r4e4d m
Figure imgf000126_0002
t l) di l d i 4N hydrochloric acid in methanol (1.32 Diethylether was added, the compound wa t p t ight and at 45°C for 6 hours. 20 f LoCrM 16S h moeutrhso.d Th 2e: M prHod bt s filtered and dried under reduced pressure at 60°C
+u =c 3t6 w7a,s R oT =ai 1n.e8d80 as m tihne HCl salt. Example -125- E ill x u a s m tra p t l e e N
d N6
fo 6 r t m he ay pr b e e pa p r r a e t p io a n re o d f e fo xa llo m w p i l n e g N g 2 e . n T e h r e al p s ro c d h u e c m t e wa 1 s a o n b d ta a in c e c d or a d s in t g he to HC th l e sa p l r t. ocedures
5 E
Figure imgf000127_0001
Exm e N7
Pxa
re a p mpl
ap ra le
tio N n 7 o m f a in y te b r e m p e r d e ia p t a e re 2 d 1 following general scheme 1.
10 t (e2r.t0-0Bu gt,yl 1-c9h.7lo7ro mdmimoel)th aynlsdila imneida (4z.o4l7e ( g2,.6299
Figure imgf000127_0002
eaction was stirred at room temperature fo26
r g6
7,23 h9o.5u4l)
rs. Tmas
heol a)dded to a mixture of piperidin-4-ol r so inlve dnicth wloarsomethane (59.31 ml).The pressure. The residue was purified by flash column chromatograph r y em ov o e v r ed si u li n ca de g r e re l d u u s c i ed 15 p dichloromethane and methanol as eluents (gradien anol). Tnhge LrCoMduSct m freathctoio t elution from 0% to 10% meth
dn 1s: w MeHre+ = co 2ll1e6c,te RdT a =nd 0. t5h1e6 s molivnent was removed under reduced pressure.
Preparation of intermediate 22 -126-
A pot masixstiuurme c oafrb ionnteartmee (d2i1a.t8e62 g1, 1 (5189.1.767
Figure imgf000128_0001
l)l) 2b oethanol (2.81 ml, 39.54 mmol) and 5 W dicahtelorro wmaesth aadndeed an adnd m the aqueous layer wa is extrtactietrdile w (i5th9. e3t1hy mll a)c iset raetfelux aendd f aor m 2i0xt huoreur os.f removed under reducee pthreasnsoulr (e9.:1 T)h.e Th rees oidrguaen wica lsay peurr wifiaesd d bryied fl,as fihlte creodlum annd c thhero smoalvtoent was over silica gel using dichloromethane and methanol as eluents (gradi graphy 0 m prethanol). The product fractions were collected and the solvent waesnt re emluotivoend fr uonmde 0r% re todu 1c0e% 1 Y LCieessur
Ml e. d dS: 3 m.0e6th go odf 1 in:t MerHm+e =di 2a6te0, 2 R2T (6 =0% 0.6)01 min
Preparation of intermediate 23
15 Sbroodmiuom-5- hcyhdlorirdoe-p (y6r0a%zo ilno[1 m,5in-ear]aply
Figure imgf000128_0002
ol) in dry N,N-dimethylformamiil
idid 1
ei55
(19 (1g
.3.5506
m g4,5
l) 6.. T45 l)
he realc) d
tiondd iendter amte 0d°Ciat teo 2 a2 s (o2l.u0t1io gn, o 7f.734- mm
20 temperatu mixture was stirred at room A ext sraactuteradter
wde f
ith aoqr
eu 1
the h
yoo
luu
asr.
ce atmatmeo annidum a m chixloturirdee of so dliuchtiolonro wmaestha andede adnd an mdet thhaeno alq (u9e:1o)u.s Th laeye sorlv weanst warsom raetmogorvaepdhy u onvdeerr sil riceadu gceeld us pinregs hsuerpeta. -127- ch ne Th aend re esthidyule ace wtaatse a psur eifliueednts by (gr faladsiehnt c eolluumn from 0 % to 7 % of ethyl acetate). The product fractions were collected and the solv tion 5 removed under ent was Y LCie reduced pressure.
MldS: 1 m.6e8t8ho gd o 1f: in MteHr+m =ed 4i5a6te, R 2T3 ( =570%.88)0 min
Preparation of intermediate 24
10 A thr mouixgthur tehe of m 1ix,4tu-dreio.x Iannteerm anedd
Figure imgf000129_0001
itt 23 ( (311.210 l) dg d by bubbling nitrogen gas acid (0.99 g, 4.19 mmol), tetrakis( 588 g, 3.49 l), (5-mino-2-fluoro-phenyl)boronic dicyclohexylphosphino-2’ triphenylphosphine)palladium(0) (81 mg, 0.07 mmol), 2- 15 phosphate tr ,4’,6’-triisopropylbiphenyl (Xphos) (67 mg, 0.14 mmol) and potassium a otrg 85°C for i 1 b 6 as h ic ou (2 rs .2 . 2 T 2 h g e , r 3 ea e c q t . i ) on we m re ix a tu d r d e ed wa a s nd co th o e le m d ix a t n u d re d w ilu a t s ed sti w rre ith d u e n th d y e l r a n c it e ro ta g t e e n . T g h a e s resdanic layer was washed with water, dried, filtered and the solvent was removed under uinugce ddic phrloersosmureet.ha Tnhee a rensdid mueeth waansol p ausrifi eeldue bnyts fl (agsrhad cieonlutm enlut ciohnro fmroamtog 0r%aph toy 5 o%ver m seitlihcaa gel 0 Y The product fractions were collected and the solvent was removed under reduced p ssure.nol). 2 LCieMldS: 1 m.4e0th go odf 1 in:t MerHm+e =di 4a8te6, 2 R4T (8 re
=3% 0.8)53 min Preparation of intermediate 25 -128-
2 in-tNeirtmroebdeinazteene 2s4ulfon (1y.l40 chlo gri,d
Figure imgf000130_0001
2 (.08877 g 34l)6, pyil) ddd portionwise to a solution of 5 ( wdaimse stthiryreladm ainto ro)poymrid teinmep (e1r7a mg, 0.14 mmol) in dichlodriometh (2a5n6e (8 µ.6l,4 m 2l.)8.8 The m rmeaocl)tion a mndixtu 4re- was washed with a 1N aquetouures h foyrd 3ro hcohulorrsi.c D aiccihdlo sroolmuteiotnh.an Tehe w oarsga andidce lday aenrd w tahse d orrigeadn,i fci layer and the solvent was removed under reduced pressure. The residue was pu ltered 0 column chromatography over silica gel using dichloromethan rified by flash 1 ( wgarasd rieemnto evleudtio unnd freorm re 0d%uc teod 8 p%re methanol). The product fractions weer aen cdol mlecettehdan aonld a thse e sloulevenntst Yield: 1.486 g of intermediate ssure.
LCMS method 1: MH+ = 671, R 2T5 ( =770%.93)6 min
15 Preparation of intermediate 26
T (1e.t4r8a6bu gty,la 2m.2m2o mnimumol) fl iunor tiedtera (h4y.d4r4
Figure imgf000130_0002
g 444 l) ddd to a solution of intermediate 25 t weamsp setriarrteudre a fto rro 2o0m h toeumrsp.e Mraoturere te f (6.66 l). Th tion mixture was stirred at room 20 fotrrab 2u4ty hloaumrsm aonndium at f 6lu0o°Crid feor (14 e hqo.)ur wsa.s Th aedd meidxt aunred w thaes m diixlututerde w soitlhutio enth.y Tlh aece otragteani acnd lay wears whaesd d wriiethd, w fialtteerr -1
ed a2n9
ad- nd a th seatu soralvteednt a wqauseo ruesmo svoeddium bicarbonate pressure. The residue was purified by flash column chromatography o under reduced heptane and ethyl acetate as eluents (gradient elution from 0% t ver silica gel using 5 p Yrioedldu:c 8t0 fr0actions were collected and the solvent was removed undero re 1d0u0c%ed e pthreylss aucreet.ate). The LCMS met mhogd o 1f: in MteHr+m =ed 5i5a7te, R 2T6 ( =650%.55)9 min
Preparation of intermediate 27
10 A a s soolluuttiioonn o off in dtieisromperodpiaytle a 26 (650
Figure imgf000131_0001
g 117 l) i 2 thyltetrahydrofuran (20 ml/mmol) and added simultaneously anzodicarb ylt (1.16 g, 5.85 ol) in toluene (20 ml/mmol) were triphenylphosphine (1.53d dropwise over a period of 3 hours at 90°C to a solution of 15 9 re0
sd°
inuC
gce fo
ddr
ic p 3
hr0
loers m
osinutes. Th4e g r,ea 5c.8ti5on m mmioxlt)ur ien t woalusen ceoo (l7e5d m anl/dmm thoel) s.o Tlvheen mt wixatusre re wmaosve sdtirr uendde art u mureet.ha Tnhee a rensdid mueeth waansol p ausrifi eeldue bnyts fl (agsrhad cieonlutm enlut ciohnro fmroamtog 0r%aph toy 7 o%ver m seitlihcaano gle).l T Yhieeld p:r 2o3d9uc mtg fra ocft iinotnesrm weedreia cteol 2le7ct (e3d and the solvent was removed under reduced pressure. 20 LCMS method 1: MH+ = 539, RT =80%.66)2 min Preparation of example N7 -130-
T adod aed so cluestioiunm o cfa inrbteornmaetedia (2te4127 m (g2,00
Figure imgf000132_0001
0.74g 037l) d tlh)i ip NhNdlim (4e0th µyl,lf 0o.r4m4a mmmidoel) (.1 T.1h1e m rel)a wctere 5 mixture was stirred at room temperature for 2 hours. The solvent was removed under reducioedn p A r ) e . s T s h ure. The residue was purified by reversed phase column chromatography (HPLC method Yield:e product fractions were collected and the solvent was removed under reduced pressure. LCMS 6 m5e mthgo odf 2 e:x MamH+pl =e 3 N574, (50%)
10 RT = 1.873 min
E Exxa 8
Preaml
pmp
apralee N
tio Nn8 o mfa inyte brem perdeiaptaere 2d8 following general scheme 1.
15 t (e2r.t9-9Bu gt,y 8l-.c7h9lo mromdioml)e athnydls tirliaentheyl (a1m.5i9ne g
Figure imgf000132_0002
eaction was stirred at room temperatu ( 1055 l) dded to a mixture of intermediate 3 r r3e.0 f5o l, 21.97 l) in dichloromethane (26.37 ml).The and tert-butyl-chlorodimethylsilane (0. r 5 hours. More triethylamine (0.30 ml, 2.197 mmol) 20 was stirred at room temperature15 o9ve gr,n 1ig.0h55 m Tmol) were added and the reaction mixture d soiclhvelonrtom weatsha rneem.o Tvheed o urngdaneric r leadyuecre wdas pr wesassuhre t
ed .
. w Thi h teh e w re
reast action mixture was diluted with iedru and brine, dried, filtered and the chrraodmieantotg erlauptihoyn o frvoemr s 0il%ica to ge 1l0 u%si)n.g T dhiech plororodmucetth rified by flash column (g farancetio annsd w 7Ne
ere am w
cmas
olo pu
lencia in methanol as eluents r Yeimeldo:ve 3.d1 u4n gde orf i rnetdeurmceeddi par ted and the solvent was 25 tees 2s8ur (e7.9%) LCMS method 1: MH+ = 456, RT = 0.676 min -131- Preparation of intermediate 29
5 t (e3r.t1-4Bu gt,ox 6y.9c1arb momnyoll) a,n trhimydertihdye (1.81
Figure imgf000133_0001
g, 8.29 l) ddd to a mixture of intermediate 28 mg, 0.35 mmol) in tetrahydroflaumrainn (2 (1.248 l, 8.98 l) nd 4-(dimethylamino)pyridine (43 More tert-butoxycarbonyl anhydride (0.73 ml). The solution was stirred at 80°C for 2.5 hours. 10 0.07 mmol) and triethylamine (0.250 m3l62 mg, 1.658 mmol), 4-(dimethylamino)pyridine (9 mg, 8 p 0 re ° s C su fo re r . 2 D ho ic u h r l s o . ro T m he et r h e a a n c e tio w n a m s ix a t d u d re ed w, 1a.
as796 mmol) were added and the mixture was stirred at nd co t o h led and the solvent was removed under reduced brrienses.ure T.he Th oerg raensiicdu leay weras wa psur difireiedd, by filt felaresdh ae
cn o
odrg
lum thanic layer was extracted with water and p ne c shorlovmenatt was removed under reduced dichloromethane and methanol as eluents (gradient elution fromography over silica gel using 15 p Yrioedldu:c 3t. f4r7ac gtio onfs in wteermree cdoiallected and the solvent was removed und 0e %r re todu 1c0e %d p orfe msseutrhea.nol). The LCMS method 1: MH+ = 55te6, 2 R9T (9 =1% 0.8)55 min
Preparation of intermediate 30
20 Iynl)tpehrmeneodlia (t7e2029 mg (1,.34.002 g, mm 2.o5l2),
Figure imgf000133_0002
1 2-diyl)l 4hflylph3p(4hi45-25,t4’,t6ra’-mtrieisthoyplr-o1p,3y,l2b-idioxaborolan-2- (i1x9tur meg o,f 01.2,45-d miomxaonl)e a anndd p wotaatsesriu (3m:1 p,h 7o.5sp6h matle) a trnibdas thice ( m1.i6x0tur ge, w 3a esq. d)e wgaesre ph
se d e
dis n
bs y yo l lv (Xphos) m beudbb inlin ag n mitmroogl)en wa gsa asdd therdou agnhd t thhee m mixixttuurree. wa Tset sratkis -(1t3ri2p-henylphosphine)palladium(0) (116 mg, 0.10 fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaboriorrleadn- u2n-ydl)eprh neintroolgen (2 g1a6s a mt 8g0,°C 0 o.9v0e6rnig mht. More 4- 5 dicyclohexylphosphino-2’,4’,6’-triisopropylbiphenyl mol), 2- p mhmosopl)h wateere tri abdadsiecd (4 a8n0d m thge, 0 m.9 (Xphos) (36 mg, 0.075 mmol) potassium ixt euqre.) w anads t settirrarekdis( utrnipdheern nyiltprohgoesnph ginaes)p aatll 8a0d°ium(0) (35 mg, 0.03 reaction mixture was cooled and the solvent was remo C for 6 hours. The acetate and water were added and th ved under reduced pressure. Ethyl The combined organic layers were drieed a,q fiulteeoreuds a lanyder th wea ssol evxetnratc wteads t rweimceov weidth u entdheyrl acetate. 10 p hreepstsaunree. an Tdhe eth reylsi adcueeta wtea ass p euluriefinetds ( by flash column chromatography over silica ge reld uusciendg product fractions were collected and thegr saodlvieenntt e wluatsio rnem froomved 0 u %nd teor 5 r0ed %uc oefd e pthreysls aucreetate). The Yield: 1.23 g of intermediate 30 ( .
LCMS method 1: MH+ = 586, RT8 =3% 0.)
15 983 min
Preparation of intermediate 31
T
Figure imgf000134_0001
20 ae stroalubtuiotynla omfm inotneirumme fluoride (1M lti i tt hyd f 066 g, 2.52 mmol) was added to m soixlututiore diate 31 (1.23 g, 2.10 l) i tt hydrofuran (6.30 ml). The reaction n w ina tset sratihrryeddro afutra rono,m 66 te mmgp,e 0r.a2t5u2re m omveorln)ig what. More tetrabutylammonium fluoride (1M temperature for 2 hours. The so s added and mixture was stirred at room di q c u h e lo o r u o s m s e o th d a iu n m e b w ic a a s rb a o d n d lvent was removed under reduced pressure and a a e te d. so T lu h t e ion o . r T ga h n e ic org la a y n e ic r l w ay a e s r w w a a s sh d e r d ied w , i f t i h lter w e a d te a r n and a saturated 25 r oevmero svielidca u gnedle urs riendgu dciechdlo prressure. The residue was purified by flash columnd c thhreom soalvtoegnrta wpahsy mreetshsanol). The product fraocmtioenthsa wneer aen cdo mlleecttheadno aln ads th eelue snotlsve (ngtra wdaiesnt re emluotivoend fr uonmde 0r% re todu 1c0e% p d 30 YCieMlure.
L dS: 7 m10et mhogd o 1f: in MteHr+m =ed 4i7a2te, R 3T1 ( =720%.64)0 min
Preparation of intermediate 32 -133-
A de sgoalsution of intermediate 31tr (680
Figure imgf000135_0001
g 144 l) i 2 thylttrahydrofuran (20 ml/mmol) was azodicsaerdbox byylate bu (b8b6l0ing mg, ni 4.o3g2 m g th gh th it . A solution of diisopropyl 5 n ait proegrieond g oafs 4 t5hro muinguhte thse a mti 9xt0u°rCe. t Boom
athol
d s) in toluene (20 ml/mmol) was degassed by bubbling eogluatsiosns were added simultaneously and dropwise over mmol) in toluene (75 ml/mmol). The mixture wed solution of triphenylphosphine (1.133 g, 4.32 was cooled and the solvent was removed und a e s r r stirred at 90°C for 1 hour. The reaction mixture 10 flash column chromatography over silica gel usieduced pressure. The residue was purified by (gradient elution from 0% to 5% methanol). The pnrogdu dcicth flroarcotmionesth waneere a cnodlle mcteetdha annodl t ahse e sloulevennts w t Yiaesld r:e 3m4oved under reduced pressure.
LCMS m6et mhogd o 1f: in MteHr+m =ed 4i5a4te, R 3T2 ( =532%.66)0 min
15 Preparation of example N8
A ml m)i wxtausre s otif intermediate 31 (346
Figure imgf000135_0002
g 076 l) d 4N hydrochloric acid in 1,4-dioxane (2.28 0 temperaturerr.e Ddie athty rlo eotmhe tre amnpde mrat f 4 h , t 50C fr 2 hours and overnight at room 2 t a e m m o p u e n r t at o u f re me fo th r a 3 n 0 ol m a i n n d ut d e r s ie . d Th u eeth
nd sa
eonol (1 ml) were added and the mixture was srtirred at room rli v d ac w u a u s m fi a lte t r 6 e 0 d º , C w . a T s h h e ed pro w d it u h c t
sa t d w ie a th s y o l b e ta h i e ned an a d s t a he sm H a C ll l Y LCielt
Ml.dS: 2 m25et mhogd o 2f: e MxaHm+p =le 35 N48, R (8T4% =)
25 2.098 min
E Exxaammppllee N N99 may be prepared following general scheme 2. Preparation of intermediate 33 -134-
Ahyd mrioxxtuyrpeip oefrid 3i-nbero-1m-coa-5rb-cohxlyolarote-py (1ra.9
Figure imgf000136_0001
9l g[1,59.89]pyi idli) i (2 d0y0 te gt,ra 8h.6y0 mmol) and tert-butyl 4- 5 s mtimrreodl) w atas ro aodmde tedm apnedra thtuere re faocrti 1on h mouixr.tu Sreod wiuams s htiyrdreridde at (6 ro0o%m in tem mpidnr
eeo
rarfau
tulran (25.80 ml) was r oeil, fo 310 mg, 12.90 sodium hydride (60% in mineral oil, 30%) was added and the reaction mixturer w 1a hso sutr. More room temperature for 1 hour. The reaction mixture was cooled to 0°C and a saturated aqirured at 10 ammonium chloride solution was added and the aqueous layer was extracted with ethyl ace e t ous The solvent was removed under reduced pressure. The residue was purified by flash coluamten. c frhormom 0a %tog troap 3h0y % ov oefr e stihliycla a gceetla utes)in.g Th heep ptraondeuc atnd ethyl acetate as eluents (gradient elution re fractions were collected and the solvent was 15 Yimeldo:ve 82d6 un mdger of reduced pressure.
LCMS method 1: in MteHr+m =ed 3i9a8te, R 3T3 ( =241%.12)5 min
Preparation of Intermediate 34
20 m Intermediate 33 (826 mg, 2.08 mmol)
Figure imgf000136_0002
di l d i 4N hyd
rel a hanol (6.24 am).
lt o T
avh
nee
dd m
w t a wi
sixct
ueur
s uen w
ed d w ea
irs
th r s
oet
udir
ture
fcd
ue r d a
the ptr reososmure t. Tphe ctompo fund 4 w hoausrs o.ro
bt Tc
aoh
inlulo
eer
dnic
ae a
s wci
thad
es in met
hydddreodch twloircice a acnid Y s d CieMldS: 6 m78et mhogd o 2f r purification in the next step.
L : in MteHr+m =ed 2i9a8te, R 3T4 ( =980%.30)
25 6 min
Preparation of Intermediate 35 -135-
S inotedrimumed tiaritaece 3t4ox (y1b.o0r5o4hy gd,ri 3d.e1 (1
Figure imgf000137_0001
339 g 632 l) ddd portionwise to a solution of mg, 4,74 mmol) and triethylam6ine (1.3l)1,82 m-[tl, 9t-.b48ty ml(mdiol)thyl)ilyl]oxyacetaldehyde (90%, 830 5 m sal)tu arantded me atqhuaenoouls (4 s modl).iu Tmhe b riceaarcbtioonnat meix sture was stirred in at a r mooixmtu treem opfe 1r,a2t-udriech folorro 2e hthoaunrse. ( A9 extracted wit olution was added and the aqueous layer was removed undher d riecdhulocreodme ptrheasnsuer.e T.h Teh organic layer was dried, filtered and the solvent was over silica gel using dichloromethane aend re msideuthean woals as pu erliufieed by flash column chromatography 10 methanol). The product fractions were collected and the sonltvsen (gtr wadaisen rte emluotvioend f uronmde 0r%
p red touc 3e%d Yr
LCiees
Mlds
S:u 1re
m.2.
e3t3ho gd o 1f: in MteHr+m =ed 4i5a6te, R 3T5 ( =860%.72)5 min
15 Preparation of intermediate 36
A thr mouixgthur tehe of m 1ix,4tu-dreio.x Ianntee
Figure imgf000137_0002
d t (31120 l) dg d by bubbling nitrogen gas acid (0.42 g, 2.70 mmorl), tedtiratkis 3(5trip (8h1e8nylpgh,os 1p.8h0in l), (5- ino-2-fluoro-phenyl)boronic 20 d pihc
toy
8sc
5plo
°hh
Caet f exy
or tlrpi 1 bh
6aoss
hipch
ou (i1n
rs .o1- .42
T6’,4
h g’,
e,6
r 3’-t
ea eri
cqis
t.o
i)p
on wreo
mrpeyl
ix ab
tu dip
rdh
eeedny
wa al
sn (dX
co tphhe oeo)p l msa)lla
ix (t3d
u3iu
re mm
wg(
a,0) (46 mg, 0.04 mmol), 2- s 0. s0ti7rre mdm uonl)de arn ndit proogtaesnsi guam a s organic layer was w ed and diluted with ethyl acetate. The reduced pressure. Thaesh reesdid wueith w wasate pru,rif dierided b,y filtered and the solvent was removed under 25 u Tshieng pr doidcuhclotr foramcetitohnasne we arned co mlleetchteadno aln ads th eelu seonlvts fl
en (ags
trh
waad c silica gel sieo
rnlu
etm
m en
oluvt c
eioh
dnro
un fmratography over
doemr r 0e%duc toed 5 p%re msseutrhea.nol). Yield: 731 mg of inteHr+m =e -136- LCMS method 1: M d 4i8a6te, R 3T6 ( =840%.87)7 min
Preparation of intermediate 37
5 2 in-tNeirtmroebdeinazteene 3s6ulfo (n7y3l1 chl
Figure imgf000138_0001
gid, ( 10.5410 g 18l1), pyild)i (1d3d4d µ pl,rtio 1n.wise to a solution of (dimethylamino)pyridine (10 mg, 0.08 mmol) 51 mmol) and 4- 10 was sti in dichloromheathnaen wea (4s.5 a3dd meld). a Tnhde th reea octrigoann micix latuyree w r an a d s w th ar
esrehd
se o d at
lv w r
en iot t hom
w a a 1 te
sNm
r ap
eqe
mura
oet
voue
eur
ds h fo
uyr
nd 3
dr e o h
rcohurs. Dichloromet
re lo d r u ic ce a d cid p s re o s lu s t u io re n . . T T h h e e organic layer was dried, filtered column chromatography over s residue was purified by flash (gara ilica gel using dichloromethane and methanol as eluents wsd rieemnto evleudtio unnd freorm re 0d%uc teod 5% methanol). The product fractions were collected and the solvent 15 Y LCieMldS: 7 m46et mhogd o 1f: in MteHr+m =ed 6i7a1te p
, R 3re 4r
T7s (s
=7u
1%e.
.03)9 min
Preparation of intermediate 38
Figure imgf000138_0002
Tetrabutylammonium fluoride (1.33 g, 1.33 -137- (7 mmol) was added to a solution of intermediate 37 tem46pe mragt,ur 1.11 mmol) in tetrahydrofuran (3.33 ml). The reaction mixture was stirred at room 5 and a satureat feodr a 4q8u heoours. The mixture was diluted with ethyl acetate and washed with water t c h h e ro s m o a lv t e o n g t ra w p a h s y r o e v m e o r vu
ses
id s
lic uo
anddium bicarbonate solution. The organic layer was dried, filtered and ge e r l r u e s d i uced pressure. The residue was purified by flash column elution from 0% to 10% methanol). Tnghe d picrohdlourcotm fethane and methanol as eluents (gradient remov ractions were collected and the solvent was Yield:e 36d2 un mdger of re indtuecrmed pressure.
10 LCMS method 1: MH+ =ed 5i5a7te, R 3T8 ( =590%.64)8 min
Preparation of intermediate 39
15 a A solution of i
Figure imgf000139_0001
ad sdoeldutio snim oufn
lta dt
nieiesrom
ope
ursod
lypiayt
ale
n a 3
dz8o dd (287 g 052 l) i 2 thyltetrahydrofuran (20 ml/mmol) and ricoaprwbiseyl otver (0 a.52 pe g, 2.60 ol) in toluene (20 ml/mmol) were triphenylphosphine (682 mg, 2.60 mmol) in toluenreiod (75 of m 2l/m hmouorls at 90°C to a solution of 9 e 0 d ° u C ce fo d r p 3 r 0 es m su in re u . te T s h . e Th re e si r d e u a e cti w on as m p ix u t r u if r ie e d w b a y s f c la o s o h le c d o a lu n m d n th c e)
hr s.
oo T
mlvh
aee
to n m
gt r wix
ap atu
hsre
y re was stirred at r o m ve o r ve s d ilic under 20 u ascientgate d)i.ch Tlohreom preotdhuacnte fr aancdtio entshy wle arceet caotelle acsted elu aenndts th (egra sodliveenntt e wluatison re fmroomve 0d% un tode 5r0 r%a edu ect ghe eyl dl p Yriessure. 5 LCeMldS: 1 m41et mhogd o 1f: in MteHr+m =ed 5i3a9te, R 3T9 ( =502%.33)
2 7 min
Preparation of example N9 -138-
T adod aed so cluestioiunm o cfa inrbtermediate 39 (14
Figure imgf000140_0001
1 g 026 l) i NNdimethylformamide (0.78 ml) were mixture was stirredo anta rtoeo (m16 t9em mpge,r 0a.t5u2re for 5l) d thiph l (30 µl, 0.31 mmol). The reaction 5 p Ar
h)e.s
e Ts
phu
rere
od p.
uro T
cdh
t w uec r
ate
s fsr d aid
rcu
ie tie
don w
usa
nd ws
ee p
rrueri
va cfi
coe
uldl u e m c btye a d re avnedrs tehd ho
e pu
shr
oas
lvs.
ee Th
nt ceo wlu s
amol
s rnve
em cnht was removed under reduced orvoemda utongdrearp rheyd (uHcPedLC pr mesestuhroed T . Yield: t 60°C for 16 hours.
LCM 18mg of example N9 (20%)
10 S method 2: MH+ = 354, RT = 1.977 min
E Exammple
illxuastraptlee N
d N1
fo10
r0 th mea pyre bpear parteiopnar oefd ex foalmlowplieng N2 g.e Tnheera plr socdhuecmt wea 1s a onbdtai ancecdo ardsin thge to HC thle sa plrt.ocedures
15 Ex x a a m m p p l l e e N1
Figure imgf000140_0002
E N1 1 1 may be prepared following general scheme 1 and starting from example N8.
Figure imgf000140_0003
A mixture of example N8 (133 mg, 0.38 mmo -l)1 a3n9d- 4.18 mmo sodium hydride (60% in mineral oil, 100 mg, atmospherel) fo inr 1 a hnohuyrd.ro Ious N,N-dimethylformamide (1.14 ml) was stirred under nitrogen 5 was stirred at room tempderoamtuerteha foner 2 (2 h7o µl, 0.44 mmol) was added and the reaction mixture e rexmtraocvteedd u wnidther d riecdhulocreodme ptrheasnsuer.e T.h Tehe or rgeau
sinrs
diuc. W
e la wya
aete
srr
p w w
uaa
rss
ifie d added and the aqueous layer was drie bdy, f flialtsehred and the solvent was over silica gel using dichloromethane and methanol as eluents (gradien cto elulumtn chromatography methanol). The product fractions were collected and the solvent was removioend f uronmde 0r% red to 5% 10 pressue. uced L Yield: 1r05 mg of example N11 (75%)
ECxaMmSp mlee Nth1o1d ( 21: MH + = 368, RT = 2.107 min
acid in 1,4-diox0a5ne mg (0,.08.729 m mmol) was dissolved in dichloromethane (2 ml).4N hydrochloric temperature for 5 hours. Diethl)yl w eathser ad adnedd m aentd the reaction mixture was stirred at room 15 s ati srrmeadll a atm roooumnt te omf mpeertahtaunreol. fo Trh 3e0 c mominpuoteusn.d T wheas shoa
dln
ridol
ied w (a1
us m
nd fiellt)e were added and the mixture was rr veadc,u wuamshed with diethyl ether and o at 60ºC. The product was Ybitained as the HCl salt.
LCeMldS: 8 m7e mthgo odf 2 e:x MamH+pl =e 3 N611 (82%)
20 8, RT = 2.114 min
E Ex
illxa
uample
smtraptlee N
d N1
fo12
r2 th mea pyre bpear parteiopnar oefd ex foalmlowplieng N8 g.e Tnheera plr socdhuecmt wea 1s a onbdtai ancecdo ardsin thge to HC thle sa plrt.ocedures
25 E
Figure imgf000141_0001
Exxamp
Pre a p m a pl
ra lee N3
tio N1
n13 of m in a te y r b m e e p d r ia e t p e a 4 re 0 d following general scheme 2. -140-
S proodpiuamne- h1y,3d-rdidioel ( (620.3%37 in m ml,i 3neral oi
Figure imgf000142_0001
l 170 g 710 l) as added at 0°C to a solution of mixture was stirred at room te2m.2p5eraturle) i for 30h mydinutes t. Tthehy mdirofuran (19.35 ml). The reaction 5 b reroamctioo-n5- mchixloturore-p wyarasz sotliorr[1e,d5- aat] rpoyorimmi tdeimnepe (1r.50 g, 6.45 mmol) wxtausre a wddaesd co inol oende to po 0r°tCion a.nd Th 3e- ml) w ature for 10 minutes. Dry N,N-dimethylformamide (2 The r a e s a a c d tio d n ed m an ix d tu t r h e e r w e a a s ctio p n ou m re ix d tur in e was stirred at room temperature for 2 hours.
aqueous layer was extracted with dichlotorom ae 5th0a%ne. a Tqhueeo cuosmb aimnemoniumchloride solution. The 10 w wiaths s burisnpee,n ddreiedd, in fi eltethryeld a acnetdat tehe (5 s molvl)e,n thte w salsu removed under reddu ocrgeadn picre lasyseurrse. w Tehree w reassihdeude ceooled to room temperature. The solid was filterrryed w,a wsa hsehaetded wi atht 6 e0th°Cyl f aocre 1ta0te m ainnudte dsrie adnd un thdeen r r Yideuldc:e 1d.2 p5ressure.
15 LCMS meth go odf 1 in:t MerHm+e =di 2a7te3, 4 R0T (7 =1% 0.5)39 min
Preparation of intermediate 41
20 i Intermediate 4
Figure imgf000142_0002
anticm a
hon
losh
rpy
ohd
mero
ereus
th aan d0 ndic (h4 e alo.0 (2 sr4 0loum g mrrlye,t 1 ) w oh4
fa. a mn8e5 se at (
dh4
dy5 l) elsdu dlfl)o.
ron Td pyh tithy wl misee.th Tantli i
esulfoi (
nt3097
ate (2.8sl,
5 c 2
go2
,o.28 mmol) were dissolved 1le6d.3 t4o m 0°mCol u)n inde arn nhiytrdorgoeun d s minutes he reaction mixture was stirred for at 0°C for 15 dichlorom aenthdan aet a rnodom the te omrgpaenraictu lraeye fror 3 hours. The reaction mixture was diluted with 25 f fiultrethreedr p aunrdifi tchaetio sonlv uent was removed und wears re wduacsehded pr wesitshu breri.n Teh.e T choem oproguanndic w laayse urs wedas w ditrhieodu,t LCMS method 2: MHse+d = i 3n5 t1h,e R nTex =t 0 st.7ep0.1 min -141- Preparation of intermediate 42
5 I cn
Figure imgf000143_0001
Nat
,Nrebr
-om
dne
imadteeiat
th (e
y2l. (7
f34
o51
rm3a gm,.24
id20
e.2 m
(6 mm
mmo)
lol
/ml,) (S)
mold(
). p)
Tht2py
e rei li
actio ididid (1th.597l g (,795.602 m mgm,o 7l).4 w0er mem suosl)p,en sdoeddium in (S)-(+)-2-pyrrolidinemethanol (1 n mixture was stirred at 60ºC for 4 hours. More added and the reacti 0%), sodium carbonate (10%) and potassium iodide (10%) were 0 c aqueous layer wason mixture was stirred at 60ºC for 2 hours. Water was added and th eee 1 po d armembined organic lay e e x r tr s ac w te e d re w d it r h ied a , f m ilt i e x r tu e r d e a o n f d d t i h ch e lo s r o o l m ve e n th t a w n a e s a r n e d mo m v e e t d ha u n n o d l e ( r 9: r 1 e ) d . u T c h mssounreia. s Tohlueti roensi adnude m weatsha pnuorlifi aesd e bluye fnlatssh (g craodluiemnnt e clhurtoiomna frtoogmra 0p%hy to ov 5e%r s aimlica gel using 7N The product fractions were co 4llected and the solvent was remov monia solution). 15 Yield: 1.53 g ed under reduced pressure.
LCMS metho odf 2 in:t MerHm+e =di 3a5te6, R2T (5 =8% 1.6)01 min
Preparation of intermediate 43
20 t (e
Figure imgf000143_0002
r1r
e.t
a5- c3Bu
tio gt
n,yl 4-c
w. a 3h
s1lo
s mro
tir mdi
re om
dl)et
a ah
tny
rdls
oo tilra
miente (078 g 517 l) dldd to a mixture of intermediate 42 th e y m l per i atur ( e 1. f 0 o 9 r 4 g, h 1 o 0 u . r 7 s 7 . More t ) e i rt-b d u ic ty h l l-o c r h o l m or e o t d h i a m n e e th ( y 1 l 2 s . i 9 la 3 ne m ( l) 2 . 0 T % he ) a hnodurs tr.ie Tthhyelam reiancetio (2n0% m)ix wtuerree w adadsed di and the -1 m42ix-ture was stirred at room temperature for 1,5 washed with water and brine. The orgalunteicd la wyeitrh w daisch dlroierodm, feiltthearende a anndd th tehe so olrganic layer was 5 under reduced pressure. The residue was purifie vent was removed g meelth uasninogl). d Tihcehlo prroom d by flash column chromatography over silica duecthta frnaectio annsd w meereth caonlolelct aesd e alnuden thtse s (gorlavednietn wta elution from 0% to 10% pressur s removed under reduced Y LCieMldS: 1e
m.8.
e1th go odf 1 in:t MerHm+e =di 4a7te0, 4 R3 (89%)
10 T = 0.707 min
Preparation of intermediate 44
A thr mouixgthur tehe o mf 1ix,t4u-rdeio.x Inatneerm aenddiat
Figure imgf000144_0001
4t3 ( (13.716 g 1,1325 l) dg sed by bubbling nitrogen gas 15 ( d0ic.7y0clo gh,ex 4yl.p5h0os mphminool)-,2’, t4e’t,r6a’k-tirsii(stroipphroepnyyllbp .
ihpohsep7h5ine)palll)a,d (5iu-m(0i)o- (21-7fl4uor mog-p,he 0n.1y5l)bo mromnoicl), ac 2id- p 8h0o°Csph oavetern trigibhat.si Mc ( nyl (Xphos) (181 mg, 0.38 mmol) and potassium o2r.e38 (5 g-,a 3m einqo.-)2 w-felureor aod-pdheedn aynl)dbo throen miixture was stirred under nitrogen gas at 2’,4’,6’-triisopropylbiphenyl (Xphos) (30%), potassicum acid ph (3o0s%ph)a,te 2-di tcryibcaloshicexy (l3p0h%os)phi annod- 20 t u e
rn tr d a e k r is n ( i t t r r i o p g h e e n ny g lp a h s o a s t p 8 h 0 in ° e C )palladium(0) (30%) were added and the reaction mixture was stirred weimthov weadte ur.nd Tehre re adquuceeodus pr le f
aso
ysr
eu 4
rre h
w.o
a Tu
shres.
ex rte T
rash
cideea
tu r
eed wcatison di mluitxetdur weit wha dsic choloolreodm aenthda tnhee a snodlve wnats wheads
25 layers were dried, f with dichloroemethane. The combined organic w maestha pnuorilfi aesd e bluyen flail
tsstehre
(gr cd
aodl aun
iemd
nn th
t e ce
lhr soomlvaetnotg wraapshy rem ovoevred si ulicnad gre reld uusciendg p driecshslourroem. Tethhean reesid auned coiellledc:t ution from 0% to 8% methanol). The product fractions were Y 1e.d3 and the solvent was removed under reduced pressure. 0 LCMS me6th go odf 1 in:t MerHm+e =di 5a0te0, 4 R4T (7 =3% 0.8)
3 89 min Preparation of intermediate 45 -143-
2 (1-N.3i6tro gb,e 2n.7z2en memsuolfl)on aynld c phylorirdidi
Figure imgf000145_0001
(0 (2686 g 299 l) ddd t a solution of intermediate 44 5 m origxatunriec la wyaesr w satirred at room temp6er µalt,u 3re.54 overnigl)h it. d Diichhlloromeththaannee (8 w.1a6s m ald).d Tehde a renadct tiohen extracted with dsic whalosrhoemde wthitahn ae.1N Th aequ ceoomubsin heyddro ocrghalonriicc a lacyider ssolu wteiorne. T dhrieed a,qu feous layer was solvent was removed under reduced pressure. The residue was iltered and the 0 chromatography over silica gel using dichloromet purified by flash column 1 e relumtioovne fdro umnd 0e%r re todu 1c0% methanol). The product frahcatinones a wnedre m ceotlhleacntoeld a asnd el tuheen stsolv (gernatd wieanst Yield: 1.65 g of intermeedd pressure.
LCMS method 1: MH+ =i 6a8te5, 4 R5T (8 =9% 1.0)20 min
15 Preparation of intermediate 46
T (1e.t6r5ab gu,ty 2la.4m1m monmiuoml) f inluo teritdreah (
Figure imgf000145_0002
y076 g 289 l) ddd t solution of intermediate 45 0 t memixtpuerera wtuares f sotirrr 3ed ho autr 8s0.° MCo froer t d
3etra f (7.23 l). Th ti mixture was stirred at room 2 hobuurtsy.la Tmhem monixiutumre flu woarsid ceo (o3le0d% a)n wdas th aed sdoelvde anntd w tahse r reemaoctvioedn u anndde ar s readtuurcaetedd p areqsuseuorues. T shoedi ruemsid buicear wbaosna dties -s1
so4
ol4vlue- tdion in. d Tihcehl oorrgomaneicth laanyeer a wndas w darsiehde,d fi wlteitrhed wa atner the solvent was removed under reduced pressure d 5 chroma . The residue was purified by flash column e relumtioovn t
e f o
dro g
um rap
nd 0 hy over silica gel using dichloromethane and methanol as eluents (gradient Y e%r re todu 10% methanol). The product fractions were collected and the solvent was LCieMldS: 9 m55et mhogd o 1f: in Mtec
Hr+med
=ed p
5ir
7ae
1tses
, R 4u
T6re (.
=690%.64)6 min
10 Preparation of intermediate 47
A de sgoalsustieodn of by inte brmubebdliinagte 4 n6itr (o9g1e5n
Figure imgf000146_0001
g g 160 th glh) i 2 thyltetrahydrofuran (20 ml/mmol) was 5 azodicarbox th iture. A solution of diisopropyl 1 n ait proegrieond g oafsy
3 tla
hht
oreouu (
rsg9h50
at th mg, 4.80 mmol) in toluene (20 ml/mmol) was degassed by bubbling 9e0 mixture. Both solutions were added simultaneously and dropwise over in toluene (75 ml/mmol). ° T C he to a degassed solution of triphenylphosphine (1.259 g, 4.80 mmol) cooled and the solvent was rem moixvteudre was stirred at 90°C for 1 hour. The reaction mixture was 20 column chromatography over silica g uenlder redu hced pressure. The residue was purified by flash e colullteiocnt t fhreom pro 2d0u%ct t fora 8c0ti%ons e.th Tyhle a scoeltvaetnet) u
w as
anin
sdg dicehplotaroneme atnhdan eet/heytlhy alce actaetteat aes (1 e:l1u)en wtsas (g ursaeddien tot LCMS method 1: MH+ = 553, RT = 0.712 min removed under reduced pressure. Preparation of example N13 -145-
T ceos aium sol cuation of intermediate 42 (1
Figure imgf000147_0001
60 l) i NNdi thylformamide (4.80 ml) were added mixture warsbo sntiarrteed (1 a.t0 r4o3 g, 3.20 l) d thiph l (200 µl, 1.92 mmol). The reaction 5 w laayser asd wdeedre a dnrdie tdh,e fi altqeureedooum
as tem
n layeprer waatusre ex otrvaecrtneidgh wt.it Ah d 1iNchl aoqroumeoeuthsa snoed.iu Tmhe h cyodmrobxinideed s oorlguatinoinc was purified by flash columdn th cehr solvent was removed under reduced pressure. The residue methanol as eluents (gradient elutioomatography over silica gel using dichloromethane and collected and the solvent was removend f urnodm 0% to 8% methanol). The product fractions were 10 Y LC ie M ld S : 3 m 58 et m ho g d o 2 f : example N13 (61%) er reduced pressure. E MH + = 368, RT = 2.064 min
(4x:a1m, 6ple N13 (358 mg, 0.97 mmol) was dissolved in a mixture of dichloromethane/methanol was st.i25 ml).4N hydrochloric acid in 1,4-dioxane (50 µl) was added and the reaction mixture 15 s ature for 30 minutes. Diethyl ether was added and the mixture was utnir
edred
ledr: 3 v arr room temper
ated at 1c r
4uoom temperature for 30 minutes. The solid was filtered and the compound was dried Yi mumg o aft e 6x0aºmCp foler N 1613 ho (8u8rs. The product was obtained as the HCl salt.
LCMS method 2: MH+ = 368, RT =% 1).987 min
20 E Ex
illxample
uam
straptlee N
d N1
fo14
r4 th mea pyre bpear parteiopnar oefd ex foalmlowplieng N8 g.e Tnheera plr socdhuecmt wea 1s a onbdtai ancecdo ardsin thge to HC thle sa plrt.ocedures
25 E E x x a a m m p p l l e e N N 1 1 5 5 may be prepared follo
Figure imgf000147_0002
ig g l h 1. 3 ca -b n ro b m e o p-r N ep -[ a 1 r-e [2 d -[
t a te
ec r
rmc t o -b
erdd u
ii t
an y
tg l(d
e t 4o im
8 t e h t e hy m l) e s t i h ly o l] d o s xye -th1y4l6]--4-piperidyl]pyrazolo[1,5-a]pyrimidin-5-amine Preparation of in described to obtain intermediate 5.
5 A piperid myl]ixptyurraezol of inter
Figure imgf000148_0001
dit 3b N[1[2[t tbutyl(dimethyl)silyl]oxyethyl]-4- mineral oil, 790o m[1g,,53-a3]p mymrimoli)di in-5 a-nhydirou (s1 N.5,N g, 3.30 l) nd sodium hydride (60% in nitrogen atmosphere for 1 hour. Iodomethane (23-d7im µel,th 3y.8lf0or mmmamide (9.9 ml) was stirred under mixture was stirred at room temperature for 2 hours. Water wasol a)d wdaesd a adndded th aen adq tuhe reaction 10 was extracted with dichloromethane. The organic layer was dried, filtered and the soelovuesnt la wyaesr r oe
gvm
rearov
die seinldi e
tca und
elu gtier
ol r
n ue
fsduced pressure. The residue was purified by flash column chromatography ( roinmg 07%N to am 5m%o anmiam soonluiatio in in methanol and dichloromethane as eluents 15 an n methanol). The product fractions were collected Y LCied
Mld the solvent was removed under reduced pressure.
S: 1 m.0e0th go odf 2 in:t MerHm+e =di 4a6te9, 4 R8T (6 =5% 0.7)06 min
Preparation of intermediate 49
20 A thr mouixgthur tehe of m 1ix,t4u-rdeio.x Inatneerm
Figure imgf000148_0002
d
ioxaborolan-2-yl)phenol (0.d61it g, 4t82.5 ( (13
6.01
m0m g 6,3
o 29 l) dg d by bubbling nitrogen gas d l).,13 tetrakisl(),t 4-fl -3-(4,4,5,5-tetramethyl-1,3,2- mg, 0.09 mmol), 2-dicyclohexylphosphino-2’,4’,6’-triisopro ri p p y henylphosphine)palladium(0) (104 5 m unmdoelr) n aintrdog peontas gsaisum at p 8h0o°sCph oavteer tnriibgahst.ic T (h1e.3 r6ea gc,t 3io enq m.)i wxteurrel
e ab
wdip
adh
seedn
co ay
onl
ld (X
ed thpeho
an ms
di)x (100 mg, 0.21 2 thtuere s wolavesn sttir wreads w removed under reduced pressure. The resid -u1e47 w-as diluted with dichloromethane and washed laiythers wa wter. The aqueous layer was extracted with dichloromethane. The combined organic 5 was pureifrieed dried, filtered and the solvent was removed under reduced pressure. The residue m coelltehcatneodl a ansd e b
thlu y
ee sn fla
ots sh
lve (g column chromatography over silica gel using dichloromethane and nrta wdaient elution from 0% to 5% methanol). The product fractions were Yield: 786 mg o s remo4v%ed under reduced pressure.
LCMS method 1f: in MteHr+m =ed 5i0a0te, R 4T9 ( =70.86)6 min
10 Preparation of intermediate 50
T (7e8tr6ab mugty,la 1m.5m7o mnimumol) fl iunor tiedtera (h0yd
Figure imgf000149_0001
49
emperature overnight. More tetrabuf g 18
tylam (8
m4.o7n1 l)
iuml). flu Toh ddd
ride (10ti to
%n a
) w m s
aixo
stluu
art
deion
d weda osf in
an sdttierrr
tem hded e ai retate 49 t a rcotoiom 15 m
s pariexture was stirred at room temperature for 2 hours. The solvent was removed under reducend so tusrsautreed. a Tqhueeo ruesidue was dissolved in dichloromethane and washed with water and a chlrvoemnatto wgarsap rheymo s
ov s
ve o
ed dium bicarbonate solution. The organic layer was dried, filtered and the 20 r s uilnicdaer g reelduced pressure. The residue was purified by flash column e relumtioovned fro umnd 0e%r re tdou 8c% methanol) u.s Tinhge d pircohdlourcotm freatchtaionne
sure. s a wnedre m ceotlhleacnteodl a asnd el tuheen stsolv (gernatd wieanst
L YCieMldS: 4 m50 ed pres
et mhogd o 1f: in MteHr+m =ed 3i8a6te, R 5T0 ( =740%.44)5 min
25 Preparation of intermediate 51
Figure imgf000149_0002
P dryyrid diicnhelo (2ro3m0 µl, 2.85 mmol) was added to a s -1o4lu8t-ion of intermediate 50 (365 mg, 0.95 mmol) in 2.85 mmol). Tehthea rneeac (1tio0n m ml/mixtmuroel). The mixture was cooled to 0°C and thionyl chloride (210 µl, 5 for 2,5 hours. The mixture was d wiluatsed sti wrriethd d atic rholoormom teemperature for 1 hour and under reflux s saotlvuerantte wda asqu reemouosve sdod uinudmer b riceadrubcoendat pere ssoslution. The org t a h n a i n c e la a y n e d r w w a a s sh d e r d ied w , it f h ilte w re a d ter an a d nd th a e further p ure. The compound was used in the next step with LCMS muertihfiocadti 1o:n M.H+ = 404, RT = 0.549 min
10 Preparation of example N15
I dnrtoeprmwiesdeia atte 9501ºC (0 o.v9e5r a mm peorli)od w oafs 2
Figure imgf000150_0001
d hi l td i NNpdiith oyflfo cremsiaummicdaerb (o3n2at mel) (1 a.5n5d g a,d 4d.e7d 15 mmol) in N,N-dimethylfo
n wea.s T choeolermamide (63 ml). The reaction mixture was stirred at 90 ºC for 1 hour5 T . dihcehlo mroixmtuerteha codm abninded wa otregran wicas lay aedrdsed w. The aqueous layer was extracted with filtered and the solvent was removed under reducede prrees wsuarseh.e Tdhe w riethsid wuaeter and brine, dried, colu d m i n chromatography over silic was purified by flas sgra a gel usin fractions were collected and th th es 20 ( g dichloromethane and methanol as eluen pohlavseenetn
co wt
lua e
mslut
n rieo
cmn
ho f
rovro
memdat u 0
on%
gdrae t
pro
h rye 1d0% methanol). The product
(HuPceLdC p mreesthsoudre A.) T.h Te product was further purified by reversed solvent was he product fractions were collected and the YCieMldS: 9 m6e mthg re
o om
df 1 eo
:xv
Maemd
H+p ul =end Ne1r5 re (d2u7c%e)d pressure. 25 L 368, RT = 2.073 min
E Exa
illxuampl
smtraptle
ee N
d N1
fo16
r6 th mea pyr be prepared following general scheme 1 and according to the procedures Preparation of intermepeadriaattieon 52 of example N2. -149-
A
Figure imgf000151_0001
sti mrreixdtu aret r oofo imnte termmepdeiraatetu 1re0 f (o0r.922 hoursl) andd a 4tN 50 hyCd forh 2l hiourcsi.d E inth 1yl,4 a-cdeiotaxatene an (2.76 ml) was 5 added. The two layers were separated and the organic layer was washed w d brine were o re rg si a d n u i e c w la a y s er pu w r a ifi s ed dr b ie y d f , la f s il h te c re o d lum an n d ch th r e om s a o t l o ve g n ra t p w h a y s ov re e m r oved under reducedi pthre wssauterer.. T Thhee methanol as eluents (gradient elution from silica gel using dichloromethane and collected and the solvent was remo 0% to 10% methanol). The product fractions were 10 Yield: 243 m ved under reduced pressure.
LCMS methogd o 1f: in MteHr+m =ed 5i3a8te, R 5T2 ( =491%.17)4 min
Preparation of intermediate 53
15 I mnt
Figure imgf000151_0002
wal)e
s.r Sm
stoe
irdd
rii
eua
dmte
a h 5
ty2
rodor (imd2e23
te (6 m 4
m0p%g,
er ian 0.
tu m1
rien foll)il, 30 dgi, 0.l82d i l)hydro audsde Nd,N an-ddim theeth reylafocrtimonam miidxetur (e2 readcetido.n Th meix ttwuroe la wyas stirred at ro r om 1 h t o e u m r. p I e o r d a o tu m re eth fo a r n 2 e ( h 2 o 9 u µ rs l, . 0 E .4 th 7 y m l a m c o e l t ) a w te as an a d dd w e a d te a r nd we th r e ad e w charsom rae ers were separated and the organic layer was dried, filtered and the solvent 20 tmogorvaepdhy u onvdeerr si rleicdauc geedl u psriensgsu driec.hlo Trohmeet rheasnideue and wa mseth paunriofield as b eylue flnatssh (g croalduimennt e relumtioovne fdro umnd 0% to 10% methanol). The prod -1u5c0t- fractions were collected and the solvent was Yield: 106 mg er of reduced pressure.
LCMS method 1 intermediate 53 (47%)
5 : MH+ = 552, RT = 1.204 min
Preparation of example N16
A mixture of intermediate 53 (106
Figure imgf000152_0001
g, 0.19 l) d i rbonate (12
10 N,N-dimethylformamide (2.0 ml) was stirred for 2 minut 4 g, 0.38 mmol) in a wd th
had
etee
srd
o w a
lven
erd
net a wde
adse reda
re.c
m Ttiho
oen
ve tdw moixt ed m s un lau
dyre
eerr wsa
re ws
deur s es. Thiophenol (20 µl, 0.23 mmol) wa cetir
ed sre ppra a
ersat
st reo
udo
re a.n Td tem
he thpeea
re or
sridgtu
uar
thromatography over silica gel using dichlorom eneic o
w lv
aae
syren
prig
u wh
rifat.
ies E
d dtrh
biey
ydl
f, a la fc
silethetar cete od a lu an mndd c n 15 elution from 0% to 30% ethy ethane and w e e th r y e l c a o c ll e e t c a t t e e d a a s nd el t u h e e n s ts ol ( v g e r n a t d w ie a n s t r Ye
LCimeoved under reduced presls aucreet.ate). The product fractions MldS: 2 m9e mthgo odf 2 e:x MamH+pl =e 3 N6176, R (4T2% =) 2.047 min 20 E Examl
illxuasmp
traptle N
eed N1
fo17
r7 th mea pyre bpear parteiopnar oefd ex foalmlowplieng N8 g.e Tnheera plr socdhuecmt wea 1s a onbdtai ancecdo ardsin thge to HC thle sa plrt.ocedures
Figure imgf000152_0002
Example N -151- E ex x a a m m p p l l e e N N1
118
78 . i T s h o e b p ta ro in d e u d ct a w s a a s s o id b e ta -p in r e o d du a c s t t d h u e ri H n C g l th sa e lt M . itsunobu reaction in the preparation of
5
Figure imgf000153_0001
E Ex le
ac xamp
ca o m rd p i l n e N
g N1
to 199 th m e a p y ro b c e prepared following general scheme 1 and starting io f n ro o m
aeindeudre ass o thfe th HeC lals sta tlwt.o steps d f e e x x a a m m p p l l e e N N 1 1 1 7 The product was obt escribed in the preparat .
10
Figure imgf000153_0002
E Exxa
Pre am
pmp
apl
ra lee N
tio N2
n20
o0 f m in a te y r b m e e p d r ia e t p e a 5 re 4 d following general scheme 1.
15
Figure imgf000153_0003
tdeiortx-Boiustoyilndo (3liSn-)2-3-y-(l)heytdhryolx mymetehtahnyel)spuiplfeornaaztiene (- - 311
.-5
7c2
4a-r gb,o 1x3yl.a8t8e mm (2o.0l), s go,diu 9m.2 c5arb momol), 2-(1,3- 27.75 mmol) and potassium iodide (1.997 g, 12.03 mmol) was stirred at 70ºC onvaete (2.941 g, 5 reaction mixture was cooled and the solvent was removed under reducedrn pigrehst.s Turhee D . Th ic e hl s o o ro lv m en e t th o a f n t e he wa fi s ltr a a d te de w d a t s o r t e h m e o r v e e s d idu u e nd a e n r d re th d e uc m e i d xtu p r r e es w s a u s re f . ilt T e h re e d re o s v i e d r u a e p w a a t s h o p f ur C if e ie li d te b ®. flash column chromatography over silica gel using dichloromethane and methanol as eluenty (gradient elution from 0% to 5% methanol). The product fractions were collected and the sol s 10 was removed under vent Y LCie reduced pressure.
MldS: 2 m.8e gth oofd in 1t:e MrmHe+d =ia 3te905,4 R (T78 =% 1).314 min
Preparation of intermediate 55
15 A eth mainxotulre (4 o5f i mntle)rm waesdia hteea 5te4d (3 a.5t06 g0,
Figure imgf000154_0001
C 8.99 ighl)t. Tdh hyd tiinoe (64%, 860 mg, 13.48 mmol) in suspension was filtered to remove the white solid. The solvent onf mixture was cooled and the 20 reduced pressure and the residue was dissolvedn in ethyl acet the filtrate was removed under w anit
udh
rifi t a
chn
ae a
tio sq
noulve
ineonu
thts
e w 1
naM
es s
xt reoum
smdi
teopv.ed hy udnrodxeirde re sdoulcuetidon pr aesdsu brrein.e T.h Tehe pr oa
ort
dge
ua.
cn T
tiche
w laa o
syreg
ura
s wn
edaics l
w da itryr hieeodu, w
t f fia ults reh trhee edd p r Preparation of intermediate 56 -153-
T
Figure imgf000155_0001
acoe ato mniitxritluere (2 o7f. i0n9ter mmle)d wiaates 5 a5d (d2e.3d43 g-,b 9ro.0m3o-5-chll)oro-dpy triazthoylol[ ine (5.076 ml, 36.12 mmol) in 5 mmol). The reaction mixture was stirred at 80 1,5-a]pyrimidine (2.10 g, 9.03 a co n l d um th n e c s h o ro lv m e a n t t og w r a a s p removed under reduce°dC p froers 2su hroeu.r Ts.he Th rees reidaucetio wna msix ptuurriefie wdas by co folalesdh produc hy over silica gel using dichloromethane and methanol as eluents. The Yield: 2t. f0r7a7cti gon osf i wnteerrem ceodlliaectete 5d6 a (n5d1 the solvent was removed under reduced pressure. 10 LCMS method 1: MH+ = 456, RT = 1%.00)5 min
Preparation of intermediate 57
A mm moixl)tu arend of tr iinettehrymlaemdiiantee ( 58624 (2
Figure imgf000155_0002
µ.0l,775 g, 4.56 l), t tbtylhl dimethylsilane (760 mg, 5.02 15 t w e
he m re pera a t d u d r e e for 18 hours. More tert-.b9u3tyl-chlol)ro idim diethhlylsilaneth (0.6 e (1q5.) a mnl)d w triaesth sytliarrmedine at (2 ro eoqm.) clloverondtim weatshdy rls a
eimlan
ond
vee ( th
d0e.1 un e m
dqe.ix)t
r wur
reae
dsu a w
cda
eds
ded s
pr at
enir
sdre
su td
rhee a
. mt
Thixet ruoro
cem
om wa f
psor
ou s
p ntidr 4re wd h
a ao
stur rs
uo.
soem M
d fo r worre ith 1o h te
uotut-rb.u Tthyle- so
LuCrMifiSca mtioenth iond th 1e: M neHx+t s =te 5p7. further 20 0, RT = 1.537 min -154- Preparation of intermediate 58
5 A t
Figure imgf000156_0001
treim m yr
traeix
hthtu
ydle
raom o
fuif
rn i
aente
n ( (1rm
3.09e0d
m1ia
l) mte
wla, 5
s 173 s. (
t64 t
ir8.56
red at 6l)l),
5°Cd for 4t-b
4(d hit y
ourtsh.y Mlb
oreiyl
te)rpn
t-yh
briyddinriede (5 (61.2 m6g, m 0l,.456.4 m7m moml)ol i)n, eq.) and 4-(dimethylamino)pyridine (0.1 eq.) were added utoxycarbonyl anhydride (1.2 ethyl acetate was added and the organic layer was extr . The reaction mixture was cooled, dried, filtered and the solvent was removed under acted with water. The organic layer was 10 f plar io cnh ch
ios
edh
ldu c
:co
2tl
. fu
6r3am
6cnt g osro
f i wm
ntea
erreto
m cg
eora
dlliaep
tetye 5d ov
8 ae
(nr
8d silica gel using re hdeupcetan peres asnudre e.th Tyhle a rceestiadtuee a wsa eslu peunritfsie.d Th bey Y 6% th)e solvent was removed under reduced pressure.
LCMS method 1: MH+ = 670, RT = 1.778 min
15 Preparation of intermediate 59
A the mix mtuixretu oref.1, I4n-tdeiromxaendeia atend 5
Figure imgf000156_0002
8t ( (31, 24 l) dg d by bbbling nitrogen gas through dioxaborolan-2-yl)phenol (1. 2.636 g, 3.94 l), 4-fl -3-(4,4,5,5-tetramethyl-1,3,2- 20 0 a.08 mmol), 2-dicyclohexylp 1 h 3 os g p , h 4 in .7 o 3 -2 m ’,4 m ’,6 o l-) t , ri t i e s t o r p a r k o is p ( y tr lb ip ip h h e e n n yl y p l h ( o X s p p h h o in s e ) ) ( p 1 a 5 l 3 lad m iu g m , 0 (0 .3 ) 2 (9 m 3 m m o g l) , nnitrdog peonta gsassiu amt 8 p5h°oCsp ohveartenig thritb.a Tshice r (e3ac etqio.)n w meixretur aed wdeads c aonodled th.e Et mhyilxt aucreeta wteas an sdti wrreadter u wndeerer a wdadsed re amndov theed tw uond laeyrers re wdeurceed sep parreastseudr.e T.h -1e5
Th o5
er-ga rneicsid lauyeer w waass dr pieudri,fie fildtere bd and the solvent chromatography over silica gel using dichloromethane and ethyl a y flash column elution from 0 % to 30 % of ethyl acetate). The product f cetate as eluents (gradient 5 w ractions were collected and the solvent Yias removed under reduced pressure.
LCeMldS: 2 m.2e3t2ho gd o 2f: in MteHr+m =ed 7i0a1te, R 5T9 ( =813%.79)4 min
Preparation of intermediate 60
10 T ae stroalubtuiotynla omfm inotneirummed fluiaoterid 5e9
Figure imgf000157_0001
(1 d
ixture was stirred at room tem (M2p.e2r3a2lt
tur gi
e, f 3 i
o.r128 tt hy
hoursl.) T if
he t mt, 4
ixth.y7d7fl,ra 4n.77 (2 m0m mol)l). w Tahse a rdedaecdtio to m n and washed with a saturated aqueous sodium bica ure was diluted with ethyl acetate 15 w pu a
lur s
eifnie die
td r
s b d
(gy ,
ra fl f
da ilt
is e
eh re
nt c d o ellu a
um nd
tionn c the solvent was removedrb uonndaetre r seodluuctieodn a pnreds bsruinree.. T Thhee o rergsaidnuice la wyaesr e fhroromma 0to %gr taoph 1y0 o %ve orf s miliceath gaenlo ul)s.in Tghe di pchrolodruocmte frtahcatnioen asn wde mreet choalnleoclte ads Y an
LCied
Mld th
S:e 1 m. s7o
e7le
t4v
ho gn
d ot e
1f w
: ina
Mtse r
Hr+mmv
=eod 5i8aed under reduced pressure.
20 7te, R 6T0 ( =951%.43)0 min
Preparation of intermediate 61
Figure imgf000157_0002
A de sgoalsustieodn of by inte brmubebdliinagte 6 n0itr (o1g0e0n mg g,a 0s.17 th m - rom15
uo6
glh)- in th 2e-me mthixytluteretr.ah Aydro sfoulruatnion (20 o mfl/m dimisol) was azodicarboxylate (170 mg, 0.85 mmol) in toluene (20 ml/mmol) was degassed by bopropyl nitrogen gas through the mixture. Both solutions were added simultaneously an ubbling 5 a in p to e l r u io e d ne of (7 4 5 h m ou l/ r m s m at o 1 l) 1 . 0 T ° h C e t m o i a xt d u e re ga w s a s s ed st s ir o re lu d tio a n t 1 o 1 f 0 tr ° i C ph f e o n r y 1 lp h h o o u s r phine (223d m dgr,o 0p.w85ise m omvoelr) cooled and the solvent was removed under reduced pressure. Th . The reaction mixture was column chromatography over silica gel using heptane and e residue was purified by flash fractions were collected and the solvent was rem ethyl acetate as eluents. The product 10 Y LCieMldS: 2 m7e mthgo odf oved under reduced pressure.
2 in:t MerHm+e =di 5a6te9, 6 R1T (2 =8% 5.1)91 min
Preparation of example N20
15 A
Figure imgf000158_0001
mrl m
i)ed wixatu
usre
nd set oirrfr ve in
adte
cu ar
utm
m roe
.od
Tmiate
he te 3
pm1
ropde (6
ura1
ctt0u wreg
as f,o 1
or.207 hours.l) Dietdhy 4lN wa hsyd ardodcehdlo,ri tche ac siodli idn w 1,a4s-d fiilotexraende a (1nd0 d LCMS method 2: MH+ = 3 btained as the HCl salt.
20 69, RT = 1.987 min
E Exm e N
illxa
uasmp
trapl
tleed N2
fo21
r1 th mea pyre bpear parteiopnar oefd ex foalmlowplieng N7 g.e Tnheera plr socdhuecmt wea 1s a onbdtai ancecdo ardsin thge to HC thle sa plrt.ocedures
25 Example N22
Figure imgf000158_0002
E ill x u a s m tra p t l e e d N fo 2 r 2 th m e a p y re b p e ar p a r t e io p n ar o e f d ex fo a l m low pl i e ng N8 g . e - Tn1
he5
er7a- pl r s o c d h u e c m t w e a 1 s a o n b d tai a n c e c d o a rd s in th g e to HC th l e sa p l r t. ocedures
Ex
Figure imgf000159_0001
5 Ex a a m m p p l l e e N N 2 2 3 3 may be prepared following general scheme 1 and starting from example N20.
A trie mthixytluarmein oef e (2x3ample N20 (230 mg
Figure imgf000159_0002
057 l) f ldhyde (37%, 50 mg, 1.14 mmol) and 10 stirred at room t8 µl, 1.71 mmol) i it f dihl bthne and methanol (4:1, 5 ml) was a addddeedd. a Tnhde r tehaecet oimorgnpe
a mra
niicxtuture
lare fo
ye wr
ra 1
ws h
a sstoirurr
ee.
xd S
tra ao
ctd
t rium
eodom tr
wi ti
teace
hm aptoex
sraytuorero fhoyrd 3rid heou (2rs4.2 D micgh,lo 1r.o1m4e mthmaonle) w waass solution. The organic layer was dri aturated aqueous sodium bicarbonate pressure. The resi ed, filtered and the solvent was removed under reduced 5 h reemptane and ethyl adcueetat wea ass p eulureifinetds. b Tyhe fl parsohdu ccotlu frmacntio cnhsro wmearteog corallpehcyted ov aenr silica gel using 1 YieMldo
S:ve 1 und
m3d9et mhoger
d o 2f re
: ed
Mxuac d the solvent was Hme
+pd pressure.
LC =le 38 N32,3 R (T64 =% 2).061 min 20 E Exxaammppllee N N2244 may be prepared following general scheme 1 and starting from example N23. -158-
E Sxoadmiupmle h Nyd2r3id (e63 (6 m0%g, i 0n.1 m6in memraoll
Figure imgf000160_0001
)il, 40 dig,l 1.6d0 i hl)yd a Ndd,Ned-di amnedth thylefo rremaamide (1 ml). 5 was stirred at room temperature for 1 hour. Iodomethane ction mixture r seaatucrtiaotned m aixmtumreon wiuams s cthirlroerdide at s rooloum (11 µl, 0.18 mmol) was added and the tion tem wepreera atudrdeed fo.r T 2he ho twuros. la Eytehrysl a wceerteate se apnadra atend a aqnudeo thus organic layer was dried, filtered and the solvent was removed under r e residue was purified by flash column chromatogra educed pressure. The 10 methanol as eluents (gr phy over silica gel using dichloromethane and c Yoiell adient elution from 0% to 10% methanol). The product fractions were ledc:t 4ed and the solvent was removed under reduced pressure.
LCMS m4e mthgo odf 2 e:x MamH+pl =e 3 N9274, R (6T9% =) 2.127 min 15 E Example N2
uasxia
lnm
t.gp thle 25
e N pro5ce mdauyre b aepp plrieepda froerd th foello pwreinpgara gteionner oafl N sc1h1e.m Thee 1 p arondduc stta wrtainsg o fbrtoamine edxa amsp thlee N H2C2 s l
20 E
Figure imgf000160_0002
Ex x a a m m p p l l e e N N 2 2 6 6 may be prepared following general scheme 1 and starting from example N8. -159-
1 su-Csphelonrsoipoynrrolidine-2,5-dione (50
Figure imgf000161_0001
g, 0.34 l) dded in one portion to a stirred stirred for at o rfo eoxmam tepmlep Ner8at (u1r00 mg, 0.28 l) i hl f (3 ml). The reaction mixture was 5 d biicchalrobroonmaeteth saonleutio ann.d Th mee athqae
uneo fo
olr
us 955 hours. The reaction mixture was diluted with a mixture of la:5yer a wndas w eaxsthed with an aqueous saturated sodium organic layers were dried, filtered and the solventracted with dichloromethane. The combined residue was purified by flash column chromatograp whays o rvemoved under reduced pressure. The 10 acetate as eluents (gradient elution from 0% to 20%er e stihliycal a gcel using heptane and ethyl d p i r c o h d l u o c ro t m fr e a t c h t a io n n e s a w n e d re m c e o t l h le a c n t o e l d a a s nd elu th e e nt s s o ( lv g e ra n d t ie w n a t s e r l e u m tio o n ve f d rom und 0e
e%tat
r r te
eo)
du 6 f
c%ollowed by using ed m p e r thanol). The residue was further purified by reversed phase column chromatography (HPLC metehsosdure. The prod ruct fractions were collected and th we. A). The 15 T Th e solvent was removed under reduced pressuras added prhe
eess me
uis
rxidue was dissolved in dichloromethane and 4N hydrochloric acid in methanol etu.re was concentrated, ethanol was added and the solvent was removed under reduced Yield: The product was obtained as the HCl salt.
LCMS 2 m7e mthgo odf 2 e:x MamH+pl =e 3 N8286, R (2T5% =) 2.250 min
20 E Exa
illxuample
smtraptlee N
d N2
fo27
r7 th mea pyre bpear parteiopnar oefd ex foalmlowplieng N8 g.eneral scheme 1 and according to the procedures Preparation of intermediate 62 -160-
A 12. m16ixture of [(3S,8aR)-1,2,3,4,6,7,8,8
Figure imgf000162_0001
thyd py l[1,2-a]pyrazin-3-yl]methanol (1.9 g, dichlorom memthoal)ne an (d36.428-(1 m,3l-)dio wxaosisoidli-2-yl) tldhyde (2.76 g, 14.59 mmol) in 5 t rroiaocmet toexmybpoerroahtuyrderi fdoer 1 (56.1 h5o4ur gs,. D 24ic.h32 st
lor mirr
ommed
eotlh) a
a wt
naes roo
w am
ad temperature for 1.5 hours. Sodium sd aeddd.e Tdh,e th reaction mixture was stirred at of a saturated aqueous sodium bicarbonate solution was addede d mroipxtwuirsee, w fas stirred and 5 ml water. The two layers were separated and aqueous layer was extracted withol dloicwhelodro bmye 5 ml of 10 The combined organic layers were dried, fil thane. p dr
oice tered and the solvent was removed under reduced 5hs
%lsourore
7m.
Ne T
atmhhae residue was purified by flash column chromatography over silica gel using t mnoen aiand so alu 7tiNon a immonia solution in methanol as eluents (gradient elution from 0% was removed under reduced pnre msestuhraenol). The product fractions were collected and the solvent 15 Yield: 3.52 g of 2 in:t MerHm+e .
LCMS method =di 3a3te0, 6 R2T (8 =8% 1.5)47 min
Preparation of intermediate 63
20 m A
Figure imgf000162_0002
l, 26.40 rem m
moix
olv)tu
e ir
dne of intermediate 62 (2.90 g, 8.80 l) d hydrazine (50/60% in water, 850 µ u entdhearn roeld (u5c1ed m pl)re wssausre st airnrded t t p ture for 16 hours. The solvent was was suspended in a mixture of ethyl t a h c e et r a e t s e id a u n e d was co-evaporated with toluene. The residue waosdhuecdt w waitsh u estheydl w acitehtoautet. fu Trhthee sro pluverinficta otfio thne in fil tthraete m
ne we
xat
tshanol (95/5), filtered and the solid was pr st reepm.oved under reduced pressure. The 25 T pr h e e pa s r u a b ti s o e n q o u f e N nt 8. steps to obtain example N -12671- are based on the procedures used for the
5 E
Figure imgf000163_0001
Ex pl
ex xam
aa m m p p l le
ee N
N N2
228
08 . i T s h o e b p ta ro in d e u d ct a w s a a s s o id b e ta -p in r e o d du a c s t t d h u e ri H n C g l th sa e lt M . itsunobu reaction in the preparation of
Figure imgf000163_0002
10 E Exa pple
ac x c am
om rdi l n e N29
g N to 29 the m p a r y oc b e e d p u r r e e p s a il r lu ed str f a o t l e lo d w f i o n r g th g e en p e re ra p l ar s a c t h io e n m o e f e 1 x , a s m ta p r l t e in N g 1 f 1 ro . m example N27 and
Example
Figure imgf000163_0003
15 E ill x u a s m tra p t l e e N
d N3
fo 30
r0 th m e a p y re b p e ar p a r t e io p n ar o e f d ex f a l m l pl i e g N8 g . l h 1 and according to the procedures Preparation of intermediate 64 -162-
[ a(n3dR, t8eartR-b)-u1ty,2l, N3,-4(2,6-o,7x,o8e,8thay-ol)cctaarhbyadmroapt
Figure imgf000164_0001
y (36l6[12g,] 2p.y30i 3ly)l] imne dthanol (300 mg, 1.92 mmol) 5 s wtairsred ad adte rdo.o Tmhe tem repaecrtaiotunre m fixotru 1re.5 w haosur sst.ir Sreoddi autm ro troiamce tteomxypb ichloromethane (5.76 ml) was eorarotuhydride (814 mg, 3.84 mmol) triacetoxyborohydride (814 mg, 3.84 mmol) was added and the rearecti for 1 hour. More sodium room temperature for 15 hours. A saturated aqueous sodium bicarboonna mixture was stirred at 10 till pH 7 and the aqueous layer was extracted with u a mixture of dichlorom te solution was added ( c9o:m1)b.in Tehde a snodlve pnutrif oiefd b boyth fl laasyher csol wuamsn r cehmroomveadtognradpehry re odvuecre sdilic pare gsesulr uee
s.th
in Ta
ghnee r aensiddu meesth waenroel and methanol as eluents (gradient elution from 0% to 20% methanol). The p driochloromethane were collected and the solvent duct fractions Yield: 40 was removed under reduced pressure.
15 LCMS m9et mhogd o 1f: in MteHr+m =ed 3i0a0te, R 6T4 ( =710%.30)4 min
Preparation of intermediate 65
20 Idn
Figure imgf000164_0002
Tihote
exram
pne
roediate 64 (409 mg, 1.37 mmol) ti d i a 4N hydrochloric acid solution in 1,4- d autct ro woams u tesmedpe wriathtuoruet f fourrth 2e hro puurif.ic Tahtion inl thet nexts s rteemp.oved under reduced pressure. T prheepa froalltoiownin ogf N s8te.p Tshe to pro odbutacitn wa esxa ombtpaliene Nd3 a0s t ahree H bCals seadlt. on the procedures used for the -163-
Exa
Figure imgf000165_0001
Example
illus m tra p t l e e N
d N3
fo 31
r1 th m e a p y re b p e a prepared following general scheme 1 and according to the procedures 5 ration of example N18 and N11.
E
Figure imgf000165_0002
Ex x a a m m p p l l e e N N 3 3 2 2 may be prepared following general scheme 1 and starting from example N20.
10 N m,mNo,Nl′,N′-Tetramethyl-O-(1H-benzotri
Figure imgf000165_0003
l1yl) i h afluorophosphate (167 mg, 0.44 mmol)) a wnads N a,dNded to a mixture of e pl N20 (80 g, 0.20 mmol), acetic acid (10 µl, 0.22 re pylethylamine (245 µl
eadcut -diisopro r , 1.40 mmol) in dimethylformamide (0.60 ml). The 15 r cioend m prixetsusruere wa asnd sti threed r aetsi rdouoem w teamsp peurraiftiuerde f boyr 2 re hveorusresd. T phheas seolv ceonlutm wnas c rhermomovaetodg uranpdheyr r (HPLC method A). The product fractions we -r1e64 c-ollected and the solvent was removed under Yeu
LCideMldc
S:e 1d
m7 p s
e mre
thgs
o ou
dfr
2 ee
:x.
MamH+pl =e 4 N32 (21%)
5 11, RT = 2.345 min E Exammple
illxuastraptlee N
d N3
fo33
r3 th mea pyre bpear parteiopnar oefd ex foalmlowplieng N8 g.e Tnheera plr socdhuecmt wea 1s a onbdtai ancecdo ardsin thge to HC thle sa plrt.ocedures
10 E Example N
Figure imgf000166_0001
ac x c a o m rd p i l n e g N3
to 344 th m e a p y ro be prepared foll ig g l h 1, starting from example N33 and obtained as the HCl scaeldt.ures illustrated for the preparation of example N11. The product was
15 E Ex p
Figure imgf000166_0002
ill xa
uam
sm tra pl
tle
ee N
d N3
fo 35
r5 th m e a p y re b p e ar p a r t e io p n ar o e f d ex fo a l m lo pl i e g N2 g 0. The l pro h duct w 1 as an o d bta a i c n c e o d rd a in s g th t e o H th C e l s p a r l o t. cedures
Example N36
Figure imgf000166_0003
E ac x c a o m rd p i l n e g N to 36 the m p a r y oc b e e d p u r r e e p s a il r lu ed str f a o t l e lo d w f i o n r g th g e e -n1
pe6
re r5a- pl ar s a c t h io e n m o e f e 1 x , a s m ta p r l t e in N g 2 f 3 ro . m example N35 and
5 E Example N37
Figure imgf000167_0001
Px re a p m a p ra le tio N n 37 of m in a te y r b m e e p d r ia e t p e a 6 re 6 d folloig g l h 2.
3-Bromo-5-chloro-pyrazolo[1,5-a]pyri
Figure imgf000167_0002
idi (40 g 17.21 mmol
10 tetrahydrofuran (51.63 ml), diisopropyl i (14.47 l, 103.26 ) was dissolved in m mimxtoulr)e a wnads c pouprgpeedr(I w)it iohd niditerog (3e2n. Bis(triphenylphosphine)palladium m(ImI)o dli)ch wloarside ad (1d.e2d07 a gn,d 1 t.7he2 folmlopweerdatu bry prop-2-yn-1-ol (1.2068 m ml,g, 202..6155 m mmmool)l). T wheere re aadcdtieodn m unixdteurre n witraosge sntirr aetdmo astp rhoeorme te
15 w e for 20 hours. The mixture was concentrated under reduced pressure. The solid c frha
ors
mom f
0ailt
%teorge
trd
oap 1h o
0yff
0 o %v aen
ord
f s t
eitlhihce
yal a g fi
celt
elr,a
ta ute
tsei)n w
aga
n hs
de tp a
htead
nnseorb
us ae
innd
gd d e o
itchn
hyto
llor a s
oci
melitc
eaa
tte g aesl e alunednts pu (grirfiaeddien bty elu fltaiosnh (gravdeient elution from 0.2 % to 10 % of methanol). Th hane and methanol as eluents sol Snt m weatsho redm 1o:v MeHd+ u =nd 2e5r3 r,e RdTuc =ed 0.4 pre e product fractions were collected and the LCM 4s msuinre.
20 2
Preparation of intermediate 67
Figure imgf000167_0003
Intermediate 66 (5.81 g, 23.05 mmol) was - s1u6s6p- methanol ended in a mixture of dichloromethane and purged wit (h1: n1i,tr 3o1g0en m.l). Diphenyl sulphide (39 mg, 0.23 mmol) was added and the mixture was 5 was stirred under hydr Wogeetn P adt/mCo (s2p0% in weight of intermediate 66) was added and the mixture i antm woespighhetre of for in 2te0rm hoeudrisa.te Th 6e6 c)at waah
lysere
st a wd a
adt
se rodom
rem aon t
vdem or 14 hours. More wet Pd/C (20% ed tphe
bera
y mture f
filtirxatutioren o wvas stirred under hydrogen with a mixture of dichloromethane and methanol (4:1). The solvent e o r f C th e e lite fi ® ltr and was washed under reduced pressure and the residue was purified by flash chromatographayte o wvears s rielimoved 10 using dichloromethane and methanol as elue ca gel, T Yhieeld p nts (gradient elution from 0 % to 5 % of methanol.
:r 3o.d3u9c3t g fractions were collected and the solvent was removed under reduced pressure. LCMS method o 2f: in MteHr+m =ed 2i5a5te, R 6T7 ( =582%.08)2 min
Preparation of intermediate 68
15 A ml) so wlu
dii atsio andd oefd m dertohpywlsiuslefo tnoy al m setha
Figure imgf000168_0001
lf t (3139 g 1802 mmol) in dichloromethane (12 misxotuprreop wyalesth sytilrarmedine at ( 05°.3C11 fo mti
r 1lr,re 3d
h1o.u2r3l
. T mti
hmeo rle)f
a i int
cti doinchdimt 67 (3.052 g, 12.01 mmol) and N,N- 20 mloirxotu n reeth waane (24 ml) at 0°C. The reaction a sonld
rvife t
icnh
ate
tio w or
nagsan
in t ri
hec
em la
noy
eve
xerd w uansde wras rehdeudce wdith p wreastseur.re T.h Teh oerg caomicp loauy s
ne d
dr il w u
wa te
as d
s d w
uri i
se th
ed dichloromethane d, f wiltiethreodut an fudrth thee pu r LCMS method 2: MH+t s =te 3p3.3, RT = 2.806 min
25 Preparation of intermediate 69
Figure imgf000168_0002
Intermediate 68 (12.01 mmol), (S)-(+)-2-pyr -r167- carbon olidinemethanol (1.823 g, 18.02 mmol), sodium in N,N-adtiem (e3t.h8y1l9for gm,a 3m6.i03 mmol) and potassium iodide (1.591 g, 15.61 mmol) were suspended 5 reaction mixture was cdoeole (3d6 a mndl). th Tehe so relvaection mixture was stirred at 60ºC overnight. The a ecxetrtaacteted w wasith a add medixtu arned o tfh deic ohrlgoaronmicet lahyaenre/ wn
mat
es w
th wa
anas
oslh re
(em
9do
:1 wve
).itd
Thhe w unad
cotee
mrr. r
b Te
inhduced pressure. Ethyl eed a oqrguaenoiucs la lyayer was dried, filtered and the solvent was removed un ers were by flas der reduced pressure. The residue was purified 10 (gradiehnt co elluumtionn ch fromatography over silica gel using dichloromethane and methanol as eluents s Yoielvlde:n 1t. w1a2s removreodm un 0d%er t roed 1u0c%ed m preetshsanol). The product fractions were collected and the t5ho gd o 2f: in ure.
LCMS me MteHr+m =ed 3i3a8te, R 6T9 ( =281%.48)0 min
Preparation of intermediate 70
15 t (e1r.t1-2B5ut gy,l-c 3h.3lo4rodimethylsilane (755
Figure imgf000169_0001
g 501 l) dded to a mixture of intermediate 69 reaction was s mtirmreodl) a atnd ro torimeth tyelammpier (1.161 l, 8.35 ol) in dichloromethane (10 ml).The 0 organic layer was washed with water. Tahtuere or ogvaenricni lgahyte.r D wicahloromethane was added and the 2 r o e v m
eetr ov
ha s e
nili d
ocla u
). g n
Te d
hl e
e u r s r
pi e n d
rog u
d d c
ui e
cc d
th flo p
rar r o e
ctm ss
ioe u
nt r
sh e a .
wn T
ee h
re a e n cd re
ol m sid
lee u
ctth e an w o a l s as pu e r l i u fi e es
nd d
ts bryied
(g f,
rl a a d s fi
ihlte
en cre
tod
elu and the solvent was m lu m ti n on ch fr r o o m ma 0 t % og t r o ap 5 h % y pressure. ed and the solvent was removed under reduced 25 Y LCieMldS: 7 m75et mhogd o 2f: in MteHr+m =ed 4i5a2te, R 7T0 ( =512%.81)9 min
Preparation of intermediate 71 -168-
A the mix mtuixretu oref.1, I4n-tdeiroxane and water (
Figure imgf000170_0001
3110 l) dg d by bubbling nitrogen gas through dioxaborolan-2-yl)pmheendoialte (49700 (775 g, 1.72 l), 4-fluoro-3-(4,4,5,5-tetramethyl-1,3,2- 5 mg, riphenylphosphine)palladium(0) (35 mmol 0).0 a3nd m pmotoals)s,iu 2m-di pchyoclsophheaxty m
elpg
trh,
iboas 2p.06 mmol), tetrakis(t
sihcin (o3-2’,4’,6’-triisopropylbiphenyl (Xphos) (33 mg, 0.07 nitrogen gas at 85°C for 16 hours. The reac etiqo.n) w meixretu aredd wed and the mixture was stirred under and the organic layer was washed with water. The organ a ic s c la o y o e le r d w . a E s th d y r l ie acetate was add th e e d 10 c solvent was removed under reduced pressure. The residue was purifiedd, by filte flaresdh a cnodlumn eh
elur
mtoioom
vna
e ft
droography over silica gel using dichloromethane and methanol as eluents (gradient r umnd 0er % re todu 5ce %d o pfr methanol). The product fractions were collected and the solvent was LCMS method 2: MH+ = 48e3s,s RuTre =.1.836 min
15 Preparation of intermediate 72
I pnutergrmeded wiaitthe n 7i1tro (8g5e1n. m Wg,et 1. P7d6/C mm (1
Figure imgf000170_0002
0l)%, 85 gp, 1.d76d) i thddoeld (5 a.2n8d m tl) and the mixture was 0 under hydrogen atmosphere at room temperature for 15 hours. The cahtaely mstix wtuarse re wmaso stirred 2 f T il h tration over Celite® and was washed with a mixture of dichloromethane and methanovle (d4:1 b)y. flaseh s cohlvreonmta of the filtrate was removed under reduced pressure and the residue was purified by eelumtioovne fdro umnd 0to
er %gra
re toph
du 8y
ce % over silica gel, using dichloromethane and methanol as eluents (gradient r d o pfre msesuthraen.ol). The product fractions were collected and the solvent was Yield: 402et mhogd o 2f: in Mt -169- LCMS m eHr+m =ed 4i8a5te, R 7T2 ( =472%.81)1 min
Preparation of intermediate 73
5 T soelturatibounty olafmmonium fluoride (1M
Figure imgf000171_0001
lti i tt hyd f , 1.0 ml, 1.0 mmol) was added to a mixture was in stteirrrmeded aita rtoeom 72 te (m402 g, 0.83 l) i tt hydrofuran (2.49 ml). The reaction and washed with water and ap searatuturarete fdor 16 hours. The mixture was diluted with ethyl acetate 10 l e e
aadydeerd w,a thse d srioeldid, w filatesre fidlte arnedd t ahned s dorliveedn utn wda a
es q
r r u
rem o
duo us sodium bicarbonate solution. The organic cveedd under reduced pressure. Acetonitrile was YieMldS: 2 m32et mhogd o pressure.
LC 2f: in MteHr+m =ed 3i7a1te, R 7T3 ( =851%.81)4 min
15 Preparation of example N37
A
Figure imgf000171_0002
de sgolution of intermediate 73 (182 g, 0.49 l) i 2 thyltetrahydrofuran (20 ml/mmol) was 20 azodaiscsaerdbox byylate bu (b2b9ling nitrogen gas through the mixture. A solution of diisopropyl n ait proegrieond g oafs 3 t hhorouursgh1
at th 9e m m
0° mg,
Cix 1
ttou.4r ae7. d Beom
gtol) in toluene (20 ml/mmol) was degassed by bubbling ahss seodlut sioonls were added simultaneously and dropwise over in tsol cuoeonleed (7 a5nd m tl/hmem soollv).e Tnhte wa msix rteumreov weads u sntidrer u e t
rd ion
re adt o
u 9 f
c0 triphenylphosphine (386 mg, 1.47 mmol) wa e°dC p froerss 3u0re minutes. The reaction mixture flash column chromatography over silica gel using heptane an.d Th eeth ryelsid auceet was purified by 25 ( agsra edluieenntts el (ugtriaodnie frnotm elu 0ti %on to fro 5m0 % 0 % of to et 1h0yl % ac oefta mtee)th foalnloowl).ed Th bey p driocdhulocrto fmraectthioa e ts nnseat
w ae
enrd as e m coeltlu lhe ean ctneodl a pnhdas tehe co sluomlvenn cth wroamsa rtemoved under reduced -1 p7r0e-ssure. The residue was purified by reversed solvent was remo ography (HPLC method A). The product fractions were collected and the Y ved under reduced pressure.
5 LC ie M ld S : 3 m 28 et m ho g d o 2 f : e M xa H m+p = le 35 N 3 3 , 7 R ( T 19 = % 2 ) .061 min
E Exa ple
illxuam
smtraptlee N
d N3
fo38
r8 th mea pyre bpear parteiopnar oefd ex foalmlowplieng N3 g0e.n Tehrael p srcohdeumcte w 1as an odbta aicnceodrd ainsg th teo H thCel s parlot.cedures
10 E
Figure imgf000172_0001
Exampl
ill x u a s m tra p t le
ee N
d N3
fo 39
r9 th m e a p y re b p e ar p a r t e io p n ar o e f d ex fo a l m low pl i e n s g N g 2 e 7 ne a r n a d l N sc 8 h . eme 1 and according to the procedures
15 E Ex p
ill xa
uamm
stra ple
tl e e N
d N4
f40
o0 r t m he ay pr b e e
Figure imgf000172_0002
tead of a tert-butyl dpia p
mr r a e
et p
tiho a
yn re
ls o d
ilf fo
yl e l
px l
raom i
tepcl g
te g
ing N g8ro uuspi l n.g h
Th ae t perrot-db 1
uu a
cty n
tl d
w d a
aisp c h c
oe o
bn rd
tay i
il n
nsi g
elydl to
a p the procedures ins sro thteect HinCgl s garoltu.p
20
Figure imgf000172_0003
Exampl -171- E ilxamplee N N4411 may be prepared following general scheme 1 and according to the procedures in lu s s te tr a a d te o d f a for the preparation of example N8 using a tert-butyl diphenylsilyl protecting group 5 tert-butyl dimethylsilyl protecting group.
Preparation of intermediate 74
A 25. s5o2lut mionmo olf) 1 wNas hex aadmdeedthy dldroispilwaizsaene
Figure imgf000173_0001
di p litd i fnh 1y5dro muisnu tetetrsah tyodro afu srauns (25.52 ml, 10 methyltriphenylphosphonium iodide (10.316 g, 15.52 mmol) in anhydrous tetrahydproefnusraionn (7 o5f m(+l))-3 a-tb -o2c0-2 to,2 -25°C and the mixture was stirred at 20 to -25°C for 15 minutes. A solution of (R)- tetrahydrofura-dnim (7e5th myllo)x waazosli addine-4-carboxaldehyde (4.50 g, 19.63 mmol) in anhydrous 5 stirred at 0°C for 5 hours andd aetd r doroompw tiesmep oevreartu are pe friod of 15 minutes and the mixture was 1 c moixotleudre t woa 5s°C stir arendd f aonr 1 a0qu meionuustes s.at Tuhrated ammonium or ch 1 l 6 ori h d o e ur s s o . lu T t h io e n re w a a c s tio a n dd m e i d xtu a r n e d w th a e s et e product was extracted with a mixture of heptane and sohlvyeln atce wtaatse ( r1:1). The combined organic layers were washed with brine, dried, filtered and the chromatographeym oovveerd s uilincdaer ge rled uusiced pressure. The residue was purified by flash column 20 f rreommov 0e %d u tnod 15 % of ethyl acetate)n.g Th heep ptraondeuc atn fdrac ettihoynls a wceertaete co allsec eteluden atnsd ( tghread sioelnvten etlu wtioans Yield: 3.80 ge orf i rnetdeurmceeddi partees 7s4ur (e8.5%)
Preparation of intermediate 75
25 p in-t T e o rm lu e e d n i e at s e u 7 lf 4 on ( i 3 c .6 a 0 ci g d , m 15 o . n 8 o 4 h m yd m ra o t l e ) i ( n 1.0
Figure imgf000173_0002
84 th g, 5 l .7 (1 0 58 m o l) l . ) T w h a e s r a ea d c d t e io d n to mi a xt s u t r i e rre w d as so s l t u ir t r io e n d o a f t room temperature for 16 hours. To the reacti -o1n72 m- The volum ixture was added sodium bicarbonate (1 ml). acetate aned w waaste rre.d Tuhcee adq tuoe 10 ml under reduced pressure. The residue was dissolved in ethyl 5 layers were washed with bri o n u e s , l d a r y ie e d r , w f a il s extracted with ethyl acetate. The combined organic pressure. The product was used without futrethreedr p aunrdific tahteion so inlve thnet n weaxst s rteemp.oved under reduced Preparation of intermediate 76
10 Ibm l
Figure imgf000174_0001
7ui
5tdya
(l1(zco
5h.8leo4ro (1) md.4imp0h2
oel)n gy,
inls 2il0
da.
in5
ce9
hlo (4 m
ro.5m
m6o
e gl)
th,,
a 14
n7e.(4d2i thyl
(31 mll) i )py
) ddidid to ( a38 s7tirr medg, so 3l.u1t7ion m omfo inl)te armnded tieartte- temperatur . The reaction mixture was stirred at room filtrate was e w fo a r sh 7 e 2 d h w ou ith rs. w T a he solids were filtered off and washed with dichloromethane. The 15 reduced pressure. The residteuer a wnads b priunreif,ie dried, filtered and the solvent was removed under u Tshieng pr hoedputcatn fera acntidon esth wyelr aece ctoallteec atesd e alunedn tthse (dg sr b
oay
ldveie fl
nna
ttsh
w ealu c
stoilumn chromatography over silica gel roenm forovmed 0 u %nd to 10 % of ethyl acetate). Yield: 6.20 g of intermediate 76 (92%) er reduced pressure. Preparation of intermediate 77
20 A stir sroelduti
Figure imgf000174_0002
monixt oufre int oefrm trieflduioartoea 7c6et (ic6.2 a0ci g, 14.57 l) i dihl methane (10 ml) was added to a was stirred at room temperature for d 2 ho d ur d s. i T h h l e solv t e h nt wa ( s 1 r :1 e , 130 ml). The reaction mixture T sohleuti roensi wduaes a wdadsed di pssoortlivoendwi isne. d Tichhelo mroimxteutrhea wnea.s A sntirr aeqdu aetou rosm
om soavt tue
erd
mat u
pen
edde
ra sr
tuo r
rde
eiduu
fmced pressure. 25 or 3 b0ica mrbinountaetse. The two layers were separated and the orga -n1i73- sodiu c layer was washed with an aqueous saturated underm re bdicarbonate solution. The organic layer was dried, filtered and the solvent was removed Yield: 4.32 uc g e o d f p i ressure. The product was used without further purification in the next step. 5 LCMS method 2n:t MerHm+e =di 3a2te6, 7 R7T (9 =1% 2.7)85 min
Preparation of intermediate 78
10 m A mixtur
Figure imgf000175_0001
bumteonl)e i (ne
1. a o
1cf
6e4t ion
mnteiltr
,rmi 1leed
2.5 (i3a
97te
m.7m777
o m (4.10 g, 12.59 l) d pt ium carbonate (1.74 g, 12.59 l)l) was adtdiedd andt the rea tctiopn mti e for 30 minutes.4-Bromo-1- hours. The mixture was cooled to room temperature. The solidxstu wreer wea fsi stirred at 90°C for 16 with ethyl acetate. The solvent of the filtrate was removed under reducedl ptereresds off and washed 15 was dissolved in ethyl acetate and was washed with an aqueous saturated soduiurem. T bhicea residue solution and brine. The organic layer was dried, filtered and the solvent was removedrb uonndaete r r LeCdMucSed m pertheossdu 2re:. M THh+e = p 3ro8d0u,c RtT wa =s 3 u.0s7e2d m wiinthout further purification in the next step. Preparation of intermediate 79
20 A ad sdoelduti dornop owfi tseert- tbou ato sxtyircraerdbo snoylult
Figure imgf000175_0002
i hydf iidt (27d5i gt 17285 (912.59 ml)m ino tetrahydrofuran (7 ml) was ml, 18.88 mmol) in tetrahydrofuran (30 ml). The solution was stirred a l) t and triethylamine (2.624 h hoeuprtas.ne Th (e8:2 s)ol wveanst a wdadsed re.m Tohvee odrg uanndiecr la reydeurc weads p wreassshuered a wnitdh a an m aixo
qtu r
ureeom
ou osf te em
stahp
tye ulrature for 16 25 ra atceedta stoed aiunmd b reicmaorbvoenda utend seorlu rteiodnuc aendd pr bersinseu.re T.h Tehe or rgeasnidi -c17
ue la4
wy-ears w puarsifie ddrie bdy, f flialtsehre cdol aunmd the solvent was over silica gel using heptane and ethyl acetate as eluents (gradie n chromatography ethyl acetate). The product fractions were collected and th nt elution from 0 % to 7 % of 5 r Yedu u e solvent was removed under LCieMldc
S:e 3d
m.7 p
e5re
th gs os
odfr
2 ine
:t.
MerHm+e =di 3a8te07 (M9H (6+2 -% B)oc), RT = 4.238 min
Preparation of intermediate 80
10 D caictahllyosrotm (seetchane was refluxed und
Figure imgf000176_0001
it g t ph f 2 hours. A solution of Grubb’s solution of inotnedrm geedniaeration, 310 g, 0.37 l) i dihl thane (10 ml) was added to a 15 atmosphere. The te 79 (3.52 g, 7.34 mmol) in dichloromethane (279 ml) under nitrogen M un o
ed r
se e
sr G
ur n r reaction mixture was stirred under nitrogen atmosphere at 30°C for 16 hours. eit u
.r b o b
Tg
he s
en c
r a a
et t
sm aly
ido s
us t
eph (s
we e r c
ae o
s a n
pt d
u 3 g
ri0 e
f n
eC er
d f a
bo t
yr io 1 n
fl6 , 0
as h .
ho 0 u 3 . q
cros e
lum T .) h w
ne a a
c s s
horolv d
me d n e
at d he to w a
gra n
as d
ph re th
ym e
oovv m
ee i
rd xtu
s u r
ilin e cd w aer as ge re s ld t u ir c re e d pr d prptane and ethyl acetate as eluents (gradient elution from 0 % to 5 % of ethyl ace using Yioedldu:c 1t. f9r0ac gtio onfs in wteermree cdoiallteect 8e0d ( a5n7d% t)he solvent was removed under reduced pressuret.ate). The 20
Preparation of intermediate 81
Figure imgf000176_0002
A stir sroeldut mioinxt oufre in otefr trmifleudoiraoteac 8e0tic (1 a.c9i0d a gn,d 4. d2i1ch m -1
lom7
roo5
ml-)e itnha dniceh (l1o:r3o,m 4e7th maln).e T (h1e0 r meal) was added to a stirred at room temperature for 2 hours. The mixture was diluted with di ction mixture was washed with water, an aqueous 1N sodium hydroxide solution and brine. T chloromethane and 5 d wriitehdo,ut fil ftuerrtehder a pnudrif the solvent wasxt removed under reduced pressure. Thhee p orrogdauncitc w laayser u wseads LCMS method 2: MiHca+t =io 3n5 in2, th ReT n =e 2.9 s1te7p m.in
Preparation of intermediate 82
10 A inte mrmixetduriaete o 8f12 (1-(.t5e0rt- gb,u 4to.2x6yc marmbool
Figure imgf000177_0001
l
iodide (1.081 g, 6.51 mmol) in N,N)y
-,l
dimedi
ti )thy
hylformbamidtth
e ( (215.5 m93lfo
l) gn
w,a
a 1t
s5e.03 (1. m2m0ol g), an 5d.0 p1ota msmsiuoml), The reaction mixture was poured into water and extracted weith y sltirred at 60ºC overnight. 15 o s g w
co r
hlrv a
oe n
mn ica
att w l
oga y
rs ers
ap rehm e
yo r
ov e
veed dri
r s u e
in d
licd ,
ae fi r lte
g ree re
ld d
uusc a
ie n
nd d
g p t
hr h
ee e
psts s
au o
nr l
ee ve
a a n
nn t
dd wa
e th s
the re
yl re m
as o eth
pr acetate. The combineed id v ue d w un a d s e u re ri d fie u d ce b d y p f r l e a s s s h ur c e o . lu T m h n from 0 % to 40 % of ethyl acetate). The product fractio cetate as eluents (gradient elution 20 remove ns were collected and the solvent was Y LCieMld 1d
S: m.1 u
e6n
th gde
od orf r
2 ie
:nd
Mteuced pressure.
Hrm+e =d 4ia9t5e, 8 R2T ( =473%.3)74 min
Preparation of intermediate 83 -176-
I dnictehrlmoreodmiaetteha 8n2e (1 (1:3.1,610 g m,l) 2.34
Figure imgf000178_0001
l) ti d i iture of trifluoroacetic acid and An aqueous 1N sodium hydr.o Txhidee r soluttiion wiast added toti thed re aatc room temperature for 2 hours. 5 p arnou
udd
rifi tchc
aet w
tio snoalsvnx
ine e
thttr
e wac
nat
esed
xt re wmitohve ddich ulnodroemre rethdauncee.d T phrees csoumreb.in Tehde o prrgoadn ti
ui o
cc n
t la m
wyae ix
sr t s ur
us w e
ee u
dre ntil pH 11. The w ditrhieodu,t f fiultretrheed p r LCMS method 2: MH+ s =te 3p9.5
10 Preparation of example N41
T
Figure imgf000178_0002
prheepa sruabtisoenq oufe Nnt8 s atnedps us tiong o ibnttearinmediatep 8l3. N T4h1e produ bct wdas o onbta thineed pr aosce thdeur HeCsl u ssaeltd. for the 15 E Exm
acxa
caomp
rdpl
ile
ne N
g N4
to422 the m paryoc beed purreepsa ilrluedstr faotlelodw fionrg th geen pereraplar sacthioenm oef e 1x,a smtaprltein Ng1 f1ro.m example N38 and
Example N43
Figure imgf000178_0003
E x x a a m m p p l l e e N N 3 4 8 3 . is obtained as a side-product d -u177- e ring the Mitsunobu reaction in the preparation of
5 E Exm
Figure imgf000179_0001
ac xa
ca o mple
rd p i l n e N
g N4
to 444 the m p a r y oc b e e d p u r r e e p s a il r lu ed str f a o t l e l d f i or g th g e prep l arat h ion of e 1 x , a s m ta p r l t e in N g 1 f 1 ro . m example N43 and
Figure imgf000179_0002
10 E Exm e N
il n lxa
ua
ssmpl te tr a ap
dtlee
od N4 f a fo45 tr5
e t r h m
t-eay
bu p t r b
yee
lp d a p
im rrae
etpioared following general scheme 1 and according to the procedures i th n yls o il f y e l p xa ro m te p c le tin N g 2 g 0 ro u u s p in . g a tert-butyl diphenylsilyl protecting group Preparation of intermediate 84
15 A mm m o i l x ), tu 4 re -(d o im f e m th e y th la y m l i ( n 2 o R )p )- y 2 r-id (t i e n rt
Figure imgf000179_0003
b
chloromethane (135.48 ml) w (5a5 t y
s cgo,o 4 b
le.5d2 yl i
to 0l) )3
°Cd h
u i yd
ndiedra x z y o -p
nlie ro
tro ( p
g4 a
e.6 noate (9.90 g, 45.16 di n12 a gt,m 6o7s.p7h4e mrem.o tle)r itn- Butyl(chloro)diphenylsilane (12.919 ml, 4 -178- min 9.68 mmol) was added dropwise over a period of 15 withu dteicsh.l The reaction mixture was stirred at 30°C for 16 hours. The reaction mixture was diluted 5 aqueous soarotumraettehdan seod aind was washed with an aqueous 1N hydrochloric acid solution and an u gnedle ursi rnegdu hceepdta pnrees asnudre u . m
et Thh b
ye ic
l a r a e r
cs b
ei onate solution. The solvent of the organic layer was removed tdautee w asas el purified by flash column chromatography over silica acetate). The product fractions were collecuteendts an (gdra thdeien st elution from 0 % to 15 % of ethyl pressure. Toluen olvent was removed under reduced LCM e was added and removed under reduced pressure.
10 S method 2: MH+ = 358 (MH+ - Boc), RT = 2.269 min
Preparation of intermediate 85
A stirred solution of int
Figure imgf000180_0001
15 was cooled to -78°C uenrdmeerd niaitrtg 84 (2t1.0 gp,h 45.8.9 Di l) i hydrous diethylether (137.67 ml) ( m1
miM
extthu in
are te
no wtr
laa
(5shy
.5 sdt mirrorfu
le).dra
T an
ht,
e - 5
m758.0
ix°tC7 m
ure fomro
wa 1l) dd
s h so w
tiua
rrrs
e.d T ah aee
t rdea oi
cvteiorb
n aty
w pl
ael
srio qdin
ue ou
nfm
c 3 h
h0y
ed mdriide solution (DIBAL) bnyute sslo.w Th aedd reitiaocntio onf p roooumred tem in -78°C for 15 minutes. The cold solution was 20 ptoer aantur aequ foerous saturated Rochelle salt solution (2 mdl:1 the m pmroodlu DcItB wAaLs) e axntdra scttierrded wi atht e sothl tvy
hel
en atc we
xataste
t re.m Tohveed co 3
um.5
nb The layers were separated
di h
eno
reu
rdrs
ed o.
urcg an
eadni pcre lasyseurrse. w Tehree p wroadsuhcetd w wasith us berdin we,ith doriuetd f,ur ftihlteerre pdur aifnicdat tihoe i n Pnrepar naetiotn s oefp i.ntermediate 86
Figure imgf000180_0002
Methyl (2R)-2-aminopropanoate hydrochlorid -e17 (9- mixture of inte 4.80 g, 34.42 mmol) was added to a stirred mmol) in dichlorrmoemdeiathtean 8e5 (1 (3475..6879 m mlmol) and N,N-diisopropylethylamine (12.024 ml, 68.84 5 hours. Sodium triacetoxyborohydride) (.14 T.h5e91 m gix,tu 6re8.8 w4as m smtiorred at room temperature for 16 r weiathct dioicnh mlorixotmureeth waanse s atnirdre adn a atq rouoemou tsem 1Npe hryadture for 5 hours. Tl)he wa resac atdiodned mi pxtourrteion wwaisse d.ilu Tthede The mi rochloric acid solution (75 ml) was added slowly. and the x o tu r r g e an w ic as la s y t e ir r re w d as at w r a o s o h m temperature for 10 minutes. The two layers were separated 10 organic layer was dried, filtereded an wdith th aen s aoqluveenotus saturated sodium bicarbonate solution. The r aecseidtautee a wsas elu peunritfsied (gr baydi felansth el cuotilounm fnro cmhr 5o%ma ttoog 5r0a w
%pahs
ey r
th oe
yvm
le arov
c se
eiltid
acta un
e) gd
.ee
Tlr
h ues re
pinduced pressure. The rgod huecptt farnaecti aonnd ethyl collected and the solvent was removed under reduc s were Yield: 16.30 g o ed pressure.
LCMS f intermediate 86 (69%)
15 method 2: MH+ = 515
Preparation of intermediate 87
In
Figure imgf000181_0001
20 0°tCer umneddeiart neitr 8o6ge (2n.6 a0tm go,s 5p.h0e5re.l T)ifl di tli di id ( dihl thane (15.1o5nw mils)e a.n Tdhe co reoalecdtio to m n aqixuteuoreus w saastu srtairtreedd s a 4 l) dded porti
otdi ruomom bic teamrbpoenraatteur se for 3 hours. The reaction was slowly poured into an Trhieed a,q fiulteeoreuds a lanyder th wea ssol evxetnratc wteads w reitmh o
o d l
vi u
ec t
dh io lo n
urno a
dm nd
eert s h t
rea ir
dn re
ue d
c.e T at room temperature for 30 minutes. d dh pere csosmubrein.e Tdhe org parondicuc latyers were 5 w LCithMoSut m fuertthhoedr p 2u:r MifiHca+t =io 4n1 in5 the next step. was used 2
Preparation of intermediate 88 -180-
Tr
Figure imgf000182_0001
mmieothl)yl ianm dinicehl (o2r.o1m0e mthla,n 1e5. (1155.15 ml)l). The rdedacdtio tn mixttiurd ltion of intermediate 87 (5.05 The reaction mixture was used dire e was stirred at 40°C for 16 hours. 5 ctly in the next step.
Preparation of intermediate 89
A ad sdoelduti
Figure imgf000182_0002
as 10 se poonti oofn te wrti-sbeut tooxy aca srtbir dyl lhytididf (1 it32 gd 6i0t688 (l5). i05 dihmloorlo,m creutdhean fero (m15 p mrel)vi wous dtinlup
dte).
ad T
n wh
aqite
uh r
e de
oiuca
shclt
soio
arnotum m
raei
ttx
eht
daunre
se w
od aa
iuns
md s wtir
biar
csed
ar wboa a
nst
ah r
teo
edom temperature for 16 hours. The reaction was a s woliuthtio ann. T ahqeue oorugsan 1icN la hyyedrro dcriheldo,ri fcilt aecreidd solution solvent was removed under reduced pressure. The residue was and the chromatography over silica gel using hepta purified bgy flash column 15 f rreommov 0e %d u tnod 5e0r r %edu ocfe edth pyrle ascseutate). The prondeuc atn fdrac ettihoynls a wceertaete co allsec eteluden atnsd ( thread sioelnvten etlu wtioans YieMldS: 1 m.9e5th go odf 2 in:t ReTrm =e 4d.ia9t2e38re.
LC m9in (80%) 20 Preparation of intermediate 90 -181-
I anntedrm ceodoilaetde 8 to9 ( 05°.C35 u gn,d 11.0
Figure imgf000183_0001
8 l) di l d i hyd tetrahydrofuran (33.24 ml) tetrahydrofuran, 5.89 ml, 7e7r.56i mtmgol) wats addpehd po.rt Bio di thysulfide (2N solution in 5 u re n a d c e t r io n n it m ro i g xt e u n re a w tm a o s s c p o h o e le re d a to t 0 0 ° ° C C a fo n r d 3 m 0 e m th i a n n u o te l s (4 a 0 n m d l) antw
w ris
aoe
so. The reaction mixture was stirred am dd te e m d p d e r rature for 16 hours. The stirred at room temperature for 1 hour. The solvent was removed undeorpw reidseu. The mixture was the residue was co-evaporated twice with methanol. The product was usecded w pitrheosustur fe and 10 purification in urther LCMS method th 2e: M neHx+t s =te 4p6.9
Preparation of intermediate 91
15 Ay
Figure imgf000183_0002
-dioxoisoindolin-2- alt)mac m
oei
stx
patu
hldr
eee
rehy of
adte ro (4 in
o.t
m9e6rm
te gediate 90 (6150 g 1312 l) and 2-(1,3
m, 2p6e.r2a4ture folr) 1 i6 d hihl th (39.36 ml) was stirred under nitrogen mmol) was added portionwise. The reactionou mrs. Sodium triacetoxyborohydride (4.171 g, 19.68 The reaction mixture was quenched by thixetur aed wdiatis stirred at room temperature for 1 hour. bicarbonate solution. The water layer was extracted on wit o h f d a ic n hlo aqueous saturated sodium 20 o rergdan
iuceicd la pyreesrssu wree.re Th wea rsehseiddue wit wha bsri pnuer,ifi derdied b,y f fillatesrhed co alunmdn th cehr sooro
mlvm
aetne
otth
gr wane. The combined aapshy re omveoved under useng pr hoedputcatn fera acntidon esth wyelr aece ctoallteec atesd e alunedn tthse (g sroaldveienntt w ealusti roenm forovmed 0 u %nde tor 4 re0d %uce odf e ptrheyr
sl s s ai uclica gel Th reet.ate). Yield: 6.80 g of intermedia -182- LCMS method 2: MH+ = 64te2, 9 R1T (8 =1% 3.3)77 min
Preparation of intermediate 92
5 A 0.5 m0ix mtul,re 15 o.f66 int mermmoeld)i iante et 9h2an (
Figure imgf000184_0001
6l.7 (053 g, 1l)0.44 ti l)d td 70 hyCd f i 4 h (o5u0r/s6.0 T%he aq reuaecotuiosn s moluixttiuorne, w
0 etahsyl c aocoeletadte a.n Tdhe th seo slvuesnpte onfsi tohne w filatrsate filt weraesd to remove the solid. The solid was washed with 1 was re-dissolved in ethyl acetate. The orga renmico lvaeyder un wdaesrh reeddu wceithd p arnes asquureeo aunsd 1 thMe r seosdidiuume h reyddurocxeidde pr seoslsuutiroen.. T Thhee pr oordguacntic wa lasy uesre wda ws dried, filtered and the solvent was removed under LCMS method 2: MH+ = 512 ithout further purification in the next step. 15 P
p Trhre
eepa
pa frora
allt
toio
iown
nin o
ogf e
f N sx
2taem
0p asple
nd to N4
us o5
inbgta iinnte ermxaemdipaltee 9 N24.5 are based on the procedures used for the
Figure imgf000184_0002
20 E Exam
ac x c a o mpl
rd p i le
ne N
g N4
to 466 the m p a r y oc b e e d p u r r e e p s a il r lu ed str f a o t l e lo d w f i o n r g th g e en p e re ra p l ar s a c t h io e n m o e f e 1 x , a s m ta p r l t e in N g 2 f 3 ro . m example N45 and -183-
E Ex 7
Figure imgf000185_0001
Pxa
re am
pmple N4
ap ra le tio N n 47 of m e a xa y m be ple pr N ep 4 a 7 red foll ig g l h 1, tarting from example N45.
5 E dixsasmolpveled N in451,2 (1-d2i0ch mlogro,e 0th.3a1ne m (2
Figure imgf000185_0002
l)l). Cdppyl(IpI)pylbtt (1i13 ac midg, (500.6 m2g m,m 0o.6l)2, mmol) were (97 mg, 0.62 mmol) and sodium carbonate (2.0 eq., 131 mg) were added. 2,2’-bipyridyl 10 stirred at the open air at 70°C for 16 hours. The reaction mixture wa The reaction was o 3f0 a mnin auqtueeso.u Tshe sa mtuixrtautreed w aamsm doiluntiuemd w cihthlo driidcehlo solution and was stirresd q auten rocohmed te bmyp theera atudrdeiti foonr threine o.rg Tahneic o largyaenric wa lasye wras whaesd d wriiethd, an aqueoruosm seathtuarnaete.d Th aem tmwoon liauymers ch wloerriede se spoaluratitoend a anndd p b ressure. The residue was purifi filtered and the solvent was removed under reduced 15 d %ic
d th
uolo
c 3ro
ed %me
pr mth
eeathnaen aonl)d. T ah 7eN pr aomdmucotne
firad
ac s b
toy
iolunt f
siloa
wnsh
e arn c
edol
co mum
lleetn
chta c
enh
dor
alo
n am
dsa
t eto
hleugera
snp
otlshy
ve (gnr o
tav
wde
airesn stil
re eic
mlua
otivo g enel d fr u uos nming de 0 re r Yield: 90 mgss oure.
LC f example N47 (69%)
20 MS method 2: MH+ = 423, RT = 2.369 min E Examp
acxcaoml
rdpile
ne N
g N4
to488 the m paryoc beed purreepsa ilrluedstr faotlelodw fionrg th geen pereraplar sacthioenm oef e 1x,a smtaprltein Ng2 f3ro.m example N45 and -184-
E Example
re e p s a
Figure imgf000186_0001
ac x c a o m rd p i l n e N
g N4
to 499 the m p a r y oc b e e d p u r il r lu ed str f at l e l d f i or g g l h 1, starting from example N45 and 5 the preparation of example N23.
E
Figure imgf000186_0002
Exa p
ac x c am
om rd ple N
il n e g N5
to 500 the m p a r y oc b e e d p u r r e e p s a il r lu ed str f a o t l e lo d w f i o n r g th g e en p e re ra p l ar s a c t h io e n m o e f e 1 x , a s m ta p r l t e in N g 2 f 3 ro . m example N45 and
10 E
Figure imgf000186_0003
Exam
ill x u a s mp
tra pl
tle
ee N
d N5
fo 51
r1 th m e a p y re b p e ar p a r t e io p n ar o e f d ex fo a l m low pl i e ng N2 g 8 e . n T e h ra e l p s r c o h d e u m ct e w 1 as an o d bta a i c n c e o d rd a in s g th t e o H th C e l s p a r l o t. cedures -185-
Examp
Figure imgf000187_0001
Ex N52
Pre a p m a ple
ra le tio N n 52 of m in a te y r b m e e p d r ia e t p e a 9 re 3 d following general scheme 1.
5 33-8b2r.o8m0o m-6m-cohl)lo wroe-riem siduaszpoe[n1d,2e-db] ipny nri-dbaut
Figure imgf000187_0002
i (l8 (19104. g8438l2)8 i am porle)s asnudre 2 t-aminoethanol (23.15 ml, for 20 hours. The reaction mixture was cool ube and heated at150°C pressure. The mixture ed and the volume was reduced under reduced 10 1 was triturated with ethyl acetate. The solids were filtered off a
Yi heo
Mldu
S:r 7 u
m.5n
e0de
th gr reduced pressure at 70°C. nd dried for LC o odf 2 in:t MerHm+e =di 2a5te8, 9 R3T (7 =6% 1.2)23 min
Preparation of intermediate 94
15 I Nn,tNer-mdiemdeiathteylf 93 (5.0 g, 19.45 mmol)
Figure imgf000187_0003
d tithyl i (4055 ml, 29.17 mmol) were dissolved in atmosph ormamide (150 ml). Th ti it as cooled to 0°C under nitrogen d teicmhploerroam e
tue re
reth fa a
on n
re d
2 ( a
h2o0 so
urs m lu
.l T) tio
h w n
ea rs of
ea acd m
tid e
oe t
nd hyl
mi d s
xr u
to l
up fo
rew n i y
ws l ea. m
s p T e
oh th
ue an
re rde e a sulfonate (4.41 g, 25.29 mmol) in 20 sclotiwonly i mntioxt wuraete wr (a6s00 st mirrl)e.d Th aet s rooloidms w dreiered f uilntedreerd v oafcfu aunmd. t Tohlueen coem wpaosu anddd weads a unsde r - de1m86
wio- thvoeudt u funrdtheer reduced pressure. The solids were Yield r purification in the next step.
LCMS: 6 m.2e9 g of intermediate 94 (96%)
5 thod 2: MH+ = 336, RT = 1.767 min
Preparation of intermediate 95
[ d(i2sSso)-lpvyerdro ilnidi dni-c2h-lyolr]mometehtahnaonel (2 (7.540.16 g,
Figure imgf000188_0001
2l4).72d ll)d td i 0Cida uznodleer (2 n.i5tr2og ge,n 3 a7t.m08os mpmheorle). w teerrte 10 b
a stu
nirt
dryel(
wdch
a al
sto
h rr
eoo
do)dmip
wi th
tee
hmn
apy
nels
ariala
qtuun
eree (
ou f7o.
sr1
111
N68 h g
ho,
ydurr 2
os7..
ch T1
lh9
oe m remaoclt)io wna msix atudrdee wda asn ddilu thteed r weaithcti doinch mlorixotmureeth wanaes-
bicarbonate solution. The ric acid solution and an aqueous saturated sodium 5 reduced pressure. The re osirdguaenic wa lasye pru wrifaiesd dr bieyd f,la fislther ceodlu amnnd t chhero smolavteongtra wpahsy re omveorve sidlic under 1 u frs m
eoi
mmng
ov 0 di
ed %chlo
un toro
d 6e %tha onfe m aentdha ano 7l)N. T ahmem pornoidau scotlu frtaiocntio inns m weethrean coolll aescte edlue anntds t (hgerad sioelnvten etlau wt gioe anl r s Y e
CieMldS: 8 m.0e0th go or
df 2 i rneduced pressure.
L :t MerHm+e =di 3a4te095 (95%)
20 Preparation of intermediate 96
Figure imgf000188_0002
A ca mrbioxntuartee o (f2 intermediate 94 (3.10 g, 9.25 mm -1o8l)7,- intermediate 95 (1.20 g, 11.10 mmol), sodium sulfoxide (27..79541 m gl), w 2a7s.75 sti mrremdol a)t a 6n0dºC potassium iodide (1.997 g, 12.03 mmol) in dimethyl 5 water (350 ml) and extracted with ethyl ace fotarte 1.6 Th heou crosm. Tbihneed re oarction mixture was poured into b pruinriefie,d dr bieyd f,la fsilhte creodlum annd ch threom saotlvoegnratp whays ov reemr soved under reducegdan picre lsasyuerres. w Tehree w reassidhueed w wiaths eluents ilica gel using dichloromethane and methanol as the solv ( e g n r t a w di a e s nt re e m lut o io v n ed fro u m nd 0 % to 5 % of methanol). The product fractions were collected and 10 column chromatography overe sril riecadu gceeld u psriensgsu hreep.ta The residue was purified by a second flash e (gluratidoinen frto emlu 0tio %n t foro 8m00 % % of to eth 4y %l ac oefta mtee) and usingn deic ahnlodro emtheythla anceet aanted a mset ehluaennotls as (g eraludeienntst so thanol). The product fractions were collected and the Yielvlde:nt 2 w.0a0s g re omf ioved uendder reduced pressure. 15 LCMS method 2:n MteHrm+ = 5ia7t9e, 9 R6T ( =373%.0)81 min
Preparation of intermediate 97
4
Figure imgf000189_0001
20 9-6(D (1im.9e0th gy,l 3 a.m28in mo)mpyorli)d ainned (0 di.-2t0t g-,b 1t.y6l4 di bl) t (1d.0d7d t a stirred solut tieotnra ohfy idn thle). rtoefrumraendi (a1t5e m s Tohlvee rneta wctaiosn r memix g, 4.92 mmol) in
otuvreed w uansde strir rreeddu acte 6d5 p°C for 4 hours. The reaction mixture was cooled and chlurtoiomna ftroogmra 0ph %y t oov 4er % si olifc mae gthealn uosl)in.g Th deic ph re
rl e
oo s
dr s o u
um r
cte .
ftrh T
aa h
cn e
tioe re
ns a s n i
wd du
er m e
ee w
ctoh as purified by flash column e llaencoteld a asnd elu theent ssolv (gernatdient 25 removed under reduced pr was Y LCieMldS: 2 m.1e5th god of 2 i:n Mte essure.
Hrm+e =d 6ia7t9e, 9 R7T ( =973%.6)23 min -188- Preparation of intermediate 98
5 Iyn
Figure imgf000190_0001
ml)t
ipe
xthrm
uerne
eod
olia
f (t
11e 5
,.40-67
dio gx, (2
a 4.45
n.1
e4 an m g,
dm 7
wo8
al).2
te a0
rn (3d:1 p, 9tl),
.51i 4fl (4,
ml). p Th3
he rpehact4,5
tion t,5i mbt
ixstr
tiucam
r (3et ehqyl.-)1 w,3e,2re-di doixssaoblovreodla inn-2 a- nitrogen gas through the mixture.2-Dicyclohexylphosphino-2 e was degassed by bubbling (153 mg, 0.32 mmol) and tetrakis(triphenylphos ’,4’,6’-triisopropylbiphenyl (Xphos) added and the mixture was stirred under nitrophine)palladium(0) (186 mg, 0.16 mmol) were 10 m anix
redtu
ss br
urei as
rn w
ee.. T Thh c
eeoo
r ole
ersgd
ia.
dn D
uiecich l walo
ayreo
srm
p we
uath
risa
fie dn
dreie w
bdy,as f fill a
ated
srd
heedd ge a n nd g t a h s e o a r t g 8 a 5 n ° ic C la f y o e r r 1 w 6 as ho w u a rs s . he T d he wit r h ea w c a ti t o e n r p co alnd the solvent was removed under reduced dichloromethane and methanol as eluents (96,5: umn chromatography over silica gel using the solvent was removed under reduced pres 3,5). The product fractions were collected and 15 Y LCieMldS: 1 m.7e6th go odf 2 in:t MerHm+e =di 7a1te0, 9 R8T (7 =8% 3.5) sure.
20 min
Preparation of intermediate 99
20 A un sdoelrut nioitnro ogfe innte artmmoesdpiahteere 98. T (1
Figure imgf000190_0002
.t71b g,ty 2l.41 il) i fl ttidhyd (1Mf lut (i7o.n23 in m tel)tr waahsyd crooofuleradn t,o 0°C mmlvoeln)t w waass a rdedmeodv.e Tdh uen rdeearc rteiodnuc meidxtu prrees wsuarse s atnirdred the at re rosoidmue te wmapse drailtuutreed f worith 20 eth hoylur asc. 3 e T .6 tah 1 so tee a dnrided w,a filstehreedd w ainthd a thne a sqoulveeonuts w saastu rreamteodve sdod - ui1
nu8
dm9- er b riceadrubcoendat pere ssosluurtieo.n T.h Tehe res oirdguaenic layer was by flash column chromatography over silica gel using dichloromethane and was purified eluents. The product fractions were collected and the solvent was removed u methanol as 5 p Yr
LCiees
Mlds
S:u 8re. nder reduced m40et mhogd o 2f: in MteHr+m =ed 4i7a2te, R 9T9 ( =742%.06)8 min
Preparation of intermediate 100
10 A de sgoalsustieodn of by inte brmubebdliinagte 9 n9itr (o4g40
Figure imgf000191_0001
g g, 0.93 th glh) i th 2 thiytlttr.ah Aydro sfouran (20 ml/mmol) was azodicarboxylate (550 mg, 2.79 mmol) in anhydrous toluene (20 ml lution of diisopropyl 15 bubbling nitrogen gas through the mixture. Both solutions were a/mmol) was degassed by d mrgo,pw 2.i7s9e m ovmerol a) i pne arinohdyd orfo 2us ho toulrusen aet 9 (07°5C m tlo/m am doel)g.a Tshseed re saoclution odfd treipdhe sinmyulplthaonsepohuinsely ( a7n3d2 sohlrvoemnatto wgarsap rheymo ovveedr s uilnicdaer g reeld uusciendg p driecshslourroem.e Tthhean rees aidnude tio w n a m s ix p t u u r r i e fie w d as by co f o la le s d h a c n o d lu t m he c n 0 elution from 0 % to 4 % of methanol). The product fractions r mee ctohllaencoteld a asnd el tuheent ssolv (gernatd wieanst 2 r Ye
CimeMldo
S:ve 5 m9d0 un we et md
hoger
d o 2f re
: induced pressure.
L MteHr+m =ed 4i5a3te, R 1T00 = (720.2%93) min
Preparation of example N52
25
Figure imgf000191_0002
Intermediate 100 (590 mg, 0.65 mmol) was -1 d90- m issolved in a 4N hydrochloric acid solution in coeotlheadn,o sl (4 ml). The reaction mixture was stirred at 50°C for 16 hours. The reaction was 5 room temlpoewrly poured into an aqueous saturated sodium bicarbonate solution and stirred at c poremsbsiunreed. T ohragt
eaunre for 30 minutes. The aqueous layer was extracted with dichloromethane. The reicsid layers were dried, filtered and the solvent was removed under reduced dichloromethane andue a 7 wNas a purified by flash column chromatography over silica gel using % to 4 % methanol). The pro m d m uc o t nia solution and methanol as eluents (gradient elution from 0 reduced pressure. The residue wa fsra fctions were collected and the solvent was removed under 10 ( rHedPuLcCed m perethsosd
oufr Ae). The product fractuiortnhser w peurreifi ceodll beycte redve arnsded th peha ssoelve cnotlu wmans c rhermomovaetodg uranpdheyr Y LCieMldS: 2 m9e mthgod 2 e:x.
MamH+pl =e 3 N5532, R (6T% =) 1.398 min
15 E Ex le
illxa
uammp
straptlee N
d N5
fo53
r3 th mea pyre bpear parteiopnar oefd ex foalmlowplieng N4 g5e.n Tehrael p srcohdeumcte w 1as an odbta aicnceodrd aisng th teo H thCel s parlot.cedures
20 E Exam e N
Figure imgf000192_0001
ex x a a m mp
ppl
ll e e N N5
554
34 . i T s h o e b p ta ro in d e u d ct a w s a a s s o id bta -p ined d as t t d he i HC g l th salt M . it bu reaction in the preparation of
E Exa ple
Figure imgf000192_0002
25 ill x u am
sm tra p t l e e N
d N5
fo 55
r5 th m e a p y re b p e ar p a r t e io p n ar o e f d ex fo a l m low pl i e ng N4 g 5 e . n T e h ra e l p s r c o h d e u m ct e w 1 as an o d bta a i c n c e o d rd a in s g th t e o H th C e l s p a r l o t. cedures -191-
Examp
Figure imgf000193_0001
i E ll x u a s m tra ple
tl e e N
d N5
fo 56
r6 th m e a p y re b p e ar p a r t e io p n ar o e f d ex f a l m l pl i e g N1 g 1. l h 1 and according to the procedures
5 E
Figure imgf000193_0002
Exa pl
Px re am
pm e N5
ap ra le tio N n 57
o7 f m in a te y r b m e e p d r ia e t p e a 1 re 0 d 1 following general scheme 2.
10 A chl morioxt-upryera ozfol toe[r1t-,5b-uaty]ply (r3imS)id-3in-aem (3in.4o8p
Figure imgf000193_0003
i gp, 1i4d.i981 lb) ydl Nte,N (-2d.i0is0op gr,o 9p.y9le9th mylmamoli)n,e 3 (-2b.r6omo-5- 14.98 mmol) in acetonitrile (30 ml) was stirred at 90°C for 24 ho 16 ml, pyhreaz reoaloc[t1io,5n-a m]pixytruimreid winaes ( c0o.5ol eeqd.) a w urs. More 3-bromo-5-chloro- T ndas th aedd seodlve anntd w thaes m reixmtuorveed wa usnd setirrre redd autce 9d0° pCre fosrsu 2r2 hours. 15 a filcteertaetde a wnads th aedd soeldve annt w thaes o rregmaonviced lay uenr was washed with water. The organic layer wa e s . d E ri t e h d y , l corlaumn chromatography over silica gdeelr u residnugce ddic phrleosrsoumree.th Tahnee re asniddue m weathsa pnuorlifi aesd b eylu felash (gvdeinetn wta eslu rteiomno fvroemd u 0nd %er t roed 8u %ced of pr meessthuaren.ol). The product fractions were collected and tnhtes sol LCMS method 2: MH+ = 397, RT = 4.609 min -192- Preparation of intermediate 102
5 I mnteetrhmaneodlia (te 101 (4.08 g, 10.30 m
Figure imgf000194_0001
l) ti d i 4N hydrochloric acid solution in nitrogen ga3s0 w mal)s a btu rboom temperat f 4 h . Mthnol and toluene were added and pressure. Toluen bled through the mixture. The solvent was removed under reduced 10 was used w e was added twice and removed twice under reduced pressure. The product LCMS methiothdo 2u:t M fuHrt+he =r 2 p9u7r,ifi RcaTti =on 1. i4n1 t8he m ninext step. Preparation of intermediate 103
15 2 i
Figure imgf000194_0002
, 5.
mn-tb
ger
,romm
4.eo
8de
6iath
mteox
m 1y
o0- l)2tert
in (4- N.b8u
,N6ty
-d ml-dmimole),th tryiel-tshilyl i (1.2 (425.027l l,8314 m.5m8o ml)m woal)s a anddde pdota toss aiu smus iopdeindseio (n80 o7f 16 hours imethylacetamide (6.7 ml). The reaction mixture was stirred at 80°C for washed w . T ith he w r a e t a e c r. tio T n he m o ix r t g u a re ni w c a la s y c e o r o w le a d s , e d t r h ie y d l , a f c il e te ta re te d w a a n s d a th dd e e s d o a lv n e d nt th w e a o s rg re a m nic layer was 20 reduced pressure. The residue was pur eified by flash column chromatog oved under u Tshieng
M pSr doi
mdch
eul
tco
htr
o fo
drma 2ce
:titoh
Mna
Hsne
+ w a
=en
4red
55 c m
,o Rleleth
Tcat =endol
2. a a
3ns
7d7 t mhlueents (gradient elution from 0 %ra toph 8y % ov oefr m seitlihcaano gle).l LC in solvent was removed under reduced pressure. Preparation of intermediate 104 -193-
D (1i.-9te2r5t-b gu,ty 4l.2 d4ica mrbmonoal),te tr (i1e.th11yl1
Figure imgf000195_0001
gi, 5.0 (90. l) ddd to a mixture of intermediate 103 5 ( 20. h2o5u9rs g., M 2.o12 mmol) in tetrahydrofuran (1828.472 ml,l).6. T3h6e reacotli)on an mdix 4tu-r(edim waesth sytlirr aemdin aot) 7p0y°rCidi fnoer mixture wasr setir drei-dte artt-b 7u0t°yCl d foicra 1rb6o hnoauters (.1 M.2or eeq d.)i- atenrdt-b turiteytlh dyilcaamrbinoena (0t.4 eq.) were added and amino)pyridine (0.3 eq.) were added and mixture was s e (3 eq.) and 4-(dimethyl 0 crude reaction mixture was purified and t tirred again at 70°C for 20 hours. The 1 d 7i0c°arbonate (2 eq.) and 4-(dimethyl amino)pyrid h i e ne r ( e 0 a .8 cti e o q n .). w T a h s e r r e e a in c i t t i i o a n te m d ix u tu s r in e g wa d s i- s te ti r r t r-e b d ut a y t l redinuC
gce fo
hdr
ep p 1
trae6
nses huo
aru
ner
d.s.
e Tth T
hehe
yl r ae r
cse
eida
tauct
teio
e a wn
sa msix
elu pt
euu
nrrie
tfsie w
(da
gr bs
ay c
die folnao
tslhed
elu cto a
iolnud
nmn th cehr soomlvaetnotgr waapshy re omveorve sdilic uand geer us l The product fractions were collected and the s fromd 0 u %nde tor 5 re0d %uce odf e ptrheysls aucreet.ate). 15 Y LCieMldS: 1 m.2e4th9o gd o 2f: i MntHe+rm =e 5d5ia5t,e R 1T04 olvent was remove
= ( 35.32%85) min
Preparation of intermediate 105
Figure imgf000195_0002
A thr mouixgthure the of m 1i,x4t-udrieoxane and water (3:1, 1 -21.094 m-l) was degassed by bubbling nitrogen gas 1,3,2-dioxaborolan-2.-y Iln)ptehremneodiate 104 (1.149 g, 2.07 mmol), 4-fluoro-3-(4,4,5,5-tetramethyl- 5 (46 mg, 0.04 mmol), 2-dicyclolhe (0x.y5lp9ho gs,p 2h.i48 mmol), tetrakis(triphenylphosphine)palladium(0) m stimrroeld) u anndde pro ntaitrsosgiuemn g pahsos apth 8a5te°C tri fboars 1ic4 (n
h1o
o.3-2
u1’
r8,4’
s. g,6
T,’- h 3trii
e es
reqo
a.p)ropylbiphenyl (Xphos) (38 mg, 0.08 ct wioenre m aixdtudreed w aansd c thoeole mdix ature was acetate was added. The organic layer washed wit nd ethyl removed unde h water, dried, filtered and the solvent was 10 over silica gelr u rseindguc heedpt parneess aunred. e Tthe residue was purified by flash column chromatography e rethdyulce adcetate). The product fractionhsyl w aecreeta cteoll aescte edlue anntds ( tgradient elution fr
su as roemmo 0v%ed to un 80d% p er LCMS mer he solvent w
theosd 2re:. MH+ = 586, RT = 3.335 min
Preparation of intermediate 106
15 T ae stroalubtuiotynla omfm inotenriummed fliuaoride (1M
Figure imgf000196_0001
lti i tt hyd f , 2.48 ml, 2.48 mmol) was added to was stirred at room temtpee 1ra0t5ure (2. f0o7r 17 holu)r is. t Thteh myidxtufre w (6.21 ml). The reaction mixture 0 washed with water and a saturated aqueous sodium bicarboansat deilu stoelduti wonith. T ehtheyl o argcetate and 2 w pu a r s ifie d d rie b d y , filtered and the solvent was removed under reduced pressure. The resaidnuice la wyaesr ehluee snotslve (gnrta fl
wdais
aeh
snt c
re eo
mlluu
otmivon
en c
d frhromatography over silica gel using dichloromethane and methanol as t uonmde 0r % red touc 8e %d p orfe msseutrhanol). The product fractions were collected and 25 Yield: 844 mg of inteHr+m =ed 4i e.
LCMS method 2: M 7a2te, R 1T06 = (826.3%51) min
Preparation of intermediate 107 -195-
A wa ssolu dteiognas osfe idnte brymediate 106 (7
Figure imgf000197_0001
44 g 158 l) i 2 thyltetrahydrofuran (20 ml/mmol) azodicarboxylate (1.5 b6u6bb mlinl,g 7.9 n0it mgmol) g in an thhydgh th itre. A solution of diisopropyl 5 b durobpbwlinisge n ovitreorg aen pe griaosd o thfr 2ou hgohurs th aet 1 m1i0xt°uCre t.o B ao dtehrou
ga ssosslu to
etdiloune
sosne
lu w (
tie20 ml/mmol) was degassed by orne o afd trdipehden simultaneously and g, 7.90 mmol) in anhydrous toluene (75 ml/mmol). The reaction mixture wasy sltpirhreodsphine (2.072 30 minutes. The mixture was cooled and t at 110°C for r he solvent was removed under reduced pressure. The 10 ee
frtahsi acyd stlu
i to ae rinc was purified by flash column chromatography over silica gel using dichloromethane and tuset
ra wa
teete
dre a
w cs
itohl eleluents (gradient elution from 0 % to 50 % of ethyl ac actee etate). The product w ctodn aitnridl the solvent was removed under reduced pressure. The residue Yield: 678 mg of int e, the solid was removed and dried under reduced pressure.
LCMS m ermediate 107 (95%)
15 ethod 2: MH+ = 454, RT = 2.365 min
Preparation of example N57
I
Figure imgf000197_0002
0 mnt
meetrhmaneodlia (t4e.41707 ml) (6 a7t8 ro mogm, t 1e.m49peraturel) for 4 htoiursd a ind at 45N0 h ºCydr foocrh 2lo hriocur asc.id Th solution in 2 n e ni ixture was stirred at room temperature for another 14 hours. Diethyl ether was aedd reeadc ationd tthro
deg
ure
ce an
dnd gas was bubbled through the mixture until the diethyl ether was evaporated. Diethyl re pre ass feuwre. d Trohpes pr oofd muethanol were added and the solid was filtered and dried under Y LCieMldS: 2 m19et mhogd o 2f: e MxaHm ct was obtained as the HCl salt.
25 +p =le 35 N45,7 R (T38 =% 2).056 min Examp -196- E ex x a a m m p ple
ll e e N
N N5
558
58 . i T s h o e b p ta ro in d e u d ct a w s a a s s o id b e ta -p in r e o d du a c s t t d h u e ri H n C g l th sa e lt M . itsunobu reaction in the preparation of
5 E Example N59
Figure imgf000198_0001
ex x a a m m p p l l e e N N 5 5 2 9 . i T s h o e b p ta ro in d e u d ct a w s a a s s o id bta -p ined d as t t d he i HC g l th salt M . it bu reaction in the preparation of
Figure imgf000198_0002
10 E Ex le
ill xa
uamp
sm tra p t l e e N
d N6
fo 60
r0 th m e a p y re b p e ar p a r t e io p n ar o e f d ex fo a l m low pl i e ng N5 g 7 e . n T e h ra e l p s r c o h d e u m ct e w 2 as an o d bta a i c n c e o d rd a in s g th t e o H th C e l s p a r l o t. cedures
E Examp
axampllee N
Figure imgf000198_0003
15 N6611 may be prepare
ocbctaoirndeindg as to th tehe H pCrlo scaeldt.ures ill d us f t o ra ll t o e w d in f g or g t e h n e e p ra re l p s a c r h a e ti m on e o 2 f , e s x ta a r m tin p g le fr N o 1 m 1. e T xa h m e p p l r e od N u 6 c 0 t w an a d s -197-
E
Figure imgf000199_0001
Exampl
ac x c a o m rd p i le
ne N
g N6
to 622 the m p a r y oc b e e d p u r r e e p s a il r lu ed str f a o t l e lo d w f i o n r g th g e en p e re ra p l ar s a c t h io e n m o e f e 1 x , a s m ta p r l t e in N g 4 f 7 ro . m example N55 and
5 E
Figure imgf000199_0002
Examl
exxaamm p
ppll e N
ee N N 6
66 3
23. is obtained as a side-product during the Suzuki reaction in the preparation of
10
Figure imgf000199_0003
Table 1 -198- C
Figure imgf000200_0001
p d N1 E pl N1 Cp d N2 E pl N2 C
Figure imgf000200_0002
p d N3 E pl N3 Compound N4, Example N4
Figure imgf000200_0003
Cp d N5 E pl N5 Cp d N6 E pl N6 C
Figure imgf000200_0004
p d N7 E pl N7 Cp d N8 E pl N8 -199- Cp d N9 E pl N9 Cp d N10 E pl N10 Cp d N11 E pl N11 Cp d N12 E pl N12 Cp d N13 E pl N13 Cp d N14 E pl N14 Cp d N15 E pl N15 Cp d N16 E pl N16
Figure imgf000201_0001
-200- C
Figure imgf000202_0001
p d N17 E pl N17 Compound N18, Example N18 C
Figure imgf000202_0002
p d N19 E pl N19 Cp d N20 E pl N20 C
Figure imgf000202_0003
p d N21, E pl N21 Cp d N22, E pl N22 C
Figure imgf000202_0004
p d N23 E pl N23 Cp d N24 E pl N24 -201- C
Figure imgf000203_0001
p d N25 E pl N25 Cp d N26 E pl N26 C
Figure imgf000203_0002
p d N27 E pl N27 Cp d N28 E pl N28 Compound N29, Example N29 C
Figure imgf000203_0003
p d N30, E pl N30 Compound N31, Example N31 Compo
Figure imgf000203_0004
d N32 E ple N32 -202- Com
Figure imgf000204_0001
p d N33 E pl N33 Cp d N34 E pl N34 Co
Figure imgf000204_0002
p d N35 E pl N35 Cp d N36 E pl N36 Compound N37, Example N37 Co
Figure imgf000204_0003
p d N38, E pl N38 Co
Figure imgf000204_0004
p d N39 E pl N39 Compound N40, Example N40 -203- Compound N41, Example N41 C
Figure imgf000205_0001
p d N42 E pl N42 Com
Figure imgf000205_0002
p d N43 E pl N43 Cp d N44 E pl N44 C
Figure imgf000205_0003
p d N45 E pl N45 Cp d N46 E pl N46 C
Figure imgf000205_0004
p d N47 E pl N47 Cp d N48 E pl N48 -204- Compound N49, Example N49 C
Figure imgf000206_0001
p d N50 E pl N50 Compound N51, Example N51 Co
Figure imgf000206_0002
p d N52, E pl N52 C
Figure imgf000206_0003
p d N53 E pl N53 Compound N54, Example N54 C
Figure imgf000206_0004
p d N55, E pl N55 Cp d N56, E pl N56 -205- Cp d N57 E pl N57 Cp d N58 E pl N58 Cp d N59 E pl N59 Cp d N60 E pl N60 Cp d N61 E pl N61 Cp d N62 E pl N62 Cp d N63 E pl N63
Figure imgf000207_0001
Compound identific -206- Meltin ation
F moerth theg m poeilntintsg point determination of the compounds of the present invention, the following 5 od was used. F M
Moe
erlt
tt ain
le ng
ru p
Fmo
Pbin
6et
2r m
a oe
pft
p ch
aoo
rmd
atpuosu.n Mdesl,tin mge pltionignt pso winetrse ( mme.pa.s) were determined in open capillary tubes on a 300°C , using a gradient of 10 °C/minute. Theu mreeldtin wgith po ain tetm vpaelureature ranging from 50°C to 10 display and was not corrected. was read from a digital Tab CleO 2: Melting points
NM UM PO B U ER ND MELTIN G C) POINT CO N M UM PO B U ER ND MELTIN ( G POINT
N1 272,3 N3 °C) N2 > 30 6 189,8 N3 N 0 N37 168,1 N4 D* N38 >300 N5 2245 N39 ND* N6 27813,,94 N N4401 N NDD* N7 258,8 N42 * N8 >300 N43 ND* N9 294, 178,1 N10 >35 N44 ND* N11 > 30000 N N4456 118684,1 N12 ND* N47 ,7 N13 > 30 154,6 N14 > 3000 N N4489 113593,,6 N15 ND* N50 1 0 N16 211,5 12,9 N17 >300 N N5512 225866,,89 -207- N N198 275,1 N53 276,8 N1 N220 2 1 288,55 N5 2892, 5,3 N N54 55 2 6 228 2831,5
N22 > 300 N57 >3,3 N23 183,2 N58 300 N24 208,3 N59 2 N/A N25 288,6 N6 60,3 N26 >300 N601 >300 N27 199,9 N62 22298,7 N63 2666,,51
* Not determined 5 L FC
woarM
s LS
uCseMdS.-characterization of the compounds of the present invention, the following method
A Glene
10 A degl
gil aenraa ansstlly p e 1s
r,2ero
9sce a0 wd uto seu
erere sriae p L mseCr
p lfM lio
eqrS rum
,ided
th c using an Agilent 6110 series LC/MSD quadrupole coupled to an ehrmroomsatatotegdra cpohlyum (LnC c)o smypsatertmme cnotn asinsdtin dgio odfe a ar brainyary pump with mass spectrometer (MS) was operated with an atmosphe detector. The ( vAoPltaI-gEeS t)o s 7o0ur Vce a innd p tohseit qivue ric pressure electro-spray ionization ad iornup mooled tee.m Tpheera ctaupreilla wrays vo mltaaignetai wnaesd s aett 1 t0o0° 3C0.00 V, the fragmentor 15 a nn
Ced
hbeu tzm
mleistearpe
tio gra
natsu
s,re
oft awt va
ar alue
e. psre wsesruere 12 o.0f L 3/5mi pns aign.d D 3a5t0a°C ac rqeuspiseitciotinvel wy.as Nit proegrfe T
onh
rm we
ea d
dsry
w uinsg itehd ga A as gs fl to ilehw net
20 LCM
Kin aedS -208- In tedxi mti Coentho
18 tod
co t 1
lhuemn ge (n5e0r malm pr looncegd xu 2re.1 L mCmMS i.d1.:; A 1.n7a µlymse psar wtiecrlees) ca artr 6ie0d°C o,ut on a Phenomenex 5 mL/min. A gradient elution was performed from 90% (water + 0.1% w fioth a flow rate of 1.5 A mcoebtiolenit prhileas teo c 1o0m%p (owsaittioenr + w 0a.s1% hel fdor fmoric a anci add)d /it 9io0n%al a 0c.e4t0on mitirnile in 1.50 minurmteisc, t ahceind) th /e 1 fi0n%al was 2 µL. Acquisition ranges were set to 254 nm for the UV . The standard injection volume the MS detector. -PDA detector and 80-800 m/z for 10 L
A InC
Q aMdS
Cd1i mt8ioe
cnth
o to
lod
um th 2
ne ( g5e0n mermal p lornogcedure LCMS1: Analyses were carried out on a YMC pack ODS- mL/min. A gradient elution w x 4.6 mm i.d.; 3 µm particles) at 35°C, with a flow rate of 2.6 Acetonitrile to 5% (water + 0.1%as fo prerformed from 95% (water + 0.1% formic acid) / 5% 15 m waosbil 2e µ pLh.a Asecq cuoismitpioosition was heldm foicr a ancid a)d /di 9ti5o%nal A 1c.e0t0on mitriinle. T inhe 4. s8t0an mdianrudte ins,je tchteionn th veolu fimnael m/z for the MS detecntor r.anges were set to 190-400nm for the UV-PDA detector and 100-1400
20 Table 3: LCMS data
CO NMUMPOBUERND MA PSESA (MKH)+ R TEIMTEEN (mTIiOnN) M LECTMHS
N1 336,2 2OD
N N2 3 2,127 2 N3 35533,,01 11,952 2 N4 N5 353,1 1,,90597 573,,0 1,8850 2 6 336 2 N7 354,22 11,,58277 2 N8 354,1 3 2 N9 35 2,098 2 N10 3647,,12 12,977 2 N11 368,1 2,,112174 22 -209- N N1123 33762,2 2,140 2 N14 8,2 1,987 2 N1 368,2 2,040 2 N156 336687,,22 22,,007437 2 N17 368,2 2,1 2 N18 368,2 2,47 2 N19 382,2 220 2 N20 369, 2,193 2 N21 352 1,987 2 N22 374,2 1,96 2 N23 0,2 2,113 2 N2 383,0 2,061 2 N245 339874,,11 22,,152372 2 N26 388,1 2,2 2 N27 409,2 250 2 N28 369, ,147 2 N29 4230 1,996 2 N30 4,2 2,307 2 N 42,2 ,20 2 N31 09,2 2,08 32 4132 22,36
N3 1, 475 22 N334 335648,,12 21,,0922 2 N35 369,1 870 2 N36 383, 1,885 2 N37 352 2,033 2 N38 43,1 2,061 2 N39 30792,,22 22,,0028700 22 -210- N N41 3368 N40 42 4626, 3,21 22,,0160 ,2120 22 N N43 2 44 44029,1 3,,1 2,210716 22 N45 383,11 2,272 2 N446 7 22,,0192 2 N N47 439 8 42234,,09 22,690 2 ,35 24 2 N49 437,0 2,3515 2 N5501 441101,,50 12,,93719 2 N 2 N52 3 2 N 53,40 1,398 2 N53 382,44 2,004 2 N54 382,44 2,073 2 N55 396,47 2,181 2 N556 24 57 4 8 353,,5430 22,,208526 2 N 2 N659 3 0 39667,,4473 21,,149313 2 N 2 N61 333593,,3480 11,,992747 2 N 2 N6623 443366,,5544 22,,442128 22 5 Kinase Activity Assay
T pehpeti idneh-ibbaitisoend o kfin LaRsReK a2ss kaiyn.ase was assessed using LRRK2 recombinant protein in an in vitro Prot -211- A kin raao
sdc
eioo
aml
cetitvriitcy. p Arollte aisnsa kyinsa asere a psesrafoyrm (3e3Pda innQ 9i6n-awseel®l F AlactsivhiPtyla Atesssay) is used for measuring the reaction volume. The reaction cocktail is pipetted in 4 ste TM from Perkin Elmer in a 50 µl 5 1205 µ µll o off n aossna-ryad bioactive ATP solution (in H2O) ps in the following order: 5 µl of test samuffer/ [γ-33P]-ATP mixture
10 µl of enzymep/lseu ibns 1tr0a%te D mMixStuOre
10 T Nhae- assay for LRRK2 contains 70 mM HEPES-NaOH pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 µM 100o5rt chpomva pneard waetell,), 1 p.2ro mteMin k DinTaTs,e 5 L0R µRgK/m2l ( P7,E3G n2M0)0 a0n0d, A suTbPst (r0a.t3e µ (GMS),K [3γ(-1334P-]2-7A)T,P 1,0 (a µpgp/r5o0x. µ 4l) x The kinase is obtained from Invitrogen Corporation. . 15 T 50he µl re oafc 2tio %n ( cvo/vc)kt Hai3lPsO w4e,r pela incubated at 30° C for 60 minutes. The reaction was stopped with NaCl. Incorporation of 33P tes were aspirated and washed two times with 200 µl 0.9 % (w/v) counter. i (counting of“cpm”) was determined with a microplate scintillation 20 Compounds
T bahteh c soomnipcoautonrd.s are dissolved to 10 mM in DMSO. Where needed, solutions are sonicated in a 25 T thaeb alebo 2v pero mveidnetison theed p kIinCa50se va alsuseasy o.f the compounds according to the invention, obtained using Table 4
Comp No1und N° IC50 fo +r+ L+RRK2 Comp No3und N° IC50 for LRRK2 N2 +++ 2 +++ N3 + N33 +++ N4 +++++ N N3345 + +++++ -212- N N56 + +++ N N337
8 ++
+++ 6 + ++++ N N7 +++ N +
N38 +++ N9 ++ N3490 + ++
N10 +++ N41 +++ N11 +++ N42 ++++ N12 +++ N43 +++ N13 ++ N44 +++ N N14
N115 +++ N45 + 6 +++++ N N446 + +++++ N + 7 +++ N17 +++ N48 +++ N18 +++ N49 +++ N129 +++ N50 +++ N20 +++ N51 +++ N21 +++ N52 +++ N22 +++ N53 +++ N234 +++ N54 +++ N25 + +++++ N N5565 + ++++ N N2276 + +++ N57 +++ N28 ++++ N58 +++ N29 +++ N59 +++ N30 +++ N60 +++ N31 ++++ N N61 + +++ ++ indicates an IC50 of between 100 nM and 1µM, an N62
d63 +++ indicates an I ++
C++ 5+0 < 100nM

Claims

-213- CLAIMS
1 p . redrug, A sa c lt o , m hy p d o r u a n te d , N of -o F x o id r e m f u o la rm I , o o r r s a olv s a t t e e re th o e is r o e m of e , r, tautomer, racemic, metabolite, pro- or
5 Wh
Figure imgf000215_0001
I
R1e isre
(C sin
=eSle)-cRted from–H,–halo, -OH, -C- lkyl, -O-C- lkyl, -S-C1-6
4, -SO2-R4, -CN, -NR9-SO2-R4, -C3- alkyl, -NR9R10, -(C=O)-R4, - 10 wherein each of said -C 6
1- cycloalkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1; R5 is su abttsatcithu 6alkyl is optionally and independently substituted with from 1 to 3 eednt tso s Ze1le ocrte Zd5 a frnodm is–h saelloe,ct -eOdR f3r5o,m -N–RH1,1R–1h2a,l -oO,- -CO1H-6,a -lkCy1l-,6a alnkdyl -,S-C1-6alkyl;
-NR6R7, -(C=O)-R8, -(C=S)-R8, -SO2-R8, -CN -O-C1-6alkyl, -S-C1-6alkyl, Ar5 and–Het5; wher , -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3-6cycloalkyl, - from 1 to 3 substitueenitns e saeclehct oefd sa friodm -C–1h-6aallok,y -lO isR o36p,ti -oNnRa2ll3yR a24n,d -O in-dCe1p-6eanlkdently substituted with 15 R2 is o spetiloencatelldy f arnodm in–dHe,p -heanlo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein eayclh, a onfd sa -Sid-C -C1-6
1-a6alklkyyl;l is OR27 dently substituted with from 1 to 3 substituents selected from–halo,– R3 is sele,c atendd f -rNomR13–RH1,4; -halo, -OH, -C1-6alkyl, and -C3-6cycl
20 optionally and independently su oalkyl; wherein each of said -C1-6alkyl is R OR28, and -NR1 bstituted with from 1 to 3 substituents selected from–halo,– NR17R18,e -C ea3-c6ch5
4 and R8 ar y iR
cnld16
oe;
aplkeynl,d -eOn-tCly3- s6ecylecclted from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, - R6, R7, R9, R10, R11, R12, R13, R14, R15, Ro1a6,lk Ryl1,7, -A Rr4
18 and -Het4; 25 R35 and R36 are each independ , R19, R20, R21, = R22, R23, R24, R31, R32, R33, R34,
- inSd-Cepeanldkeynl,tl -yC s3-u6cbysctiltouatelkdyl, w -iAthre6n
fr at
only
md s–e
1Hle
tec
ott6e;d
3 w fr
sho –
uem
brsetiinH
tue e,
na -h
tca
shlo
s o,
efle sO
ca,
tied -O
d -CH
fr1,
o-6 - maClk1- –y6
hlalky
a islo, ol,p -O-C1-6 1-6 alkyl, –tOioHna,ll -yO a-Cn1d- R 6aldky Rl, -S-C1-6aaclkhy iln,d -Ce3p-6ecnydcelonatllyky sle,l -eHcetet6d, - fArorm6 a–nHd,– -NR37R38
27 an 28 are e ; 0 R R ch independently selected from–H, C -1 h -6 a a lo lk , y -l, O -H C , 3-6 -C cy 1 c -6 l a o l a k l y k l y , l - a O n-d C1 --H 6a e l t k 2
37 and 38 are ea y :
3 l, -S-C1- X 6alky e l l , e -c C te 3- d 6
1 is s cy fr c
,o lo m alk
and y C l,
-1O- -6 A
-a r
;l 7 k wy a lh-n , d
er
eO H
in-e C t7
e1 ;
a-6cahlky ol-f, saSid-C -1C-6
1a-6lkaylkl-y,l- -C is1-6 oaplktiyol-nNaRlly3-C a1n-d6al iknydl-e,pe -NnRde3-nCtl1y- 6alkyl-, -NR3- -214- sC u 1 b-st l i k tu y ted with from 1 to 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6al s6aeleclt,e -dph kyl, -S- X feronmyl, a–nCd1-6 -aNlRky3l3-R,3–4
2 is ;O-C1-6alkyl-,–S-C1-6
6a alkyl-, -C1-6alkyl-NR ll 2-C1-6alkyl-, -NR2-C1- 5 sulbksytl-it,ut -eNdR w2-i,th a fnrodm -O 1- t;o w 3h seurbesintitu eeancths s oefle scatiedd - fCro1m-6a–lkhyal-lo, is -O oHp,tio -Cn1a-6aylk aynl,d -O in-Cde1-p6aelnkdyle,n -tSly- Ar1, C A1r-6
4,a Alkry5l,, -phenyl and -NR31R32;
comprisin Agr61, t aond 3 Ar7 are each independently a 5- to 10-membered aromatic cycle optionally 10 Ar7 being optionall hye atenrdo iatoms selected from O, N and S; each of said Ar1, Ar4, Ar5, Ar6, and ish oaploti,o -nOaHlly, - aCn1d-6a inlkdyl, -O- n C d 1 e -6 p a e lk n y d l e , n -S tly -C s 1 u -6 b a s lk ti y tu l, te a d nd w it N h R fr 1 o 9 m R2 1 0; t w o h 3 er s e u i b n s e ti a tu c e h n o ts f s s a e i l d ec -t C e 1 d -6 f a r l o k m yl Het1, Het2, Het4, Het5, Heepte6,nd aenndtl Hye stu7b asrteitu eteadch w iinthde frpom 1 to 3 -halo;
having from 1 to 3 heteroatoms selected from O,e Nnd aenndtly S; a w 3h- to 10-membered heterocycle Het4, Het5, Het6, and Het7 is optionally and independently seurebisntit euach of said Het1, Het2, 15 substituents selected from–halo, -OH,–C1-6alkyl, -O-C1-6alkyl, -S-C1-t6eadlky wl,it =hO f
6a ,ro -m
Figure imgf000216_0001
(C= 1O t)o-C13- sulbksytl, and -NR21R22; wherein each of said -C1-6alkyl is optionally and ind
20 S; 3itu-t teod 1 w0-itmh p d tly Het8 is a e frmombe 1re tdo h 3e -thearoloc;ycle having from 1 to 3 heteroatoms selected from O, N and w sehleerceteind s fraoidm H–ehta8lo is, - oOpHtio,n–aClly1-6 aanlkdyl, in -dCe1p-6eanlkdyelenntley, s -uCb1s-6taitluktyed with from 1 to 3 substituents O-C lkyl, -S-C1-6alkyl, =O, -
Figure imgf000216_0002
(C=O)-C1-6alkyl, -C1- l-C3-6cycloalkyl, -C3-6
1-6a cycloalkyl, - each of said -C 6
1-6alkyl is optionlly d idp dentlya slkuybl-sO-C1-6alkyl and -NR21R22; wherein 25 wherein when R1–H,hen at le t ht tm of Het8 itsitu attetadc wheitdh t foro Xm21 to 3 -halo;
Z1 t
A1, a Zn2d, Z A3
2, a Zr4e a enadc Zh5 in adreep eeancdhe inntdlyep seenledcetendtly fr soemle Ccte adnd fro Nm. C and N; and 2 R.1 is se Ale ccotemdp foruonmd– aHs, de–fhinaelod, in -O cHla,im -C 11,-6 wherein
30 ( wCh=
beS
srte)- itiunR4
e e,
na - tscShO
se o2
lef-R
c s4
tea,
did -C
fr -oCN, -NR9-SO2-Ra4lkyl, -O-C1-6alkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, - m1-6–ahlkayllo, is -O oRpt , -C3-6cycloalkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1; su 3i5o,nally and independently substituted with from 1 to 3 R s 6 attached to Z1 or Z5 and is selected fro -NmR–11HR,1–2,h -aOlo-C, -1O-6aHlk,y -lC, a1-n6adlk -ySl-,C -O1-6
5 i Ha,lk -yCl;1-6alkyl, -O-C1- 35 - inOal
d-k
eCyl, -S-C1-6alkyl, -NR6R7, -(C=O)-R8, -(C=S)-R8
p3e-6ncdycelnotalylk syul,bs -tAitur5ted an wdith– frHoemt5; 1 t woh 3e sreuibnsti e,
tua - ecSO2-R8, -CN, -NR6-SO2-R8, -C3-6cycloalkyl, nhts of said -C1-6alkyl is optionally and O-C selected from–halo, -OR36, -NR23R24 1-6a , - R2 is selectelkdyl f,ro amnd– -HS,-C -h1-6alkyl;
oOpRti2o7n,a alnlyd a -NndR1 in3Rde alo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein each of said -C1-6alkyl is 40 14p;endently substituted with from 1 to 3 substituents selected from–halo,– -215- R3 is o spetiloencatelldy f arnodm in–dHe,p -heanldoe,n -OtlyH s,u -Cbs1-t6itaulkteydl, w anitdh - fCro3m-6cy 1c tlooa 3lk syul;b wshtietureenints ea sechl of said -C1-6alkyl is OR2 ected from–halo,– 5 R 8
4 a
R6, R NndR1 R,8 a
7R an
18r,ed
-C e -Na3-cR
6ch15
y iR
cnld16
oe;
aplkeynl,d -eOn-tCly3- s6ecyleccloteadl from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, - R7
3,5 R a9n,d R R10
3,6 R ar1e1, e Ra1c2,h R in1d3,e Rpe14n,d Re1n5t,ly R s16e, k
le R yl
c1 ,
t7 - e, A
d R r4
f1r8 a
o, n
m R d 1–9 - H, H R et4
, -2h0 ; ,a Rlo2,1 =,O R,22 -,O RH23, R24, R31, R32, R33 R34, -S-C1-6alkyl, -C3-6cycloalkyl, -Ar6 and–Het6; wherein each o , -C1-6alkyl, -O-C1-6alkyl, independently substituted with from 1 to 3 substituents sf said -C1-6alkyl is optionally and 10 S-C N elected from–halo,–OH, -O-C1- R 6alkyl, - R37 and R38, a r r e1- e e6a
eal
ack
chyl,
h in - in dC
de3
ep-6
pecy
enc
ndl
deo
ena
ntllk
tyy
ly sl,
se - A
elHe le ce
ctte6,
te d - d fr f or6
ro m an
m–dH –H ,–
, -CR37
27 and R28, a -h 1- a 6aR
lo lk38
,y;
-l O , - H C , 3 --6 C c 1 y-c 6a lo lk a y lk l, y -l O an -C d 1 --6 H a e lk t2 y : l, -S-C1- X 6 s alk s y e l l , e -c C te 3- d 6cy fr c o lo m alk y C l, 1- -6 A a r l 7 ky a l- n , d–Het7
1 i ;
15 –O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- X 6
2 is alk s y e l l-e , c -t N e R d 3- fr a o n m d– O C-1 ; -6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1- Ar 6
1, c Aa
orlk
m4,yl-,
p Arirs5 - i,N
n AR
gr2
6- 1,,
t a a
onndd
3 A -O
her7-;
te arroeat eoamcsh s inedleecpteendd feronmtly O a, 5 N- to 10-membered aromatic cycle optionally 20 A–hralo,in -OgH o,p -tCio1n-6aalllyky al,n -dO i-nCd1e-6paelknydle,n -Stly-C s1u-6bstituted w ainthd f Sro;m ea 1ch to o 3f s sauibds Atitru1e,n Atrs4, s Aelre5,ct Aerd6
7 be , fr aonmd is optionally and independently substi alkyl, and–NR19R20; wherein each of said -C1-6alkyl Het1, Het2, Het4, Het5, Het6, and Het7 aretu eteadch w iinthde frpoemnd 1e tnotl 3y - aha 3lo-; t
25 having from 1 to 3 heteroatoms selected from O, N and S; wheroei 1n0 e-macehmbered heterocycle
H suebt4s,tit Hueent5t,s H seetl6e,ct aendd fr Homet7–h isal oop,t -ioOnHa,lly–C a1n-6dalk inydl,e -pOe-nCd1e-6natllkyyl s,u -bSs-tCitu1-t6ead o
lky wf
l,it said Het1, Het2, =hO f,ro -m(C= 1O t)o-C13- 6albkyl, and -NR21R22; wherein each of said -C1-6alkyl is optionally and i
Figure imgf000217_0001
30 8 s
S iu
;s ast 3itu-t teod 1 w ndp d tly Het 0-itmhe frmombe 1re tdo h 3e -thearoloc;ycle having from 1 to 3 heteroatoms selected from O, N and w sehleerceteind s fraoidm H–ehta8lo is, - oOpHtio,n–aClly1-6 aanlkdyl, in -dCe1p-6eanlkdyelntly substituted with from 1 to 3 substituents O-C1-6alkyl, -S-C1-6alkyl, =O, -(C= ene, -C1-6alkyl-C3-6cycloalkyl, -C3-6cycloalkyl, - 35 each of said -C1-6alkyl is opt
Figure imgf000217_0002
O)-C1-6alkyl, -C1-6alkyl-O-C1-6alkyl and -NR21R22a;lo w;herein Z1, wherein when R1 is–H, thenio ant lllytd id hpt daetonmtly o sfubstituted with from 1 to 3 -h a Zn2d, Z A3
2, a Zr4e a enadc Zh5 in adre Het8 is attached to X2 A1 ep eeancdhe inntdlyep seenledcetendtly fr soemle Ccte adnd fro Nm. C and N; and 3. A compound as defined in claim 1, wherein -216- R1 is( selected from–H,–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, - wCh=eSre)-inR4 e,a -cShO o2f-R4, -CN, -NR9-SO2-R4, -C3-6cycloalkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1; 5 substituents selec steadid fr -oCm1-6–ahlkyl is optionally and independently substituted with from 1 to 3 R5 is -N aRtta6Rch7,e -d(C to=O Z1)- oRr8 Z, -5(C an=dS i)s-R sa
8el
,loe,
-ScOt -eO
2dR
-R f3r5
8o,
,m -N
-C–R
NH1
,,1R
-N–1h2
Ra,l - 6-oO-C1-6alkyl, and -S-C1-6alkyl;
S,O -O2H, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, Ar5 and–Het5; wherein each of said -C1-6alkyl is optiona-Rlly8, a -nC3-6cycloalkyl, -O-C3-6cycloalkyl, - from 1 to 3 substituents selected from–halo, -OR36, -NR23R24,d -O in-dCe1p-6eanlkdently substituted with R selected from–H, -halo, -OH, -C1-6alkyl, and -C3-6cycloalkyl; wherein eayclh, a onfd s -S-C1-6
2 is alkyl; 10 o O p R ti 2 o 7 n , a a l n ly d a -N nd R1 in 3R de 14 p ; endently substituted with from 1 to 3 substituents selectedai fdro -mC1–-6haalkloyl, i–s R3 is o spetiloencatelldy f arnodm in–dHe,p -heanldoe,n -OtlyH s,u -Cbs1-t6itaulkteydl, w anitdh - fCro3m-6cy 1c tlooa 3lk syul;b wshtietureenints ea sechle octfe sdai fdro -C1-6alkyl is 15 OR28, and -NR15R1 m–halo,– R NndR1 R7R18,e -O ea-Cch3-6 incyd6
4 a 8 ar ce;
lpoeanlkdently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, - R, R7, R9, R10, R yl, -C3-6cycloalkyl, -Ar4 and -Het4
6 ;
R 11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R31, R32, R33, R34 20 -S3-5C a1n-6dal Rky3l6, a -Cre3- e6caycchlo inadlkeypl,e -nAdre6ntly selecte;d w from–H, -halo, =O, -OH, -C1-6alkyl, -O-C1-6alkyl, independently substituted with fr aonmd– 1H teot63 shuebrsetiintue enatcsh s oefle scatiedd -C fr1o-6malk–yhla islo, op–tOioHna,ll -yO a-Cn1d- R 6
27 aanldky Rl,28 - 8,S
, a-C
ar r e1- e e6a
eal
ack
chyl,
h in - in dC
de3 yc
ep-6
pec
en n dl
deo
ena
ntllk
tyy
ly sl,
se - elHe le ce A
ctte6,
te d - d fr f or6
ro m and–NR37R38;
R7 and R3 m –H –H , - , C -h 1- a 6a lo lk , y -l O , - H C , 3 --6 C c 1 y-c 6a lo lk a y lk l, y -l O an -C d 1 --6 H a e lk t2
3 y : l, -S-C1- 25 X 6
1 is alk s y e l l , e -c C te 3- d 6cy fr c o lo m alk y C l, 1- -6 A a r l 7 ky a l- n , d O H-e C t7
1; -6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 6 saulbksytl-it,ut -eNdR w3-i,th a fnrodm -O 1- t;o w 3h seurbesintitu eeancths s oefle scateidd f -rCo1m-6a–lkhyal-lo i,s -O oHpt,io -Cna1-l6laylk aynl,d -O in-Cde1-p6aelnkdyle,n -tSly- 30 X C1-6alkyl, -phenyl, and -NR33R34
2 is selected from–C1-6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1- 6 saulbksytl-it,ut -eNdR w2-i,th a fnrodm -O 1- t;o w 3h seurbesintitu eeancths s oefle scatiedd - fCro1m-6a–lkhyal-lo, is -O oHp,tio -Cn1a-l6laylk aynl,d -O in-Cde1-p6aelndently C1-6alky
compris5l
i,,
n A -p
grh61,e
t an
ony kyl, -S- Ar Ar dl a
3 An
herd7 - te aN
rrR
oe3
at e1R
oamc32
1, 4, Ar sh;
s inedleecpteendd feronmtly O a, 5 N- t aond 10 S-m; eeamcbhe orefd sa aidrom Ara1,tic Ar c4y,c Aler5, optionally 35 A –h r7 being optionally and independently substituted with from 1 to 3 substituents select Aerd6, fr aonmd is oaploti,o -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, and–NR19R20; wherein each of said -C1-6alkyl Het1, Het2,n Haellty4, a Hndet i5n,d Heepte6,nd aenndtl Hye stu7b asrteitu eteadch w iinthd from 1 to 3 -halo;
having from 1 to 3 heteroatoms selected from Oep,e Nnd aenndtly S; a w 3h-e troei 1n0 e-macembered heterocycle 40 Het4, Het5, Het6, and Het7 is optionally and independently substitutedh o wfit shaid fro Hmet11, H toet23, -217- substituents selected from–halo, -OH,–C1-6alkyl, -O-C1-6alkyl, -S-C1-6alkyl, =O, -
Figure imgf000219_0001
(C=O)-C1- 6 saulbksytl,itu atendd w -iNthR fr2o1Rm221; to wh 3e -rhein each of said -C1-6alkyl is optionally and indp d tly 5 Het8 O is, N a a bnivda Sle;nt 3- to 10-membearleod; heterocycle having from 1 to 3 heteroatoms selected from w whheerreeiinn a wth leenas Rt1 o inse– oHf, s tahiedn h aette leroaastto omnes i hse atettraocahtoed to X1 or X2;
wherein said Het8 is optionally and indepe m of Het8 is attached to X2; and selected from–halo, -O ndently substituted with from 1 to 3 substituents 10 O ea-Cch1-6 oaflk syali,d - -SC-1C1-6
-6alkaylkly isl,H
o =,
pO–C
t,1 --
Figure imgf000219_0002
(6Cal=kOyl),-C -C1-6
1-6aalklkyyl,le -nCe1,-6 -aClk1-y6la-Olk-yCl-1C3-6
-6alckyycllo aanldky -l,N -RC3-6
21Rc2y2;clo wahlkeyrel,in - Z1, Z2, Z3, Z4 and Z5 a ionlly d idp dently substituted with from 1 to 3 -halo;
A1 and A2 are each indreep eeancdhe inntdlyep seledctedtly froml Ct adnd fro Nm. C and N; and 15 4 p.redrug, A sa clot,m hpydoruantde, o Nf-o Fxoidrmeu folarm Ia, o orr so alva stteer tehoeisreoomf,er, tautomer, racemic, metabolite, pro- or
Wherei
Figure imgf000219_0003
I 20 R1 is(C snelected from–H,–hal, -OH, -C- lkyl, -O
wh=S)-R4, -SO2-R4, -CN, -NR9-SO2-R4, -C3-6cy-Cclo-alklkyyl,l, - -OS--CC- 3-6acylkcylol,a -lNkyRl,9R -A10r,1 -( aCn=dO)–-HRe4,t1 -; subesrteitiune enatsch se olefc steadid fr -oCm1-6–ahlkayllo, is -O oRpt3i5o,n -aNlRly11 aRn1d2, i -nOdependently substituted with from 1 to 3 R5 is attached toO Z1 or Z5 and is selected f -C1-6alkyl, and -S-C1-6alkyl; l, 25 A -N
frr5 R rom–H,–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6 a6R nd 7, -( alky HC e = t5; ) w -R h 8 e , r -e ( i C n = e S a ) c-h R8 o , f - s S a O id 2-R -C 8
1,- -6 C al N ky , l -N is R o 6 p -S tio O2-R8, -C3-6cycloalkyl, -O-C3-6cycloalkyl, - s soem 1 to 3 substituents sel nally and independently substituted w;ith R2 i ected from–halo, -OR36, -NR23R24, -O-C1-6alkyl, and -S-C1-6alkyl optiloencatelldy f arnodm in–dHe,p -heanldoe,n -OtlyH s,u -Cbs1-t6itaulkteydl, w and -C3-6cycloalkyl; wherein each of said -C1-6alkyl is 30 isO
o sR
pe2 ith from 1 to 3 substituents selected from–halo,– R tiloe7, 8nc a ,atendd alnly f - d arN -NnodmR13 R1 in–R 5RdH1
e,4
3 ; 16p -h
;eanldoe,n -OtlyH s,u -Cbs1-t6itaulkteydl, w anitdh - fCro3m-6cy 1c tlooa 3lk syul;b wshtietureenints ea sechle octfe sdai fdro -mC1–-6haalkloyl, i–s OR2 -218- R4 aNndR R8 are each independently selected from–halo,–OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6
17R18, -C3-6cycloalkyl, -O-C3-6 alkyl, - R6, R7, R9, R10, R11, cycloalkyl, -Ar4 and -Het4; 5 R nd R R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R31, R32, R33
35 a 36 are eac R34, - inSd-Cep1-e6anldkeynl,tl -yC s3- h independently selected from–H, -halo, =O, -OH, -C1-6alkyl, -O-C1-6alkyl, u6cbysctiltouatelkdyl, w -iAthr6 fr aonmd– 1H teot6; 3 w shuebrsetiintue enatcsh s oefle scatiedd -C fr1o-6malk–yhla islo, op–tOioHna,ll -yO a-Cn1d al - R a 6ndky Rl,28 -,S a-Cre1- e6aalckhyl, in -dCe3p-6ecyncdleonatllkyy sl,e -lHecette6,d -A fror6m an–dH–NR37R38
27 ;
R37 and R38, are each independently selected from–H , - , C -h 1-6alkyl, -C3-6cycloalkyl and -Het2:
10 alo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1- X 6
1 is alk s y e l l , e -c C te 3- d 6cy fr c o lo m alk y C l, 1- -6 A a r l 7 ky a l- n , d O H-e C t7
1; -6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 6 saulbkyl-, -NR3-, and -O-; wherein each of said -C1-6alkyl- is optionally and independently C1 stituted with from 1 to 3 substituents selected from–halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S- 15 X -6alkyl, -phenyl, and -NR33R34
2 is s y e l l-e , ct -e N d R2 f-r , om and –C -1 O -6-a ; lk w yl h -, er e O in -C e 1 a -6 c a h lky o l f -, s a S id -C -1 C -6
1a -6 lk a y l l-, -C1-6alkyl-NR3-C1-6alkyl-, -NR2 6alk -C1- substituted with from 1 to 3 substituents selected from–khyal- is optionally and independently C1-6alk lo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S- Ar1, Ar4, Ary5l,, A -prh6,e annydl a And -NR31R32;
20 c Aor7m bperiisnigng op 1tio tona 3ll hyer7
ate a
nrr
doe
ia each independently a 5- to 10-membered aromatic cycle optionally ntdoempse selected from O, N and S; each of said Ar1, Ar4, Ar5, Ar6, andhalo, -OH, -C1-6alkyl, -O-C1-6 ndently substituted with from 1 to 3 substituents selected from is optionally and independenalkyl, -S-C1-6alkyl, and–NR19R20; wherein each of said -C1-6alkyl 25 Het1, Het2, Het4, Het5, Het6, andtl Hye stu7b asrteitu eteadch w iinthde frpoemnd 1e tnot 3 -halo;
h Haevt4in,g H ferot5m, H 1e tto6, 3 a hnedte Hroeat7tom iss o spetlioenctaeldly fr aonmd O in,d Nep aenndly
de Sn; a
tl w 3
yh- se t
uroebi 1
sn0
tit e-membered heterocycle uatecdh of said Het1, Het2, substituents selected from–halo, -OH,–C1-6alkyl, -O-C1-6alkyl, -S-C1-6alky wl,it =hO f,ro -m
Figure imgf000220_0001
(C= 1O t)o-C13- 6alkyl, and -NR21R22; wherein each of said -C1-6alkyl is optionally and indp d tly 30 Het8 s
S iusb ast 3itu-t teod 1 w0-itmhe frmombe 1re tdo h 3e -thearoloc;ycle having from 1 to 3 heteroatoms selected from O, N and w;
sO eher
-l C eceteind s fraoid
,m H
-S –e
-C hta8lo is, - oOpHtio,n–aClly1-6 aanlkdyl, in -dCe1p-6eanlkdyelenntley, s -uCb1s-6taitluktyel-dC w3-6ith from 1 to 3 substituents 35 1-6alkyl 1-6alkyl, =O, -
Figure imgf000220_0002
(C=O)-C1-6alkyl, -C1-6al c k ycloalkyl, -C3-6cycloalkyl, - e wahcehre oinf s wahiden -C R1-6
1a islk–yHl i,s optionlly d idp dently skuybl-sOtit-uCt1e-6da wliythl a frnodm - 1N tRo231R -2h2a;lo w;herein Z Z4 and Z5 are each th iennde apte lndetntly s heletctedat foromm o Cf H aentd8 i Ns. attached to X2
1, Z2, Z3,
5. A compound as defined in claim 4, wherein -219- R1 is(C s=eSle)-cRte4,d - fSroOm2-R–H4,, -–ChNa,lo, -N -OR9H-S,O -C1-6
2-Ra4,lky -Cl,3 --6O-C1-6alkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, - w cycloalkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1; 5 suhbesrteitiune each of said -C1-6alkyl is optionally and independently substituted with from 1 to 3 R5 is -N aRtta6Rch7,e -dnt
(C tso s
=O Ze1le
)- oc
Rrte
8 Zd
, -5( a frnodm is–h saelloe,ct -eOdR f3r5o,m -N–RH1,1R–1h2a,l -oO,- -CO1H-6,a -lkCy1l-,6a alnkdyl -,S -O-C-C1-6
1a-6laklykly;l, -S-C1-6alkyl, Ar5 and–Het5; whereiCn=S)-R8, -SO2-R8, -CN, -NR6-SO2-R8, -C3-6cycloalkyl, -O-C3-6cycloalkyl, - from 1 to 3 substituents e saeclh of said -C1-6alkyl is optionally and independently substituted with R2 is selected from–H, -halo, -eOcted from–halo, -OR36, -NR23R24, -O-C1-6alkyl, and -S-C1-6alkyl; 10 i s
Figure imgf000221_0001
O o R p 2 t 7 io , n a ally and independentHly, s -Cub1-s6atiltkuytel,d an wdith -C fr3o-6mcyc 1lo toalk 3y sl,u;b wshtietureeinnts ea scehle octfe sdai fdro -mC1–-6haalkloy,l R3 iptil tn
llydd f -NR1
d id–3RH14;
p -hdaelon,tl -yO sHu,bs -Cti1-6alkyl, -C3-6cycloalkyl; wherein each of said -C1-6alkyl is 15 OR28, and -NR15R16 tuted with from 1 to 3 substituents selected from–halo,– R4 a NndR R8 are each inde;pendently selected from–halo,–OH, -C1-6alkyl, -O-C1-6
17R18, -C3-6cyclo alkyl, -S-C1-6alkyl, - R6, R7, R9, R10, R11, R12a,lk Ry1l3,, -O R1-C4,3 R-6c15y,c Rlo1a6,lk Ryl1,7, -A Rr4
18 a,n Rd19 -,Het4;
R 36 are each independently selected from–H R,2 -0h,a Rlo2,1, R22, R23, R24, R31
35 and R , R32, R33, R34, 0 -S-C1-6alkyl, -C3-6cycloalkyl, -Ar6 and–Het6; wherein each of =O, -OH, -C1-6alkyl, -O-C1-6alkyl, 2 i 6 n a d lk e y p l, e -n S d-e C n 1 t-l 6 y alk s y u l b , s -tituted with from 1 to 3 substituents sele scatiedd -C fr1o-6malk–yhla islo, op–tOioHna,ll -yO a-Cn1d- R C3-6cycloalkyl, -Het6, -Ar6 and–NR37
27 and R38;
R R28, are e e e a a c c h h in in d d e e p p e e n n d d e e n n tl t y ly s s e e le le c c te te d d fr f o ro m m –H –H , - , C -h 1- a 6
37 and R38, ar a lo lk , y -l O , - H C , 3 --6 C c 1 y-c 6a lo lk a y lk l, y -l O an -C d 1 --6 H a e lk t2 y : l, -S-C1- 25 X 6 s alk s y e l l , e -c C te 3- d 6cy fr c o lo m alk y C l, - 6 A a r l 7 ky a l- n , d O H-e C t7
1 i 1- 1 ; -6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- X 6
2 is alk s y e l l-e , c -t N e R d 3- fr a o n m d– O C-1 ; -6alkyl-,–O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR2-C1-6alkyl-, -NR2-C1- 30 Ar 6alkyl-, -NR2
1, Ar4, Ar5, -, and -O-;
c is matic cycle optionally Aor7m bperinign Agr6
op 1,
tio t aond
na 3 A
ll hyer7 are each independen
atenr tly a 5- to 10-membered aro
do iantdoempse selected from O, N and S; each of said Ar1, Ar4, Ar5, Ar6, and –halo, -OH, -C1-6alkyl, -O-C1-6anlkdyently substituted with from 1 to 3 substituents selected from optionally and independently subst l i , t -S-C1-6alkyl,–NR19R20; wherein each of said -C1-6alkyl is 35 Het1 h, Het2, Het4, Het5, Het6, and Het7 aurete eda wcihth in frdoempe 1n tdoe 3nt -lyha alo 3;- to 10-memb
Haevt4in,g H ferot5m
t,s H 1
se t
eto
l6e, 3
ct a h
ene
ddte
fr Hro
omeat7tom
h iss
al o s
ope
,tl
-ioe
Onct
Haed
,lly fr
C ao
1nm
-6d O
alk in,
yd Ne and S; wherein each ofer seadid h Heetet1ro,c Hyectl2e, substituen l, -pOe-nCd1e-6natllkyyl s,u -bSs-tCitu1-t6eadlky wl,it =hO f,ro -m(C= 1 to 6a O)-C13- su l b k s y t l, itu a te n d d w -i N th R fr 2 o 1R m 22 1 ; to wh 3 e -r h e a in lo; each of said -C1-6alkyl is optionally and ind
Figure imgf000221_0002
p d tly -220- Het8 S is
w; a 3- to 10-membered heterocycle having from 1 to 3 heteroatoms selected from O, N and sehleerceteind said Het8 is optionally and independently substituted with from 1 to 3 substituents 5 O-C1-6alky frlo,m -S–-Cha1-l6oa,lk -yOl,H =,O–C,1 --
Figure imgf000222_0001
(6Cal=kOyl),-C -C1-6
1-6aalklkyyl,le -nCe1,-6 -aClk1-y6la-Olk-yCl-1C3-6
-6alckyycllo aanldky -l,N -RC3-6
21Rc2y2;clo wahlkeyrel,in - e wahcehre oinf s wahiden -C R1-6
1a ilkyl is optionlly d idp dently substituted with from 1 to 3 -halo;
Z s–H, then at l t ht atom of Het8 is attached to X2
1, Z2, Z3, Z4 and Z5 are each independently selected from C and N.
10 6 R.1 is(C s=e A
Sle c
)-co
Rtem
4,dp
- fo
Sruon
Omd
2-R– aHs
4,, de
-–f
Chin
Nae
,lod, in
-N -O c
R9Hla
-S,im
O -C 41-6 w
2-Rah
4,lkeyr
-Cle,in
3 --6Ocy-Cc1-6alkyl, -S-C1-6alkyl, -NR9R10, -(C=O)-R4, - wherein each of said -C1-6alkyl is optionally andl ionadlkyl, -O-C3-6cycloalkyl, -Ar1 and–Het1; substituents selected from–halo, -OR35, -NR11R12, -O- e C p 1 e -6 ndently substituted with from 1 to 3 15 R5 is -N aRtta6Rch7,e -d(C to=O Z1)- oRr8 Z, -5(C an=dS i)s-R s8e,le -ScOte2d-R fr8o,m -C–NH,, -N–hRa6l-oS,O -O2-HR,a
8, -lkCy
-C1l-,6
3-a a
6clnkd -S
yyl, -O-C-C1-6
1a-6laklykly;l, -S-C1-6alkyl, Ar5 and–Het5; wherein each of said -C1-6alkyl is optionally and incloalkyl, -O-C3-6cycloalkyl, - from 1 to 3 substituents selected from–halo, -OR36, -NR23R24, -O-dCe1p-endently substituted with 20 R -halo, -OH, -C 6
2 is selected from–H, 1-6alkyl, and -C3-6cycloalkyl; whe alkyl, and -Sd-C1-6alkyl; optionally and independently substituted with from 1 to 3 substitureenints ea sechle octfe sdai fro -mC1–-6haalkloyl, i–s R is O
o sR
pe2
tiloe7,
nc a
aten
lldd
y f - arN
nodmR13
in–R
dH1
e,4
3 ;
p -heanldoe,n -OtlyH s,u -Cbs1-t6itaulkteydl, w anitdh -C3-6cycloalkyl; wherein each of said -C1-6alkyl is 25 OR2 R1 from 1 to 3 substituents selected from–halo,– R 8
in6d,e Rpe7,nd R,
e9 a
n,n
t Rd
ly1 -0N,R
se R15
le11c,te R6;
d12, fr Rom13,– RH14,, R -h1a5,lo R,16 =,O R,19 -,O RH2,0, - RC21
1-6,a Rlk2y2l,, R -3O1,-C R32
1-6a,l Rky3l3, a -nSd-C R34
1-6al akryel, e -aCc3h- 6 s c u y b c s lo tit a u lk te y d l, w -A ith r6 fr a o n m d 1 t H o e 3 t6; su w b h s e ti r tu e e in nts ea s c e h lec o t f ed sa fr id om -C 1 h -6 a a lo lk , y l O is H, o -p O ti-o C n 1 a -6 l a ly lky a l n , d -S- in C d 1 e -6 p a e lk n y d l, e -n C tl ycloa 3 y- 30 6 Rc
R dlk Ry2l,8 - 8, -H
, a a re
ret6
e e,
ea -A an
ac c hr6
h in in dd
de e p–
peN
enR
nd d e37
27 an e nR
ntl3
ty8;
ly s s e e le le c c te te d d fr f o ro m m –H –H , - , C -h 1 a 6
37 and R3 a lo lk , y -l O , - H C , 3 --6 C c 1 y-c 6a lo lk a y lk l, y -l O an -C d 1 --6 H a e lk t2 y : l, -S-C1- X i 6 s alk s y e l l , e -c C te 3- d 6cy fr c o lo m alk y C l, 1- -6 A a r l 7 ky a l- n , d O H-e C t7
1 1 ; -6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR3-C1- 35 6 sa
Cul 6l
1bk
-6 sy
atl- li k t,u y t - l, eN
-dR
ph w3- ei,th a fnrodm -O 1- t;o w 3h seurbesintitu eeancths s oefle scateidd f -rCo1m-6a–lkhyal-lo i,s -O oHpt,io -Cna1-laylk aynl,d -O in-Cde1-p6aelnkdyle,n -tSly- X lected 2 f-ronmyl, a–nCd1-6 -aNlRky3l3
2 is se -R,3–4O-C1-6alkyl-,–S-C1-6alkyl-, -C1-6alkyl-NR3-C1-6alkyl-, -NR2-C1- 6a
0 sCu l b k
6s y
at l- likt , ut - yl,e N
-d R
ph wei , tnh a
y f n
lr ao d
nm -O
d 1- -N t ;
Ro w
33 h
1R s e
3u r
2b e
;s in titu e e a n c t h s s o e f le s c a t i e d d - f C ro 1 m -6a lk h y a l- lo, is -O o H p , tio -C n 1 a-l 6 l a y lk a y n l, d -O in -C de 1- p 6 endently 4 1- alkyl, -S- -221- Ar1, c Aorm4,p Arirs5i,n Agr61, t aond 3 A her7te arroeat eoamcsh s inedleecpteendd feronmtly O a, 5 N- t aon 1d0 S-m; eeamcbhe orefd sa airdomatic cycle optionally Ar7 being optionally and independently substituted with fr Ar1, Ar4, Ar5, Ar6, and –halo, -OH, -C1-6alkyl, -O-C1-6alkyl, -S-C1-6 om 1 to 3 substituents selected from 5 Het1 i,s H oeptt2io,n Haellty4, a Hndet i5n,d Heepte6,nd aenn alkyl, and–NR19R20; wherein each of said -C1-6alkyl dtl Hye stu7b asrteitu eteadc with from 1 to 3 -halo;
having from 1 to 3 heteroatoms selec h independently a 3- to 10-membered heterocycle Het et ted from O, N and S; wherein each of said Het1
4, Het5, H 6, and Het7 is optio , Het2, 10 substituents selected from–halo, -OnHa,lly–C a1n-6dalk inydl,e -pOe-nCd1e-6natllkyyl s,u -bSs-tCitu1-t6eadlky wl,it =hO f,ro -m
Figure imgf000223_0001
(C= 1O t 6a )o-C13- sulbksytl,itu atendd w -NR21R22; wherein each of said -C1-6alkyl is optionally and indp d tly Het8 S is; a 3- to 10-itmhe frmombe 1re tdo h 3e -thearoloc;ycle having from 1 to 3 heteroatoms selected from O, N and 15 w wh
wheer
ere
reiinn a wth leenas Rt1 o inse– oHf, s tahiedn h aette leroaastto omnes i hse atettraocahtoemd t oof X H1e ot8r i Xs2 a;ttached to X2; a seh
-lCeceteind s fraoidm H–ehta8lo is, - oOpHtio,n–aClly1-6 aanlkdyl, in -dCe1p-6eanlkdyelenntley, s -uCb1s-6taitluktyel-dC w3-6ith from 1 to 3nd substituents O 6alkyl, -S-C1-6alkyl, =O, -
Figure imgf000223_0002
(C=O)-C1-6a cycloalkyl, -C3-6
1- cycloalkyl, - each of said -C1-6alkyl is opt lkyl, -C1-6alkyl-O-C1-6alkyl and -NR21R22; wherein 20 Z1, Z2, Z3, Z4 and Z5 are each indioenpllyd dtly idlptdde fnrotlmy s Cub asntidtu Nte.d with from 1 to 3 -halo; 7. A o c r o p m re p d o r u u n g d , s o a f l F t, o h r y m d u ra la te Ia , N o-r o F x o id r e m f u o la rm I , o o r r a so stereoisomer, tautomer, racemic, metabolite, pro- 6, wherein each of said Z1, Z2, Z3, Z4 a lvate thereof as defined in anyone of claims 1 to 25 provisions as defined in claims 1 to 6 appnlyd. Z5 is C; and wherein the further definitions and 8 A.
R1 A
1 a isn c
sdom
e Ale2po aurend ea acsh d ienfdineepden inde onntely o sfe clleacimtesd 1 fro tom 3 C w ahnedre Nin;
30 R R5
2 i iss s seellecteedd f fr
ect
ct roomm––HH, a -nhdal–oh aanlod; -C1-6alkyl;
R3 is selecteedd f frrom–H and -C1-6
1alkyl; X X1
2 is sel oomm l- 35 Het is8 i s ec
selectteedd f frrom––
-OH
C-1C a1n-6d
-6alka - yllkC
-y,–-6,a
O -l
-Nky
CRl;3
1-6-aClk1-y6la-,lk -yNl-R,2 --NCR3
1-6-a,l -kOyl--;, -NR2-, -O- sub asti 3tu-e tnots 10 s-emleecmtebder freodm he–thearlooc,y -cOleH;, w–hCe1r-e6
6ainlk syal,id -C H1-e6at8lk iysle onpeti,o -n;
Ca3ll-y6c syuclbosatliktuytle,d -C w1-i6thalk 1yl t-oC33- Z 6
1, Z2c,y Zcl3o,a Zl4ky aln,d -
Figure imgf000223_0003
(C Z=O)-C1-6ahlk Cyl, and -(C=O)-C3-cycloalkyl ; and 40 9. A compound as defined in claim 8 wherein -222- A R1
1 a isn sde Ale2c atered e fraocmh– inHde apnedn–dheanltoly selected from C and N;
R
5 R5
2 i iss s seelleecctteedd f frroomm––HH, -halo and; -C1-6alkyl;
R3 is s and -C1-6alkyl
1 is sel l e e c c t te ;
X e
X2 is selecteed dr
d f f
frro o
om m
m
O H
O--C a
C1 n -6 d
1-6a - al C
lkky 1
yl- l-6
-, a
, - l N ky R l; 3-C1-6alkyl-, -NR3-, -O-;
Het -NR2-C1-6alkyl-, -NR2
8 is a 3- to 10 -, -O-; 10 substituents s-emleecmtebdere frdom het–ehroacloy,cle -O;H w,he–rCei1n-6a slakiydl, H -eCt8
1-6 iaslk oypletionnea,ll -yC s3-u6cbysctiltouatelkdyl w,it ahnd 1 t -oC13- Z 6
1, Z2a,lk Zy3l,C Z3-6
4c ayncdlo Za5lk ayrle; a enadch C.
10. A compound as defined in claim 8 or 9 wherein A1 is N and A2 is C.
15 11. A sa clto,m hypdoruanted, o Nf- Foxoirdmeu floarm Ia, o orr a so slvtearteeo tihseormeoefr,, tautomer, racemic, metabolite, pro- or predrug,
Whe
Figure imgf000224_0001
I 20 R R1 irein R5
2 is
is se s a settl
lae
ecc
chte
teed
dd f
f tr
room
o Z1– aHnd an isd s–ehleclte;d from–H and -C1-6alkyl;
R m–H and -C1-6
X3 alkyl; X1
2 i iss s seelleected from–H and -C1-6alkyl; Het is8 sele c c t t e e d d f f r r o o m m O O--C C 1-6
1-6 a a l l k k y y l l--, -NR3-C1-6alkyl-, -NR3-, -O-;
25 w isith a 13- to to 31 s0u-mbsetmitubeenrtesd s Nel-,
ec - coN
tnR
etda2i- fnC
roin1- mg6a hlk
ey
htael- lr,
oo - ,cN
-yR
Ocl2e-,; - wOh-e;rein said Het8 is optionally substituted , ZO-C1-6alkyl, -S-C1-6alkyl, =O, -(C= H1-6,–C1-6alkyl, -C1-6alkylene, -C3-6cycloalkyl, - Z1 2, Z3, Z4 and Z5 are each C. O)-C1-6alkyl, -C alkyl-O-C1-6alkyl and -NR21R22
Figure imgf000224_0002
; and 30 -223- 12. A compound selected from the list comprising:
C
Figure imgf000225_0001
p d N1 E pl N1 Cp d N2 E pl N2 C
Figure imgf000225_0002
p d N3 E pl N3 Cp d N4 E pl N4 C
Figure imgf000225_0003
p d N5 E pl N5 Cp d N6 E pl N6 C
Figure imgf000225_0004
p d N7 E pl N7 Cp d N8 E pl N8 -224- C
Figure imgf000226_0001
p d N9 E pl N9 Cp d N10 E pl N10 Cp d N11 E pl N11 Cp d N12 E pl N12 C
Figure imgf000226_0002
p d N13 E pl N13 Cp d N14 E pl N14
Co
Figure imgf000226_0003
p d N15 E pl N15 Cp d N16 E pl N16 -225- C
Figure imgf000227_0001
p d N17, E pl N17 Cp d N18, E pl N18 C
Figure imgf000227_0002
p d N19 E pl N19 Cp d N20 E pl N20 C
Figure imgf000227_0003
p d N21, E pl N21 Cp d N22, E pl N22 C
Figure imgf000227_0004
p d N23 E pl N23 Cp d N24 E pl N24 -226- Co
Figure imgf000228_0001
p d N25 E pl N25 Cp d N26 E pl N26 Cp d N27 E pl N27 Cp d N28 E pl N28 C
Figure imgf000228_0002
p d N29 E pl N29 Cp d N30 E pl N30 Co
Figure imgf000228_0003
p d N31 E pl N31 Cp d N32 E ple N32 -227- Comp
Figure imgf000229_0001
d N33 E pl N33 Cp d N34 E pl N34 Co
Figure imgf000229_0002
p d N35 E pl N35 Cp d N36 E pl N36 Co
Figure imgf000229_0003
p d N37, E pl N37 Cp d N38, E pl N38 Co
Figure imgf000229_0004
p d N39 E pl N39 Cp d N40 E pl N40 -228- Co
Figure imgf000230_0001
p d N41, E pl N41 Cp d N42, E pl N42 Comp
Figure imgf000230_0002
d N43 E pl N43 Cp d N44 E pl N44 Co
Figure imgf000230_0003
p d N45 E pl N45 Cp d N46 E pl N46 C
Figure imgf000230_0004
p d N47 E pl N47 Cp d N48 E pl N48 -229- C
Figure imgf000231_0001
p d N49 E pl N49 Cp d N50 E pl N50 Co
Figure imgf000231_0002
p d N51 E pl N51 Cp d N52 E pl N52 C
Figure imgf000231_0003
p d N53 E pl N53 Cp d N54 E pl N54 C
Figure imgf000231_0004
p d N55, E pl N55 Cp d N56, E pl N56 -230-
C
Figure imgf000232_0001
p d N57 E pl N57 Cp d N58 E pl N58 C
Figure imgf000232_0002
p d N59, E pl N59 Cp d N60, E pl N60 C
Figure imgf000232_0003
p d N61, E pl N61 Cp d N62, E pl N62 C
Figure imgf000232_0004
p d N63, E pl N63
5 -231- 13. A compound as defined in claim 11 which is selected from
Cp d N46 E pl N46 Cp d N49 E pl N49
Cp d N47 E pl N47 Cp d N27 E pl N27
Cp d N48 E pl N48
Figure imgf000233_0001
Cp d N43, E pl N43
Co
Figure imgf000233_0002
p d N50 E pl N50
Cp d N44 E pl N44 -232-
Co
Figure imgf000234_0001
p d N45 E pl N45 Cp d N59, E pl N59
Cop d N60 E pl N60
Cd p d N63 E pl N63
Co
Figure imgf000234_0002
p d N62 E pl N62
14. A compound as defined in claim 13 which is selected from
C
Figure imgf000234_0003
p d N27 E pl N27 Cp d N43 E pl N43 -233-
Co
Figure imgf000235_0001
p d N44 E pl N44 Cp d N60, E pl N60
Co
Figure imgf000235_0002
p d N45 E pl N45 Cp d N62, E pl N62
Cp d N59 E pl N59
Figure imgf000235_0003
Cdp d N63, E pl N63. 15. A compound as defined in claim 12 which is selected from
Compou
Figure imgf000235_0004
d N60 E pl N60 d
Cp d N45, E pl N45 -234- 16. h Aete croomarpyolu mnodie atycc aotr pdoinsgitio ton Z a1n iyn a ocnceor odfan cclaeim wsith 1 th toe n 1u1m;b wehreinrgei ans R p5ro ivsid leindke ind F toorm thuela a Ir oyrl I oar. 17.e Ana cnotmiopmoeurn.d according to any one of claims 1 to 12; wherein said compound is the S- 18.e Ana cnotmiopmoeurn.d according to any one of claims 1 to 12; wherein said compound is the R- 19. A pharmaceutical composition comprising a compound according to anyone of claims 1 to 18. 20. A us ceo amsp aou mnedd aiccincoer.ding to anyone of claims 1 to 18 or a composition according to claim 19 for 21. u Ase co inm tphoeu dniadg ancocsoisrd,i pnrgev toen atnioynon aend o/ofr cl tareimatsm 1en tot o 1f8 a o LrR aR cKo2m-kpionsaistieon as ascoccoiardteindg d tiose calasiem.19 for 22. u Ase co imnp tohuend dia agccnoorsdisin,g p troev aennytoionne o afnd c/laoirm tsre 1at tmoe 1n8t o orf a a co LmRpRoKs2it-iokinna asceco ardsisnogc tiaote cdlaim dis 1e9a for wheraesien o thre A LlzRhReiKm2e-rk’sin daisseea asses.ociated disease is se; dise a neurological disorders, such as Parkinson’s 23. c Ulasime o 1f9, a s cuoitmabpleou fnodr in ahsib diteinfigne thde in ac atnivyity on oef a o kfin claasime;s in 1 p taort 1ic8u,la orr a a L cRoRmKp2os kiitnioanse a.s defined in 24.1 U9s,e fo orf th ae c doimagpnoousnisd, a pcrecoverdnitniogn to an adn/yoorn treea otfm celanimt osf 1 a t LoR 1R8K o2r-k ain caosmep aosssiotiocinat aecdc doirsdeinagse to. claim 25. m Aet mhoedth coodm fporris tihneg a pdremviennistitoenrin agn tdo/o ar s turebajtment of a LRRK2-kinase associated disease; said of claims 1 to 19 or a composition accordinegc tto in cl naeimed 1 t2h.ereof a compound according to any one
PCT/EP2015/071349 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors WO2016042089A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP15766801.3A EP3194405B1 (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors
AU2015316801A AU2015316801B2 (en) 2014-09-17 2015-09-17 Macrocyclic LRRK2 kinase inhibitors
CA2960777A CA2960777A1 (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors
BR112017005299A BR112017005299A2 (en) 2014-09-17 2015-09-17 macrocyclic lrrk2 kinase inhibitors
ES15766801T ES2717510T3 (en) 2014-09-17 2015-09-17 Macrocyclic kinase inhibitors LRRK2
JP2017515823A JP2017529365A (en) 2014-09-17 2015-09-17 Macrocyclic LRRK2 kinase inhibitor
SG11201701936WA SG11201701936WA (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors
CN201580061216.1A CN107108641A (en) 2014-09-17 2015-09-17 Big ring LRRK2 kinase inhibitors
EA201790626A EA032838B1 (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors
DK15766801.3T DK3194405T3 (en) 2014-09-17 2015-09-17 MACROCYCLIC LRRK2 KINase INHIBITORS
US15/511,879 US10377772B2 (en) 2014-09-17 2015-09-17 Macrocyclic LRRK2 kinase inhibitors
MX2017003470A MX2017003470A (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors.
KR1020177010322A KR20170048599A (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors
PL15766801T PL3194405T3 (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors
IL251054A IL251054B (en) 2014-09-17 2017-03-09 Macrocyclic lrrk2 kinase inhibitors
ZA2017/01841A ZA201701841B (en) 2014-09-17 2017-03-15 Macrocyclic lrrk2 kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14290279.0 2014-09-17
EP14290279 2014-09-17

Publications (1)

Publication Number Publication Date
WO2016042089A1 true WO2016042089A1 (en) 2016-03-24

Family

ID=51752058

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/071349 WO2016042089A1 (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors

Country Status (20)

Country Link
US (1) US10377772B2 (en)
EP (1) EP3194405B1 (en)
JP (1) JP2017529365A (en)
KR (1) KR20170048599A (en)
CN (1) CN107108641A (en)
AU (1) AU2015316801B2 (en)
BR (1) BR112017005299A2 (en)
CA (1) CA2960777A1 (en)
DK (1) DK3194405T3 (en)
EA (1) EA032838B1 (en)
ES (1) ES2717510T3 (en)
HU (1) HUE043972T2 (en)
IL (1) IL251054B (en)
MX (1) MX2017003470A (en)
PL (1) PL3194405T3 (en)
SG (1) SG11201701936WA (en)
TR (1) TR201904514T4 (en)
TW (1) TW201625639A (en)
WO (1) WO2016042089A1 (en)
ZA (1) ZA201701841B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021152165A1 (en) * 2020-01-31 2021-08-05 Oncodesign S.A. Macrocyclic rip2-kinase inhibitors
WO2021224320A1 (en) 2020-05-06 2021-11-11 Les Laboratoires Servier New macrocyclic lrrk2 kinase inhibitors
WO2022194976A1 (en) 2021-03-18 2022-09-22 Les Laboratoires Servier Macrocyclic lrrk2 kinase inhibitors
WO2023064768A1 (en) * 2021-10-11 2023-04-20 Baylor College Of Medicine G-protein-coupled receptor regulators and methods of use thereof
WO2023073013A1 (en) * 2021-10-27 2023-05-04 H. Lundbeck A/S Lrrk2 inhibitors
US11958865B1 (en) 2022-09-15 2024-04-16 H. Lundbeck A/S Leucine-rich repeat kinase 2 (LRRK2) inhibitors

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111221514B (en) * 2020-01-13 2023-03-03 陕西心像信息科技有限公司 OsgEarth-based three-dimensional visualization component implementation method and system
WO2023222005A1 (en) * 2022-05-18 2023-11-23 上海翊石医药科技有限公司 Aromatic heterocyclic compound and intermediate, pharmaceutical composition and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
WO2013046029A1 (en) * 2011-09-30 2013-04-04 Ipsen Pharma S.A.S. Macrocyclic lrrk2 kinase inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (en) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
DK0721331T3 (en) 1993-10-01 2002-02-11 Astrazeneca Ab Course of action
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
AU747708B2 (en) 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
CA2432148C (en) 2000-12-28 2011-01-18 Ono Pharmaceutical Co., Ltd. Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient
CA2450167A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
EP2316927B1 (en) 2004-10-21 2014-11-05 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Kaspp (lrrk2) gene, its production and use for the detection and treatment of neurodegenerative disorders
NO323175B1 (en) 2004-12-23 2007-01-15 Jan O Aasly Procedure for showing a mutation that causes hereditary parkinsonism
FI123725B (en) 2005-08-01 2013-10-15 Reijo Viljanen Procedure for clamping and controlling a blade in a sawing device as well as control and tensioning devices
KR101499594B1 (en) 2005-11-16 2015-03-09 씨티아이 바이오파마 코포레이션 Oxygen linked pyrimidine derⅳatives
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
ES2512727T3 (en) 2009-09-29 2014-10-24 Glaxo Group Limited New compounds
CR20170098A (en) * 2010-05-20 2017-07-17 Array Biopharma Inc MACROCICLICAL COMPOUNDS AS QUINASA TRK INHIBITORS
DK2760867T3 (en) * 2011-09-30 2016-04-11 Oncodesign Sa Macrocyclic FLT3 kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
WO2013046029A1 (en) * 2011-09-30 2013-04-04 Ipsen Pharma S.A.S. Macrocyclic lrrk2 kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAGHAVA R KETHIRI ET AL: "Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013)", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 24, no. 7, 1 July 2014 (2014-07-01), pages 745 - 757, XP055149873, ISSN: 1354-3776, DOI: 10.1517/13543776.2014.907275 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021152165A1 (en) * 2020-01-31 2021-08-05 Oncodesign S.A. Macrocyclic rip2-kinase inhibitors
CN115698020A (en) * 2020-01-31 2023-02-03 昂科迪塞恩精密医药公司(Opm) Macrocyclic RIP 2-kinase inhibitors
WO2021224320A1 (en) 2020-05-06 2021-11-11 Les Laboratoires Servier New macrocyclic lrrk2 kinase inhibitors
WO2022194976A1 (en) 2021-03-18 2022-09-22 Les Laboratoires Servier Macrocyclic lrrk2 kinase inhibitors
WO2023064768A1 (en) * 2021-10-11 2023-04-20 Baylor College Of Medicine G-protein-coupled receptor regulators and methods of use thereof
WO2023073013A1 (en) * 2021-10-27 2023-05-04 H. Lundbeck A/S Lrrk2 inhibitors
US11780851B2 (en) 2021-10-27 2023-10-10 H. Lundbeck A/S LRRK2 inhibitors
US11993612B2 (en) 2021-10-27 2024-05-28 H. Lundbeck A/S LRRK2 inhibitors
US11958865B1 (en) 2022-09-15 2024-04-16 H. Lundbeck A/S Leucine-rich repeat kinase 2 (LRRK2) inhibitors

Also Published As

Publication number Publication date
CA2960777A1 (en) 2016-03-24
HUE043972T2 (en) 2019-09-30
JP2017529365A (en) 2017-10-05
MX2017003470A (en) 2017-08-07
ES2717510T3 (en) 2019-06-21
EA032838B1 (en) 2019-07-31
EA201790626A1 (en) 2017-07-31
EP3194405B1 (en) 2018-12-26
DK3194405T3 (en) 2019-04-15
TR201904514T4 (en) 2019-04-22
EP3194405A1 (en) 2017-07-26
CN107108641A (en) 2017-08-29
AU2015316801B2 (en) 2019-03-07
KR20170048599A (en) 2017-05-08
IL251054B (en) 2019-03-31
ZA201701841B (en) 2019-08-28
BR112017005299A2 (en) 2017-12-12
PL3194405T4 (en) 2019-07-31
AU2015316801A1 (en) 2017-04-27
SG11201701936WA (en) 2017-04-27
PL3194405T3 (en) 2019-07-31
TW201625639A (en) 2016-07-16
IL251054A0 (en) 2017-04-30
US10377772B2 (en) 2019-08-13
US20170240565A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
EP3194405A1 (en) Macrocyclic lrrk2 kinase inhibitors
JP7566731B2 (en) Compounds and compositions for treating conditions associated with STING activity
CA2975033C (en) Cdk2/4/6 inhibitors
CN110072863A (en) RIP1 kinase inhibitor and application method
TWI498325B (en) 3-substituted pyrazoles and uses thereof
US6716856B1 (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
CN109475531A (en) The heterocycle inhibitor of PTPN11
TW202043198A (en) Compounds and compositions for treating conditions associated with sting activity
CN112823151A (en) Compounds and compositions for treating diseases associated with STING activity
TW202112744A (en) Compounds and compositions for treating conditions associated with sting activity
CN1964979B (en) Novel water-soluble prodrug
KR20180042368A (en) A condensed pyrimidine compound or a salt thereof
CN115348957A (en) Compounds and compositions for treating diseases associated with STING activity
ES2946632T3 (en) AHR modulators
CN113382772A (en) Compounds and compositions for treating diseases associated with STING activity
EA030426B1 (en) 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF mGluR2 RECEPTORS
KR20120120252A (en) Pteridinones as inhibitors of polo-like kinase
TW201245193A (en) Triazolopyridine compounds as PIM kinase inhibitors
CN115279770A (en) Compounds and compositions for treating diseases associated with STING activity
JP6728503B2 (en) Pharmaceutical composition for preventing or treating brain tumor containing as an active ingredient a compound capable of crossing the blood-brain barrier
CN111303159A (en) Pyrazole carboxamide compounds for the treatment of diseases mediated by Bruton&#39;s Tyrosine Kinase (BTK)
CN101267816A (en) Methods of treatment using hydroquinone ansamycins
EA013244B1 (en) 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents
KR20220151160A (en) SMARCA disintegrant and its uses
CN113874010A (en) Compounds and compositions for treating diseases associated with STING activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15766801

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2960777

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 251054

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2017515823

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/003470

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 15511879

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017005299

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2015766801

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20177010322

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201703669

Country of ref document: UA

Ref document number: 201790626

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2015316801

Country of ref document: AU

Date of ref document: 20150917

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112017005299

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170316